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Abstract 
The fluorinase enzyme, originally isolated from Streptomyces cattleya, has the unique ability 
to generate a C–F bond from aqueous fluoride ion and S-adenosylmethionine, making the 
fluorinase an attractive biochemical tool for radiolabelling biomolecules with fluorine-18 for 
application to positron emission tomography (PET). The inherent substrate specificity of the 
enzyme is, however, limiting, as only small modifications to the natural nucleoside substrate 
were known to be tolerated. This thesis describes an exploration and expansion of the 
substrate scope of the fluorinase enzyme, and its application to radiolabelling biomolecules 
for PET. 
The design and synthesis of a novel acetylene bearing substrate for the fluorinase, 5'-chloro-
5'-deoxy-2-ethynyladenosine (ClDEA) is described. ClDEA proved an excellent substrate for 
the fluorinase, and the kinetics of the transformation and binding affinities of the new 
substrate and product were investigated. The fluorinated acetylenic product was 
demonstrated to undergo a copper-catalysed azide-alkyne cycloaddition (CuAAC) reaction 
with an azide bearing RGD peptide, and this methodology was investigated for the synthesis 
of a novel fluorine-18-bearing prosthetic group for the synthesis of a radiolabelled RGD 
peptide, which was assessed in vivo in a rat. 
After the demonstration that the fluorinase can be used for “last step” radiolabelling of 
bioactive peptides, the synthesis of dimeric and tetrameric RGD-bearing substrates for the 
fluorinase was investigated. These large constructs underwent efficient enzymatic 
fluorination, and the fluorinated products showed increased binding affinity to their targets, 
compared to monomeric analogues. The challenges encountered during radiolabelling of 
these multimers with fluorine-18 using the fluorinase are discussed. 
A difluoromethyl-bearing nucleoside substrate (F2DA) was synthesised as a potential 
substrate in the reverse direction for the fluorinase, to further probe the substrate specificity if 
the fluorinase. Upon incubation with the enzyme, F2DA did not appear to undergo reaction, 
despite the demonstration that F2DA binds to the enzyme. 
Finally, the optimisation of a fluorinase-based protocol for the synthesis of the PET radiotracer 
[18F]fluoroacetate is described. The enzymatic method proved unsuitable for a small animal 
study due to contamination of the final product, and a chemical method was investigated and 
optimised as an alternative approach. [18F]Fluoroacetate synthesised using the developed 
chemical method was employed in an in vivo evaluation of acetyl CoA synthetase (ACSS2) 
activity in healthy and tumour-bearing mouse models, in an study to assess the activity of 
ACSS2 in breast and colon cancer models in mice. 
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1. Introduction 
1.1. Fluorine and the fluorinase  
1.1.1. Fluorine in nature 
Fluorine is the 13th most abundant element in the earth’s crust, existing predominantly 
in the form of insoluble fluorous minerals such as fluorite. Elemental fluorine, first 
prepared by Moissan in 1886, has recently (2012) been confirmed to exist in minute 
quantities in nature, in inclusions within the mineral antozonite.1 Antozonite releases a 
pungent odour when crushed and many possible causes for this odour, including 
ozone, fluorine gas, acyl fluorides and oxyfluorides have been proposed as the 
causative agent. Fluorine gas was confirmed to be responsible for the odour when 
elemental fluorine was detected in samples of antozonite using solid state 19F NMR 
spectroscopy.1 Radioactive decay of uranium within the calcium fluoride-based mineral 
leads to breakdown of calcium fluoride into small calcium inclusions, responsible for the 
dark colour of the mineral. Fluorine radicals generated in this process combine to form 
fluorine gas, responsible for the mineral’s pungent odour. 
In contrast to the other halogens, chlorine, bromine and iodine, fluorine serves no role 
in regular metabolism. The limited biological role of fluorine is reflective of the low water 
solubility of fluorous minerals and the high solvation energy of aqueous fluoride ion. In 
addition, the oxidation of fluoride ion by mechanisms used in most other 
biohalogenations, where oxidation of the halide ion is coupled to reduction of peroxide, 
is not available for fluoride. The oxidation potential of fluoride (+2.87 V) is higher than 
that of peroxide (+2.07 V), and cannot be reduced via the haloperoxidase mechanism. 
Despite the abundance of fluorous minerals, fluorine has limited presence in the 
biosphere and is known to occur in only about 20 natural products. 
Fluoroacetate 1 (Figure 1), first isolated from the plant Dichapetalum cymosum in 
1943,2,3 is a potent metabolic toxin produced by a number Dichapetalum and other 
plant species, and also by several bacteria.4 The toxicity of fluoroacetate 1 arises from 
its incorporation in the citric acid cycle. Fluoroacetate 1 is first condensed with 
coenzyme A to give fluoroacetyl coenzyme A (fluoroacetyl CoA). Fluoroacetyl CoA 
reacts with a unit of oxaloacetate, catalysed by citrate synthase, to give 
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(2R,3R)-fluorocitrate 2.5 The (2R,3R)-fluorocitrate 2 is then converted, by aconitase, to 
4-hydroxy-trans-aconitate, a potent inhibitor of aconitase. The process was termed 
“lethal synthesis” by Peters, as inhibition of aconitase severely reduces energy 
production within the cell, which is a potentially lethal effect.5 
 
Figure 1. Fluorinated natural products. 
The β-lactam producer Streptomyces cattleya (NRRL 8057) was known to produce an 
unidentified anti-metabolite when grown in selected media. After extensive 
chromatographic fractionation of cell culture extracts, the unknown anti-metabolite was 
identified as 4-fluorothreonine 3.6 4-Fluorothreonine 3 showed weak antibacterial 
activity, proposed to be a result of its structural similarity to threonine. In addition to 
4-fluorothreonine 3, 19F NMR spectroscopy of S. cattleya extracts revealed that the 
organism also produced fluoroacetate 1 in millimolar concentrations when the growth 
media was supplemented with inorganic fluoride. 
In addition to accumulating fluoroacetate 1 in the leaves, the plant species 
Dichapetalum toxicarium also accumulates significant organofluorine in its seeds, 
however, not as fluoroacetate 1.7 Peters et al.8 identified the principal entity of this 
organofluorine accumulation to be ω-fluorooleic acid 5, shown in Figure 1. A number of 
additional ω-fluoro fatty acids have also been identified as minor components of the 
seed oil. These products include arachidic- (C20:0), eicosenoic- (C20:1), linoleic- (C18:2), 
palmitic- (C16:0), palmitoleic- (C16:1), myristic- (C14:0) and capric- (C10:0) ω-fluoro-
derivatives.4,9 A dihydroxylated fluorooleic acid derivative has also been identified in the 
D. toxicarium seed extracts, hypothesised to arise via an epoxide intermediate.10 
Fluorinated fatty acids are proposed to arise from use of fluoroacetyl CoA as a starter 
unit during fatty acid biosynthesis.11 Fluorine is only ever observed at the terminal 
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position of the fatty acid, indicating acetyl CoA producing enzymes, such as acetyl CoA 
carboxylase, do not utilise fluoroacetate 1 as a substrate. It is also possible that 
fluoromalonyl CoA is not a substrate for the fatty acid synthase complex.4  
More recently, engineered polyketide synthases (PKSs) have been coaxed to use 
fluoroacetyl CoA 7 or 2-fluoromalonyl CoA 9 and incorporate terminal or mid-chain 
fluorine substituents into polyketide architectures, as shown in Scheme 1. Spencer 
et al.12 showed that fluoroacetyl CoA 7 was incorporated into octaketide 8 (Scheme 
1 A) by an overexpressed minimal PKS. Chang et al.13 showed incorporation of 
2-fluoromalonyl CoA 9 into 10 and 11 also using an engineered PKS (Scheme 1 B). 
These strategies illustrate the possibility of applying the well understood polyketide 
biosynthetic pathways for the production of fluorinated analogues using this biocatalytic 
approach. Engineering PKSs to have the ability to incorporate fluorinated precursors 
has the potential to generate motifs that would otherwise be challenging to access by 
traditional organic chemistry. 
 
Scheme 1. Incorporation of A. fluoroacetyl CoA12 and B. 2-fluoromalonyl CoA13 into polyketides by 
engineered PKSs. 
5-Fluoro-5-deoxyribonic acid 4 was identified in fermentation broths of the soil 
bacterium Streptomyces sp. MA37, isolated from soil samples from Ghana.14 When 
incubated in fluoride supplemented culture media, 19F NMR spectroscopy of cell free 
extracts from this organism showed the production of fluoroacetate 1 and 
4-fluorothreonine 3, along with 5-fluoro-5-deoxyribonic acid 4.14 Total synthesis of 
5-fluoro-5-deoxyribonic acid 4, and spiking extracts with the reference material 
confirmed the identity of this new fluorinated natural product. Additionally, a series of 
unidentified fluorometabolites were observed in these culture broths. 
The most unusual of the fluorinated natural products discovered to date is 
nucleocidin 6, a trypanosome active antibiotic isolated from Streptomyces calvus.15 
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Other fluorinated natural products all bear a conserved -CH2F moiety and are all 
related to fluoroacetate 1 (except fluorocitrate 2, but this is known to derive from 
fluoroacetate 1). Nucleocidin 6, however, contains a quaternary fluorinated centre, 
which bears no obvious relationship to a fluoroacetate origin. 
Nucleocidin 6 was first isolated from the soil bacterium S. calvus in 1957.15 Initially 
misidentified and thought not to contain fluorine, the correct, fluorinated structure of this 
natural product was proposed in 1969.16 Doubled signals in the 1H NMR spectrum of 
the compound were suggested to be a result of coupling to a fluorine atom rather than 
the presence of rotamers.17,18 The correct stereochemical assignment and 
fluorine-containing structure of nucleocidin 6 was confirmed in 1976 by total 
synthesis.19 
Recent efforts to induce nucleocidin 6 production in a number of commercial and 
proprietary strains of S. calvus have shown limited success.20 The lack of production is 
suggested to be due to loss of the appropriate biosynthetic genes upon freezing of 
cultures for storage.21 The lack of a producing strain of S. calvus has frustrated 
investigation of what would be an unusual biosynthetic pathway for the activation and 
incorporation of fluoride into biomolecules. 
Three other classes of molecules have been proposed as fluorinated natural products, 
but have been misidentified, or are unlikely to be of biological origin. Fluoroacetone 12, 
Figure 2, was proposed as a volatile fluorinated intermediate in fluoride metabolism 
from Acacia georginae, however, it is more likely that the volatile carbonyl compound 
detected was fluoroacetaldehyde, now known as an intermediate in the biosynthetic 
pathway of 4-fluorothreonine 3 and fluoroacetate 1. 
 
Figure 2. Compounds proposed as fluorinated natural products. 
5-Fluorouracil 13 and a number of derivatives thereof (14 to 17) have been isolated 
from the marine sponge Phakellia fusca.22 5-Fluorouracil 13 is an anticancer agent, 
produced and used on an industrial scale. Rather than the sponge synthesising these 
compounds, 5-fluorouracil 13 is suggested to bio-accumulate in the sponge, 
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sequestered either from industrial or domestic effluent.23 Metabolic action on the 
5-fluorouracil 13 core is proposed to give rise to derivatives 14 to 17. 
In 2014, fluoroarene 18 (Figure 2) was proposed as the structure of a compound 
isolated from Streptomyces sp. TC1 broths.24 Arene 18 was prepared synthetically and 
found to have distinctly different spectroscopic properties to the isolated product.25 
Specifically, a sharp peak in the 19F NMR spectrum at –110.1 ppm was observed, in 
contrast to the broad “peak” (−140 ppm to −180 ppm) observed for the compound 
isolated from S. sp. TC1. Further investigations showed that the isolated compound 
was in fact the 4-hydroxy-derivative 19, and did not contain a fluorine atom.26  
1.1.2. Biological halogenation 
There are over 4000 natural products containing halogens described.27 The majority of 
these are chlorinated (approx. 2300) or brominated (approx. 2100). Fewer than 150 
natural products containing iodine are known, but only about 20 natural products 
containing fluorine have been isolated and described, as discussed above.27 Most 
biological halogenations utilise oxidative or radical reactions to generate formal 
electrophilic “X+”28–31 or radical “X●”32,33 equivalents respectively from the corresponding 
bioavailable chloride, bromide or iodide ions. An additional class of halogenating 
enzymes has more recently been described, capable of catalysing the formation of  
C–X bonds directly from either fluoride or chloride ion by nucleophilic substitution.34,35 
A haem-containing chloroperoxidase from Caldariomyces fumago was the first 
described halogenase. This enzyme is responsible for the chlorination event in the 
biosynthetic pathway of caldariomycin.36 In this class of enzymes, a haem-Fe(III) 
species is oxidised by H2O2 to form an Fe(IV) species. The Fe(IV) species performs a 
2-electron oxidation of chloride ion to produce iron-bound hypochlorite, the active 
chlorinating agent, as shown in Scheme 2 A.28,29  
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Scheme 2. Mechanisms of oxidative halogenation of natural products catalysed by A. haem-iron, 
B. vanadium or C. flavin mediated generation of an electrophilic halogenating agent and its 
reaction with the appropriate nucleophile. D. Radical halogenation by non-haem iron species 
of unactivated centres. 
Similar electrophilic halogenases operating through vanadium-oxo species are also 
known. The vanadium centre co-ordinates a peroxide ion to give an oxo-peroxo-V(V) 
species (Scheme 2 B), which reacts with halide ion to form a hypohalite ion. 
Hypohalite then reacts with the appropriate substrate to produce a halogenated 
product.30,31 
Flavin also acts as a source of hypohalite in some enzymes. FADH2 reacts with 
peroxide to generate an oxidised flavin intermediate. The peroxo-intermediate oxidises 
halide ions to generate hypohalous acid (Scheme 2 C), which diffuses through the 
enzyme to halogenate the substrate.37  
A number of non-haem-iron halogenases are known to catalyse radical halogenation.32 
These iron-containing enzymes are dependent on molecular oxygen and 
α-ketoglutarate, which in the presence of chloride or bromide ion, react to give a 
halo-Fe(IV)-oxo species. This species abstracts a hydrogen radical from the 
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appropriate enzyme-bound substrate, forming an Fe(III) species. The C-centred radical 
is then quenched by forming a bond to the halogen, restoring the iron centre to the 
ferrous oxidation state, as shown in Scheme 2 D.33 
Of particular interest to this thesis are the halogenases catalysing reactions through 
nucleophilic substitution. The first enzyme described in this class was the fluorinase, 
isolated from Streptomyces cattleya in 2002, which catalyses the formation of a C–F 
bond from fluoride and SAM 20, to generate FDA 22.34 This enzyme is responsible for 
the first committed step of biosynthetic pathway of fluoroacetate 1 and 
4-fluorothreonine 3, shown in Scheme 3. Subsequently, a chlorinase operating through 
the same mechanism was discovered in the marine bacterium Salinospora tropica. The 
chlorinase forms part of the biosynthetic pathway of salinosporamide A 24, and is 
responsible for generating ClDA 23, the first committed product in the biosynthetic 
pathway. Salinosporamide A 24 is currently in clinical trials as an anticancer agent.35 
 
Scheme 3. Nucleophilic biohalogenation by A. the fluorinase enzyme, in the biosynthetic pathway 
towards fluoroacetate 1 and 4-fluorthreonine 3 and B. the chlorinase enzyme, in the 
biosynthetic pathway of salinosporamide A 24. 
The chlorinase and fluorinase activate halide ion by replacing hydrogen bonds 
(H-bonds) to solvent with H-bonds to amino acid residues in the active site. The 
enzyme then presents this activated nucleophile to S-adenosylmethionine 20 (SAM). 
The desolvated halide attacks the C-5' of the sulfonium centre, displacing 
methionine 21 as a leaving group and generating a 5'-halo-5'-deoxyadenosine (22 or 
23). More detail regarding this mode of halogenation will be provided below.  
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1.1.3. The fluorinase 
Enzymatic synthesis of a C–F bond was first reported in mutant glycosidases under 
high fluoride ion concentration. Fluoride was able to intercept highly electrophilic 
glycosyl donors, producing fluorinated sugars.38,39 This activity was not native to the 
glycosidases, and provided no information about the origin of fluorinated natural 
products. 
Investigation into the biochemistry of fluorine metabolism in Streptomyces cattleya 
(NRL 8057) led to the isolation of 5'-fluoro-5'-deoxyadenosine synthase (FDAS, more 
commonly termed “fluorinase”) in 2002.34 Addition of adenosine triphosphate (ATP) and 
methionine to fluoride-containing cell free extracts of S. cattlyea led to enhanced 
fluorometabolite production. This pointed to S-adenosylmethioinine 20 (SAM) as the 
immediate biosynthetic precursor to the observed fluorometabolites. A partially purified 
protein preparation from S. cattleya was able to convert SAM 20 and inorganic fluoride 
to 5'-fluoro-5'-deoxyadenosine 22 (FDA) shown in Scheme 4, the first committed step 
in the fluorometabolite biosynthetic pathway. The fluorinase was also found to operate 
in the reverse direction, and upon incubation of the fluorinase with FDA 22 and 
L-methionine 21, SAM 20 was produced as a product. 
 
Scheme 4. The first step in the fluorometabolite pathway in S. cattleya is catalysed by the fluorinase to 
give FDA 22. Cell free extracts from the organism were capable of transforming SAM 20 and 
inorganic fluoride to fluoroacetate 1 and 4-fluorothreonine 3. 
Crude cell free extracts from S. cattleya were capable of converting SAM 20 and 
inorganic fluoride to fluoroacetate 1 and 4-fluorothrenonine 3,40 showing that all the 
necessary biosynthetic enzymes for fluoroacetate 1 and 4-fluorothreonine 3 production 
were expressed in S. cattleya.  
The fluorinase (E.C. 2.5.1.63) was further purified from cell homogenates using a 
combination of ammonium sulfate precipitation, hydrophobic interaction, size exclusion 
and anion exchange chromatography.41 Sodium dodecylsulfate polyacrylamide gel 
electrophoresis (SDS PAGE) and mass spectrometry revealed that the monomer of the 
fluorinase had a molecular weight of 32.2 kDa. Size exclusion chromatography showed 
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that the intact protein had a mass of approximately 196 kDa, suggesting that the 
enzyme organised as a hexamer in solution.41 
Subsequent crystallisation of both native and recombinant variants of the fluorinase42,43 
allowed the structure of the enzyme bound to substrate to be solved to 1.9 Å, revealing 
the fluorinase to be a dimer of trimers. A single trimer is shown in Figure 3 A. The 
monomer (Figure 3 B) consists of distinct N-terminal and C-terminal domains linked by 
a short polypeptide chain. The enzyme also has a distinctive 21 amino acid loop in the 
N-terminal domain, which contacts the C-terminal domain and makes up a part of the 
active site. The structural fold of the fluorinase places the enzyme in a superfamily of 
proteins which, up to that point, had no known function. Other members of the family 
lack the flexible loop in the N-terminal domain of the fluorinase, suggesting that the 
loop may play a critical role in the function of the enzyme. The organisation of three 
monomers into a trimer gives the minimal functional unit of the fluorinase, as the active 
site of the enzyme (Figure 3 C) is located at the interface of the N-terminal domain of 
one monomer and the C-terminal domain of another. Two trimers interact through the 
C-terminal domains to form the hexamer in solution. 
 
Figure 3.  Crystal structure of the fluorinase with SAM 20 bound in the active site. A. Top view of the 
fluorinase trimer. B. Single fluorinase monomer showing the N- and C-terminal domains, with 
the characteristic loop highlighted in light blue. C. SAM 20 in the active site, which lies 
between two monomers. 
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1.1.4. Mechanism of enzymatic fluorination 
The location of the sulfonium centre in the substrate:enzyme complex and the fluorine 
atom in the product:enzyme complex suggested that the fluorinase enzyme operated 
through an SN2-like mechanism. The position of these atoms suggested that 
desolvated fluoride ion acts as a nucleophile, attacking the sulfonium centre of 
SAM 20, displacing methionine as a leaving group and generating FDA 22 Feeding 
experiments with chiral deuterated glycerols had previously suggested that the 
fluorination reaction proceeded with an inversion of configuration at C-5'.44 This was 
confirmed by the synthesis of a chiral deuterated SAM 20 derivative, 
(5'S)-[5'-2H1]-SAM, and the stereochemical outcome of a fluorinase catalysed reaction 
was explored.45 The resultant chiral FDA 22 was purified by reverse phase 
chromatography and subjected to 2H NMR spectroscopy in a chiral liquid-crystalline 
solvent. The NMR experiment revealed that the reaction had proceeded with inversion 
of configuration at C-5', implying an SN2 process. 
Comparison of the enzyme-substrate and enzyme-product complexes reveals that the 
C–S bond is oriented at 164° compared to the C–F bond in the product. This 
orientation agrees with the interpretation that the reaction occurs through an SN2 
process. Distinguishing water from fluoride in the active site proved difficult due to their 
similar size and electron count, however crystal structures of S159A mutants with 
S-adenosylhomocysteine (SAH, a high affinity inhibitor) and SAM 20 were solved 
where chloride ion was distinguishable in the active site. In these cases, a water 
molecule fulfilled the role of the hydroxyl group of Ser-158, participating in hydrogen 
bonding contacts with the halide ion. In this structure, the halide ion was oriented at 
approximately 130° to the C–S bond rather than the optimal 180° required for an SN2 
substitution, but this may be due to the shifting of residues in the active site to 
accommodate the larger chloride, rather than fluoride ion. 
The native fluorinase isolated from S. cattleya was found to co-crystallise with SAM 20 
bound within the active site. The crystal structure revealed extensive interactions 
between SAM 20 and residues in the active site. The active site itself is buried within 
the enzyme, suggesting that the enzyme also exists in an open conformation, capable 
of binding the substrate.  
Fluoride ion appears to bind in a 1.4–1.6 Å pocket in the active site, optimally sized to 
bind fluoride (1.3 Å ionic radius) rather than chloride (1.81 Å ionic radius) or the other 
larger halide ions. HOLE46 analysis showed no obvious ion channel through which 
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fluoride ion could enter the active site after the binding of SAM 20. Fluoride therefore 
enters the active site first, and is forced into its binding pocket upon the binding of 
SAM 20. This process is consistent with a model where fluoride ion exchanges 
H-bonds with water to residues within the active site.  
Incubating SAM 20 and fluoride with the fluorinase prior to crystallisation afforded a 
second X-ray structure with FDA 22 and L-methionine 21 bound to the active site. The 
location of FDA 22 revealed that the fluoromethyl group makes contacts with a number 
of residues in a hydrophobic pocket defined by Phe-156, Tyr-77 and Thr-80, as 
illustrated in Figure 4. In addition, the fluorine atom itself makes two contacts with the 
amide hydrogen and hydroxyl hydrogen of Ser-158, and possibly Thr-80.47  
 
Figure 4. Fluorinase (black) interactions with FDA 22 and L-Met 21 (red). Residues belonging to the 
individual monomers making up the active site are shown in green and blue. Adapted with 
permission from Naismith et.al.43 
Ser-158 and Asp-16 were suggested to be critical residues which formed H-bonds to 
incoming fluoride ion in an otherwise hydrophobic environment formed partly by 
Phe-156. To probe the importance of these residues, mutants at these positions were 
investigated. In the S158A mutant, catalytic activity was reduced due to the loss of 
H-bond donors for fluoride in the active site.48 Similarly, little activity was observed in 
an F156A mutant, while a F156V mutant led to the restoration of some catalytic activity. 
The loss of activity suggested that the hydrophobic pocket was involved in increasing 
the reactivity of fluoride ion. D16A, D16S and D16N mutants were also found to have 
little activity, suggesting that the aspartate residue that interacts with the 2',3'-diol of the 
ribose ring plays a key role in organising the substrate for catalysis. 
The mechanism of the fluorination reaction was further investigated using isothermal 
titration calorimetry (ITC) in order to deduce the order in which each of the components 
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necessary for reaction bound into the active site of the enzyme.48 Fluoride showed no 
detectable binding by ITC, and steady state kinetic measurements suggested that 
fluoride had a low affinity (KM > 5 mM). 
SAM 20 was found to bind with high affinity to the fluorinase (Kd = 1.3 µM) in a highly 
thermodynamically favoured process. The high affinity for SAM 20 may contribute to 
securing the fluoride in the active site, promoting its desolvation and activation. Binding 
is further favoured by the formation of multiple hydrogen bonding and π-π stacking 
interactions between the adenine base and the enzyme. The high affinity of the 
fluorinase for the adenosyl fragment of the substrate is illustrated in the binding 
affinities of both adenosine (Kd = 0.82 µM) and the product of the reaction, 
FDA 22 (Kd = 0.22 µM), both higher than that of the substrate SAM 20. 
In the reverse direction, L-methionine showed no appreciable binding to the 
apo-fluorinase. Binding affinity was restored upon incubation of the fluorinase with 
either FDA 22 or adenosine, suggesting that in the reverse direction, the binding of the 
nucleoside organises the binding site for L-methionine. 
Density functional theory (DFT) and quantum mechanics/molecular mechanics 
(QM/MM) calculations were used to further investigate the fluorinase reaction.47 A 
number of reaction pathways were explored in terms of their thermodynamic feasibility. 
Formation of a sulfur ylide by deprotonation at one of the four acidic sites (the three 
positions alpha to the sulfonium, or at C-4') followed by HF addition was found to be 
either highly endothermic or kinetically prohibitive and, therefore, improbable as viable 
reaction pathways. Alternatively, all three positions alpha to the sulfonium centre offer 
potential electrophilic sites for nucleophilic attack of fluoride ion. Calculating the 
reaction energies of attack at the three positions showed all three to be similarly 
exothermic. The regioselectivity observed was concluded to result from the 
organisation of the nucleophile and electrophile within the active site of the enzyme, 
rather than from an intrinsic thermodynamic driving force for reaction at a specific site 
of SAM 20. 
The fluorinase was found to lower the activation energy barrier for the formation of the 
transition state complex. Activation energy for the reaction between the free species in 
solution was found to be 93 kJ.mol−1, while this was reduced to 53 kJ.mol−1 in the 
active site. This reduction in activation energy represents a rate acceleration of 106 to 
108 times for the enzyme catalysed reaction versus the reaction in solution. This rate 
acceleration was determined to largely result from pre-organisation of the substrates 
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within the active site, rather than from other factors intrinsic to the protein environment. 
There was also a small contribution to rate acceleration from lowering the 
HOMO-LUMO gap by substrate distortion and the electric field within the active site. 
The steady state kinetics of the enzymatic transformation were also investigated, 
revealing that the fluorinase has a KM for SAM 20 of between 6.5 µM and 29 µM.48,49 
The high affinity observed in the kinetic experiments was in agreement with the affinity 
previously determined by ITC. More interestingly, the fluorinase enzyme was found to 
exhibit very low turnover numbers, with a kcat value of 0.06 min−1. Considering that the 
enzyme enhances the rate of catalysis by a factor as high as 2 × 1015 times,50 this low 
turnover number illustrates the difficulty in the formation of a C–F bond under aqueous 
conditions, even in specially evolved enzymatic systems. 
When the fluorinase was originally isolated and characterised, its selectivity for halide 
ion was investigated and the enzyme was found to react only with fluoride.34,43 When 
incubated with chloride ion, no conversion to the analogous chlorinated product, 
5'-chloro-5'-deoxy-adenosine 23 (ClDA) was observed. The enzyme-catalysed reaction 
was, however, found to be reversible and able to catalyse the cleavage of the C–F 
bond when incubated with FDA 22 and L-methionine (or its selenium analogue), to 
generate SAM 20 (or its selenium analogue) and fluoride ion.51 The equilibrium for this 
reaction was found to lie in favour of FDA 22, by a factor of three.  
The reversibility of the transformation led to the discovery that the fluorinase could 
utilise chloride ion and synthesise ClDA 23 from SAM 20 in the presence of an L-amino 
acid oxidase (L-AAO). The equilibrium for this transformation lies heavily in favour of 
SAM 20 and chloride ion, in contrast to reaction with fluoride (Scheme 5). Addition of 
an L-AAO to the reaction drives the forward reaction by removing L-methionine 21 from 
solution by its irreversible conversion to the corresponding oxo-acid 25. 
 
Scheme 5. Chlorinase activity was observed with the fluorinase when reactions were carried out coupled 
to the action of L-AAO, which removes L-methionine 21 from the medium and drives the 
synthesis of ClDA 23. 
The reversibility of the reaction coupled to the ability to use chlorinated substrates led 
to the demonstration of a fluorinase catalysed transhalogenation. In this reaction, the 
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chlorinated nucleoside 23 was fed to the enzyme which catalysed reaction to produce 
the seleno-SAM intermediate 26. The equilibrium for this reaction favours production of 
SeSAM 26, which then acts as a substrate for a subseqent fluorination reaction, to 
generate FDA 22, driven by the enzyme equilibrium lying towards the products as 
shown in Scheme 6.51 
 
Scheme 6. Fluorinase–catalysed transhalogenation of chloro-nucleosides to fluoro-nucleosides though a 
SeSAM 26 intermediate. 
This process is a useful alternative route towards fluorinated products from chlorinated 
starting materials. This transformation has allowed the discovery of new substrates for 
the fluorinase, as SAM 20 analogues are difficult to prepare synthetically. More detailed 
discussion of these non-natural substrates will be provided in Chapter 2. 
1.1.5. Fluorometabolite biosynthesis  
S. cattleya was known to produce millimolar quantities of fluoroacetate 1 and 
4-fluorothreonine 3 when grown in fluoride supplemented media. Most work towards 
the elucidation of fluorometabolite biosynthetic pathway (Scheme 7) has therefore 
been undertaken in the organism. 
Feeding experiments with 13C- and 2H- labelled metabolic precursors, including 
acetate, glycine and serine, suggested that there was a single fluorination enzyme 
present in S. cattleya, as both fluorinated products showed similar incorporations of the 
heavy isotopes.52–54 Fluoroacetaldehyde 29 subsequently emerged as the key 
branching point in the biosynthetic pathway to fluoroacetate 1 and 
4-fluorothreonine 3.55 Feeding of fluoroacetaldehyde 29 to cultures of S. catteya was 
found to increase the production of both fluoroacetate 1 and 4-fluorothreonine 3. 
A 55 kDa aldehyde dehydrogenase was purified from S. cattlyea homogenates which 
oxidises fluoroacetaldehyde 29 to fluoroacetate 1.56 This NAD+-dependent enzyme was 
non-specific, and oxidised glycolaldehyde (150% activity compared to 
fluoroacetaldehyde 29) and chloroacetaldehyde (80%) as well as some other short 
chain aldehydes to a lower degree. 
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Scheme 7. Biosynthesis of 4-fluorothreonine 3 and fluoroacetate 1 in S. cattleya. 
4-Fluorothreonine 3 production was enhanced upon incubation of threonine, 
fluoroacetaldehyde 29 and pyridoxal phosphate (PLP) with cell free extracts of 
S. cattleya.57 These experiments led to the isolation of a 60 kDa PLP-dependent 
fluorothreonine transaldolase from S. cattleya homogenates. Threonine transaldolase 
was suggested to catalyse a novel reaction between PLP and threonine to form a 
PLP-bound glyoxylic acid Schiff base, releasing an equivalent of acetaldehyde. The 
Schiff base was proposed to react with fluoroacetaldehyde 29 in an aldol-type reaction 
to generate 4-fluorothreonine 3.57  
The fluorinase enzyme itself was identified from S. cattleya homogenates,34 and a 
genomic library from S cattleya was sequenced,58 accelerating the elucidation of the 
remainder of the biosynthetic pathway. The fluorinase gene, flA, was identified at the 
centre of a gene cluster, known as the Spencer cluster, illustrated in Figure 5.58 Based 
on the location of the fluorinase gene, the genes flanking the flA gene were 
hypothesised to be involved in fluorometabolite biosynthesis.  
 
Figure 5. The fluorinase gene in S. cattleya determined from a cosmid library, showing the open 
reading frames surrounding the gene responsible for the first step in the pathway, flA. Image 
reproduced and modified with permission from O’Hagan et al.49 
Directly adjacent to the fluorinase gene, an open reading frame was identified and 
named flB, which showed high homology to known purine nucleotide phosphorylases. 
5-Fluoro-5-deoxyribose-1-phosphate 27 (FDRP) was previously shown to be an 
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intermediate in the biosynthetic pathway,59 and the identification of the gene suggested 
that FDA 22 was phosphorylated by this enzyme to release FDRP 27 and adenine. 
Overexpression of this 299 amino acid protein proved challenging as the recombinant 
protein was largely insoluble, however, sufficient protein was obtained to confirm its 
role in the transformation of FDA 22 to FDRP 27, as illustrated in Scheme 7.58 
After the identification of FRDP 27 as an intermediate, it remained to be determined 
how FDRP 27 was transformed to fluoroacetaldehyde 29. An analogous ribose 
phosphate, 5-S-methyl-5-thioribose-1-phosphate 30 (MTRP), is a known intermediate 
of the methionine salvage pathway. MTRP 30 (Scheme 8) is known to undergo 
transformation to the corresponding ribulose phosphate derivative 31, under the action 
of an MTRP isomerase.60 The ribulose phosphate products of such isomerisations, are 
well characterised substrates for aldolase enzymes, generating aldehyde intermediates 
through a retro-aldol reaction. It was hypothesised that a similar isomerase possibly 
played a role in metabolism of FDRP 27 to 5-fluoro-5-deoxyribulose-1-phosphate 28 
(FDRulP). Under the action of such an aldolase, FDRulP 28 may be converted to 
fluoroacetaldehyde 29, they key intermediate in the fluorometabolite biosynthetic 
pathway. 
 
Scheme 8.  A. MTRP isomerase involved in the methionine salvage pathway, generating a ribulose 
phosphate 31. B. Proposed biosynthetic pathway to fluoroacetaldehyde 29 involving an 
isomerase and aldolase, via an intermediate ribulose phosphate 28. 
Incubation of FDRP 27 with S. cattlyea cell free extracts led to the production of 
FDRulP 28, identified by GCMS after derivatisation.61 Comparison of 19F NMR chemical 
shifts to those of a standard confirmed the identity of the product as FDRulP 28. These 
experiments provided evidence that FDRulP 28 was a biosynthetic intermediate, 
though the enzyme responsible for its biosynthesis remained to be isolated and 
identified. Incubation of FDRP 27 with an MTRP isomerase cloned from S. coelicolor 
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generated FDRulP 28, providing further support for the hypothesis that a similar 
homologue in S cattleya may be responsible for the generation for FDRulP 28.62  
PCR amplification of genomic DNA from S. cattleya using primers generated from 
conserved regions of two Streptomyces MTRP isomerases led to the discovery of a 
similar gene in S. cattleya. This gene was amplified and cloned into and overexpressed 
in E. coli. The resultant 80 kDa dimer was able to transform FDRP 27 to FDRulP 28,62 
though this activity was proposed to be secondary to its role in the methionine salvage 
pathway, as this gene was not located in the Spencer cluster.  
Isolation of the aldolase responsible for the cleavage of FDRubP 28 to 
fluoroacetaldehyde 29 and dihydroxyacetone phosphate 33 has proved challenging. 
Aldolase activity has been isolated from cell free extracts from S. cattleya, but found to 
convert fluoroacetaldehyde 29 and dihydroxyacetone phosphate 33 to a stereoisomer 
of FDRubP 28 when the reaction was explored in the reverse direction. The aldolase 
responsible for cleavage of FDRubP 28 to fluoroacetaldehyde 29 remains to be 
definitively identified.62  
Substitution of this aldolase with a putative fuculose aldolase from S. coelicolor in an 
in vitro reconstitution of fluorometabolite biosynthesis, using overexpressed variants of 
the other enzymes in the pathway, led to the production of fluoroacetate 1 and 
4-fluorothreonine 3 in cultures, detected by 19F NMR spectroscopy.62 This result 
provided strong evidence that an aldolase is responsible for the generation of 
fluoroacetaldehyde 29 in the fluorometabolite biosynthetic pathway, but this enzyme 
remains to be isolated and characterised. 
1.1.6. Fluorinases and analogues from other species  
In 2008, salL, a chlorinase enzyme with moderate homology (30%) to the fluorinase 
was found to be responsible for a chlorination reaction during the biosynthesis of the 
anticancer agent salinosporamide A 24 (Scheme 9 A) from the marine organism 
Salinospora tropica.35 The enzyme was unable to utilise fluoride ion as a substrate and 
selected for larger halide ions, specifically chloride. Comparison of the amino acid 
sequences of these two related enzymes revealed that the chlorinase lacked the 
distinctive 21 amino acid loop identified in the fluorinase, further suggesting that the 
loop may be essential for the selectivity of the fluorinase for fluoride ion over other 
halides.  
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Scheme 9. A. Biosynthesis of salinosporamide A 24 by the chlorinase enzyme. B. Engineered 
production of fluorosalinosporamide A 34 by a mutant S. tropica strain containing the 
fluorinase gene from S. cattleya. 
While salL, the enzyme responsible for the biohalogenation step, was found to be 
halide ion selective, fluorinated substrates were well tolerated by the downstream 
biosynthetic machinery. In salL knockouts, the organism was found able to synthesise 
fluorosalinosporamide A 34 when the medium was supplemented with FDA 22.63 In 
knockouts where the salL gene was replaced with the flA gene, production of 
fluorosalinosporamide A 34 was detected when the medium was supplemented with 
fluoride ion near the end of the exponential growth phase, as high fluoride ion 
concentration was toxic to the organism.64 
Until 2014, the fluorinase from Streptomyces cattleya was the only known enzyme able 
to synthesise a C–F bond. Gene mining of publically available databases revealed two 
genes in bacterial species that shared high homology to the fluorinase from S. cattleya. 
The first gene was identified from the genome of Nocardia brasiliensis HUJEG-1 
(ATCC 700358), a hospital pathogen.49 The predicted amino acid sequence showed 
81% similarity to the fluorinase from S. cattleya. The second was identified in an 
Actinoplanes sp. N902-109 and showed 80% similarity to the known fluorinase.49,65 A 
third gene with 87% similarity to the S. cattleya was identified after sequencing of 
Streptomyces sp. MA37, an organism isolated from a Ghanaian soil sample.49 
Sequence analysis revealed that, unlike the chlorinase from S. tropica, these proteins 
contained the unique fluorinase N-terminal domain 21 amino acid loop.43 The amino 
acid sequences of these proteins showed that all active site residues were highly 
conserved. 
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The three proteins were overexpressed in E. coli and found to be able to catalyse the 
reaction of fluoride ion with SAM 20 to generate 5'-fluoro-5'-deoxyadenosine 22. 
Steady state kinetic characterisation of these three new fluorinases showed them to 
have similar kcat values (0.122 to 0.262 min−1) to the S. cattleya fluorinase 
(0.082 min−1), confirming that the enzymatic fluorination reaction is inherently slow and 
this was not a feature unique to the S. cattleya fluorinase. The KM values for SAM 20 
for these three fluorinases were all similar to that for S. cattleya. 
The identification of fluorinases in these organisms opened up the possibility for the 
discovery of new fluorometabolites. The genomes of all three organisms (Figure 6 B, C 
and D) bore homologues to fluorometabolite biosynthetic genes identified in S. cattleya 
(Figure 6 A), suggesting that all three have latent capacity for fluoroacetate 1 and 
4-fluorothreonine 3 biosynthesis. 
 
Figure 6. Fluorometablite biosynthesis gene organisation in A. S. cattlyea,66 B. S. sp. MA37,49 
C. N. brasiliensis67,68 and D. Actinoplanes sp. D69 contain genes for functional fluorinases. 
Gene maps are centred around the fluorinase gene, flA, shown in red. Image reproduced and 
modified with permission from O’Hagan et al.49  
The organisation of the biosynthetic genes within the four species was of interest. In 
S. cattleya, the genes encoding for 4-fluorthreonine transaldolase and 
FDRP isomerase were both located external to the Spencer cluster which contains the 
fluorinase gene. In the genomes of the three new species, these two genes were found 
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clustered near to flA as shown in Figure 6. This further confirmed their involvement in 
the fluorometabolite biosynthetic pathway in S. cattleya and suggested greater 
evolutionary regulation of fluorometabolite biosynthesis in the newly discovered 
organisms.  
The N. brasiliensis strain was successfully cultured but found not to produce detectable 
quantities of fluorometabolites, using 19F NMR spectroscopy.49 This result suggested 
that the fluorometaboilte genes, while present, were not active in the organism. The 
Actinoplanes sp. strain is not publically available and it remains to be determined 
whether the organism has the capacity for fluorometabolite biosynthesis.  
Streptoymyces sp. MA37 was successfully cultured and found to produce 
fluoroacetate 1 and 4-fluorothreonine 3 in culture broths, similar to S. cattleya.49 An 
19F NMR profile of culture broths also revealed the presence of at least seven new, 
unidentified, fluorometabolites. One of these was successfully identified as 
5-fluoro-5-deoxyribonic acid 4 by total synthesis, as discussed in Section 1.1.1.14 
The only remaining fluorometabolite biosynthetic genes in the S. cattleya Spencer 
cluster with known functions are flK, coding for a thioesterase, and flI, coding for a 
S-adenosylhomocysteine (SAH) hydrolase. SAH is a potent inhibitor of the fluorinase, 
and flI is thought to relieve this inhibition.58 The flK protein was hypothesised to confer 
resistance to fluoroacetate 1 to S. cattleya. The 18 kDa enzyme was overexpressed in 
E. coli and found to selectively hydrolyse fluoroacetyl CoA, while showing no activity 
towards acetyl CoA.58 Hydrolysis of fluoroacetyl CoA prevents its entry into the citric 
acid cycle, and the formation of trans-4-hydroxyaconitate, the potent inhibitor of 
aconitase responsible for the toxicity of fluoroacetate 1. Chang et al.70 recently showed 
that hydrolysis of fluoroacetyl CoA proceeds through a ketene intermediate, and that 
the enzyme specifically recognises the fluorine atom of fluoroacetyl CoA. The residues 
in the active site recognise the fluorine atom of a mixed anhydride, orienting the 
substrate for selective abstraction of the pro-R proton by His-76. This fluorine 
recognition mechanism offers an explanation for the selectivity of flK for 
fluoroacetyl CoA over acetyl CoA. 
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1.2. Positron emission tomography (PET) 
Introduction of C–F bonds into organic molecules remains an active area of research,71 
and the fluorinase enzyme offers a complimentary method to accomplish such a 
transformation. In contrast to the many other fluorination methods, the enzymatic 
reaction takes place in water, under mild conditions (neutral pH, ambient temperature). 
As the enzyme utilises fluoride ion as a fluorine source, the methodology is particularly 
applicable to labelling molecules with fluorine-18 for positon emission 
tomography (PET). 
1.2.1. PET for molecular imaging 
Molecular imaging techniques have emerged in the clinic as a means to supplement 
more common structural imaging techniques such as CT (computerised tomography) 
and MRI (magnetic resonance imaging).72 Two of the most widely used molecular 
imaging techniques are SPECT (single photon emission computerised tomography), 
with technicium-99m, and PET (positron emission tomography) with isotopes such as 
fluorine-18 and carbon-11. Molecular imaging provides access to images of dynamic 
metabolic events and has provided new methods to investigate complex biological 
processes. PET has found application predominantly for imaging of cancer and 
neurodegenerative disorders and compliments the anatomical information obtained 
from structural imaging modalities. 
PET imaging makes use of drug-like molecules known as radiotracers that bear 
unstable isotopes that decay through the emission of a positron (β+). The emitted 
positrons undergo annihilation upon meeting their anti-particle, the electron (β–), and 
this process emits two co-linear 511 keV γ-rays, as illustrated in Figure 7. These two 
γ-rays are registered by γ-cameras, usually arranged in a ring around the patient. 
Detection of the annihilation events and processing these to form an image, allows 
localisation of the radiotracer within the body. 
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Figure 7.  Decay of the 11C nucleus and annihilation of a positron (β+) by an electron (β-). The 
γ-photons are detected by the circular ring of gamma cameras. Image used with permission 
from Gee et al. 73 
The most commonly used radioisotopes used for PET, shown below in Table 1, include 
both metals and non-metals. Isotopes such as carbon-11, nitrogen-13 and oxygen-15 
are attractive as PET radioisotopes as they are elements which form the natural 
building blocks of biological molecules. Replacement of stable nuclei in such molecules 
with positron emitting isotopomers offers a route for imaging the distribution of these 
biological molecules within the body. The synthesis of radiotracers containing PET 
radioisotopes is restricted by the nuclear synthetic methods available for the production 
of such isotopes. These methods usually involve a range of accelerator-based 
technologies and provide a limited range of radioactive staring materials, as shown in 
Table 1. 
Table 1. Radioisotopes commonly used in PET imaging applications, their energy of emission and 
their maximum range in water. Table adapted from Frey.74 
Isotope Half-life Form available for synthesis 
Max. energy 
(MeV) 
Max. range 
(mm in H2O) 
11C 20.4 min 
[11C]CH4 
[11C]CO 
[11C]CO2 
0.97 4 
13N 9.97 min [
13N]NOx 
[13N]NH3 
1.20 5 
15O 2.04 min [15O]O2 1.74 8 
18F 109.8 min 
[18F]F2 
[18F]F– 0.64 2 
68Ga 68.1 min [68Ga]Ga3+ 1.90 9 
89Zr 78 h [89Zr]Zr4+ 0.987 - 
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Nitrogen-13 and oxygen-15 have synthetically-limiting half-lives and it is often not 
practical to synthesise complex molecules bearing these isotopes. Their application 
has therefore been mostly limited to simple derivatives such as [15O]H2O and [13N]NH3, 
which have been used for imaging processes such as cerebral75 and myocardial 
blood76 flow respectively.  
The longer half-life of carbon-11 (t1/2 = 20.4 min) allows a greater freedom in the 
synthetic transformations available for incorporation of this isotope into biological or 
drug molecules.73 Incorporation is generally accomplished using one of three 
strategies. The first transforms [11C]CH4 into either [11C]CH3I or [11C]CH3OTf, powerful 
electrophiles for methylation of nucleophilic sites of target molecules.77 These 
electrophiles are also suited for use in metal-catalysed cross couplings, such as 
Suzuki78 or Stille79 couplings. [11C]CO2 can be used directly in Grignard reactions 
where quenching an alkyl or aryl magnesium halide species generates the 
corresponding [11C]carboxylate.80,81 [11C]CO2 can also be reduced to [11C]CO which is 
suited for a variety of metal-catalysed carbonylation reactions, providing access to 
carbonates, amides, ketones, esters and acids.82 
Gallium-68 and zirconium-89 are radiometal-type isotopes used primarily for the 
synthesis of radiolabelled chelates. These agents can also be deployed as biometal 
mimics.83 Zirconium-89 in particular finds increasing application for PET due to its 
extended half-life of 78 hours. Zirconium-89 is employed for radiolabelling large 
molecules which are particularly slow to distribute through the body, requiring several 
hours or days before they reach a representative distribution equilibrium. These large 
molecules include biologics, such as antibodies, and more novel approaches to 
imaging, such as nanoparticles.84,85 
Despite the utility of these other radioisotopes, fluorine-18 remains the most popular 
radionuclide for the majority of clinical applications of PET. Fluorine-18 is particularly 
suitable due to its relatively long half-life (109.8 min) and the low energy of the positon 
emitted by the decaying nucleus (see Table 1).  
The longer half-life of fluorine-18 enables off-site production of isotope or radiotracers, 
as well as their transport to imaging locations. In addition, longer and more complex 
synthetic procedures are available as decay of the isotope is less of a concern than 
with shorter lived isotopes such as carbon-11. The low energy of the positron emitted 
results in the positron having a short mean free path (2 mm) in aqueous biological 
tissue. This mean free path approximates the theoretical maximum resolution of a PET 
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image, and therefore use of nuclides with low energy positrons, such as fluorine-18, is 
often preferred.86 
Although fluorine does not feature in mammalian metabolism, fluorine substitution of 
bioactive molecules has found wide application in PET. The widespread use of 
fluorine-18 has arisen in part due to an understanding of the effects of fluorine 
substitution that has emerged from the field of medicinal chemistry.87 Fluorine 
substitution is often employed during the development process to modify the 
pharmacokinetic and pharmacodynamic properties of candidate drug molecules.88 In 
this setting, fluorine can act as a bioisostere for hydrogen or oxygen.89 Fluorine has a 
van der Waals radius (1.47 Å) in-between those of hydrogen (1.2 Å) and oxygen 
(1.52 Å).90 Fluorine substitution is also employed to reduce metabolic processing at 
specific sites due to the high bond dissociation energy of the C–F bond 
(105.4 kcal.mol−1) compared to other bonds found commonly in organic molecules (e.g. 
98.8 kcal.mol−1 for C–H).90 
Over 90% of clinical PET applications utilise a single [18F]-radiotracer, namely 
2-deoxy-2-[18F]fluoro-D-glucose [18F]-35 ([18F]FDG).91,92 [18F]FDG [18F]-35 has emerged 
as an ubiquitous PET radiotracer as it is an excellent glucose mimic, leading to high 
uptake via GLUT transporters into metabolically active cells.93 Following uptake, 
[18F]FGD [18F]-35 is phosphorylated at C-6 by hexose kinase, illustrated in Scheme 10. 
 
Scheme 10. Phosphorylation of [18F]FDG [18F]-35 by hexokinase leads to trapping of the radiotracer in the 
cell as [18F]-36. 
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However, unlike glucose-6-phosphate, [18F]-36 is not a substrate for the next enzyme in 
the glycolytic pathway (glucose-6-phosphate isomerase) due to the lack of a hydroxyl 
group at C-2. The phosphorylated derivative [18F]-36 remains trapped in the cell, 
allowing for imaging of glucose uptake (Figure 8) as a proxy for metabolic activity, until 
the radioactive nucleus decays.93 
 
Figure 8. Patient with diffuse large B-cell lymphoma imaged with [18F]FDG [18F]-35 A. before treatment 
and B. after treatment. Image used with permission from Mankoff et al.94 
The favourable metabolic profile of [18F]FDG [18F]-35, coupled with large infrastructure 
and research investment into this tracer has led to the monopolisation of FDG [18F]-35 
as the primary radiotracer in the clinic. This situation is changing however, as research 
into new labelling methods and applications of new and old tracers continues to 
emerge, particularly in cases where PET imaging with [18F]FGD [18F]-35 has proved 
inefficient.72  
1.2.2. Sources of 18F for radiotracer synthesis 
Fluorine-18 is available for use in synthetic chemistry in two forms, either as 
[18F]fluoride or [18F]fluorine gas. These two preparations of fluorine-18 can be used to 
introduce fluorine-18 into organic molecules using either nucleophilic or electrophilic 
approaches respectively.  
[18F]Fluorine gas is obtained through the 20Ne(d,α)18F nuclear reaction, where a neon 
target is bombarded with deuterons accelerated in a cyclotron, to release an α-particle 
and a fluorine-18 nucleus.95 As these reactions usually produce only traces 
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(nM or pM amounts) of the radioactive nucleus, [19F]F2 gas is added as a carrier, to 
ensure efficient transfer of [18F]F2 from the production site to the reaction vessel.96 
The necessity of using [19F]F2 as a carrier gas results in dilution of fluorine-18 with 
fluorine-19 in the final product. This ratio is measured as “specific activity”, and tracers 
synthesised using this carrier-added approach have low specific activity 
(1-55 GBq.µmol−1).97 Low specific activity is an undesirable property for clinical tracers, 
as the unlabelled compound, present in larger amounts, competes with its labelled 
analogue for binding to the appropriate receptor, leading to receptor saturation with the 
competitor and increased background uptake of the label. Despite these limitations, 
[18F]F2 is employed for the synthesis of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine 
[18F]-39 ([18F]FDOPA, Scheme 11) using a stannylated precuror,98,99 used for routine 
clinical imaging the dopaminergic pathways. 
 
Scheme 11. Synthesis of [18F]FDOPA [18F]-39 using a fluorodestannylation approach with [18F]F2 gas.97 
[18F]F2 gas is also used for the synthesis of other electrophilic fluorination reagents 
(Figure 9), including [18F]acetyl hypofluorite [18F]-40 and [18F]perchloryl 
fluoride [18F]-41. These reagents suffer from the drawback of being difficult to handle 
due to their high reactivity and produce products with low specific activity. Milder  
N–F based electrophilic fluorination reagents, including [18F]-N-fluoropyridinium 
triflate [18F]-42, [18F]Selectfluor™ bistriflate [18F]-43,100 and [18F]NFSI 
(N-fluorobenzenesulfonimide) [18F]-44101 have been developed to overcome handling 
difficulties, but these too are synthesised from [18F]F2 and share similar drawbacks, 
giving access to 18F-labelled products with low specific activity.102 
 
Figure 9. Electrophilic fluorinating reagents derived from [18F]F2.97 
[18F]Fluoride is most commonly produced by the 18O(p,n)18F nuclear reaction, where a 
metallic target containing [18O]H2O is bombarded with protons accelerated using a 
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cyclotron.73 This process generates a dilute solution of [18F]fluoride in [18O]H2O. Under 
these conditions, [18F]fluoride is strongly hydrated, and requires drying before use as a 
nucleophile.103 
The most common method for the preparation and activation of [18F]fluoride ion 
involves passing the dilute [18F]fluoride solution though a quaternary ammonium resin, 
which traps [18F]fluoride ion, separating it from adventitious metal ions that are 
produced during target bombardment. This procedure also allows for the recovery and 
recycling of [18O]H2O, if required. [18F]Fluoride is eluted from the anion exchange 
column using an aqueous solution of potassium carbonate containing Kryptofix 222, an 
aminopolyether cryptand with high affinity for potassium ions. The addition of 
Kryptofix 222 serves to complex potassium ions, leaving charge separated [18F]fluoride 
ion with increased nucleophilicity. Water is then removed by azeotropic distillation 
under a stream of inert gas, following the addition of anhydrous acetonitrile. This 
azeotropic drying procedure is repeated two or three times, as required by the synthetic 
procedure. The drying procedure provides a potassium-kryptofix 222 salt of the fluoride 
ion, [K•Kryptofix222][18F]F [18F]-45, as illustrated in Scheme 12.  
Most infrastructure surrounding the generation of PET radiotracers is geared towards 
the delivery of [18F]fluoride for the preparation of [18F]FDG [18F]-35. [18F]FDG [18F]-35 is 
synthesised by nucleophilic substitution of the corresponding protected mannosyl 
triflate derivative 46 by [18F]fluoride complex [18F]-45 (Scheme 12). As [18F]FDG 
[18F]-35 remains the most commonly used radiotracer, most research into new 
methodologies for the synthesis of PET radiotracers utilises [18F]fluoride as the source 
of the radioactive isotope. 
 
Scheme 12. Preparation of [18F]fluoride ion as the potassium-kryptofix 222 salt [18F]-45, where m<n, and 
reaction with a protected mannose triflate 46, which after protecting group cleavage gives 
[18F]FDG [18F]-35.103,104  
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1.2.3. Synthesis of 18F-bearing radiotracers by nucleophilic substitution 
The widespread availability of nucleophilic [18F]fluoride ion has meant that most 
radiolabelling methodology employs this source of isotope as a means to label 
appropriate tracers. The most common approaches for radiolabelling with [18F]fluoride 
can be divided into those using SN2 reactions and those using SNAr reactions. More 
recently, a number of novel approaches using heavy atom carriers or heavy atom 
catalysis have also been developed.103 
Aliphatic substrates with appropriate leaving groups, including sulfonate esters, 
bromide, iodide and cyclic precursors have been successfully employed as methods for 
introduction of fluorine-18 into molecules. Reactions work best with leaving groups at 
primary centres, as competing elimination reactions lower yields on substitutions 
performed at secondary centres.102 This method generally uses polar aprotic solvents, 
including acetonitrile, DMSO or DMF and involves heating of the appropriate precursor 
in the solvent with the prepared [18F]fluoride salt [18F]-45 and a non-nucleophilic 
base.105 The desire for reduced synthesis times means that such reactions are heated 
strongly so that synthetic reactions are complete within minutes. 
[18F]FDG [18F]-35 is synthesised using this approach, as shown in Scheme 12. Other 
commonly used tracers synthesised in this manner include 
3'-deoxy-3'-[18F]fluorothymidine [18F]-48 ([18F]-FLT)106 and [18F]fluoroacetate [18F]-1,107 
as illustrated in Scheme 13. In some cases, addition of small amounts of protic 
solvents (such as tBuOH) to such reactions leads to higher incorporation and 
radiochemical yields (RCY).108,109 Protic solvents are thought to both increase the 
nucleophilicity of [18F]fluoride and promote the departure of the leaving group through 
hydrogen bonding interactions.110  
 
Scheme 13. SN2 reactions for the synthesis of radiotracers including A. [18F]FLT [18F]-48106 and 
B. [18F]fluoroacetate [18F]-1.107 DMTr = dimethoxytrityl. 
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Substitutions on aromatic rings97 through SNAr reactions are confined to substrates 
bearing a good leaving group (such as –N+Me3, –F, –Cl, –Br, –OTf, –OMs and  
–NO2),105 and an electron withdrawing substituent ortho or para to the leaving group. 
The reaction conditions for these substitutions are similar to those employed for SN2 
reactions, using high temperatures (120–180 °C) and polar aprotic solvents. These 
conditions have proved successful for the synthesis of many tracers, including 
[18F]haloperidol [18F]-51 in Scheme 14, a brain imaging agent.111,112 
 
Scheme 14. Synthesis of [18F]haloperodol [18F]-51112 using an SNAr approach. 
1.2.4. Late-stage fluorinations for PET 
In addition to these common modes of reactivity for the introduction of fluorine-18, 
metal-catalysed fluorinations have recently emerged as an alternative to the harsh 
conditions usually employed in the reactions described above. Metal-catalysed 
reactions tend to offer milder reaction conditions and high selectivity.113,114 
Substitution of electron rich arenes is challenging, and fluorination of such motifs was 
previously accessible through the use of electrophilic fluorinating reagents such as 
[18F]F2. Oxidative [18F]-fluorination of electron rich phenols has been reported,115 but a 
more common and versatile approach utilises unsymmetrically substituted diaryl 
iodonium salts.116 Unsymmetrical 2-thienyl aryl iodonium salts favour substitution at the 
less electron rich aryl ring, provided no ortho-substituent is present, giving access to 
electron rich [18F]fluorinated aromatics using more accessible and easier to handle 
[18F]fluoride as the source of radioactivity.117 Peroxisome proliferator-activated 
receptor-γ (PPARγ) ligands, such as [18F]-53 in Scheme 15 A, for investigating lipid 
metabolism in metastatic cancers, has been synthesised using a 2-thienyl aryl 
iodonium precursor 52.118 2-Thienyl aryl iodinium salts suffer from moderate selectivity 
and poor tolerance to functional groups and mixtures of products are sometimes 
observed.113 Spirocyclic 119 or Meldrum’s acid 120 derived iodonium ylides, 54 and 56 
respectively, shown in Scheme 15 B and C, offer increased precursor stability while 
retaining reactivity towards [18F]fluoride. 
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Scheme 15. SNAr reactions for the synthesis of A. [18F]-53 using the diaryliodonium approach,118 
B. [18F]-55 using the Meldrum’s acid iodonium ylide approach,120 and C. [18F]-57 using the 
spirocyclic iodonium ylide approach.119 
Ritter et al.121 have developed a palladium catalysed electrophilic fluorination 
methodology that uses [18F]fluoride as a source of radioactivity, as shown in Scheme 
16 A. High-valent palladium(IV) complex 58 has the ability to sequester azeotropically-
dried [18F]fluoride from an acetone solution to generate an electrophilic complex [18F]-
59. This electrophilic palladium(IV) [18F]fluoride complex [18F]-59 transfers the fluorine-
18 centre to a nucleophilic aryl palladium(II) complex 60 through a series of single 
electron transfer events to generate an aryl [18F]fluoride palladium(IV) species. This 
palladium(IV) intermediate undergoes reductive elimination to give [18F]-labelled 
arenes, such as [18F]-61, in high radiochemical yield.122 This method requires 
azeotropically dried sources of [18F]fluoride, as the palladium(IV) [18F]fluoride complex 
[18F]-59 is sensitive to traces of air and moisture. 
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Scheme 16. A. High valent palladium(IV) complex 58 sequesters [18F]fluoride from solution, and reacts 
with nucleophilic Pd(II) complex 60, effectively acting as a source of electrophilic 
fluorine-18.121 B. Oxidative nickel-catalysed fluorination of arenes that does not require 
stringently dry conditions.123 
To circumvent this air and moisture sensitivity, Ritter and Hooker et al.123 developed an 
analogous Ni(II)-based oxidative 18F-fluorination of arenes and alkenes utilising pre-
prepared nickel complexes of the arene/alkene as shown in Scheme 16 B. Addition of 
aqueous [18F]fluoride to a solution of Ni(II) complex 62 and oxidant 63 in acetonitrile at 
room temperature generated the corresponding aryl [18F]fluoride [18F]-64 rapidly and in 
high radiochemical yields. This procedure utilises aqueous [18F]fluoride, without the 
need for exhaustive pre-drying and securing as the potassium-kyrptofix-222 salt, 
offering a mild and selective route to radiolabelled arenes and alkenes. 
Gouverneur et al.124 have reported an allylic 18F-fluorination of cinnamyl methyl 
carbonates, such as 66, using Pd(dba)2 as catalyst (Scheme 17 A), in combination 
with tetrabutylammonium [18F]fluoride in acetonitrile. In addition to carbamates, other 
leaving groups, including bromide and chloride were tolerated in this substitution 
reaction. The halides however required more forcing conditions (110 °C) to give good 
radiochemical yields. Similarly, Nguyen et al.125 reported 18F-fluorination of secondary 
and tertiary allyl trichloroacetimidates such as 68 using (Ir(COD)Cl)2 as a catalyst and 
potassium-kryptofix [18F]fluoride as fluoride source, to give access to branched allyl 
[18F]fluorides, such as [18F]-69 shown in Scheme 17 B. Using the same iridium catalyst, 
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Gouverneur et al.126 reported the transformation of linear and substituted cis and trans 
allyl carbonates to their analogous allyl [18F]fluorides, with good retention of double 
bond geometry (Scheme 17 C). Allyl fluorides, such as [18F]-71 are not common motifs 
in drug molecules, however they could provide access to useful [18F]fluorinated building 
blocks.114 
 
Scheme 17. A. 18F-Fluorination of cinnamyl carbonates under Pd(II) catalysis.124 B. Reaction of allyl 
trichloroacetimidates to give allyl [18F]fluorides under iridium catalysis.125 C. Extension of 
iridium catalysis for 18F-fluorination of allyl carbonates, with good control of alkene 
geometry.126 
The first enantioselective synthesis of a C–18F bond was reported by Doyle et al.127 
who utilised a Co(salen)-mediated opening of racemic epoxides to generate 
enantioenriched [18F]fluorohydrins, such as [18F]-73. The [18F]fluoro-Co(salen) complex 
is generated by elution of [18F]fluoride from a quaternary ammonium resin with a 
solution of Co(salen)OTs pre-catalyst. The catalyst is added to the racemic epoxide in 
methyl t-butyl ether (MTBE) at 50 °C to generate fluorohydrins in greater than 95% 
enantiomeric access (ee), as shown in Scheme 18 A. The use of a dimeric Co(salen) 
species allowed fluorination of substrates that are Lewis basic, which had been 
challenging using the mononuclear cobalt complexes. This procedure was used for the 
synthesis of a number of validated radiotracers, including [18F]FMISO [18F]-73, used for 
imaging and detection of hypoxia.128 
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Scheme 18. A. Stereoselective epoxide opening using a [18F](salen)CoF complex, generated from 
[18F]fluoride.127 B. Synthesis of an ibuprofen [18F]-analogue [18F]-75, using a Mn-catalysed  
C–H activation approach.129 
Using a similar Mn(salen) complex, Hooker and Groves et al.129 have demonstrated a 
radical C–H activation approach to 18F-fluorination at substituted benzylic positions, as 
illustrated in Scheme 18 B. This methodology is attractive as it does not require 
pre-functionalisation of substrates, but the substrate scope remains limited. The 
reaction proceeds through the generation of Mn(III)(salen) [18F]fluoride, which is 
oxidised by iodosylbenzene to generate a Mn(V)(salen) [18F]fluoride complex. This 
complex is reduced by hydrogen abstraction from the benzylic substrate to give 
Mn(IV)(salen) [18F]fluoride and a benzylic radical. Radical transfer of the radioligand to 
the benzylic substrate generates a radiolabelled product and reforms the catalyst. The 
utility of this approach was demonstrated by synthesis of a number of fluorinated 
analogues of common drugs, including ibuprofen methyl ester 74, cinnacalcet, and 
celecoxib. 
Copper catalysis has found widespread application for the synthesis of [18F]-bearing 
radiotracers. Copper catalysis has been used for the direct synthesis of aryl fluorides 
from boronic esters130 and iodonium salts.131 Gouverneur et al.130 have shown that a 
range of electron rich, neutral and deficient (hetero)aryl pinacol boronic esters are 
efficiently fluorinated using potassium-kryptofix [18F]fluoride and [Cu(OTf)2(py)4]. The 
utility of this approach was illustrated by preparation of [18F]FDOPA [18F]-39, a 
neuroimaging agent, as shown in Scheme 19 A. 
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Scheme 19. A. Copper-catalysed 18F-fluorination of boronic acids using [18F]fluoride.130 B. Copper 
catalysis also proves useful for the 18F-fluorination of mesityl aryl iodonium salts.131 
Scott and Sanford et al.131 have illustrated a similar reaction using mesityl aryl iodonium 
salts and the copper (I) catalyst (MeCN)4CuOTf. In contrast to the previously described 
2-thienyl iodonium salt approach, the copper(I)-mediated protocol offers high selectivity 
and radiochemical yield, with the added advantage of proceeding at lower 
temperatures (85°C vs 150 °C). The authors showed that this method had similar 
substrate scope to the boronic ester method reported by Gouverneur et al.,130 and also 
illustrated its utility by applying the approach to the synthesis of a protected 
[18F]FDOPA [18F]-78, as shown in Scheme 19 B. 
Copper (I) salts of the trifluoromethyl anion ([Cu]CF3) have emerged as powerful 
reagents for the introduction of [18F]-labelled trifluoromethyl groups onto arenes. These 
reactions are predicated on the generation of difluorocarbene 80 from an appropriate 
precursor, which is then intercepted by [18F]fluoride to generate [18F]CF3– anion 
[18F]-81, stabilised by a Cu(I) counterion. Gouverneur et al.132 have reported the 
synthesis of a reagent for iodoarene [18F]trifluoromethylation. Their method uses a 
methyl chlorodifluoroacetate 79, which decomposes to difluorocarbene 80 which is 
intercepted by a TMEDA complex of Cu(I)I (Scheme 20 A) to generate the active 
[Cu][18F]CF3 [18F]-81 reagent. Riss et al.133 have reported a similar 
[18F]trifluoromethylation of iodoarenes using difluoromethyl iodide 84 in the presence of 
bicarbonate, diisopropylethylamine and copper (I) bromide to accomplish a similar 
transformation, as illustrated in Scheme 20 B. 
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Scheme 20. A. Generation of difluorocarbene 80 under copper catalysis, and trapping by [18F]fluoride to 
generate Cu[18F]CF3 [18F]-81,132 which reacts efficiently with aryl iodides to give aryl 
[18F]trifluoromethyl compounds, such as [18F]-83. B. Similarly, difluoroiodomethane 84 can be 
used as a source of difluorocarbene 80.133 
Alternatively, [18F]trifluoromethyl anion can be synthesised directly from [18F]CF3H 
[18F]-88. Labar and Jubault et al.134 have reported the use of a dimethylsulfonium tetra-
arylborate 87 as an efficient source of in situ [18F]trifluoromethane [18F]-88, upon 
treatment with potassium-kryptofix [18F]fluoride, as shown in Scheme 21 A. 
[18F]Trifluoromethane [18F]-88 is deprotonated by the addition of a potassium cuprate 
salt to generate [18F][Cu]CF3 [18F]-81 directly, rather than through the generation of 
difluorocarbene. Reaction of [18F][Cu]CF3 [18F]-81 with either aryl iodides or boronic 
esters generated the corresponding [18F]trifluoromethylated products. Vugts et al.135 
have reported the use of difluoromethyl iodide 84 to generate [18F]trifluoromethane 
[18F]-88 in situ, as shown in Scheme 21 B. Under the action of a copper (I) salt, base 
and 3HF.Et3N, [18F]trifluoromethane [18F]-88 generates [18F][Cu]CF3 [18F]-81 with high 
specific activity, which they showed reacts with aryliodides and arylboronic acids to 
give [18F]trifluoromethylarenes. 136 
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Scheme 21. Generation of [18F]trifluoromethane [18F]-88 from A. sulfonium salt 87134 and 
B. difluoroiodomethane 84 to generate Cu[18F]CF3 [18F]-81, which reacts with aryl iodides 
and aryl boronic acids.135 
Most recently, silver(I) catalysis has been employed to extend the scope of 
[18F]trifluoromethylation beyond that of simple aryl substrates to aryl [18F]trifluoromethyl 
ethers, [18F]trifluorothiomethyl ethers, and aryl [18F]difluoromethyl ethers as shown in 
Scheme 22.137 The corresponding alkyl halides 94, 96 and 98 were found to react with 
silver(I) triflate and potassium-kryptofix [18F]fluoride in dichloromethane or 
dichloroethane to give radiolabelled products in moderate to good radiochemical yields. 
This approach compliments a previously reported procedure where difluoroenol ethers 
were utilised as electrophilic traps for [18F]fluoride, generating aryl [18F]trifluoroeethyl 
ethers.138–140 
 
Scheme 22. A. Synthesis of fluorinated aryl [18F]trifluoromethyl ethers and thioethers under silver (I) 
catalysis. B. Difluoroenol ethers as electrophilic traps for [18F]fluoride ion also generate 
[18F]trifluoroethyl ethers.137 
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Clearly, metal catalysis will continue to play an innovative role in [18F]fluorinations, as 
many reactions, including the generation of simple alkyl [18F]fluorides by such mild and 
selective processes, remain to be discovered. 
1.3. Protein and peptide labelling strategies for PET 
1.3.1. Prosthetic groups 
Labelling of large peptides with PET isotopes has attracted increasing attention as this 
technique allows imaging of protein or peptides and their targets in the body.141 
Labelling of such molecules for PET allows more rapid development and better 
understanding of a new generation of diagnostic and therapeutic agents.142 
Biomolecules are attractive labelling targets compared to small molecules as they tend 
to higher specificty for receptors. Better radioligands lead to increased image quality 
and reduced background uptake, both desirable qualities for PET imaging. PET 
labelling with 18F is especially suited for biomolecule labelling as it offers higher 
sensitivity and lower radiation dose compared to SPECT or CT.142 
The 18F-labelling methods discussed in the previous sections generally make use of 
organic solvents, heating and strongly acidic or basic reaction conditions to incorporate 
[18F]fluoride. While small molecules are usually tolerant to such conditions, direct 
labelling of biomolecules requires milder conditions, such as lower temperatures, 
aqueous solvents and neutral pH conditions, all in an effort to maintain the structural 
integrity of the biomolecule. 
A two-step “prosthetic group” approach is most commonly used for labelling 
biomolecules. A prosthetic group is a bifunctional molecule, such as [18F]SFB [18F]-103 
shown in Scheme 23. One site bears the fluorine-18 atom, while the second, in this 
case an N-hydroxysuccinimide activated ester, is available for coupling to a 
biomolecule of interest. Fluorine-18 labelling of the prosthetic group (102 to [18F]-103) 
is accomplished using one of the radiolabelling methods described above, before the 
18F-labelled tag is conjugated to the biomolecule. This second step is usually carried 
out in water or buffer to ensure stability and structural integrity of the biomolecule. 
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Scheme 23. Prosthetic group approach for labelling peptide 104 with fluorine-18, using [18F]SFB [18F]-103. 
Labelling strategies can either use reactive groups naturally present in a peptide, most 
often free amines or thiols, or alternatively, biomolecules can be chemically or 
biologically modified to introduce biorthogonal reactive sites.141 Free thiols are usually 
conjugated to maleimides or sulfides, while amines are conjugated to activated esters 
or acids. 
Amine bioconjugation strategies target the N-terminus or amines of lysine residues in 
peptides or proteins. An abundance of free amine residues can affect the homogeneity 
of the product, as labelling may occur at multiple sites. This can be advantageous as it 
increases the likelihood of successful labelling.142  
The two best characterised amine-reactive prosthetic groups are 
N-succinimydyl-4-[18F]fluorobenzoate [18F]-103 ([18F]SFB)135 and p-nitrophenyl 
2-[18F]fluoropropionate [18F]-106 ([18F]NFP).145 [18F]NFP [18F]-106 has been used for 
labelling of integrin-targeting cyclic RGD peptides for imaging of angiogenesis in 
cancers.145 [18F]SFB [18F]-103 has been used for labelling many proteins and 
peptides,146,147 including antibody fragments to image colorectal cancer in xenograft 
tumour mice.148 
 
Figure 10. Amine-reactive prosthetic groups for 18F-labelling of peptides and protein. 
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To overcome problems with selectivity and the difficulty in preparing these activated 
esters, the acid derivatives p-[18F]fluorobenzoic acid [18F]-107 ([18F]FBA)149 and 
2-[18F]fluoropropionic acid [18F]-108 ([18F]FPA),150 have been developed. These two 
reagents have been used for automated solid phase synthesis of radiolabelled 
peptides. [18F]FPA [18F]-108 offers advantages over [18F]FBA [18F]-107 as it does not 
significantly alter the lipophilicity of peptides.151 
Amine groups on peptides and proteins can also be modified to contain more reactive 
groups such as hydrazines 109 or hydroxylamines 112, as shown in Scheme 24. 
These two functional groups react rapidly and selectively with aldehydes, such as 
p-[18F]fluorobenzaldehyde [18F]-110 ([18F]FBAld),142 to give radiolabelled hydrazones152 
[18F]-111 or oximes153 [18F]-113 respectively. 
 
Scheme 24. Coupling of amines to groups containing either A. hydrazine 109 or B. hydroxylamine 112 
react with labelled aldehydes to give hydrazone [18F]-111 or oxime [18F]-13 labelled peptides. 
Thiols have also been used extensively for conjugate addition with maleimides.73,141 
This approach has the advantage of being highly selective, as maleimides react only 
with thiols at physiological pH, as illustrated in Scheme 25. In addition, most proteins 
and peptides bear one or two free cysteine residues, and multiple labelling events are 
rarely observed.154 
Maleimide prosthetic groups (Scheme 25) have been prepared by reaction of a 
maleimide with [18F]FBAld [18F]-110, [18F]FBA [18F]-107,155 or [18F]FDG [18F]-35 to give 
[18F]-116 to [18F]-118.156 The maleimide functionality can also be introduced after 
[18F]fluorination, as in the case for [18F]-119.157 
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Scheme 25. Maleimide derivatives used for protein and peptide labelling. 
The benzenethiosulfonate [18F]FDG conjugate [18F]-121 is a useful reagent for labelling 
thiols on proteins.158 Thiosulfonate [18F]-121 is prepared from a protected [18F]FDG 
[18F]-35 and is accessible by routine automated synthesis. This reagent reacts with 
thiols such as 120 as shown in Scheme 26, to give disulfide [18F]-122 to provide 
access to radiolabelled peptides. 
 
Scheme 26. Reaction of thiols with [18F]FDG derivatives to give 18F-radiolabelled disulfide [18F]-122. 
The Cu-catalysed and strain-promoted variants of the Huisgen 1,3-dipolar cycloaddition 
between alkynes and azides have emerged as powerful tools for PET 
radiochemistry.159 The reactions proceed rapidly in water and are chemoselective. The 
reactions give access to triazoles which are stable under physiological conditions.141 
These features are desirable for PET radiolabelling reactions where biomolecules need 
to be rapidly and selectively labelled with short-lived radioisotopes under mild 
conditions. 
The general strategy for labelling of proteins or peptides using copper-catalysed 
alkyne-azide coupling (CuAAC) involves the synthesis of a small, minimally 
functionalised alkyne- or azide-bearing [18F]-labelled prosthetic group, which is then 
coupled to a pre-functionalised protein or peptide. This strategy avoids the sometimes 
lengthy radiochemical synthesis of more complex prosthetic groups (such as the 
maleimides or N-hydroxysuccinimides described above). 
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The first application of the CuAAC reaction for 18F-radiolabelling involved the reaction 
between ω-[18F]fluoroalkynes, such as [18F]-124 with peptides, functionalised at the 
N-terminus with an azide, as shown in Scheme 27 A.160 Alkyne [18F]-124 was 
synthesised by SN2 methods, similar to those described above. Primary alkyl 
[18F]fluorides usually suffer from poor in vivo stability, and azide-labelled 
[18F]fluorobenzenes have been utilised to circumvent this problem.161 
 
Scheme 27. ‘Click’ chemistry for PET labelling, showing the two possible modes of reaction: A. A peptide 
bearing azide 123 and B. a peptide bearing alkyne 126. 
N-Terminal propargylglycinic peptides, such as 126, have been reacted with 
18F-labelled azides, reversing the reactivity, to generate 18F-labelled peptides such as 
[18F]-128, as shown in Scheme 27 B, in a similar Cu(I)-based protocol.162 Based on this 
strategy, a glycosylation approach was reported using an azido-[18F]FDG prosthetic 
group [18F]-127, as glycosylation of proteins and peptides had been shown to improve 
pharmacokinetic properties.163 This approach was used to label a variety of peptides 
and the triazole products of these reactions, such as [18F]-128 in Scheme 27, were 
found to be stable and effective imaging agents in vivo.162 
The use of copper salts to catalyse the CuAAC reaction had led to difficulties in 
translating this methodology into the clinic. Copper salts show toxicity even at low 
levels,164 and ensuring complete copper removal from radiolabelled products has 
proved challenging.165 The utility of this reaction for live cell labelling and the desire for 
a biocompatible reaction, led to the development of copper-free, strain-promoted 
variant of the (3+2) cycloadditon by Bertozzi et al.166,167 The reaction takes advantage 
of the strain energy of cyclooctynes (19.9 kcal.mol–1),168 which promotes their 
cycloaddition to azides to give fused triazoles, as a mixture of regioisomers. Shortly 
after the reaction was reported, variants using both [18F]-labelled cyclooctynes with 
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azides169 and [18F]-labelled azides with cyclooctynes165 were reported. This reaction 
had been applied to 18F-labelling of aza-dibenzocyclooctyne (ADIBO)170 labelled 
peptides including the lysine-modified bombesin 129 shown in Scheme 28, where a 
strain-prompted cycloaddition with p-[18F]fluorobenzyl azide [18F]-130 gave 
radiolabelled peptide [18F]-131.171 A number of peptides synthesised using this 
methodology have since been assessed in small animal models.172,173 
 
Scheme 28. Strain-promoted alkyne-azide cycloaddition to generate 18F-labelled bombesin analogue 
[18F]-131. 
Further exploration of copper free bioconjugations for PET led to inverse electron 
demand Diels Alder reactions between tetrazines and trans cyclooctenes,174 
norbornenes,175 or cyclooctynes176 as reactions suitable for rapid PET labelling. 
Generally, a low concentration of one reaction partner, such as an 18F-labelled 
prosthetic group, leads to long reaction times for complete conversion. Using reactions 
which show remarkably fast kinetics allows such reactions to proceed to completion, 
even when the concentration of one of the reaction partners is extremely low. The 
reaction of trans-cyclooctenes is an order of magnitude faster (k2 > 2000 M–1.s–1)174 
than similar reaction with other alkenes due to the release of the large strain energy 
(17.9 kcal.mol–1)168 in the trans-cyclooctene system. This rapid reaction is especially 
suited to PET labelling as the concentration of the reaction partner bearing the fluorine-
18 radiolabel is very low. 
The first PET imaging experiments using this tetrazine/trans-cyclooctene (TCO) 
approach were reported by Fox et. al.177,178 When heated or treated with strong bases, 
the tetrazines proved unstable to radiolabelling with fluorine-18, giving only 1% 
radiochemical yield. In response, they developed a synthesis of [18F]TCO [18F]-136, a 
radiolabelled trans-cyclooctene, in 71% radiochemical yield, which reacted efficiently 
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with tetrazine-conjugated RGD peptide 135, as illustrated in Scheme 29. This gave 
radiolabelled RGD-peptide [18F]-137 as a mixture of regioisomers in 90% radiochemical 
yield, in only 5 minutes. 
 
Scheme 29. Radiolabelling of an RGD peptide by conjugation to a tetrazine prosthetic group to give 135, 
which reacts rapidly with [18F]-TCO [18F]-136 to give peptide [18F]-137. 
The rapid kinetics of this ligation makes it attractive as a PET labelling protocol for 
peptides for small animal imaging using traditional nucleophilic fluorination 
chemistry.179 Neither of the reaction partners are naturally present in biological systems 
and there is interest in using this methodology for pre-targeted PET imaging.87 
Pre-targeting would involve prior administration of a biomolecule (such as an antibody) 
bearing either a tetrazine or trans-cyclooctene, allowing distribution through the body 
hours or days, before the radiolabelled coupling partner is administered. The two 
coupling partners would react in vivo, and allow PET imaging of the localised 
biomolecule of interest.180 Physiologically stable tetrazines have been developed,181 
and the first in vivo antibody-fragment labelling experiments with 18F-labelled tetrazine-
containing dextrans, has recently been reported.182  
1.3.2. “Last step” radiolabelling of peptides 
All of the above prosthetic group approaches for fluorine-18 labelling rely upon a 
fluorination event on a small molecule, which is then subsequently coupled to a 
biomolecule. “Last step” fluorination protocols of peptides are less well developed due 
to the incompatibility of peptides with non-aqueous solvents and heating, conditions 
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which are usually required to carry out nucleophilic [18F]fluoride chemistry. In addition, 
such peptides bear multiple functional groups, which would lead to side reactions and 
lower yields if such reactions were employed.  
Last step fluorination protocols are, however, desirable in PET radiochemistry due to 
the short half-life of fluorine-18. Such protocols reduce handling time and the number of 
purification steps required. The main challenge for “last step” radiolabeling is need for 
reactions to be carried out in aqueous, biocompatible solvents, however, the strong 
hydration of fluoride ion severely reduces its nucleophilicity in these solvents. 
Small peptides, such as p-trimethylammonium amide 138,183 aziridine-bearing 140,184 
and p-nitroamide 142185 in Scheme 30 have been labelled in a single step from 
[18F]fluoride. These methods use [18F]fluoride which is azeotropically dried in the 
presence of Kryptofix 222, and the peptides heated in organic solvents to accomplish 
[18F]fluorination. The use of these harsh conditions is similar to those used for labelling 
prosthetic groups, and precludes use of similar methodology for labelling larger, more 
sensitive biomolecules. 
 
Scheme 30. Direct labelling of peptides under standard nucleophilic conditions using 
A. trimethylammonium-138,183 B. aziridine-140184 and C. nitro-142 precursors.185 
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The desire for last step labelling strategies has led to the development of inorganic 
species, including boron,186 silicon187 and aluminium-derived188 complexes which have 
high affinity for fluoride ion and have the ability to sequester fluoride from the solvent. 
Silicon fluorides are well characterised species, and the strength of the Si–F bond has 
been exploited for silicon-based protecting group chemistry. Schirrmacher et al.187 have 
developed a fluorine isotope exchange reaction at silicon (SiFA) in DMSO at room 
temperature (Scheme 31 A) as a means of radiolabeling biological molecules, such as 
144, in a single step.189–191 While this method proves operationally simple, the isotopic 
dilution inherent to the process lowers specific activity of the final 18F-labelled products. 
While suitable for rapidly labeling peptides, the isotope exchange reaction requires dry 
[18F]fluoride and the reaction is performed in DMSO, and thus not compatible with 
biomolecules that are not stable in organic solvents. 
 
Scheme 31. “Last step” peptide labelling strategies using [18F]fluoride. A. SiFA (silicon-based fluoride 
acceptor) direct labelling approach using isotope exchange of 19F for 18F in DMSO.187 
B. Borate ester based labelling strategy gives [18F]-trifluoroborate-labelled products under 
carrier added conditions at pH 2.192 C. Aluminium 1,4,7-triazacyclononane-1,4-diacetate 
(NODA) complex labelling of linear peptides at high temperatures in water. HSG = histamine-
glycinyl-serine.193 
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Perrin et al.192 have developed a last-step labelling strategy based on the formation of a 
B–F bond under aqueous conditions. The method uses acid-catalyzed fluorolysis of a 
diaryl boronate ester 145 by potassium bifluoride/potassium [18F]fluoride solution in 
water at pH 2, generating a [18F]trifluoroborate species such as [18F]-146. The resultant 
[18F]trifluoroborates were found to be stable in vivo and did not eliminate [18F]fluoride 
ion.194 This labelling methodology was subsequently used for last step labelling of a 
RGD peptide with fluorine-18, as illustrated in Scheme 31 B.195 While labelling is 
efficient, the method is not suitable for use with acid sensitive biomolecules. 
Goldenberg et al.193 have developed a fluoride-capture strategy using pre-formed 
aluminium hydroxide NODA- or NOTA-chelates, such as 147 shown in Scheme 
31 C.196 When reacted with [18F]fluoride in an ethanol/saline mixture and heated to 
100 °C, these complexes sequester fluoride ion to give the [18F]fluoro complex [18F]-
148 in good radiochemical yields.197 This methodology has been transferred to kit form 
for ease of use,198 and a 18F-labelled dimeric RGD peptide synthesised using this 
protocol has been investigated in human patients for imaging of angiogenesis 
associated with lung cancer.199  
1.4. Fluorinase and PET 
The direct aryl labelling at carbon and SiFA exchange process both require the use of 
azeotropically dried [18F]fluoride ion and are consequently not compatible with aqueous 
reaction conditions. [18F]Fluoride capture by boronic esters or aluminium chelates are 
also not suitable, as they use low pH and high temperature labelling conditions 
respectively for efficient labelling. 
In this context, the fluorinase enzyme and its ability to catalyse C–F bond formation 
under mild aqueous conditions is immediately attractive for synthesis of either 
prosthetic groups or direct labelling of biomolecules for PET. The fluorinase reaction 
takes place at 37 °C in aqueous buffer at near neutral pH, ideal conditions for carrying 
out 18F-fluorinations of sensitive biomolecules. 
There is precedent for the application of enzymes for PET radiotracer synthesis for 
nitrogen-13-,200,201 carbon-11-202–206 and fluorine-18-based207 tracers. Two examples 
where enzymatic syntheses of radiotracers had advantages over chemical syntheses 
are discussed below. 
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Daunorubicin 151 (Scheme 32 A) is a potent anti-cancer agent, derived enzymatically 
from carubicin 150, its desmethyl analogue. O-Methylation of carubicin 150 with 
[11C]methyl iodide gave many radiolabelled products, but not 
[11C]daunorubicin [11C]-151. Carubicin 150 bears four hydroxyl groups and a primary 
amine, all reactive towards methylation by [11C]MeI. As an alternative approach, SAM 
synthetase was used to synthesise S-adenosyl-L-[11C]methionine [11C]-20 ([11C]SAM) 
from L-[11C]methionine [11C]-21 and ATP 149.206 The enzymatically synthesised 
[11C]SAM [11C]-20 was used for O-[11C]methylation of carubicin 150 under the action of 
carubicin O-methyl transferase to give [11C]daunorubicin [11C]-151 in good yield. In this 
case, enzymatic control of regiochemistry gave access to the desired compound 
through a biomimetic approach, without resorting to complex protecting group 
chemistry. 
 
Scheme 32.  Enzymatic synthesis of A. [11C]daunorubicin [11C]-151206 and B. [18F]-FDOPA [18F]-39207 for 
use as PET tracers. 
In addition to the regioselectivity of enzymes, their stereoselectivity has also been 
exploited for the synthesis of radiotracers. [18F]FDOPA [18F]-39 (Scheme 32 B), an 
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imaging agent for neurodegenerative disorders, has also been synthesised 
enzymatically using β-tyrosinase.207 Catechol [18F]-154 was prepared chemically, using 
an SNAr reaction with [18F]fluoride in a the key step. The catechol [18F]-154 was reacted 
with an ammonium salt and α-ketoglutarate under the action of β-tyrosinase to give 
[18F]FDOPA [18F]-39. This methodology allowed for the synthesis of [18F]-39 from 
[18F]fluoride rather than [18F]F2, offering higher specific activities and better control of 
regioselectivity compared to electrophilic fluorination routes. In addition, the enzymatic 
transformation allows complete control of the stereochemistry of the product, which had 
proved difficult with previous syntheses. 
1.4.1. Applying the fluorinase to PET 
After discovery of the fluorinase in 2002, it was immediately attractive to explore 
application of the enzyme for the synthesis of PET radiotracers. Initial incubations of 
partially purified fluorinase fractions from S. cattleya with [18F]fluoride and SAM 20 at 
40 °C led to the production of 5'-[18F]fluoro-5'-deoxyadenosine [18F]-22 ([18F]FDA), 
shown in Scheme 33. Conversions for this enzymatic transformation were very low 
(approx. 1%) and the synthesis took approximately 5 hours, conditions not suitable for 
synthesis of PET radiotracers. The observation that the enzyme-catalysed reaction was 
reversible51 led to coupling of the fluorinase reaction to a second enzyme, an L-amino 
acid oxidase, driving the reaction in the forward direction. Under similar radiolabelling 
conditions to those previously reported, but with the addition of an L-amino acid 
oxidase, the reaction proceeded to greater than 90% conversion to [18F]-22 within 2 
hours, when high enzyme concentrations (24 mg.mL–1) were utilised.208 
 
Scheme 33. Synthesis of C–18F bonds using the fluorinase coupled to an L-amino acid oxidase. Coupling 
the transformation to other enzymes gives access to novel potential radiotracers. 
49 
 
High conversions with relatively short reaction times meant that the fluorinase enzyme 
compared well to the more traditional methods as a means for the synthesis of C–18F 
bonds for PET. [18F]FDA [18F]-22, however, proved to be a poor radiotracer, undergoing 
rapid defluorination to release [18F]fluoride ion in vivo.209 While [18F]FDA [18F]-22 is a 
poor tracer, the radiolabelled compound was used as a substrate for further enzymatic 
transformations, showing that fluorinase-derived [18F]FDA [18F]-22 could act as a 
source of novel radiotracers. Coupling the enzymatic 18F-fluorination to an adenosine 
deaminase gave 5'-[18F]fluoro-5'-deoxyinosine [18F]-155 ([18F]FDI), while coupling to a 
purine nucleotide phosphorylase and phytase gave 5-[18F]fluoro-5'-deoxyribose 
[18F]-156 ([18F]FDR), as shown in Scheme 33 A.208 
1.4.2. Base swaps 
Nucleosides are an attractive prospect for radiolabelling due to their role in DNA and 
RNA synthesis during cell proliferation in cancers.210 In this context, the fluorinase 
offers access to a range of 5'-[18F]-fluorinated nucleosides, as shown in Scheme 34, 
which have traditionally been difficult tracers to access through chemical 
synthesis.211,212 Coupling of a fluorinase-catalysed synthesis of [18F]FDA [18F]-22 to a 
purine nucleotide phosphorylase generated 5-[18F]fluoro-5-deoxyribose-1-phosphate 
[18F]-27 ([18F]FDRP).213 [18F]FDRP [18F]-27 was used as a substrate for a thymidine 
phosphorylase and a range of uracils to generate a series of 
5'-[18F]fluoro-5'-deoxyuridine analogues [18F]-157 to [18F]-159 in Scheme 34. The 
analogues were not used in imaging experiments, but these experiments illustrate the 
utility of the fluorinase enzyme for the synthesis of a fluorinated nucleoside analogues. 
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Scheme 34. Synthesis of a range of thymidine analogues from [18F]FDA [18F]-22 though an [18F]FDRP 
[18F]-27 intermediate in a series of one-pot transformations.213 
1.4.3. Fluoroacetate 
[18F]Fluoroacetate [18F]-1 ([18F]FAc) has found application in PET imaging, primarily as 
an acetate surrogate for investigating metabolic changes associated with disease, and 
is discussed further in Chapter 5.214–217 In this context, it became desirable to develop 
a synthesis of [18F]FAc [18F]-1 using the fluorinase, to complement existing methods for 
its synthesis, which traditionally use SN2 substitution with [18F]fluoride on an 
appropriate substrate.217,218 The Kuhn-Roth oxidation219,220 is a reaction used to oxidise 
pendant methyl groups in organic compounds to carve out acetate, and has found 
application in determining the number of such groups in 14C- and 3H- labelled natural 
products. A similar transformation could be used with [18F]FDA [18F]-22, where the 
[18F]fluoromethyl group would be oxidised using a mixture of CrO3 and H2SO4 to 
generate [18F]FAc [18F]-1, as shown in Scheme 35. 
 
Scheme 35. Synthesis of [18F]fluoroacetate [18F]FAc [18F]-1 from [18F]FDA [18F]-22 using strongly oxidising 
conditions. 
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This oxidation was trialled using [18F]FDA [18F]-22 derived from reaction of SAM 20 with 
[18F]fluoride, coupled to L-amino acid oxidase.221 The reaction was found to produce 
[18F]FAcOH [18F]-160, very efficiently, and was successfully extracted as the carboxylic 
acid from the reaction mixture using diethyl ether. Extraction into aqueous potassium 
carbonate gave [18F]FAc [18F]-1 in a 36% decay corrected radiochemical yield. More 
detail about [18F]FAc [18F]-1 will be discussed in Chapter 5. 
1.4.4. Fluorodeoxyribose 
2-[18F]Fluoro-2-deoxyglucose [18F]-35 ([18F]FDG) is used in over 90% of clinical PET 
applications.91,92 A fluorinase-catalysed transformation of SAM 20 to [18F]FDA [18F]-22 
could provide access to a similar [18F]fluoro-deoxy sugar by cleavage of the adenine 
base from the nucleoside. As stated, the fluorinase transformation could be coupled to 
a PNP and a phytase to generate [18F]FDR [18F]-156,208 however, a single step 
transformation using a nucleoside hydrolase Trypanosoma vivax was reported in an 
effort to remove a synthetic step and improve the efficiency of this synthesis, as shown 
in Scheme 36.222 This route offered significantly shorter reaction times and 
radiochemical incorporations of 80%, excellent for the synthesis of PET radio tracers. 
 
Scheme 36. Synthesis of 5-[18F]fluoro-5-deoxyribose [18F]-156 ([18F]FDR) from [18F]FDA [18F]-22 derived 
from a fluorinase reaction. 
[18F]FDR [18F]-156 was compared with [18F]FDG [18F]-35 as a radiotracer in mice 
bearing human epithelial cell carcinoma xenograft tumours, as shown in Figure 11.223 
This represented the first reported in vivo use of a radiotracer prepared using the 
fluorinase enzyme. In this experiment, it was found that [18F]FDR [18F]-156 behaved 
similarly to the gold standard for PET imaging, [18F]FDG [18F]-35, and was concentrated 
in the tumours, as shown in Figure 11. Additionally, [18F]FDR [18F]-156 appeared 
metabolically stable to [18F]fluoride ion elimination as no accumulation of radioactivity 
was seen in the bone. The new radiotracer was however cleared from the tumours 
more rapidly, predominantly via the urinary system. These experiments illustrate the 
compatibility of the fluorinase enzyme with small animal PET imaging, and open the 
possibility for exploration of novel fluorinase-synthesised radiotracers in in vivo models. 
52 
 
 
Figure 11. PET images of mice bearing tumours (white arrows) imaged with A. [18F]FDR [18F]-156 and 
B. [18F]FDG [18F]-35. Image reproduced with permission from O’Hagan et al.223 
1.5. Conclusions 
The isolation and characterisation of a fluorinating enzyme form S. cattleya provided 
insight into the biosynthesis of rare fluorinated natural products. The enzyme was 
found capable of sequestering fluoride anion from aqueous solution, and activating this 
anion for reaction with S-adenosylmethionine 20. Under non-enzymatic conditions in 
the context of PET, the activation of fluoride from aqueous solutions is accomplished 
by azeotropic dying in the presence of cryptands. A potential advantage of coupling the 
fluorinase to traditional PET radiotracer synthetic methodology is to circumvent pre-
drying required to activate the nucleophile. 
Fluorination methodology for PET is an area of growing interest. There is a major effort 
to develop mild and selective transformations to introduce [18F]fluoride ion into organic 
molecules, either for use as radiotracers themselves, or for the development of novel 
prosthetic groups for labelling of biomolecules. In addition, last-step labelling protocols 
continue to receive attention in an effort to reduce synthesis times and improve 
labelling efficiency for biomolecules. 
The fluorinase occupies a unique position in this regard, in that it represents the only 
method capable of catalysing the formation of C–F bonds under neutral pH and 
ambient conditions in water. The utility of the fluorinase has been explored, generating 
a range of novel radiotracers. However, all potential radiotracers developed thus far, 
including 5'-[18F]fluorouridine nucleosides 157, 158 and 159, [18F]fluoroacetate [18F]-1 
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and 5-[18F]fluororibose [18F]-156, have used [18F]FDA [18F]-22 as an intermediate in 
their synthesis. 
In order to further capitalise on the mild conditions offered by fluorinase catalysis, we 
were interested in exploring the use of the fluorinase for the synthesis of a novel 
prosthetic group, with the possibility of extending this methodology for “last step” 
labelling of biomolecules with fluorine-18. Application of the fluorinase to such labelling 
approaches required the development of novel substrates that bore either reactive sites 
for reaction with biomolecules, or more ambitiously, already conjugated to 
biomolecules. 
One foreseeable limitation of such an approach is the inherent substrate specificity 
usually exhibited by enzymes, especially near the site of reactivity. This may limit the 
choice of sites for modification of the fluorinase substrate. The substrate specificity of 
the fluorinase has previously been explored to some degree, and will be discussed in 
Chapter 2. In addition, a strategy for exploiting the fluorinase for the synthesis of a 
novel prosthetic group is explored. 
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2. Synthesis and evaluation of an alkynyl-bearing 
substrate for the fluorinase 
2.1. Modified fluorinase substrates 
The fluorinase enzyme has found applications for positron emission tomography 
through the synthesis of [18F]-FDA 22 and its subsequent modification, as discussed in 
the previous chapter.1–3 We were interested in exploring novel ways of using the 
fluorinase for [18F]-labelling of biomolecules through the design of modified substrates. 
When the fluorinase was first discovered, the substrate scope of the enzyme was 
explored. Investigations showed that the fluorinase utilised chloride ion as a substrate 
for the synthesis of 5'-chloro-5'-deoxyadenosine 23 (ClDA) (Scheme 1).4 This reaction 
does not proceed in the forward direction under standard conditions, i.e. incubation of 
the enzyme with SAM 20 and chloride, but required the presence of an L-amino acid 
oxidase (L-AAO). The native fluorinase-catalysed reaction of SAM 20 to FDA 22 is an 
equilibrium process lying in favour of FDA 22. The synthesis of ClDA 23 is also an 
equilibrium process, but the equilibrium lies heavily in favour of SAM 20 and chloride 
ion. This equilibrium is moved in favour of ClDA 23 production by the removal of 
L-methionine 21 by L-AAO. 
 
Scheme 1. Fluorinase reaction using chloride ion as the nucleophile to generate ClDA 23, while 
L-methionine 21 is removed by of L-AAO, generating the corresponding α-oxo acid 25.  
The equilibrium relationship between ClDA 23, SAM 20, and FDA 22 led to the 
discovery of a fluorinase-catalysed transhalogenation reaction.4 Incubation of ClDA 23 
with the fluorinase and fluoride ion in the presence of catalytic L-methionine gave 
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SAM 20, which then undergoes a fluorinase-catalysed reaction with fluoride ion in a 
one-pot transformation to FDA 22, as shown in Scheme 2.  
 
Scheme 2. Fluorinase-catalysed transhalogenation in water, where ClDA 23 reacts with L-Met to give 
SAM 20, which then reacts with fluoride ion to generate FDA 22. 
The brominated analogue, 5'-bromo-5'-deoxyadenosine (BrDA) was also investigated 
as a substrate for the fluorinase. In the presence of fluoride ion, BrDA was converted to 
FDA 22.5 This conversion was, however, independent of the presence of L-methionine. 
It was hypothesised that rather than the bromine atom occupying the fluoride binding 
site, it was located in the sulfonium binding site (as had been observed for the chloro 
analogue in the active site of the fluorinase ClDA 23 co-crystal structure).4 Bromine 
atom is acting as a surrogate for the sulfonium leaving group of SAM 20. While this 
allows for direct conversion of BrDA to FDA 23, the brominated substrate was not a 
true fluorinase substrate as no SAM 20 intermediate is involved. Bromide and iodide 
were also explored as substrates in the L-AAO coupled assays, but no brominated or 
iodinated products were observed.5  
A range of L-methionine 21 analogues were also investigated.5 L-Selenomethionine 
161 proved an excellent substrate for the fluorinase, generating FDA 22 from ClDA 23 
at 6 × the rate compared to L-methionine (Scheme 3).4 L-Selenomethionine is a better 
nucleophile than L-methionine due to the presence of a higher energy HOMO on the 
chalcogen atom. It is also a better leaving group due to the larger and more polarisable 
selenium atom, which is able to stabilise the departing electron pair more efficiently. 
Other L-methionine 21 analogues were also investigated as substrates, including 162 
to 166 shown in Scheme 3. Only D-methionine 162 generated traces of FDA 22, while 
the remaining analogues showed no conversion. It has been recently reported that the 
N-methylaza-SAM analogue 167 (Scheme 3) is a substrate for the fluorinase with 
[18F]fluoride, generating [18F]FDA [18F]-22.6  
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Scheme 3. A fluorinase catalysed transhalogenation in the presence of L-selenomethionine 161 led to 
the efficient generation of FDA 22. L-Methionine analogues (162 to 166) were not substrates 
for the fluorinase enzyme, while 167 has been reported to generate [18F]FDA [18F]-22 in the 
presence of fluorinase and [18F]fluoride. 
A number of modified nucleosides have also been explored as substrates for the 
fluorinase, shown in Scheme 4. The carbacyclic nucleoside 168 was investigated as a 
substrate, however it did not undergo transhalogenation, emphasising the importance 
of the endocyclic oxygen for catalysis.7  
 
Scheme 4. Modified nucleosides explored as substrates for the fluorinase. 
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The 2'-deoxy 169 analogue was prepared and assessed as a substrate for fluorinase 
catalysed transhalogenation. 2'-Deoxy-ClDA 169 proved to be a substrate, and did 
generate 2'-deoxy-FDA 171. This reaction proceeded at approximately 50% the rate of 
ClDA 23.8  
2-Amino substrate 172 was efficiently transformed into the corresponding 
2-amino-SAM 173 analogue by the fluorinase.5 Examination of the crystal structure of 
the fluorinase bound to SAM 20 (Figure 1 A and Figure 1 B)9 revealed that the C-2 
position of the adenine base is oriented towards the surface of the enzyme at the 
interface of two subunits. Plotting the inner surface of the active site (Figure 1 C) 
reveals a “hole” which aligns with the C-2 position, and it is possible that the amine 
substituent of 172 is accommodated in this free space. 
 
Figure 1. A. Crystal structure of the fluorinase bound to its native substrate, SAM 20 showing the 
active site located near the surface of the enzyme. B. A closer view of SAM 20 in the active 
site of the fluorinase, between two monomers of the fluorinase shown in green and red. 
C. The surface profile of the active site, showing a hole in this surface which aligns with C-2 
of the adenine of SAM 20. 
We were intrigued by this apparent “hole” in the active site, and wished to further 
explore the C-2 position as a site of further substrate modification, where such 
modification to incorporate a reactive group would improve the scope of fluorinase as a 
biocatalyst. 
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Towards this end, we envisaged substituting the C-2 position of ClDA 23 with a small 
reactive group which would be suitable for bio-orthogonal reaction after enzymatic 
fluorination. An alkyne was an immediate candidate, as it is linear and offers low steric 
impact and was envisaged to project through the “hole” in the active site. In addition, 
the alkyne would be available for reaction with an appropriately substituted azide, 
through a copper-catalysed alkyne-azide cycloaddition (CuAAC), coupling the 
fluorinase to “click” chemistry, an established protocol for bioconjugations for PET 
appplications.10 
2.2. Aims 
Modifying the substrate of the fluorinase at C-2 of adenine with an acetylene moiety 
generates 5'-chloro-2-ethynyl-5'-deoxyadenosine 174 (ClDEA), which became a 
synthetic target. The fluorinated analogue, 5'-fluoro-2-ethynyl-5'-deoxyadenosine 176 
(FDEA), was also required as a reference compound. ClDEA 174 would be 
investigated as a fluorinase substrate for the generation of selenoethynyl-SAM 
intermediate 175 (SeEAM), which was proposed to undergo fluorination in the 
presence fluoride to generate FDEA 176, as shown in Scheme 5. Bioconjugation of the 
enzymatically synthesised FDEA 176 to a relevant biomolecule, such as an azide 
modified peptide, is clearly attractive. If successful, the goal would be to transfer this 
system to the PET environment for radiolabelling of peptides. 
 
Scheme 5. A. ClDEA 174 will be explored as a transhalogenation substrate for the fluorinase. B. The 
resultant FDEA 176 will be explored in a CuAAC reaction with an azide-labelled peptide to 
generate triazole 177. 
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Utilisation of [18F]fluoride as a fluoride source offers a two-step radiolabelling protocol 
where [18F]FDEA [18F]-176 acts as a prosthetic group for coupling to biomolecules of 
interest. Unlike most radiolabelling procedures with fluorine-18, which use heating, 
organic solvents and high temperatures, if successful, the synthesis of this radiolabel 
would take place under aqueous conditions at neutral pH, ideal for biomolecules. 
2.3. Synthesis of an ethynyl substrate for the fluorinase 
While both ClDEA 174 and FDEA 176 are novel compounds, the 5'-hydroxy analogue, 
2-ethynyladenosine 180, has been synthesised by two strategies. The first, reported by 
Matsuda et al.11–13 and Nair et al.,14 started from guanosine 178, and through a series 
of functional group manipulations, generated iodoadenosine 179 as a key intermediate. 
The report utilised 179 in Sonogashira couplings with a variety of alkynes, including 
ethynyltrimethylsilane, which, after deprotection, furnished 2-ethynyladenosine 180, as 
shown in Scheme 6 A. 
 
Scheme 6. Synthetic route to 2-ethynyladenosine 180 from A. guanosine 178 as described 
by Matsuda et al.11–13 and Nair et al.14 and B. from 2-amino-6-chloropurine 181 as described 
by Lee et al.15 
Lee et al.15 coupled a substituted purine 181 to ribosyl donor 182 to generate protected 
nucleoside 183, which was also converted to 2-iodoadenoisine 179, and on to 
2-ethynyladenosine 180 via the same route as Matsuda and Nair. 11–14 
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The route from guanosine described by Matsuda and Nair 11–14 avoids coupling of a 
ribosyl donor to the base, where generation of α- and β- anomers is possible. 
Therefore, synthesis of 180 from guanosine, and subsequent chlorination or 
fluorination would be expected to give targets ClDEA 174 and FDEA 176 respectively. 
2.3.1. Synthesis of 5'-chloro-2-ethynyl-5'-deoxyadenosine (ClDEA) 174 
Guanosine 178 was heated in the presence of acetic anhydride and pyridine in 
dimethylformamide (DMF) to furnish per-O-acetylated guanosine 184 (Scheme 7). The 
product was recrystallised from isopropanol to give 184 as a white powder in 85% 
yield. 
 
Scheme 7. Synthetic route to 2-(trimethylsilylethynyl)adenosine 187 from guanosine 178.  
Chlorination at the 6-position of the nucleoside had been reported to be poor yielding 
and difficult to replicate,16 and has been investigated by Robins et al.17 They 
determined that while the initial activation of the oxygen at C-6 of 184 was rapid, attack 
of chloride to form the Meisenheimer complex, and subsequent departure of oxygen 
was slow. They also found that the intermediate phosphorodichloridate was prone to 
decomposition, leading to low yields and that the addition of another chloride ion 
source, such as Et4NCl, led to improved yields.  
The reaction required a meticulously dry source of highly hygroscopic Et4NCl. Thus 
recrystallisation of Et4NCl from absolute ethanol followed by drying over P2O5 in vacuo 
afforded the dry salt. This consistently provided higher yields of the chlorinated product. 
The reaction yield was low when performed on any scale larger than ~1 g or when left 
to react for longer than 30 minutes.  
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The optimised reaction was carried out by heating 184 in a solution of dry acetonitrile, 
POCl3, dry Et4NCl and dimethylaniline (DMA) in small batches (<1 g), in parallel 
reactions, to furnish 185 in 77% yield. 
Chlorinated nucleoside 185 was subject to diazotization in the presence of iso-amyl 
nitrite and copper (I) iodide in refluxing THF in a Sandmeyer-type reaction. The aryl 
radical formed after expulsion of N2 is quenched in situ by either diiodomethane or 
molecular iodine, generating 186 in 69% yield.18 
2-Iodoadenosine 179 was synthesised by heating 189 in a freshly saturated solution of 
ammonia in methanol in a sealed tube for 16 hours. The acetyl protecting groups are 
concomitantly cleaved by aminolysis during this reaction. The product was purified from 
the reaction mixture by recrystallisation from water to give 179 as a colourless powder 
in 69% yield. 
The key reaction for installing the acetylene functionality involved a Sonogashira 
coupling of 179 to ethynyltrimethylsilane in the presence of Pd(PPh3)2Cl2 and copper (I) 
iodide, as shown in Scheme 8. The yields for the reaction were found to be moderate, 
furnishing 187 in 60% yield, giving access to the desired protected acetylenic 
compound. 
 
Scheme 8. Synthesis of 2-ethynyladenosine 180 from 2-iodoadenosine 179. 
Conventional silyl deprotection of 187 with TBAF in THF furnished the free 
acetylene 180. The product, however, proved difficult to separate from residual 
tetrabutylammonium salts. A fluoride-free deprotection method was investigated using 
30% methanolic ammonia solution, as reported by Lee et al.,15 and this furnished 180 
as a pale brown powder after purification by recrystallisation from water (77% yield). 
With acetylene 180 in hand, attention turned to chlorination at the 5'-position. 
Robins et al.19 have reported a method for the chlorination of adenosine 188 directly 
using thionyl chloride and pyridine in acetonitrile. The procedure generates a 2',3'-
cyclic sulfite intermediate, which can be isolated and characterised, before hydrolysis 
with aqueous ammonia in methanol (Scheme 9) yields the chlorinated product. Upon 
trialling this reaction with adenosine 188, it was found that the intermediate 
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cyclic sulfite 189 need not be isolated, and that after concentration, the crude cyclic 
sulfite 189 was hydrolysed directly to 23 in quantitative yield. 
 
Scheme 9. A. Synthesis of 5'-chloro-5'-deoxyadenosine 23 via the cyclic sulfite intermediate. 
B. Chlorination of ethynyladenosine 180 gave the desired compound 174 in low yield, with an 
inseparable dichlorinated by-product 190. 
Repeating these reaction conditions with 2-ethynyladenosine 180 afforded a mixture of 
two products that could not easily be separated. LC-MS of this mixture resolved two 
compounds: ClDEA 174, with a m/z = 310 ([M+H]+); and a dichlorinated species with a 
m/z = 346 and the characteristic isotope pattern for the presence of two chlorine atoms. 
This mass represents the addition of HCl to 174. Based on this mass, the lack of a 
signal for an associated acetylenic proton in the 1H NMR spectrum, and the presence 
of resonances associated with a distinctive AB system at 6.72 ppm suggested 190 
(Scheme 9) as the structure of the adduct. The substitution pattern of the alkene was 
not determined.  
It was found that by-product 190 was not formed when the chlorination reaction was 
performed directly on TMS-protected acetylene 187 (Scheme 10). The TMS group 
appears to protect the alkyne from HCl addition, and is conveniently cleaved during the 
hydrolysis of the cyclic sulfite. In the end, this synthetic route gave ClDEA 174 in a 
moderate yield (47%). 
 
Scheme 10. Synthesis of ClDEA 174 directly from TMS-protected ethynyladenosine 187. 
76 
 
Single crystal X-ray structure analysis of ClDEA 174 (Figure 2) revealed that the 
stereochemistry of the ribose ring was intact and the molecule adopted the South 
conformation (C2'-endo-C3'-exo) in the solid state. Interestingly, the linearity of the 
acetylene functionality was slightly distorted, showing a C-C≡C angle of 173.5°, likely 
due to crystal packing forces. 
 
Figure 2. Single crystal X-Ray structure of ClDEA 174. Data collected and refined by Prof. Alexandra 
Slawin at the University of St Andrews. 
With the proposed new substrate for the fluorinase, ClDEA 174 in hand, we explored 
the synthesis of the anticipated product of the enzymatic transformation, FDEA 176.  
2.3.2. 5'-fluoro-2-ethynyl-5'-deoxyadenosine (FDEA) 176 
Reported syntheses of 5'-fluorinated nucleosides often involve an initial activation of 
the 5'-position of a suitably protected nucleoside as a sulfonate ester.20–22 Subsequent 
fluorination with a fluoride source such as tetrabutylammonium fluoride (TBAF) 
generates the fluorinated product. This approach, however, leads to the formation of 
cyclised by-products, where N-3 of the purine ring attacks the 5'-position, in an 
intramolecular substitution reaction. Aston et al.23 and Spitale et al.24 have reported a 
one-pot conversion of 5'-hydroxy compounds to 5'-fluoro compounds by the action of 
tosyl fluoride (TsF) and TBAF in refluxing THF. These are attractive conditions as they 
do not involve isolation of the sulfonate ester intermediate. 
Protection of 187 as its acetonide, under the action of the 2,2-dimethoxypropane and 
Amberlyst 15 H+, gave 191 (71% yield) as shown in Scheme 11. Fluorination of 
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acetonide 191 under the reported23,24 TBAF-TsF conditions afforded fluorinated 
nucleoside 192 in 71% yield. During the reaction, the TMS group was cleaved by 
fluorolysis to generate the free alkyne. Fluorinated acetonide 192 was then hydrolysed 
in a 9:1 mixture of trifluoroacetic acid and water to furnish 176 (53% yield). 
 
Scheme 11. Synthesis of the anticipated product of the fluorination reaction, FDEA 176. 
Single crystal X-ray structure analysis (Figure 3) of FDEA 176 showed that the 
fluorinated nucleoside adopts an almost identical conformation to ClDEA 174 in the 
solid state. The ribose ring was also observed in the South conformation (C2'-endo-
C3'-exo) and the acetylene is marginally more distorted from linear than that of the 
acetylene of ClDEA 174, with a C-C≡C angle of 171.6°. 
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Figure 3. Single crystal X-Ray structure of FDEA 176. Data collected and refined by Prof. Alexandra 
Slawin at the University of St Andrews. 
With both ClDEA 174, and FDEA 176 in hand, attention turned to over-expression and 
purification of the fluorinase for use in the appropriate assays. 
2.4. Over-expression and purification of recombinant 
 fluorinase 
2.4.1. Fluorinase over-expression 
The over-expression of a recombinant fluorinase in Escherichia coli using a Luria Broth 
(LB) and isopropyl β-D-1-thiogalactopyranoside (IPTG) based system has been 
reported previously.9 This method uses E. coli BL21 Gold cells containing the pET-28a 
plasmid, into which the fluorinase gene has been cloned. This plasmid offers 
kanamycin resistance to the cells, while also incorporating an N-terminal polyHis tag 
onto the fluorinase. 
Baffled shake flasks (2 L) containing LB media (1 L) containing kanamycin (50 µg/mL−1) 
were inoculated with transformed E. coli and cultured at 37 °C until the optical density 
(OD600) reached 0.6. Overexpression of the fluorinase was induced by addition of IPTG 
and the temperature was lowered to 30 °C. The cultures were incubated with shaking 
for 16 hours before harvesting by centrifugation. 
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Alternatively, the fluorinase was overexpressed using an autoinduction protocol.25 This 
protocol uses a media containing a mixture of glucose, lactose and glycerol to control 
the lac operon and the induction of overexpression. During the initial stage of growth, 
glucose provides the primary energy source for the cells and strongly represses the 
activation of the lac operon by inhibiting lactose uptake via the membrane transporter 
lactose permease. Depletion of glucose reactivates lactose permease and lactose is 
transported into the cell, ceasing the repression of the lac operon. The cells are 
consequently induced to overexpress the desired protein.  
In this case, autoinduction media (400 mL) containing kanamycin (100 µg.mL−1) was 
inoculated with E.coli and the culture grown for 4 hours at 37 °C. The temperature was 
lowered to 16 °C and the cells were grown at this temperature for 48 hours. Cells were 
harvested by centrifugation and the same purification protocol used for the LB-IPTG 
method was followed.  
The cells were disrupted after addition of DNAse, and the lysate clarified by 
centrifugation and filtration. The polyHis-tagged fluorinase was purified by affinity 
chromatography by trapping on a Ni2+ Sepharose column. Bound protein was eluted 
from the Ni2+ column using a high concentration (400 mM) imidazole buffer. 
SDS-PAGE analysis of samples taken throughout the purification process (Figure 4) 
showed that the elution fractions from the column contained fluorinase and were free 
from significant amounts of other proteins. Fractions containing the fluorinase were 
pooled and dialysed overnight against a low salt buffer (150 mM NaCl, 20 mM Tris-HCl 
pH 7.8) to remove imidazole and salt from the protein. The identity of the fluorinase 
was confirmed by mass spectrometry of a trypsin digest of the elution band from the 
SDS-PAGE gel.  
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Figure 4.  SDS-PAGE of the fluorinase, showing the insoluble and soluble fractions after centrifugation 
of the crude lysate, the flowthrough after loading of the clarified supernatant, the wash 
fractions (20 mM imidazole) and the elution fractions (400 mM imidazole). Some fluorinase is 
identified in the insoluble fraction and wash fractions, however yields of soluble enzyme were 
good. 
Both induction methods furnish the fluorinase in high purity, however the yields for the 
autoinduction method tended to be higher per litre of culture. The average yield of 
fluorinase enzyme after the first Ni2+ column for the autoinduction method was 60 mg 
per litre of culture, while the yield for LB/IPTG induction method was 29 mg per litre of 
culture. 
2.4.2. Removal of adenosine from the fluorinase 
Recombinant fluorinase is known to co-purify with adenosine 188 (Figure 5) bound.8 
Previous isothermal titration calorimetry experiments had confirmed this binding, and 
found that adenosine 188 has a binding constant (Ka) of 12.2 × 105 M–1, the same order 
of magnitude as FDA 22 (45.5 × 105 M–1).26 HPLC analysis of a denatured sample of 
the fluorinase from these preparations reveals that the protein did contain adenosine, 
and that 188 was not efficiently removed by dialysis. 
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Figure 5. Comparison of adenosine 188 and the product of the fluorinase reaction, FDA 22. 
Adenosine 188 bound to the active site of the fluorinase can act as a competitive 
inhibitor for the enzyme. Adenosine can be removed from the enzyme by incubating 
the fluorinase-adenosine mixture with adenosine deaminase (ADA), an enzyme that 
irreversibly deaminates adenosine 188 to generate inosine 193 (Scheme 12).26 
Inosine 193, unlike adenosine 188, does not bind to the fluorinase and is readily 
dialysed away to give an apo-fluorinase for use in assays. 
 
Scheme 12. Conversion of adenosine 188 to inosine 193 under the action of adenosine deaminase. 
Two commercially available preparations of ADA were assessed for removal of 
adenosine 188. The first, a recombinant human ADA expressed in E. coli, showed very 
low activity (reported to be less than 1 unit.mL–1). Upon incubation with the fluorinase 
during dialysis, this preparation was found to be ineffective at removing adenosine 188 
from the enzyme. The activity of the enzyme was found to vary between preparations. 
A second commercial preparation of ADA, isolated directly from calf spleen, was found 
to be efficient at converting adenosine 188 to inosine 193. This preparation of ADA had 
much higher activity (250 units.mL–1) and converted 80–90% of the endogenous 
adenosine 188 to inosine 193. The inosine 193 formed was removed by dialysis. A 
fluorinase preparation (100 to 200 mg fluorinase in 30 mL) was usually treated with  
20–50 µL of this ADA preparation (equating to approx. 5 units ADA) at 4 °C overnight, 
while undergoing dialysis. HPLC analysis of fluorinase samples before and after ADA 
treatment confirmed the removal of adenosine from the fluorinase, as shown below in 
Figure 6. For crystallography and calorimetry experiments, where complete adenosine 
removal was required, the ADA treatment was repeated. 
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Figure 6. HPLC analysis of fluorinase samples before and after treatment by ADA. Adenosine 188 
(red) has been reduced by 82% from the original isolate. Inosine is not observed as dialysis 
removes inosine from the sample as it is formed. 
The protein solution was passed through a second Ni2+ column after ADA treatment to 
separate the two enzymes. ADA, as a preparation from calf spleen, does not bear a 
polyHis tag, and does not bind to the Ni2+ beads. The fluorinase was eluted from the 
column using a high-imidazole concentration (400 mM) buffer.  
Although chloride is a poor substrate for the fluorinase, it is possible that chloride in the 
buffer could act as a (weak) competitive inhibitor for fluoride. This problem would be 
particularly pertinent when fluorinase is used for PET experiments where chloride ion 
concentration would be 6–9 orders of magnitude higher than [18F]fluoride ion 
concentration. Consequently, chloride free buffers were used and the enzyme was 
dialysed into a phosphate buffer (50 mM, pH 7.8). 
Post dialysis analysis showed the fluorinase as a single band on SDS-PAGE, as shown 
below in Figure 7, with no other proteins present. Concentration of the enzyme solution 
through a membrane-spin concentrator and storage at 4 °C, or freeze drying 
appropriate aliquots, furnished the fluorinase for use either in assays or for PET 
experiments respectively. 
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Figure 7.  SDS-PAGE gel of the fluorinase post ADA treatment, after purification through a second Ni2+ 
Sepharose column to remove the adenosine deaminase. The fluorinase monomer (36.5 kDa) 
is a single band. 
2.4.3. Cleavage of His-Tag for protein crystallisation 
We also wished to prepare the fluorinase for use in crystallisation trials with the new 
ligands. This required cleavage of the polyHis tag from the N-terminus of the fluorinase. 
The fluorinase expressed from the pET-28a plasmid contains a thrombin cleavage site, 
as shown below in Scheme 13. 
 
Scheme 13. Cleavage of the N-terminal polyHis tag from the recombinant fluorinase by thrombin to give a 
fluorinase which is 2 kDa smaller. 
Incubation of the fluorinase with human thrombin at room temperature overnight 
cleaved the polyHis tag from the fluorinase, as evidenced by the SDS-PAGE shown in 
Figure 8. Since neither the fluorinase nor thrombin bore an affinity tag, the two species 
were separated by size exclusion chromatography (SEC). Thrombin has a molecular 
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weight of 33.6 kDa, while the fluorinase (monomer of 32.7 kDa) exists as a dimer of 
trimers with an effective mass 196 kDa. The mass difference allows for efficient 
separation of the fluorinase from thrombin and the cleaved polyHis tag by SEC. SEC 
also showed that the fluorinase exists as a monodisperse species in solution, ideal for 
crystallography. Pooling of fractions containing fluorinase and concentration (to 
6 mg.mL–1) using a membrane-spin concentrator gave a solution of the fluorinase, free 
of adenosine, and suitable for use in crystallisation trials. 
 
Figure 8.  SDS-PAGE showing cleavage of the polyHis tag by incubation with thrombin. In some gels, a 
fluorinase dimer was observed, likely due to incomplete reduction of a disulfide bridge. 
2.5. Evaluation of ClDEA 174 as a substrate for the fluorinase 
With both the fluorinase and the candidate new substrates in hand, attention turned to 
investigating whether the fluorinase was able to catalyse a transhalogenation of 
ClDEA 174 to FDEA 176.  
2.5.1. Evaluation of ClDEA 174 as a substrate for the fluorinase 
ClDEA 174 (0.2 mM), was incubated with a solution of the prepared fluorinase 
(5 mg.mL–1) in phosphate buffer at pH 8, in the presence of fluoride ion (75 mM) and 
L-selenomethionine (0.1 mM) to assess the viability of the reaction, as illustrated below 
in Scheme 14. 
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Scheme 14. Proposed fluorinase-catalysed-transhalogenation of the ethynyl-modified substrate 
ClDEA 174 to FDEA 176 proceeding through a selenoSAM intermediate 175. 
Reaction progress was monitored by HPLC analysis of aliquots of the reaction solution 
(Figure 9). The samples were heat-treated to 95 °C and centrifuged, to stop the 
reaction and precipitate the denatured fluorinase as a pellet respectively. A new peak 
was evident in the chromatograms at tR = 7.8 min, which showed time dependent 
increase in peak area. This peak was confirmed to be FDEA 176 by comparison of 
retention time to that of the synthetic sample of FDEA 176, prepared previously. 
 
Figure 9. HPLC time course (260 nm) of incubation of ClDEA 174, yellow, (tR = 10.0 min) with the 
fluorinase, showing samples taken at t = 0, 0.5, 1 and 2 h. A new peak appeared at 
tR = 7.8 min, green, identified as FDEA, 176. 
This new product was confirmed as FDEA 176 by liquid chromatography-mass 
spectrometry (LC-MS). The supernatant of a reaction (run for 24 h) was analysed by 
LC-MS (Figure 10) and revealed a single retained peak in the UV (Figure 10 A) and 
total ion chromatogram (Figure 10 B) at tR = 14.2 min. The summed mass spectrum of 
this peak (Figure 10 C) showed a peak at m/z = 294, the [M+H]+ ion of FDEA 176, 
confirming this as the product of the transhalogenation. 
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Figure 10. A. UV (254 nm) trace of a fluorinase-ClDEA 174 reaction mixture incubated with fluoride ion 
after 24 hours showing a single major peak at tR = 14.0 min, identified as FDEA 176. B. Total 
ion chromatogram of the reaction mixture, showing the corresponding ion peak at 
tR = 14.2 min. C. Combined mass spectra acquired for the peak at tR = 14.2 min showing a 
peak at m/z = 294, corresponding to FDEA 176. D. Zoomed region showing the isotope 
pattern is as expected for FDEA 176.  
A control experiment, incubating ClDEA 174, L-selenomethionine and fluoride ion for 
24 hours without fluorinase enzyme showed only the presence of ClDEA 176. No 
FDEA 176 or SeEAM 175 was observed by HPLC, confirming that the 
transhalogenation reaction is catalysed by the fluorinase. 
Incubation of ClDEA 174 with the fluorinase in the absence of fluoride ion, but with a 
stoichiometric amount of L-selenomethionine showed complete consumption of 
ClDEA 174. SeEAM 175 was detected, but only at low levels in the LC-MS 
experiments, eluting with the solvent front (Figure 11). 
 
Figure 11. Ion selective chromatogram for m/z = 471, corresponding to the mass of SeEAM 175, 
showing detection of ions of this mass eluting with the solvent front. 
Three new products were detected by LC-MS (Figure 12 A and B) in this experiment. 
These products were derived from the breakdown of the SeEAM 175 intermediate, 
either during the incubation period, or during heating to precipitate the fluorinase.  
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Figure 12. A. UV (254 nm) trace of a fluorinase-ClDEA 174 reaction mixture in the absence of fluoride 
ion after 24 hours showing a three major products at tR = 9.0 min, tR = 12.6 min and tR = 16.4 
min. B. Total ion chromatogram of the reaction mixture, showing the corresponding ion peaks 
at tR = 9.2 min, tR = 12.9 min and tR = 16.8 min. C. Combined mass spectra acquired for the 
peak at tR = 16.8 min showing a peak at m/z = 370, corresponding to methyl 
selenoether 194. D. Zoomed region showing the distinctive isotope pattern expected for 
selenium containing 194. 
The breakdown product at tR = 16.4 min was identified as 
5'-selenomethyl-5'-deoxy-2-ethynyladenosine 194, with m/z = 370 ([M+H]+), showing 
the characteristic isotope pattern for the presence of selenium (Figure 12 C and D). 
S-Adenosylmethionine is known to break down when heated to generate the sulfur 
analogue of 194, along with homoserine lactone.27,28  
The two other major peaks in Figure 12 A were identified as hydrolysis products of 
SeEAM 175. The peak at tR = 9.0 min showed a mass of m/z = 160 (Figure 13 A), and 
corresponded to the free base 195 derived from hydrolysis at the anomeric position. 
The peak at tR = 12.6 min showed a mass of m/z = 292 (Figure 13 B) and 
corresponded to the adenosine analogue 180 derived from hydroxide displacement at 
the 5'-position.  
 
Figure 13. A. Combined mass spectrum of SeEAM 175 breakdown product eluting at tR = 9.0 min, 
identified as free base 195. B. Combined mass spectrum of SeEAM 175 breakdown product 
eluting at tR = 12.3 min, identified as hydroxylated analogue 180.  
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Identification of SeEAM 175 breakdown products confirmed that the transhalogenation 
takes place via an activated selenonium intermediate, as observed with other 
fluorinase-catalysed transhalogenations. This confirms that the transhalogenation does 
not take place through a direct substitution of chloride for fluoride, as observed for the 
brominated substrate analogue (see Section 2.1). 
The alkyne substituent at C-2 of the nucleoside appears to be well tolerated by the 
fluorinase. The C-2 modified substrate, ClDEA 174 (Figure 14), behaves similarly to 
the unmodified chlorinated substrate, ClDA 23, undergoing substitution by 
L-selenomethionine to generate the activated intermediate. Intermediate 175 then acts 
as a substrate for a subsequent fluorinase-catalysed fluorination. 
ClDEA 174 is the second substrate with a modification at the C-2 position known to be 
well tolerated by the fluorinase (172 was the first)5. The tolerance most likely arises as 
a result of the location of the active site near the surface of the protein, rather than 
being buried within the protein. C-2 adenine site is specifically oriented towards the 
solvent, projecting out of the active site, leaving this position open for modification.  
 
Figure 14. Substrates for the fluorinase, 174 and 172, with substitutions at C-2 of the adenine base of 
unmodified 23. 
Following the qualitative analysis of ClDEA 174 as a fluorinase substrate, the kinetic 
behaviour of ClDEA 174 was investigated. 
2.5.2. Comparison of rate of transhalogenation for ClDEA 174 and 
 ClDA 23 
The fluorinase-catalysed transhalogenation couples two independent reactions i.e. 
generation of the selenonium intermediate from the corresponding chlorinated 
substrate and then fluorination of the selenonium intermediate. The net transformation 
involves a number of distinct events; therefore a simple kinetic analysis was initially 
undertaken. 
In this study, the rates of production of FDA 22 from ClDA 23, and FDEA 176 from 
ClDEA 174 (Scheme 15) were determined in separate experiments. The 
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substrate (0.25 mM) and fluorinase (2.5 mg.mL−1) were incubated at 37 °C in the 
presence of L-selenomethionine (0.075 mM) and potassium fluoride (50 mM) in 
phosphate buffer (pH 7.8, 8 mM). Aliquots of the solution were removed every 
15 minutes and the concentration of FDA 22 or FDEA 176 were determined by HPLC, 
by comparison of peak area to those of standard curves. The results are summarised 
in Figure 15. 
 
Scheme 15. Fluorinase-catalysed transhalogenations investigated for comparison of the rate of 
production of fluorinated products.  
 
Figure 15. Graph showing the concentration of FDA 22 (●) and FDEA 176 (▲) produced by the 
fluorinase under identical reaction conditions. Reactions were repeated in duplicate. 
FDA 22 was generated more rapidly than FDEA 176, showing that the 
transhalogenation reaction on the unmodified substrate is the faster of the two 
reactions. FDEA 176 is produced at approximately 60% of the rate of FDA 22 
throughout the duration of the experiment. 
90 
 
The alkyne substituent at C-2 affects the rate of transhalogenation and the nature of 
this effect was further explored by closer examination of the kinetic and binding 
parameters of this new substrate. 
2.5.3. Michaelis-Menten kinetic evaluation of ClDEA 174 as a fluorinase 
 substrate 
Michaelis-Menten kinetics cannot be easily evaluated for the two step 
transhalogenation reaction, however, it was possible to isolate and investigate the first 
step in the sequence involving the displacement of chloride to generate the modified 
SAM intermediate, SEAM 196, as shown in Scheme 16. L-Methionine rather than 
L-selenomethionine was used in these investigations to facilitate comparison to similar 
measured parameters from previous experiments.  
 
Scheme 16. First step of the fluorinase-catalysed transhalogenation reaction, showing conversion of 
ClDEA 176 to SEAM 196 by substitution with L-methionine. This product decomposes upon 
heating to give thiomethyl ether 197. 
Steady state kinetic experiments were conducted with ClDEA 176 at six different 
concentrations (10 µM, 25 µM, 50 µM, 100 µM, 250 µM and 500 µM). The reactions 
were run in the presence of saturating concentrations of L-methionine (10 mM), which 
had previously been reported to have a KM of 4.5 mM in the reverse direction with 
FDA 22 as a substrate.4 
Measuring the decreasing concentration of ClDEA 174 proved difficult, as quantifying 
small changes in area of a dominant peak is prone to large errors. As an alternative, 
changes in the concentration of the product SEAM 196 were measured. 
S-Adenosylmethionine is unstable and decomposes to 
5'-thiomethyl-5'-deoxyadenosine upon heating.27,28 Similarly, SEAM 196 decomposed 
through the same pathway, to generate the thiomethyl ether 197 (Scheme 16) and this 
could be detected by HPLC. Quantification of 197 was achieved by comparison to a 
standard curve for ClDEA 174, as both bear the same 2-ethynyladenyl chromophore. 
The results of these experiments are illustrated in Figure 16. 
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Figure 16. Steady state kinetic analysis of reaction of ClDEA 174 with L-methionine. A. Product 
concentration against time for various substrate concentrations. B. Michaelis-Menten plot, 
revealing substrate inhibition at high concentration, fitted without factoring in substrate 
inhibition (- - -) and factoring in substrate inhibition (—). 
The data show that the fluorinase is subject to substrate inhibition at high substrate 
concentration. This may arise due to the way the chlorinated substrates bind in the 
active site. It has previously been shown in X-ray crystal structures that the ClDA 23 
resides in two conformations within the active site.4 The first has the chlorine atom 
bound within in the halogen binding site, as required for reaction. A second is observed 
where the chorine atom is rotated into the vacant sulfonium binding pocket. 
Observation of these two conformers in the solid state would suggest that they are of 
similar energy. Investigations into the binding order of the reactants have shown that 
L-methionine binds after the nucleoside, and that no appreciable L-methionine binding 
was detected by isothermal titration calorimetry in the absence of a nucleoside (such 
as adenosine). 
In the case of substrate inhibition, binding of L-methionine and subsequent reaction is 
slowed as the concentration of substrate increased. More binding events would give 
rise to the conformer of the substrate that is not productive to binding of L-methionine, 
resulting in the observed inhibition at high substrate concentrations. 
Fitting of the kinetic data to a model which factors in the observed substrate inhibition 
gives a KM of 81.7 ± 32.5 µM, and kcat of 0.062 ± 0.004 min–1 for ClDEA 174 as 
substrate. The fluorinase is reported to have a KM for SAM 20 of between 6.5 µM and 
29 µM,26,29 while the KM for FDA 22 in the reverse direction was previously found to be 
140 µM. The modified substrate 174 has a KM within the same order of magnitude as 
other known fluorinase substrates.4,26,29 The turnover number is reflective of the 
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number of turnovers per active site (kcat). The value of kcat for ClDEA 174 is low 
compared to kcat values for other enzymes, but is comparable to the values obtained 
with SAM 20 and native fluorinases from S. cattleya and other  
organisms (0.08–0.26 min−1). 
2.5.4. Competition experiment with ClDEA 174 and ClDA 23 
Assessing the ability of the fluorinase to discriminate ClDA 23 from ClDEA 174, 
provides a crude measure of affinity of the fluorinase for the novel acetylene bearing 
substrate ClDEA 174. If the affinity of the modified substrate is significantly lower than 
that of the natural substrate, we would expect the natural substrate, ClDA 23, to act as 
an effective “inhibitor” of the reaction of ClDEA 174.30 Therefore, the two substrates 
were simultaneously presented to the fluorinase, as illustrated in Scheme 17, in order 
to assess whether they were both converted to the corresponding fluorinated products, 
and whether turnover of ClDA 23 acted as an “inhibitor” for turnover of ClDEA 174.  
 
Scheme 17.  Competition experiment where ClDA 23 and ClDEA 174 were simultaneously presented to 
the fluorinase and their conversion to products monitored. 
The two substrates, each at 0.2 mM were incubated with the fluorinase (6 mg.mL–1) in 
phosphate buffer (20 mM, pH 7.8) in the presence of catalytic L-selenomethionine 
(0.08 mM) and excess fluoride (75 mM) and the conversion to products monitored over 
2 hours by HPLC, as shown in Figure 17. 
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Figure 17. HPLC chromatograms of a competition experiment. The traces show conversion of ClDA 23 
(blue) to FDA 22 (red), while conversion of ClDEA 174 (yellow) to FDEA 176 (green) is 
almost negligible. 
HPLC analysis showed that there was almost no conversion of ClDEA 174 to 
FDEA 176, with only traces of the acetylene-modified product observed after 2 hours. 
Conversely, there was approximately 70% conversion of ClDA 23 to FDA 22 during the 
same time period. Considering that the acetylene modified substrate is processed at 
approximately 60% of the rate of the unmodified substrate when investigated 
separately, the enzyme shows a distinct preference for the unmodified substrate in the 
competition experiment. 
ClDA 23 outcompeted ClDEA 174 as a substrate, effectively behaving as a competitive 
inhibitor with a significantly higher affinity. The result is exaggerated over the two 
independent reactions which make up the transhalogenation. Following this result, we 
were interested in quantifying the affinity of the novel compounds to the fluorinase in 
order to determine whether this was responsible for the high selectivity observed in the 
competition experiment. 
2.5.5. Thermodynamic characterisation of ClDEA 174 and FDEA 176 as 
 ligands 
The binding affinities of the new ligands were determined using isothermal titration 
calorimetry (ITC) in a series of independent experiments where the ligands (ClDA 23, 
ClDEA 174, FDA 22, and FDEA 176) were titrated into a solution of the fluorinase in 
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phosphate buffer. The raw ITC data and binding curves for ClDA 23 and ClDEA 174 
are shown below in Figure 18 A and B respectively. 
 
Figure 18. Isothermal titration calorimetric determination of the binding affinity of A. ClDA 23 (0.70 mM) 
into the fluorinase (53.6 µM) and B. ClDEA 174 (0.57 mM) into the fluorinase (53.6 µM).  
The data show that ClDEA 174, the acetylene-modified substrate has a lower binding 
affinity (Ka = 0.106 ± 0.012 × 105 M–1) when compared to the unmodified substrate 
ClDA 23 (Ka = 1.81 ± 0.058 × 105 M–1). There is an order of magnitude difference in the 
binding affinity which explains the ability of the fluorinase to effectively distinguish the 
two substrates in the competition experiments.  
Binding of either ligand is a thermodynamically favourable process, with a large 
contribution from the enthalpy factor for both ligands. The calculated entropy change 
for both ligands is negative, indicating that binding is entropically unfavourable. 
A similar study was undertaken where the two products of the reaction, FDA 22 and 
FDEA 176 were titrated into the fluorinase enzyme in phosphate buffer. The raw traces 
and peak data after integration are shown in Figure 19 A and B respectively. 
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Figure 19. Isothermal titration calorimetric determination of the binding affinity of A. FDA 22 (1.03 mM) 
into the fluorinase (53.6 µM) and B. FDEA 176 (0.89 mM) into the fluorinase (58.8 µM). 
The binding data for the fluorinated analogues show a similar trend to the chlorinated 
compounds. FDA 22 displays higher binding affinity (Ka = 14.7 ± 1.08 × 105 M–1) for the 
fluorinase, as has been shown previously.26 The acetylene modified FDEA 176 has a 
binding constant of Ka = 1.73 ± 0.09 × 105 M–1, an order of magnitude lower than the 
unmodified analogue.  
The presence of the acetylene lowers the affinity of the compound for the enzyme for 
both the chlorinated and fluorinated nucleosides. The enthalpy of binding is again 
similar for both compounds, while the entropy change is again negative, and is greater 
for the acetylenic compound FDEA 176. 
A comparison of the thermodynamic binding properties of all four compounds, as 
shown in Figure 20, reveals interesting detail about the binding of these ligands to the 
fluorinase. The enthalpic change (ΔH) for the chlorinated ligands is larger than for the 
analogous fluorinated ligands. The improved enthalpic term is compensated for by a 
much larger entropic penalty (-TΔS), and this entropic penalty is greater for the 
acetylenic compounds. The nett result is that the free energy change of binding (ΔG, 
directly related to Ka) is lower for the chlorinated compounds. The origin of this large 
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entropic penalty is unknown. While the fluorinated analogues show lower enthalpic 
gains upon binding, the entropic penalty is much lower, and together this results in a 
higher binding affinity for the fluorinated compounds. 
 
Figure 20. Comparison of the thermodynamic parameters of binding for ClDA 23, ClDEA 174, FDA 22 
and FDEA 176. ΔH was measured directly, while the –TΔS term was calculated using 
T = 298.15 K. ΔG was calculated as the sum of these two terms. 
The enthalpic term for both acetylenic compounds is greater than that for the 
analogous unmodified substrates, evidence of increased interaction through hydrogen 
bonding or van der Waals interactions.31 The only change in the compounds is the 
addition of the acetylene functionality, and the substitution must be partly responsible 
for the increased enthalpic effect. From previous crystallographic work showing the 
FDA 22 within the active site of the enzyme,9 it is evident that the adenine moiety is 
bound between a tryptophan (Trp-50) and phenylalanine (Phe-254) residue through 
π-π interactions. It is possible that the presence of the electron donating triple bond 
may increase the strength of this interaction. The acetylenic compounds are also more 
hydrophobic than their unmodified analogues (as estimated by HPLC).32 Their entry 
into to the relatively hydrophobic active site of the enzyme and out of aqueous solvent 
is also likely contributes to the favourable gain in enthalpy observed.  
The entropic term for the two acetylenic compounds is also shown to be greater than 
their analogous unmodified compounds. This increase in entropic contribution could 
arise due to enhanced π-π-stacking in the active site, reducing conformational degrees 
of freedom for residues in the active site. The presence of the acetylene in the “hole” in 
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the active site may also restrict the conformational flexibility of residues which are 
normally free to move into or out of this gap. 
Following the kinetic and thermodynamic evaluation of the novel acetylenic substrates, 
it was immediately attractive to investigate the structural impact of the acetylene 
substitution, therefore attention turned to co-crystallising these new substrates with the 
fluorinase. 
2.5.6. Crystallographic study of FDEA 176 as a ligand 
Fluorinase enzyme was overexpressed, treated with adenosine deaminase and the 
polyHis tag cleaved by treatment with thrombin, to give a preparation of the fluorinase 
suitable for X-ray crystallisation trials, as described in Section 2.4. 
The fluorinase (6.5 mg.mL−1) was incubated with both ClDEA 174 and FDEA 176 at 
1 mM (from DMSO stock solution), at room temperature overnight, before a series of in 
house and commercial stochastic crystallisation screens were set up in collaboration 
with Dr Stephen McMahon and Prof. Jim Naismith. 
Crystals were obtained under a number of conditions, with both ClDEA 174 and 
FDEA 176 bound, however best diffracting crystals grew from solutions with FDEA 176, 
20% PEG 3350 and 0.2 M ammonium formate. Cryoprotection of a crystal was 
achieved by doping the mother liquor with 20% glycerol and flash freezing in liquid 
nitrogen. The resultant diffraction data were collected at the DIAMOND Light Source 
beam I03 at 100 K. The data were solved by molecular replacement from previous 
fluorinase crystal structures by Dr Stephen McMahon, to generate a crystal structure of 
FDEA 176 bound into the active site of the fluorinase. The structure was solved to a 
resolution of 2.4 Å, and is shown in Figure 21 A. 
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Figure 21. A. Crystal structure of FDEA 176 in the active site of the fluorinase, showing the trimeric 
structure of the enzyme with individual monomers shown in green, blue and red. B. Close up 
of one of the active sites of the fluorinase showing FDEA 176 and its interaction with 
surrounding residues. The alkyne projects between the two subunits as predicted. C. Solvent 
accessible surface profile of the interior of the active site, showing the hole through which the 
acetylene of FDEA 176 projects. 
FDEA 176 binds in the active site in a manner similar to FDA 22, showing similar 
contacts to active site residues as shown in Figure 21 B. Asp-16 forms hydrogen 
bonds to the 2',3'-diol system, and the proton of the amide nitrogen of Ser-158 forms a 
close contact with the fluorine atom in FDEA 176. Both interactions are known to be 
critical for catalysis.26 As for FDA 22, the adenine base forms a hydrogen bonding 
network in the active site through a bridging water molecule to residues Ala-279, 
Ala-280, Asn-215 and further out of the active site. The adenine base also participates 
in π-π stacking interactions with Trp-50 and Phe-254. The acetylene moiety of 
FDEA 176 projects from the active site, out towards the solvent void as predicted by 
initial observations of the hole in the active site. A solvent accessible surface profile of 
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the active site (Figure 21 C) shows a gap in the active site through which the acetylene 
projects. The projection of the acetylene out of the active site opens up the possibility 
of tethering molecules of interest from the acetylene through an appropriate linker. 
Direct comparison of the co-crystal structures of FDA 22 and FDEA 176 shows that the 
gross conformation adopted by the proteins is essentially identical, as illustrated in 
Figure 22 A. A comparison of the binding of the nucleoside within the active site 
(Figure 22 B) also reveals that they are bound in a similar orientation within the active 
site, with the two adenines co-planar. The ethynyl nucleoside is slightly offset to 
accommodate the steric impact of the acetylene. 
 
Figure 22. A. Overlay of the structure of fluorinase bound to FDA 22 (pastel colours) and FDEA 176 
(bright colours) showing no gross conformational change. B. Close up of the active site of the 
fluorinase showing an overlay of the two ligands, FDA 22 (yellow backbone) and FDEA 176 
(grey backbone). C. Close up of the active site showing the water molecule (pink sphere) in 
the cavity in the FDA 22 structure which is displaced by the alkyne in the FDEA 176 
structure. 
100 
 
2.6. Bioconjugation of FDEA 176 to a peptide 
With the goal of using the fluorinase and this modified alkyne substrate for 
bioconjugations, attention turned to selecting an appropriate biomolecule with which to 
evaluate this bioconjugation. Previous work in the St Andrews group33 has made use of 
cyclic Arg-Gly-Asp-bearing peptides (cRGDs), biomarkers for cell surface proteins 
known as integrins, as suitable test peptides for evaluating bioconjugations for PET.  
The αVβ3 integrin (the vitronectin receptor) is an important biomarker of angiogenesis, a 
hallmark of tumours in many cancers.34 Binding of vitronectin to αVβ3 integrin occurs 
through an RGD tripeptide motif 196 (Figure 23) present on the surface vitronectin.35,36 
Incorporating this simple tripeptide motif into peptides has resulted in a range of 
analogues bearing the RGD sequence being developed as imaging biomarkers for the 
angiogenesis process.37 
The most successful range of these mimics are the cyclic pentapeptide 
RGD-containing species, which were found to generally show an order of magnitude 
greater affinity to αVβ3 integrin when compared to their linear analogues.38 The cyclic 
peptides were found to have highest affinity when bearing a hydrophobic residue (such 
as D-phenylalanine) adjacent to the Asp residue, while the final remaining residue 
could be substituted without loss of affinity for αVβ3 integrin.39 Two of the most 
commonly utilised RGD peptides for bioconjugations contain a cysteine residue, 
bearing a free thiol 197 for reaction with soft electrophiles like maleimides; or a lysine 
residue 198 for bioconjugation to activated carboxylic acids or aldehydes.37  
 
Figure 23. The RGD motif 196, identified as the binding element of vitronectin to its receptor, 
αVβ3 integrin, along with two of the more commonly used cRGD peptides for bioconjugations, 
cysteine bearing 197 and lysine bearing 198. 
The acetylenic product of the enzymatic fluorination FDEA 176 requires an azide for 
bioconjugation through a copper-catalysed alkyne-azide cycloaddition (CuAAC), 
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therefore an azide-modified derivative of a cRGD peptide was required. A derivative of 
the lysine bearing peptide c(RGDfK) 197, where the lysine ε-amine group has been 
modified to an azide, gives c(RGDfK[N3])40 199, as shown in Figure 24, which is 
commercially available. This RGD-peptide was investigated in a CuAAC reaction with 
ClDEA 174 and FDEA 176.  
 
Figure 24. Azide modified cRGD peptide 199 for coupling to alkynes through CuAAC reaction. 
2.6.1. Preparation of synthetic samples of ClDEA-RGD 200 and 
 FDEA-RGD 201 
Prior to investigating the CuAAC reaction with enzymatically synthesised FDEA 176, 
synthetic samples of the CuAAC reaction products of both ClDEA 174 and FDEA 176 
with c(RGDfK[N3]) 199 were prepared synthetically for use as reference compounds, as 
shown in Scheme 18. 
The alkynes were taken up in solution in either water, or a mix of water and DMSO to 
obtain a homogenous solution (0.16 mM), to which the RGD peptide 199 (1.25 eq.) and 
a freshly prepared aqueous solution of sodium ascorbate were added.41 Sodium 
ascorbate acts as an oxygen scavenger and reducing agent during the reaction. The 
reaction was initiated by addition of a copper source, in this case a premixed aqueous-
DMSO solution of copper (II) sulfate and the ligand TBTA 202. The copper (II) ions are 
reduced to copper (I) species by ascorbate, while TBTA 202 acts as a protective ligand 
for the active copper (I) species.42 
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Scheme 18. Synthetic reactions to prepare standards of the anticipated products, ClDEA-RGD 200 and 
FDEA-RGD 201. 
The progress of the reactions was monitored by HPLC, and the starting alkynes were 
found to be consumed within 30 min and new products were evident. The products 
were trapped on a reverse phase C18 silica cartridge and washed with water to remove 
DMSO, ascorbate and copper salts. The triazoles (and residual TBTA 202) were eluted 
from the cartridge using 50% acetonitrile in water, before concentration under a stream 
of compressed air afforded the crude product.  
The triazoles were purified by semi-preparative HPLC on a reverse phase column to 
give ClDEA-RGD 200 in 48% yield and FDEA-RGD 201 in 49% yield. 
2.6.2. Coupling the enzymatic transhalogenation with the CuAAC 
 reaction 
The coupling reaction was now explored using FDEA 176 which had been synthesised 
by enzymatic transhalogenation of ClDEA 174. It was anticipated that this process will 
be developed for the 18F-labelling of peptides, where unreacted ClDEA 174 will not be 
removed from the solution before “click” reaction. Therefore the “click” reaction was 
conducted using a crude reaction mixture directly, after precipitation and removal of the 
fluorinase. The solution will still contain phosphate buffer and L-selenomethionine, 
along with residual ClDEA 174. 
ClDEA 174 (0.2 mM, yellow, tR = 10.0 min, Figure 25) was incubated with the 
fluorinase (5 mg.mL−1) and L-selenomethionine (0.1 mM) in phosphate buffer (20 mM, 
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pH 7.8) and in the presence of potassium fluoride (75 mM). The reaction was 
monitored by HPLC from when the enzyme was added (t = 0 h) and then after 2 hours 
of reaction time (t = 2 h). HPLC (Figure 25) revealed that the reaction had proceeded 
to 78% completion, producing FDEA 176 (tR = 8.1 min, green), while residual 
ClDEA 174 (tR = 10.0 min, yellow) is still observed. The reaction mixture was heated to 
95 °C and subsequently centrifuged, and the resultant supernatant transferred to a new 
vial for the CuAAC reaction. 
 
Figure 25. A. Fluorinase-catalysed transhalogenation of ClDEA 174 (tR = 10.0 min, yellow) at t = 0 min. 
B. After 2 h, conversion of ClDEA 174 (tR = 10.0 min, yellow) to FDEA 176 (tR = 8.1 min, 
green) was observed to be 78% complete. C. Click reaction with azido peptide 199 after 1 h 
showing new triazole product, FDEA-RGD 201 (tR = 11.4 min, dark blue). ClDEA-RGD 200 
(tR = 12.7 min, red) was also observed, from residual ClDEA 174 present after the 
transhalogenation. 
A sample of the supernatant containing FDEA 176 (0.1 mM) (and residual ClDEA 174) 
was added to an aqueous solution of c(RGDfK[N3]) 199 (0.2 mM) before sodium 
ascorbate solution (0.5 mM) and CuSO4.TBTA (1 mM) were added. The mixture was 
left to react for 1 h before HLPC analysis (Figure 25) confirmed that all of the alkyne 
products were consumed. Two new peaks were observed in the chromatogram, with a 
similar ratio to that of the starting alkynes. Comparison of the retention time of the 
standards, FDEA-RGD 201 and ClDEA-RGD 200, confirmed these two new peaks 
were the corresponding fluoro- and chloro-triazoles, 201 and 200 respectively. 
The identity of these new products was further confirmed through LC-MS. A similar 
CuAAC experiment was performed on an enzymatically derived mixture of FDEA 176 
104 
 
and ClDEA 174, but in this case, with only 0.5 equivalents of c(RGDfK[N3]) 199. The 
mixture was analysed by LC-MS, and the results are shown below in Figure 26. 
 
Figure 26. A. Portion of the LC chromatogram obtained from the CuAAC mixture, showing the identities 
of the major peaks, identified by their distinctive masses. B. Total ion chromatogram (TIC) for 
the same region. Peaks in the TIC were individually combined to produce a summed mass 
spectrum for each peak. Peaks at tR = 10.8 min and tR = 12.2 min were identified as 
FDEA 176 and ClDEA 174 respectively. C. Summed mass spectrum for the peak at 
tR = 13.0 min, showing m/z = 923.8 and m/z = 462.4, as the singly and doubly charged 
species of FDEA-RGD 201. D. Summed mass spectrum for the peak at tR = 13.7 min, 
showing m/z = 939.8 and m/z = 470.4, as the singly and doubly charged species of 
ClDEA-RGD 200. E. Summed mass spectrum for the peak at tR = 14.1 min, showing 
m/z = 999.8 m/z = 500.4, as the singly and doubly charged species derived from the CuAAC 
reaction of the intermediate selenium containing alkyne and the azido RGD peptide 199, as 
SeDEA-RGD 203. F. Expansion of the peak at m/z = 500.4, showing the distinctive selenium 
isotope pattern. 
LC-MS showed peaks corresponding to the unreacted alkynes, FDEA 176 
(tR = 10.7 min) and ClDEA 174 (tR = 10.7 min). In addition three new peaks were 
observed and found by their masses to be the triazole products of the CuAAC reaction. 
The first new peak at tR = 12.8 min was identified as FDEA-RGD 201 by the m/z peak 
at 923.8, corresponding to the [M+H]+ species shown in Figure 26 C. This peak was 
well separated from the corresponding chloro-triazole ClDEA-RGD 200, at 
tR = 13.5 min, with m/z = 939.8 shown in Figure 26 D. The separation of this 
chlorinated triazole from the fluorinated triazole is important, as these two compounds 
need to be resolved upon preparation of the radiolabelled version of FDEA-RGD 201. 
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In addition to the two expected halogenated products, a third minor peak was observed 
(Figure 26 E), found to be the triazole formed by reaction of c(RGDfK[N3]) 199 with the 
selenomethyl ether by-product from the breakdown of the transhalogenation 
intermediate SeEAM 174. Triazole 203 was identified both by the peak at m/z = 999.8 
and a distinctive selenium isotope pattern (Figure 26 F). 
The CuAAC reaction produced the desired triazole compounds efficiently, in a reaction 
coupled to the enzymatic transhalogenation. The next step was to demonstrate this 
new labelling methodology in the PET environment. However, before the synthesis was 
optimised with [18F]fluoride, the anticipated triazole products were assessed for their 
affinity towards αVβ3 integrin. 
2.6.3. Binding assay of FDEA-RGD 201 to αVβ3 integrin 
A multitude of synthetic RGD peptide derivatives are known to maintain high affinity for 
αVβ3 when modified at the lysine residue.43,44 We wished to establish that the 
bioconjugation to the fluoroadenosine moiety of FDEA 176 though the triazole linker 
was not detrimental to the binding affinity of the RGD motif. 
The binding affinity of the prepared RGD construct was determined by evaluation of the 
binding of the peptide to immobilised αVβ3.37 These experiments were conducted by Dr 
Ian Fleming at the University of Aberdeen. In an ELISA based assay, the compounds 
were evaluated for their ability to complete with c(RGDfK[PEG-PEG-biotin]) for binding 
to immobilised αVβ3, and the values compared to those of reference peptides. The 
results of these investigations are summarised in Table 1. 
Table 1.  IC50 values of selected RGD-containing peptides measured as the ability to compete with 
c(RGDfK[PEG-PEG-biotin]) for binding to immobilized αVβ3 integrin. Results are the average 
± standard error (s.e.) from three independent experiments performed in triplicate. Q is the 
normalised affinity of the peptides, referenced to GRGDSPK. Measurements were performed 
by Dr Ian Fleming. 
Compound IC50 ± s.e /µM Q 
RGD 8.56 ± 2.24 4.019 
GRGDSPK 2.13 ± 0.41 1.000 
c(RGDfK[N3]) 199 0.09 ± 0.01 0.042 
FDEA-RGD 201 0.33 ± 0.03 0.155 
 
The RGD motif itself shows only a moderate competitive ability, with an IC50 value of 
8.56 µM, while the more standard reference peptide GRGDSPK38 shows higher 
affinityy with an IC50 value of 2.13 µM. Unmodified azido-peptide c(RGDfK[N3]) 199 
106 
 
shows an order of magnitude greater binding affinity for αVβ3 than the linear peptides, a 
well-documented feature of the cyclic RGD peptides.39 Conjugation of azido peptide 
199 to the fluoroacetylene FDEA 176 results in an RGD peptide which retains high 
affinity. While the IC50 value for FDEA-RGD 201 is three times higher than that of the 
unmodified peptide 199, the construct still retains an affinity approximately an order of 
magnitude greater than the linear reference compounds. The presence of the 
fluoroadenosine moiety is therefore not deleterious to the integrin affinity of the peptide, 
and would be expected to show similar in vivo binding properties to other RGD 
peptides, assuming the peptide is not metabolised upon administration. 
2.7. Radiosynthetic evaluation of ClDEA-fluorinase system 
 for PET 
PET experiments described in this section were conducted at Imanova Ltd., based at 
the Hammersmith Hospital in London. Radiolabelling experiments were performed by 
Dr Mayca Onega, while animal studies were performed by Dr Sharon Ashworth. All of 
the experiments described were performed in accordance with the U.K. Animals 
(Scientific Procedures) Act 1986. The procedures used were approved by the Animal 
Ethical Review Committee of Imperial College, London. 
2.7.1. Fluorinase mediated [19F]fluoride labelling vs [18F]fluoride labelling 
Enzymatic assays conducted with the fluorinase enzyme using [19F]fluoride are usually 
conduced with catalytic quantities of the enzyme (29–145 µM), and an excess of 
fluoride ion (20–75 mM). This ratio changes dramatically when using [18F]fluoride, 
where the fluoride ion concentration is very much lower, and the enzyme concentration 
very much higher. 
The amount of fluorine-18 in a sample is quantified in terms of activity, in units of 
Bequerel (Bq), where 1 Bq = 1 decay per second. Specific activity is the measure of 
the activity per mole of compound and specific activity decreases in the presence of 
any fluorine-19. The theoretical maximum specific activity of [18F]fluoride ion is 
6.4 × 107 GBq.mmol−1.45 Therefore, a 0.5 GBq sample of [18F]fluoride used in a 250 µL 
volume reaction (average fluorinase PET experiment) has a [18F]fluoride ion 
concentration of 31 nM. In real terms, [18F]fluoride concentrations are used in the low 
nanomolar or picomolar range.45 This, coupled to fluorinase concentrations of 0.5 mM 
(20 mg.mL−1), means there is ~106 excess of fluoride compared to enzyme. The 
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fluorinase is operating under single turnover conditions. The result of this is that the 
fluorinase has been found to be very efficient in transforming [18F]fluoride to organic 
fluorine-18, where reactions are rapid and incorporations high.1,46,3,47,48 
2.7.2. Synthesis of [18F]FDEA-RGD [18F]-201 
The reaction of the alkyne-modified substrate ClDEA 174 was explored in a 
transhalogenation reaction with [18F]fluoride to produce [18F]FDEA [18F]-176, as 
illustrated in Scheme 19.  
 
Scheme 19. Fluorinase catalysed transhalogenation reaction with [18F]fluoride where the fluorinase is 
used to synthesise [18F]FDEA [18F]-176. 
ClDEA 174 (~0.1 mg, final concentration ~1 mM) was incubated with the fluorinase 
(20 mg.mL−1), L-selenomethionine (0.08 mM) and [18F]fluoride (up to 525 MBq) for 
30 minutes at 37 °C. The enzyme was denatured and precipitated by heating to 95 °C 
for 5 min and the reaction centrifuged at 13 000 rpm for 5 min. The supernatant was 
analysed by HPLC coupled to a UV- and radio- detector in series, and the resulting 
chromatograms are shown in Figure 27. In the radio-HPLC trace shown in Figure 27 A 
two peaks were evident, one with tR = 1.7 min, which was identified as unreacted 
[18F]fluoride, while the second, at tR = 7.2 min represented a new product. The new 
product was identified as [18F]FDEA [18F]-176 by spiking with a synthetic sample of 
[19F]-176, which was found to co-elute. This can be seen in the UV trace shown in 
Figure 27 B. The radiochemical incorporation of [18F]fluoride into [18F]-176 was found 
to be 69%. 
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Figure 27. A. Radio-HPLC chromatogram of the transhalogenation mixture after 30 minutes, showing 
residual [18F]fluoride at tR = 1.7 min and a new product, [18F]FDEA [18F]-176, at tR = 7.2 min. 
B. UV HPLC chromatogram after spiking this sample with FDEA 176 confirmed that the new 
product was [18F]-176. Chromatograms acquired by Dr Mayca Onega at Imanova.  
The crude fluorinase reaction mixture containing [18F]FDEA [18F]-176 was subjected to 
a CuAAC reaction with the azido RGD peptide 199 as described previously in 
Section 2.6.2, and shown in Scheme 20. c(RGDfK[N3]) 199 (0.3 mg) was dissolved in 
the supernatant after centrifugation. This was followed by addition of fresh sodium 
ascorbate solution and a solution of CuSO4.TBTA. This mixture was incubated at room 
temperature for 30 min, before the crude reaction mixture assessed by radio-HPLC 
(Figure 28). Conversion to the triazole [18F]-201 (tR = 8.8 min) was complete, and only 
residual excess [18F]fluoride (tR = 1.7 min) from the labelling step was still present. 
 
Scheme 20.  CuAAC reaction between radiolabelled [18F]-176 and c(RGDfK[N3]) 199, to generate triazole 
[18F]-201. 
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Figure 28. Radio-HPLC trace after the CuAAC reaction showing residual [18F]fluoride, and the 
production of a new compound, [18F]FDEA-RGD [18F]-201 at tR = 8.8 min. [18F]FDEA 
[18F]-176 (tR = 7.2 min) is not observed. 
[18F]FDEA-RGD [18F]-201 was purified by semi-preparative HPLC. Fractions containing 
the product were collected, diluted in water and the product [18F]-201 was trapped on a 
C18 cartridge. The cartridge was washed with water to remove any acetonitrile before 
eluting [18F]-201 with ethanol into saline to give a solution suitable for injection. The 
non-decay corrected radiochemical yield for the synthesis of [18F]-201 from [18F]fluoride 
was found to be up to 20%, delivering up to 95 MBq of the product for injection after a 
2 h synthesis procedure. 
After formulation, the product, [18F]-201 was analysed for its purity by UV- and 
radio-HPLC, as shown in Figure 29. The radio-HPLC trace shown in Figure 29 A 
indicates that all residual [18F]fluoride has been removed from the reaction mixture, and 
that [18F]-201 has a high radiochemical purity. Spiking the final product with a synthetic 
sample of [19F]-201 (Figure 29 B) was consistent with the identity of the isolated tracer 
as [18F]FDEA-RGD [18F]-201. 
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Figure 29. A. Radio-HPLC chromatogram of the purified triazole product [18F]-201, a single peak at 
tR = 8.8 min. B. UV HPLC chromatogram after spiking with FDEA-RGD 201 confirmed that 
the product was [18F]-201. Chromatograms acquired by Dr Mayca Onega at Imanova. 
These results illustrate that the synthetic procedure with the new fluorinase substrate 
works well under the conditions of a PET radiolabelling experiment. The fluorinase 
coupled to this novel alkyne-bearing substrate, can clearly be applied further as a tool 
for radiolabelling peptides. The [18F]-triazole [18F]-201 synthesis was investigated in an 
imaging experiment in healthy rats to assess the stability of the new construct and to 
investigate the biodistribution of the tracer in vivo. 
2.7.3. In vivo evaluation of [18F]FDEA-RGD 201 
One of the requirements of a good radiotracer is that it remains stable in vivo for the 
duration of the imaging experiment. Radiotracers, like other drugs, pass through 
normal metabolic pathways and have defined metabolic half-lives once administered. 
Metabolism of the tracer compromises its utility on two fronts. If the metabolism 
involves cleavage of the 18F–C bond, the primary agent which interferes with the 
imaging process is [18F]fluoride. [18F]Fluoride that is released from the tracer into 
systemic circulation is absorbed by the bone due to the high affinity of fluoride for the 
calcium minerals.49 Bone uptake can mask other pathologies and is an undesired 
quality for radiotracers. Metabolites which do still contain the fluorine-18 label will have 
altered pharmacokinetic properties to the parent tracer, obscuring accurate 
determination of its imaging profile.  
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[18F]FDEA-RGD [18F]-201 was synthesised as described above and administered to 
two healthy, male Sprague-Dawley rats. For one of the rats, a dynamic PET scan was 
acquired over 60 min, co-registered with a CT scan for attenuation correction. Arterial 
blood samples were periodically drawn from both rats for metabolite monitoring. The 
rats were euthanased post-imaging and dissected post mortem and the activity 
accumulation in the dissected tissues assessed by gamma counting. 
The summed PET-CT image of the rat is shown below in Figure 30. PET image scales 
are presented as standard uptake values (SUV = {(tissue activity/mL)/(injected 
activity/animal weight[g])}). The image illustrated that [18F]FDEA-RGD [18F]-201 
accumulated predominantly in the liver of the rat during the scan. Lower uptake was 
also observed in the skin and lungs, but it was clear that [18F]-201 did not cross the 
blood-brain barrier into the CNS. 
The image also confirmed that the 18F–C bond of [18F]-201 was metabolically stable 
in vivo. No uptake of radioactivity was observed in the bone in Figure 30, indicating 
that the tracer was stable to defluorination. Further information about the biodistribution 
of the tracer was obtained from post mortem gamma counting. 
 
Figure 30.  A. Coronal and B. sagittal fused summed PET (colour) and CT (greyscale) images 
(0-70 min). [18F]FDEA-RGD [18F]-201 in the liver. PET image scales are presented as 
standard uptake values (SUV= {(tissue activity/mL)/(injected activity/animal weight[g])}). 
Images acquired by Dr Sharon Ashworth and Dr Mayca Onega of Imanova Ltd. 
The biodistribution of activity (Figure 31, expressed as SUV values) showed that the 
tracer was excreted rapidly by the urinary system, and that after 60 min most of the 
activity was present in the urine, with significant levels also present in the kidneys and 
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bladder. Accumulation of the tracer however was observed in the liver, small and large 
intestines and the lungs. This is consistent with the natural biodistribution profile of αVβ3 
integrin and similar accumulation has been observed in heathy controls for other 
radiolabelled RGD constructs.50 
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Figure 31. The mean biodistribution of radioactivity in the tissues of healthy rats (n=2) expressed as 
standardised uptake values (SUV) at 60 minutes injection of [18F]FDEA-RGD [18F]-201. 
SI = small intestine, LI = large intestine. Data collected by Dr Sharon Ashworth. 
The blood plasma of the rats was analysed for the presence of radiolabelled 
metabolites to investigate whether the tracer is metabolised at sites other than 
the 18F-C bond. Arterial blood samples were drawn from both rats at 5, 15, 30 and 
60 min post injection and the plasma fractions extracted with acetonitrile and the 
extracts analysed by HPLC. Thirty fractions were collected from the HPLC over 10 min, 
and these fractions were analysed for their radioactivity content. In the samples from 
both rats at all time points, only a single peak was observed in the reconstructed 
chromatograms. The chromatograms for the 60 min samples are shown in Figure 32. 
The single peak was confirmed to be [18F]FDEA-RGD [18F]-201 by co-elution with a 
synthetic standard of [19F]FDEA-RGD 201. This data confirms that in addition to 
demonstrating 18F–C bond stability, the circulating tracer in the blood was not subject to 
significant metabolism at other sites and that the intact compound was successfully 
perfusing the tissues. 
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Figure 32. Reconstructed radiochromatogram of acetonitrile plasma extracts of arterial blood 
from A. rat A and B. rat B, taken 60 min post injection and showing a single peak, 
corresponding to unmetabolised [18F]FDEA-RGD [18F]-201.  
The biodistribution data confirm that the compound behaves in a manner consistent 
with an intact RGD motif and that [18F]-201 targets organs that have naturally higher 
levels of expression of the αVβ3 integrin. 
2.8. Conclusions 
The aim of this project was to design and investigate a novel substrate for the 
fluorinase for application towards novel labelling strategies for positron emission 
tomography. Based on known protein crystal structures of the fluorinase, there was an 
indication that an acetylenic substrate, ClDEA 174, may be a suitable candidate for 
investigation. The acetylene was expected to lie in a void projecting from the active site 
of the fluorinase. 
Towards this end, the new substrate and its anticipated product were synthesised and 
the fluorinase was overexpressed for biotransformation assays. ClDEA 174 was 
investigated as a substrate and it was found to be a relatively good substrate for the 
fluorinase, undergoing a transhalogenation reaction when incubated with the enzyme. 
The kinetics of this new substrate with the fluorinase were investigated and the 
transhalogenation reaction was found to operate at approximately 60% of the rate of 
the unmodified substrate. Steady state kinetic parameters, similar to those of other 
known fluorinase substrates were obtained. In a competition experiment, where 
ClDEA 174 was incubated with the fluorinase in the presence of the unmodified 
substrate ClDA 23, the fluorinase catalysed the reaction only of unmodified substrate 
confirming that the enzyme was able to distinguish the two substrates. 
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The ability of the enzyme to distinguish these two substrates prompted investigation of 
the binding parameters of the new substrate 174 and product 176, by comparison to 
ClDA 23 and FDA 22. Isothermal titration calorimetry indicated that the acetylenic 
substrates bind with lower affinity than their non-modified analogues, while maintaining 
the trend that the fluorinated compounds show an order of magnitude higher binding 
affinity when compared to their chlorinated analogues. 
Crystallographic investigations of FDEA 176 bound to the fluorinase showed that the 
acetylene occupied the pocket that was predicted when the substrate was designed. 
FDEA 174 was investigated in a CuAAC reaction with and azide-bearing RGD 
peptide 199, and found to undergo a rapid reaction. The addition of the fluoroacetylene 
moiety to the cyclic peptide did not significantly affect the binding of the motif to 
immobilised αVβ3 integrin, and showed a similar sub-micromolar affinity to that of the 
unmodified cyclic RGD peptide. 
This novel biotransformation was transferred to the PET environment, and the 
transhalogenation experiments repeated with [18F]fluoride. [18F]FDEA [18F]-176 was 
prepared with a 69% radiochemical conversion, and this compound was reacted with 
c(RGDfK[N3]) 199 in a CuAAC reaction to efficiently generate [18F]FDEA-RGD 
[18F] 201. The “click” product was purified by HPLC and formulated to prepare a dose 
ready for injection into a rat. The non-corrected radiochemical yield was found to be 
20% for the synthesis of [18F]-201.  
[18F]FDEA-RGD [18F]-201 was injected into two rats and was found to accumulate in 
tissues in accordance with the natural distribution of αVβ3 integrin. The novel tracer, 
[18F]-201, was found to be metabolically stable up to 60 minutes in vivo. 
These protocols extend the application of the fluorinase as a mild and efficient 
18F-labelling tool beyond the natural substrate. One limitation of this approach is that it 
requires the availability of azide-bearing biomolecules, which are pre-functionalized 
prior to labelling. This can be achieved by recombinant protein expression with azide-
containing amino acids51 or by using traditional bioconjugations at lysine or cysteine to 
azide-bearing linkers.52 However, it was discovered that the alkyne functionality 
projects out of the active site and into the solvent, and this opened up the additional 
possibility of extending a linker from the terminus of the acetylene to pre-tag a peptide 
for single step labelling. This development is discussed in the next chapter. 
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3. Synthesis and evaluation of multimeric RGD 
substrates for the fluorinase 
3.1. Extension of the fluorinase system to “last step” 
 labelling for PET 
The development of ClDEA 174, the acetylenic substrate for the fluorinase, showed 
that the enzyme has a tolerance at the 2-position of the adenine base. Chapter 2 
discussed how the modification of the nucleoside substrate at this position generated a 
novel substrate for the enzyme. The modified substrate was employed in a fluorinase-
catalysed transhalogenation reaction coupled to a CuAAC reaction for the synthesis of 
a novel PET radiotracer, [18F]FDEA-RGD [18F]-201, in a two-step procedure for peptide 
radiolabelling. 
There is a need for simple, “last step” radiolabelling procedures with fluorine-18 that 
are conducted under conditions suitable for labelling peptides and proteins.1 The poor 
nucleophilicity of aqueous [18F]fluoride ion precludes direct labelling of biomolecules in 
buffer, and to do so requires the use of either prosthetic groups2 or fluoride 
sequestering species (boron,3 aluminium4 or silicon5). Based on the substrate tolerance 
of the fluorinase, we were interested in exploring this enzymatic system for “last step” 
radiolabelling of peptides. 
The 2-position of the fluorinase substrate lies close to a hole at the surface of the 
enzyme active site. A co-crystal structure of FDEA 176 with the fluorinase (Figure 1 A) 
showed that the acetylene at C-2 projects out of the active site of the enzyme, towards 
the bulk solvent. It was immediately attractive to explore tethering a peptide cargo to 
the acetylene through an appropriate linker. 
The enzymatic approach could offer a novel protocol for “last step” fluorination of 
peptides. A “last step” labelling procedure using an enzyme is attractive as it avoids the 
use of heating, low pH, or organic solvents during the radiolabelling reaction. Harsh 
conditions are required for all of the other presently available “last step” labelling 
procedures. 
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Based on this hypothesis, a peptide-bearing substrate for the fluorinase was designed, 
as shown in Figure 1 B. The proposed substrate, ClDEA-TEG-RGD 204, bears a 
chlorinated nucleoside for transhalogenation with fluoride, a tetraethyleneglycol (TEG) 
linker to extend the peptide cargo away from the surface of the enzyme, and an RGD 
peptide as a PET-relevant biomolecule. The acetylene of the modified substrate was 
preserved, extending the linker and peptide cargo out of the active site as it was 
suspected to be essential for maintaining activity.  
 
Figure 1. A. Co-crystal structure of the fluorinase and FDEA 174 showing the acetylene oriented out of 
the active site, between two subunits of the trimer. B. Tethering a biomolecule to the 
acetylene through an appropriate linker offers the potential of a “last step” biomolecule 
labelling for PET using the fluorinase enzyme. 
3.1.1. Development of a peptide-bearing substrate for the fluorinase 
ClDEA-TEG-RGD 204 was synthesised by Dr Qingzhi Zhang (St Andrews), using a 
similar approach to that employed in the synthesis of ClDEA 174, described in 
Chapter 2. A Sonogashira coupling of mono-protected TEG-derivative 205 to 
2-iodoadenosine 179, followed by chlorination and silyl deprotection generated 
ClDEA-TEG 206 as a key intermediate. ClDEA-TEG 206 was coupled to azido-RGD 
peptide 199 using a CuAAC reaction, to give ClDEA-TEG-RGD 204. 
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Scheme 1. Synthetic route towards ClDEA-TEG-RGD 204, using a CuAAC reaction to tether the peptide 
cargo 199 to the linker-bearing nucleoside 206. Synthesis conducted by Dr Qingzhi Zhang. 
ClDEA-TEG-RGD 204 was incubated with the fluorinase in the presence of L-SeMet 
and fluoride in a phosphate buffer, and found to undergo enzymatic transhalogenation 
to rapidly generate FDEA-TEG-RGD 207, as shown in Figure 2. The construct was 
also found to retain high affinity (0.07 µM) for immobilised αVβ3 integrin in a 
competition-based assay, similar to that described for FDEA-RGD 201 in Chapter 2. 
 
Figure 2. Fluorinase catalysed transhalogenation of ClDEA-TEG-RGD 204 to FDEA-TEG-RGD 207, 
showing that the fluorinase can be applied to “last step” fluorination of peptides. Experiments 
conducted by Dr Qingzhi Zhang. 
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3.1.2. “Last step” radiolabelling of a peptide with fluorine-18 
The “last step” fluorination protocol was explored under PET radiolabelling conditions 
at Imanova Ltd by Dr Mayca Onega. When the ClDEA-TEG-RGD 204 (0.3 mM) was 
incubated with the fluorinase (20 mg.mL−1) and [18F]fluoride solution, the 
transhalogenation reaction was found to proceed to completion within 30 minutes. No 
residual [18F]fluoride was observed by radio-HPLC, suggesting that all [18F]fluoride was 
incorporated into the radiolabelled product, [18F]-207, as shown in Figure 3 A. 
 
Figure 3. A. Radio- and UV- HPLC traces of a fluorinase-catalysed transhalogenation reaction with 
ClDEA-TEG-RGD 207 and [18F]fluoride showing complete conversion to [18F]-207 after 
30 min. No residual [18F]fluoride was observed in the supernatant. B. Co-registered PET-CT 
image of a healthy rat dosed with [18F]FDEA-TEG-RGD [18F]-207. No uptake of radioactivity 
is seen in the bone indicating that the construct is stable to defluorination. Experiments 
conducted by Dr Mayca Onega and Dr Sharon Ashworth at Imanova Ltd. 
The radiolabelling reaction with ClDEA-TEG-RGD 204 was repeated and the product, 
[18F]-207 purified by semi-preparative HPLC. Isolated [18F]-207 was formulated into 
sterile saline and injected into a healthy rat in order to assess if this new peptide 
construct was metabolised in vivo. The summed PET-CT image of the rat obtained 
post administration is shown below in Figure 3 B. The image revealed uptake of the 
RGD-construct [18F]-207 into tissues of known high expression of the αVβ3 integrin, 
including the kidneys and the liver.6 Importantly, little bone uptake of radioactivity was 
observed, indicating that [18F]-207 is not metabolised to release [18F]fluoride ion. 
Blood plasma metabolite analysis revealed that the construct was metabolised at a site 
other than the C–18F bond. A more polar radioactive metabolite was observed in blood 
extracts, suggesting oxidative metabolic processing of [18F]-207. In contrast, 
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[18F]FDEA-RGD [18F]-201, discussed in Chapter 2, did not undergo metabolism after 
administration. The difference between these two constructs is the presence of the 
acetylene and TEG chain in [18F]FDEA-TEG-RGD [18F]-207, suggesting that this may 
be the site of metabolic processing. The most likely position for metabolism is the 
internal alkyne, which could be a substrate for oxidation by P450 enzymes,7 resulting in 
metabolism to more polar metabolites. 
The ability of the fluorinase to recognise and react with the construct 204 revealed that 
the substrate tolerance of the fluorinase can be exploited beyond a simple acetylene. 
The tolerance of a more elaborate peptide-bearing substrate opened the possibility of 
tethering a range of larger and more complex peptide cargos to the PEG linker. 
With an appropriate substrate, the fluorinase offers novel methodology for “last step” 
radiolabelling of peptides, under neutral pH conditions directly from aqueous 
[18F]fluoride. The above experiments have demonstrated that a simple peptide-linked 
substrate could be efficiently fluorinated by the enzyme using both high concentrations 
of [19F]fluoride, and under low [18F]fluoride concentration conditions for PET. It was 
therefore attractive to explore more elaborate substrates for the fluorinase enzyme, in 
an effort to further probe the extent of the tolerance at the C-2 position of the substrate. 
Multimeric RGD peptides are well characterised8,9 constructs employed for PET 
imaging using either fluorine-18 or other heavy metallic PET isotopes. We were 
therefore interested in exploring such constructs as potential substrates for the 
fluorinase enzyme. 
3.2. RGD multimers in molecular imaging 
Multimeric interactions play a key role in recognition events between biological ligands 
and receptors.10 For such interactions, multiple weak non-covalent interactions 
between monovalent ligands and individual receptors are enhanced by attaching the 
individual ligands to a single scaffold. For such interactions, many individually weak 
binding interactions can give rise to a highly thermodynamically favourable association. 
The increased strength of the binding interaction between a multivalent ligand and 
multiple receptors arises as the entropic penalty associated with binding is largely paid 
upon binding of the first component of the multimeric ligand. The subsequent binding of 
additional ligands each provides a favourable enthalpic contribution to the total free 
energy of the interaction, while contributing a smaller entropic penalty.11 
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An example of multimeric enhancement of binding is observed with the association of 
the pentameric cholera toxin (as a pentavalent receptor) to ganglioside GM1 on the 
surface of cells.12 The total free energy change of the sequential binding of the cholera 
toxin to five individual oligomers of ganglioside GM1 in solution (first binding event 
shown in Figure 4 B) was less than the total free energy change upon binding to 
densely packed GM1 on a cell surface. On the lipid surface, the individual units of GM1 
are no longer free to translate and rotate, and the assembly behaves more like a 
multivalent ligand. The binding of the pentavalent toxin to GM1 on the surface of a 
bilayer (Figure 4 C) was essentially irreversible. The cholera toxin- GM1 system was 
also found to exhibit positive cooperativity, where the binding of one oligomer of GM1 to 
the toxin led to a larger enthalpic gain upon binding of the second, and subsequent 
oligomers of GM1. For such multimeric systems, cooperativity can be positive, neutral or 
negative, however, the nett effect of enhanced free energy of binding is still observed in 
truly multivalent interactions.13 
 
Figure 4. A. Binding of a monomeric ligand to a monomeric receptor. B. Binding of multiple monomeric 
ligands to a multimeric receptor. In this case, the increased affinity largely results from 
increased effective molarity of the receptor. C. An assembly of effectively pentavalent ligands 
binding to a pentavalent receptor in a multivalent interaction, which was found to be 
essentially irreversible for the cholera toxin-GM1 system. 
The inherent increase in strength of the receptor-ligand interaction upon 
multimerisation, through either simple multimeric or more complex multivalent effects, 
is attractive within the context of molecular imaging. High affinity ligands are most 
desired as they show lower non-specific uptake coupled to stronger association with 
their target. The result of stronger binding interactions is improved signal to noise ratios 
(or tumour/blood ratios in the contexts of cancer), leading to improved images for use 
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in tumour diagnosis and monitoring.14 The search for high affinity ligands for biological 
receptors has led to the development of imaging agents based on multivalent antibody 
fragments15 or multivalent small peptides.16 
The integrin proteins are a series of cell surface receptors that play a role in cellular 
recognition and adhesion. One such integrin, αVβ3, has been identified as a biomarker 
of angiogenesis, and is strongly associated with malignant tumours.17 The ligand 
recognition sequence for binding to αVβ3 integrin is the arginyl-glycinyl-aspartyl (RGD) 
tripeptide motif. This motif has been incorporated into many monovalent molecular 
imaging agents, as discussed in Chapter 2.18 
Cyclic RGD-containing peptides are high affinity ligands for αVβ3 integrin,19 and 
multimerisation of these peptides has proved a reliable strategy for further enhancing 
the affinity (or avidity) of the resultant radiotracer.8,9,14  
3.2.1. Multimeric RGD peptides based on amides 
Amide couplings have been widely applied for the synthesis of multimeric RGD 
peptides. c(RGDfK), bearing a lysine side chain has been used as a source of the RGD 
peptide for such multimers. The constructs are synthesised by coupling a suitably 
protected cRGD peptide, bearing a free amine, to a divalent (or tetravalent) acid 
derivative. 
The first synthesis of a radiolabelled multimeric RGD peptide was reported by Barret 
et al.16 who synthesised technetium-99m labelled RGD-dimer [99mTc]-208 (Figure 5) for 
use in SPECT (single photon emission computerised tomography) imaging. This 
assembly is based on a glutamic acid core, conjugated to the lysine residues of 
c(RGDfK). Subsequent coupling of the α-amine of the glutamic acid to a 
hydrazinonicotinic acid (HYNIC) ligand, followed by coordination to technetium-99m, 
gave the active dimeric RGD radiotracer [99mTc]-208.  
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Figure 5. RGD-dimer [99mTc]-208 synthesised by Barret et al.16 as the first multimeric RGD peptide for 
application to molecular imaging. 
Janssen et al.20 subsequently synthesised a monovalent analogue of [99mTc]-208, 
where the ε-amine of the lysine residue was coupled directly to the HYNIC ligand. 
Dimer [99mTc]-208 exhibited a 100-fold lower IC50 in in vitro assays compared to its 
monomeric analogue (0.1 vs 10 nM). SPECT imaging experiments in mouse tumour 
models, revealed that that the dimeric RGD peptide [99mTc]-208 showed higher tumour 
retention compared to the monomer. The authors suggested that this was due to the 
effect of the multimeric nature of [99mTc]-208, resulting in increased affinity αVβ3 integrin 
present on tumour cell surfaces. 
Following these initial results, a range of multimeric RGD peptides based on amide 
couplings have been developed for use in both SPECT and PET imaging. Many of 
these investigations have attempted to optimise the linker between the RGD units to 
develop truly multivalent ligands, as opposed to multimeric ligands.21 If the linker 
between two ligands is not sufficiently long, or is unable to access the required 
conformation to interact with two distant receptor sites, the multivalent effect is lost.9 A 
tetrameric RGD peptide construct based on a central deca-peptide linker led to 
decreased mobility of integrins on the surface of cells, suggesting that correctly 
designed multimers can lead to multivalent binding events.22  
Modification of the linkers has also been used to tune the pharmacokinetic properties of 
the resultant tracers. Linkers of various lengths based on polyethyleneglycol (PEG),23 
triglycinyl,24 triaspartyl,25 and sugar-amino acids26 (Figure 6) have been used in 
multiple architectures in an attempt to maximise binding, promote urinary rather than 
gastrointestinal clearance, and also for accelerating washout of non-specific bound 
tracer, improving signal to noise ratios. 
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Figure 6. Dimeric and tetrameric RGD scaffolds and linkers used to identify multimers with optimal 
binding properties. Figure adapted from Liu.9 
Many multimeric RGD peptides bear metal chelating groups, as co-ordination to 
radiometals is often the last step in the synthesis of such tracers. Fewer fluorine-18-
based multivalent radiotracers have been developed, as incorporation of fluorine-18 
into such scaffolds often requires a multi-step, prosthetic group-based strategy.27–30 
Two multimeric RGD compounds, synthesised using a “last step” radiofluorination 
protocol have been recently evaluated in humans for the first time. These aluminium 
chelates, [18F]alfatide I [18F]-21031,32 and [18F]alfatide II [18F]-21233,34 as shown in 
Scheme 2, have been prepared using a kit-like35 form of the methodology described in 
Chapter 1. 
An aluminium [18F]fluoride complex is chelated by a NOTA-ligand attached to a 
peptide, which in both cases is a dimeric RGD peptide. These two clinical imaging 
candidates differ in the linker topology. Alfatide I [18F]-210 bears a thiourea-PEG linker 
between the radiolabel and the dimeric c(RGDfK) peptides, which are conjugated by 
amide bonds to a central glutamic acid core. The NOTA chelating unit of alfatide II 
[18F]-212 is directly attached to a glutamate core, to which two units of c(RGDfK) are 
conjugated through PEG linkers. 
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Scheme 2. Syntheses of [18F]alfatide I [18F]-210 and [18F]alfatide II [18F]-212 as multimeric RGD 
complexes, labelled with fluorine-18 using “last step” methodology.31–34 
[18F]Alfatide I [18F]-210 was evaluated for imaging of αVβ3 integrin expression in patients 
with lung squamous carcinoma and adenomatous carcinoma. The tracer showed 
excellent tumour to blood ratios, an outcome suggested to be due to the 
multimerisation of the RGD peptide.31 The novel radiotracer had the ability to identify 
almost all tumours in the nine lung cancer patients, however in one case, additional 
lesions were detected using [18F]FDG-based imaging, the gold standard for 
assessment of PET radiopharmaceuticals.  
[18F]Alfatide II [18F]-212 has been evaluated in patients with metastatic brain tumours 
which had previously been identified by MRI or CT.34 In this case, the novel tracer 
proved superior to [18F]FDG [18F]-35, visualising all lesions that had been previously 
identified in the anatomical scans, whereas [18F]FDG [18F]-35 only identified 10 of the 
20 previously identified lesions. These clinical results emphasise the need for the 
development of novel, selective tracers to compliment the widespread use of 
[18F]FDG [18F]-35. 
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3.2.2. Multimeric RGD peptides based on triazoles 
The CuAAC reaction between an alkyne and an azide-modified RGD peptide has 
proven to be a useful reaction for the assembly of dendrimeric peptides.36,37 The 
ε-amine of the lysine residue of c(RGDfK) has been exploited for functionalisation to 
make the scaffold applicable to CuAAC-based “click” chemistry. Incorporation of an 
azide is accomplished either using a diazo-transfer reaction,36,38,39 or alternatively by 
coupling the terminal amine to an azidopentanoic acid.37  
Liskamp et al.38 reported the use of the CuAAC reaction for the synthesis of indium-111 
labelled di- and tetra-meric RGD peptides. Their approach began with the synthesis of 
a dipropargyldihydroxybenzoic ester derivative, used as the core of the dendrimeric 
assembly. This core was either used to generate a dimeric scaffold, or it was coupled 
to two further dipropargyldihydroxybenzoic ester derivatives to offer a tetrameric 
scaffold. The scaffolds were coupled to a protected DOTA (1,4,7,10-tetraazadodecane-
N,N',N'',N'''-tetraacetate) chelator via an ethylenediamine linker, to generate 213 and 
215 as shown in Scheme 3. These dendrimeric assemblies were then coupled to 
c(RGDfK[N3]) 199 using a CuAAC reaction. 
 
Scheme 3. Divalent 213 and tetravalent 215 dendrimeric alkynes were found to undergo efficient CuAAC 
reaction with c(RGDfK[N3]) 199 under microwave conditions, generating 214 and 216. 
129 
 
The CuAAC reaction between 213 or 215 and c(RGDfK[N3]) 199, catalysed by a 
CuSO4-ascorbate-Cu wire system, was found to be inefficient at room temperature. 
The reaction proceeded rapidly (5-30 min) to generate 214 or 216 when heated by 
microwave irradiation in DMF/H2O mixtures. Isolated yields for the synthesis of 
chelators 214 and 216 were moderate, at 11% and 36% respectively. The dendrimers 
214 and 216 were subsequently labelled with 111In and in vivo assessment revealed 
that the [111In]-labelled tetrameric RGD dendrimer was taken up in renal cell carcinoma 
xenografts in mice to a higher degree than the dimeric analogue. In vitro assays 
showed that tetrameric dendrimer 216 showed lower IC50 values (50 nM) compared to 
the dimeric construct 214 (356 nM). These results illustrate the advantage of 
multimerisation of RGD peptides for imaging of αVβ3 integrin expression in cancers. 
A similar multimerisation approach using the CuAAC reaction based on a 
trifunctionalised melamine core (Scheme 4) was reported by Reichert et al.40 They 
synthesised a DOTA-bearing melamine derivative bearing either one or two 
propargyl-diethyleneglycol units. Using a similar microwave-enhanced CuAAC reaction, 
the coupled the alkynes to c(RGDfK[N3]) 199 to generate monomeric and dimeric RGD 
constructs. They found the dimeric analogue 218 to have a higher affinity for 
immobilised αVβ3 integrin than its monovalent counterpart.  
 
Scheme 4. Synthesis of a dimeric RGD peptide 218 using the CuAAC reaction, as reported by 
Reichart et al.40 
In both reports, the CuAAC reaction was reported to require forcing conditions 
(microwave or conventional heating) to ensure complete reaction. Wängler et al.37 have 
reported a failed attempt to synthesise high order polyamidoamine (PAMAM) RGD 
dendrimers using the CuAAC reaction. They found that the CuAAC reaction with di- 
and tetra- alkynyl PAMAM dendrimer scaffolds gave only mono- or di-meric triazole 
products, even when large excesses of an azido-modified RGD peptide were 
employed.  
130 
 
3.3. Aims 
It was recently demonstrated in St Andrews (Dr. Qingzhi Zhang) that the fluorinase 
could be utilised to radiolabel an RGD peptide in a “last step” protocol for PET. 
Exploration of tethering of larger peptide cargos to the nucleoside substrate for the 
enzyme became an immediate objective. The set objective was now to design and 
synthesise multimeric RGD peptide assemblies as potential substrates for the 
fluorinase enzyme, as illustrated in Figure 7. The multimeric substrates derive from a 
divalent or tetravalent linker, for attachment to two or four bioactive peptides 
respectively. 
 
Figure 7. Extension of fluorinase substrates towards “last step” radiolabelling of multimeric peptides. 
c(RGDfK[N3]) 199 was an attractive building block for the assembly of the multimeric 
substrates using the CuAAC reaction. In order to utilise this RGD-azide, dimeric and 
tetrameric alkynes, bearing the ClDEA motif were required.  
Using the dipropargyl-diphenol ether core described by Liskamp et al.,38 and a PEG 
linker bearing an amine as the site for multimerisation, ClDEA-PEG-(C≡CH)2 219 and 
ClDEA-PEG-(C≡CH)4 220 in Scheme 5 were designated as synthetic targets. The 
analogous 5'-fluoro compounds were also required for use as reference compounds for 
anticipated enzyme assays. Mono- and di-alkylation of amine 222 by aldehyde 223 
under reductive amination conditions were anticipated to produce a trialkyne and 
penatalkyne respectively. Sonogashira coupling of the terminal, unprotected alkynes to 
an appropriate 2-iodoadenosine, such as 221, was expected to furnish the desired 
multimeric constructs after silyl deprotection. 
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Scheme 5. Synthetic targets and retrosynthetic analysis to 5'-chloro-5'-deoxy-2-iodoadenosine 221, a 
PEG linker 222, and a protected dialkynyl aldehyde core 223. 
These di- and tetra-meric compounds would be investigated in CuAAC coupling with 
c(RGDfK[N3]) 199 to generate multimeric RGD peptides 224 and 225, as shown in 
Scheme 6. Compounds 224 and 225 are potential new substrates for the fluorinase-
catalysed transhalogenation reaction. If the constructs prove successful as substrates, 
the goal would be to explore radiolabelling of these constructs in the PET context with 
[18F]fluoride. It was hoped that this would provide access to a “last step” radiolabelling 
of larger peptides (10-20 amino acids) using the fluorinase under neutral pH, ambient, 
aqueous conditions. 
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Scheme 6. CuAAC reaction of alkynes 219 and 220 with c(RGDfK[N3]) 199 to generate 
ClDEA-PEG-(RGD)2 224 and ClDEA-PEG-(RGD)4 225 as potential new substrates for the 
fluorinase. 
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3.4. Synthesis of di- and tetra-alkynes for a CuAAC 
 reaction 
3.4.1. Synthesis of the alkyne fragments for Sonogashira couplings 
Methyl 3,5-dihydroxybenzoate 226 was dialkylated using potassium carbonate and 
propargyl bromide in refluxing acetone (Scheme 7).38 The resultant dialkyne 227 was 
purified by recrystallisation from methanol. The two acetylene functional groups were 
protected with silyl groups by treatment of 227 with lithium diisopropylamide (LDA), and 
quenching the resultant dianion with TMSCl, furnishing ester 228.  
 
Scheme 7. Synthesis of protected aldehyde 220 for reductive amination. 
Ester 228 was reduced to the corresponding benzylic alcohol 229 using lithium 
aluminium hydride. The resulting alcohol 229 was oxidised using Dess-Martin 
periodinane.41 Quenching with sodium thiosulfate, followed by a base extraction, 
generated aldehyde 220 in quantitative yield without further purification.  
Tetraethylene glycol 230 was treated with propargyl chloride and a dispersion of 
sodium hydride in mineral oil, to give the monoalkylated PEG derivative 231 shown in 
Scheme 8, along with its dialkylated analogue. Separation of these products by column 
chromatography allowed 231 to be purified in 47% yield, which was then converted to 
tosylate 232.  
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Scheme 8.  Synthesis of amino-alkyne linker 222 from tetraethyleneglycol 230. 
Nucleophilic displacement of the tosyl group by azide gave 233 in good yield, and a 
Staudinger reduction42 of the azide generated amine 222. With both aldehyde 223 and 
amine 222 in hand, attention turned to coupling the two fragments by reductive 
amination. 
Condensation of amine 222 with aldehyde 223 in a direct reductive amination was 
expected to produce predominantly the monoalkylated amine product.43 To this end, a 
slight excess of amine 222 was added to a solution of the aldehyde 223 in THF, before 
acetic acid and sodium triacetoxyborohydride were added (Scheme 9). TLC analysis 
showed the formation of two major species, found to be the mono- and di-alkylated 
products 234 and 235, respectively. As the dialkylated species 235 was also desired 
for the construction of the multimeric assembly, and that the mono- and di- alkylated 
products were easily separable by chromatography, no attempt to improve the 
formation of the mono-alkylated product was made. Separation of the two products by 
column chromatography revealed that monoalkylated product 234 had been formed in 
35% yield (based on aldehyde 223), while dialkylated product 235 was formed in 21% 
yield (based on aldehyde 223). 
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Scheme 9. Reductive amination of aldehyde 223 to generate alkynes 234 and 235. 
With the alkyne substrates for the anticipated Sonogashira reactions in hand, attention 
turned to the synthesis of the required iodinated coupling partners. 
3.4.2. Synthesis of the iodinated fragments for Sonogashira couplings 
During the chlorination of hydroxy-alkynes 180 and 236 (Scheme 10) described in 
Chapter 2 and Section 3.11 respectively, a by-product, the alkyne-HCl adduct, was 
observed. Adducts 190 and 237 are thought to arise from HCl generation during the 
reaction, which then adds across the triple bond. These HCl adducts were found to be 
difficult to separate from their alkyne analogues, therefore, an alternative to late-stage 
chlorination was investigated. 
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Scheme 10. Chlorination of alkynes 180 and 236 led to undesired HCl adducts 190 and 237. 
To this end, the chlorination of 2-iodoadenosine 197 prior to the Sonogashira coupling 
was investigated. 2-Iodoadenosine 179 was treated with thionyl chloride and pyridine in 
acetonitrile,44 to generate an intermediate chlorinated cyclic sulfite. Base hydrolysis of 
this intermediate furnished the corresponding 5'-chloro analogue 238 in moderate yield, 
as shown in Scheme 11.  
 
Scheme 11. Synthesis of halogenated 2-iodo coupling partners 238 and 241 for the anticipated 
Sonogashira coupling. 
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Similarly, it was envisaged that 2-iodoadenosine 179 could be fluorinated prior to the 
Sonogashira couplings. 2-Iodoadenosine 179 was protected as its 2',3'-acetonide 
derivative using 2,2-dimethoxypropane in acetone, catalysed by perchloric acid, to give 
acetonide 239 in quantitative yield. Acetonide 239 was then fluorinated by the action of 
TsF and TBAF in refluxing THF, to give 240 in moderate yield. Deprotection of 240 with 
TFA/water mixtures led to hydrolysis of the N-glycosidic bond, giving 2-iodoadenine as 
a decomposition product. 2-Iodoadenine was found to be difficult to separate from 241 
and alternative conditions for the deprotection of 240 were investigated. Successful 
deprotection was achieved in good yield with catalytic anhydrous TsOH in dry MeOH.45 
Stirring at room temperature for 48 h resulted in an incomplete conversion to the free 
nucleoside 241, but refluxing the reaction for 16 h led to complete deprotection to 241. 
Happily, cleavage of the N-glycosidic bond was not observed under these conditions. 
3.4.3. Sonogashira couplings towards multimeric alkynes 
Sonogashira couplings46–48 of the halogenated 2-iodonucleosides with acetylenes 234 
and 235 were now investigated.  
The first reactions to be investigated involved coupling of chloro-nucleoside 238 to 
alkynes 234 and 235, as shown in Scheme 12. The conditions employed were the 
same as those reported for the coupling of 2-iodoadenosine 179 to TMS-acetylene 
described in Chapter 2. 5'-Chloro-5'-deoxy-2-iodoadenosine 238 was added to an 
excess of either 234 or 235 in dry, degassed DMF, before 10 mol% of Pd(PPh3)Cl2 and 
CuI were added and the mixture heated to 60 °C. TLC monitoring of both reactions 
revealed the formation of a number of by-products, and consumption of the starting 
materials was slow. Reaction progress was also difficult to monitor by 1H NMR 
spectroscopy, as an excess of the alkyne used in each case masked the 
disappearance of the alkynyl proton as the product formed. Mass spectrometry of the 
reaction mixtures did, however, indicate that the coupled products 242 and 243 were 
being produced.  
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Scheme 12. Sonogashira coupling of 238 to 234 and 235. Crude products were silyl-deprotected under 
the action of 3HF.Et3N, before the products 219 and 220 were purified by semi-preparative 
HPLC. 
While evidence from MS suggested that products were being formed in significant 
amounts in both cases, TLC analysis did not reveal the appearance of a major reaction 
product in either case.  
Dimer 242 proved particularly difficult to isolate by chromatography, and required the 
use of extremely polar conditions (10:89:1 MeOH:acetone:1% aqueous ammonia 
(30%)) for elution from silica gel. Tetrameric alkyne 243 was found to require less polar 
conditions for elution from silica gel, but in both cases, the products obtained were not 
sufficiently pure, even after multiple rounds of purification by silica gel chromatography. 
At this point, the crude reaction mixtures (20 mg containing 242 and 40 mg 
containing 243) were subjected to fluoride-based deprotection of the silyl groups using 
3HF.Et3N in methanol. After quenching the reactions with aqueous sodium bicarbonate, 
the crude deprotected products 219 and 220 were passed through a plug of silica gel, 
eluting with MeOH:acetone:aqueous ammonia (30%) or DCM:MeOH mixtures 
respectively. This gave access to products 219 and 220, each of which required further 
purification before use in CuAAC reactions. 
The two products were each passed through a C18 reverse phase cartridge, before 
being purified by semi-preparative HPLC, to give ClDEA-PEG-(C≡CH)2 219 and 
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ClDEA-PEG-(C≡CH)4 220. The yield over two steps in both cases was low, at only 
4.2% and 2.8% respectively, when calculated based on 238. Despite the low yield, the 
synthetic route gave access to 3–5 mg of each of the products, which was sufficient for 
investigation of the respective CuAAC reactions, and for the preparation of milligram 
quantities of multimeric RGD peptides. 
Following a similar protocol to that described for the chlorinated analogues, 
FDEA-PEG-(C≡CH)2 245 and FDEA-PEG-(C≡CH)4 247 were prepared as shown in 
Scheme 13. Sonogashira coupling of 5'-fluoro-5'-deoxy-2-iodoadenosine 241 to 
alkynes 234 and 235 were performed under identical conditions, and the crude 
components of the product, identified using MS, were separated from the reaction 
mixture by passage through a plug of silica. At this stage, the mixture was subjected 
directly to silyl deprotection with 3HF.Et3N in MeOH. After quenching with aqueous 
sodium bicarbonate, the mixtures were concentrated and immediately applied to a C18 
reverse phase cartridge. The products were further purified by semi-preparative HPLC 
to give FDEA-PEG-(C≡CH)2 245 and FDEA-PEG-(C≡CH)4 247 in a similar yield to their 
chlorinated analogues, at 2.5% and 2.3% respectively. 
 
Scheme 13. Sonogashira coupling of 241 to 234 and 235 Crude products were silyl-deprotected under the 
action of 3HF.Et3N, before the products were purified by semi-preparative HPLC. 
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3.4.4. Assessment of ClDEA-PEG-(C≡CH)2 219 as a fluorinase substrate 
With a modified nucleoside substrate in hand, ClDEA-PEG-(C≡CH)2 219, which was 
soluble in water, unlike 220, was investigated as a substrate for fluorinase-catalysed 
transhalogenation. ClDEA-PEG-(C≡CH)2 219 (0.3 mM) was incubated with the 
fluorinase (10 mg.mL−1) in the presence of fluoride (75 mM) and L-SeMet (0.5 mM), as 
shown in Figure 8 A, and the reaction progress monitored by HPLC (Figure 8 B).  
 
Figure 8. A. Fluorinase-catalysed transhalogenation of ClDEA-PEG-(C≡CH)2 219. B. HPLC trace of 
the reaction mixture showing ClDEA-PEG-(C≡CH)2 219 (tR = 9.5 min, yellow) at t = 0 min. 
After 4 hours, conversion to FDEA-PEG-(C≡CH)2 245 (tR = 9.0 min, green) was complete. 
HPLC analysis revealed that ClDEA-PEG-(C≡CH)2 219 (tR = 9.5 min) was consumed, 
and a new product (tR = 9.0 min) was steadily produced. Over a period of 4 h, the 
conversion to this new product was found to be complete. LC-MS analysis of the 
reaction mixture revealed a peak in the total ion chromatogram with tR = 13.6 min, and 
whose summed mass spectrum (Figure 9) revealed a peak at m/z = 697.2 and 
m/z = 349.2. This corresponds to the [M+H]+ and [M+2H]2+ ions of 
FDEA-PEG-(C≡CH)2 245, confirming that the transhalogenation reaction was 
successful. Control experiments in the absence of the enzyme or L-SeMet, did not 
show conversion to any new products, confirming the role of the fluorinase enzyme in 
this transformation. 
The successful transhalogenation demonstrated that the new linker was well tolerated 
by the fluorinase. The presence of the substituted aromatic ring coupled to the amino-
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PEG linker appeared to have minimal effect on the fluorinase-catalysed 
transhalogenation reaction. 
 
Figure 9. Summed mass spectrum of peak corresponding to the product of the transhalogenation 
reaction mixture after 4 h, showing [M+H]+ and [M+2H]2+ peaks of the anticipated fluorinated 
product, FDEA-PEG-(C≡CH)2 245. 
3.5. CuAAC reaction with c(RGDfK[N3]) 199 
With the proposed alkynes in hand, the CuAAC reaction between 219 and 220 and 
c(RGDfK[N3]) 199 were explored for the generation of the multimeric RGD substrates 
for the fluorinase. It had been reported in the literature that the CuAAC reaction of 
c(RGDfK[N3]) 199 with a variety of alkynes was slow, and required microwave heating 
in order to achieve good conversions.38,40  
3.5.1. Investigation of the CuAAC reaction under microwave heating 
Initial trials of the reaction were performed on an analytical scale using 
ClDEA-PEG-(C≡CH)4 220 as the starting alkyne, as illustrated in Scheme 14. With 
sodium ascorbate and CuSO4.TBTA as the catalyst system, the CuAAC reaction of 
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ClDEA-PEG-(C≡CH)4 220 with c(RGDfK[N3]) 199 was investigated. The reaction 
mixture was heated by microwave irradiation at 100 °C for 2 hours in DMF. HPLC 
analysis of the reaction mixture after 2 hours revealed a complex mixture of products. 
LC-MS analysis showed the presence of traces of the desired product, 
ClDEA-PEG-(RGD)4 225, along with many unidentified products of lower mass. These 
lower molecular weight species were thought to be decomposition products. Under 
identical reaction conditions, but with MeOH as the solvent, only the mono-triazole 
product was observed by LC-MS. 
 
Scheme 14. Investigation of CuAAC reaction with ClDEA-PEG-(C≡CH)4 220 under microwave conditions 
only gave traces of the desired product 225. 
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The observation of products of lower mass suggested that the tetrameric product may 
be unstable to the harsh microwave conditions, and that the product was perhaps 
decomposing. Milder conditions were therefore investigated for the CuAAC reaction. 
In Chapter 2, the CuAAC reaction with c(RGDfK[N3]) 199 proceeded quantitatively at 
room temperature in water, when fluorinase generated FDEA 176 was reacted with 
c(RGDfK[N3]) 199. These conditions were trialled on a small scale with water soluble 
FDEA-PEG-(C≡CH)2 245, produced by the enzymatic transhalogenation described in 
Section 3.4.4, and illustrated below in Figure 10 A. Fluorinase-generated 
FDEA-PEG-(C≡CH)2 245 was added to a solution of c(RGDfK[N3]) 199 in water before 
sodium ascorbate was added and a sample removed for HPLC analysis. After addition 
of CuSO4.TBTA, the mixture was allowed to react for 30 min at room temperature, at 
which point a second sample was removed for HPLC analysis. The resultant HPLC 
traces are illustrated below in Figure 10 B. 
 
Figure 10. A. Fluorinase-generated FDEA-PEG-(C≡CH)2 245 was subjected to the CuAAC reaction with 
azido peptide 199 in water, at room temperature to generate FDEA-PEG-(RGD)2 245. 
B. HPLC trace (260 nm) of the reaction showing FDEA-PEG-(C≡CH)2 245 (tR = 9.5 min, 
green) before addition of the catalyst, and 30 min after catalyst addition showing new di-
triazole product, FDEA-PEG-(RGD)2 248 (tR = 7.8 min, red).  
After 30 min, HPLC analysis revealed that all the starting alkyne 245 (tR = 9.5 min) had 
been consumed, while a new product was evident at tR = 7.8 min. Conversion 
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appeared complete. LC-MS analysis of the reaction mixture revealed the product as 
FDEA-PEG-(RGD)2 248, showing peaks at m/z = 979.3, 652.8 and 489.9, and 
corresponding to the [M+2H]2+, [M+3H]3+and [M+4H]4+ ions of 248 respectively. 
3.5.2. Synthesis of ClDEA-PEG-(RGD)2 224 and FDEA-PEG-(RGD)2 248 
After the success of the analytical scale CuAAC reaction under mild conditions, to 
produce the dimeric RGD compound 248 identical conditions were trialled on a 
preparative scale for the synthesis of the desired multimeric compounds. 
ClDEA-PEG-(C≡CH)2 219 was taken up into water, before c(RGDfK[N3]) 199 (1.25 eq. 
per alkyne) was added. Sodium ascorbate solution was added to the reaction mixture 
and the reaction, illustrated below in Figure 11 A, was initiated by addition of 
CuSO4.TBTA. After 1.25 h the reaction was found to be complete by HPLC. 
Ditriazole 224 was trapped on a C18 reverse phase cartridge, and the product eluted 
with 50:50 MeCN:H2O (2 × 5 mL) and concentrated under a stream of compressed air. 
The crude product was purified by semi-preparative HPLC to give 1.8 mg of 
ClDEA-PEG-(RGD)2 224 in 78% yield. MALDI-TOF MS (Figure 11 B) confirmed the 
identity of the isolated product, showing a diagnostic peak at m/z = 1971.9, 
corresponding to the [M+H]+ ion of ClDEA-PEG-(RGD)2 224. 
 
Figure 11. A. Preparative scale synthesis of ClDEA-PEG-(RGD)2 224. B. MALDI-TOF MS spectrum of 
the product after purification, showing the [M+H]+ ion at m/z = 1971.9. MALDI-TOF MS 
acquired by the University of St Andrews Mass Spectrometry Service. 
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FDEA-PEG-(RGD)2 248 was synthesised in a similar manner to that described for its 
chlorinated analogue as shown in Figure 12 A. The dialkyne 245 was taken up in a 
solution of 50:50 DMSO:water before addition of c(RGDfK[N3]) 199 (1.25 eq. per 
alkyne), sodium ascorbate solution and CuSO4.TBTA. The reaction was found to be 
complete after 90 min by HPLC, after which the solution was passed through a 
C18 reverse phase cartridge. The cartridge was washed with water (10 mL) to remove 
DMSO and residual sodium ascorbate, before the product was eluted with 
50:50 MeCN:H2O (2 × 10 mL). Crude 248 was purified by semi-preparative HPLC to 
yield 0.67 mg of FDEA-PEG-(RGD)2 248 (27% yield). MALDI-TOF MS (Figure 12 B) 
again confirmed the identity of FDEA-PEG-(RGD)2 248, showing a peak at 
m/z = 1955.9, corresponding to the [M+H]+ ion of FDEA-PEG-(RGD)2 248. 
 
Figure 12. A. Preparative scale synthesis of FDEA-PEG-(RGD)2 248. B. MALDI-TOF MS spectrum of 
the product after purification, showing the [M+H]+ ion at m/z = 1955.9. MALDI-TOF MS 
acquired by the University of St Andrews Mass Spectrometry Service. 
3.5.3. Synthesis of ClDEA-PEG-(RGD)4 225 and FDEA-PEG-(RGD)4 249 
ClDEA-PEG-(C≡CH)4 220 was found to be poorly soluble in water, and initial CuAAC 
reactions carried out in water led to the production of mixtures of products. Addition of 
DMSO (50%) was sufficient to complete dissolution of ClDEA-PEG-(C≡CH)4 220, 
allowing the reaction to proceed rapidly to completion. 
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For the preparative scale synthesis of ClDEA-PEG-(RGD)4 225 (Figure 13 A), the 
ClDEA-PEG-(C≡CH)4 220 was taken up into a 75:25 mixture of DMSO:water before the 
addition of c(RGDfK[N3]) 199 (1.25 eq. per alkyne) in an equal volume of 25:75 mixture 
of DMSO:water. This gave DMSO:water (50:50) as the final reaction solvent. Sodium 
ascorbate solution and CuSO4.TBTA were added to initiate the reaction. The reaction 
was followed by HPLC and found to be complete after 70 min. DMSO was removed 
from the sample following a similar protocol to that described above, where the product 
was trapped on a C18 reverse phase cartridge, washed with water to remove DMSO, 
and the product eluted with MeCN:water mixtures. Purification by semi-preparative 
HPLC gave 1.4 mg of ClDEA-PEG-(RGD)4 225 (70% yield). MALDI-TOF MS (Figure 
13 B) confirmed the identity of the isolated product, showing a diagnostic peak at 
m/z = 3428.5, corresponding to the [M+H]+ ion of ClDEA-PEG-(RGD)4 225. In this 
sample, a peak corresponding to the loss of water (−18 Da) was also observed.  
 
Figure 13. A. Preparative scale synthesis of ClDEA-PEG-(RGD)4 225. B. MALDI-TOF MS spectrum of 
the product after purification, showing the [M+H]+ ion at m/z = 3428.5. The ion produced by 
loss of water is also evident. C. Full MALDI-TOF MS spectrum showing the base peak 
(m/z = 1971.9) produced as a result of N–C bond cleavage. MALDI-TOF MS acquired by the 
University of St Andrews Mass Spectrometry Service. 
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The expanded MALDI-TOF MS spectrum observed for 225 (Figure 13 C) was found to 
be more complex than its dimeric analogue. The base peak in the MALDI-TOF MS 
spectrum for ClDEA-PEG-(RGD)4 225 was found to be at m/z = 1971.9, an identical 
mass to that of ClDEA-PEG-(RGD)2 224. The ionisation process for this large 
tetrameric construct 225 appears to result in the cleavage of the N–C bond. 
The fluorinated tetrameric RGD peptide 249 was synthesised in a similar manner to 
that described for 225, as shown in Figure 14. FDEA-PEG-(C≡CH)4 247 was taken up 
in a mixture of DMSO:water, along with c(RGDfK[N3]) 199 (1.25 eq. per alkyne). 
Sodium ascorbate solution and CuSO4.TBTA were then added. The reaction was 
followed by HPLC and found to be complete after 90 min. A similar C18 reverse phase 
extraction protocol was used to remove DMSO, and the crude product eluted from the 
cartridge using an MeCN:water mixture. Purification by semi-preparative HPLC gave 
0.66 mg of FDEA-PEG-(RGD)4 249 (27% yield). MALDI-TOF MS (Figure 14 B) 
confirmed the identity of FDEA-PEG-(RGD)4 249, showing a peak at m/z = 3412.6, 
corresponding to the [M+H]+ ion. A peak corresponding to the loss of water (−18 Da) 
was observed for this compound too. The full MALDI-TOF MS spectrum tetrameric 
assembly 249 (Figure 14 C) was more complex than that of its dimeric analogue 248, 
with a species of the same mass as its dimeric analogue (m/z = 1955.9) forming the 
base peak. 
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Figure 14. A. Preparative scale synthesis of FDEA-PEG-(RGD)4 249. B. MALDI-TOF MS spectrum of 
the product after purification, showing the [M+H]+ ion at m/z = 3412.6. The ion produced by 
loss of water is also evident. C. Full MALDI-TOF MS spectrum showing the peak (m/z = 
1955.9) produced as a result of N–C bond cleavage. MALDI-TOF MS acquired by the 
University of St Andrews Mass Spectrometry Service. 
3.6. Evaluation of multimeric RGDs as substrates for the
 fluorinase 
With the multimeric substrates and products in hand, the fluorinase catalysed 
transhalogenation reactions with these peptide-modified substrates were explored. 
3.6.1. Evaluation of ClDEA-PEG-(RGD)2 224 as a substrate for the 
 fluorinase 
Initial gradient-based HPLC based assays did not clearly resolve the chlorinated 
dimeric substrate 224 from its fluorinated analogue 248, therefore a series of HPLC 
conditions were explored for separation of these two compounds. Isocratic conditions 
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(22 % MeCN + 0.05% TFA in water + 0.05% TFA) provided a good separation of the 
two species, suitable for assaying the new substrate. 
ClDEA-PEG-(RGD)2 224 (40 µM) was added to a mixture of L-SeMet (75 µM) and 
potassium fluoride (50 mM) in a total volume of 1 mL and the reaction, shown in 
Scheme 15, was initiated by addition of the fluorinase (1 mg.mL−1). Aliquots of the 
reaction mixture were removed every 30 min over 4 h. The enzyme was heat 
denatured and the protein removed by centrifugation, and then the clear supernatant 
was analysed by HPLC in order to assess conversion. 
 
Scheme 15. Fluorinase catalysed transhalogenation of ClDEA-PEG-(RGD)2 224 to  
FDEA-PEG-(RGD)2 248. 
The HPLC traces, shown below in Figure 15 showed the time-dependent appearance 
of a new peak at tR = 8.2 min. This peak was identified as FDEA-PEG-(RGD)2 248 by 
comparison of the retention time to that of the synthetic standard of  
FDEA-PEG-(RGD)2 248, synthesised as discussed in Section 3.5.2. 
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Figure 15. HPLC time course (220 nm) of incubation of ClDEA-PEG-(RGD)2 224, blue, (tR = 12.2 min) 
with the fluorinase, showing samples taken every 0.5 h over 4 h. A new peak was evident at 
tR = 8.2 min, red, identified as FDEA-PEG-(RGD)2 248. 
LC-MS analysis of the reaction mixture at t = 0 h and t = 4 h confirmed that the 
transhalogenation had produced FDEA-PEG-(RGD)2 248. The summed mass 
spectrum of the peaks corresponding to the multimeric species are shown below in 
Figure 16. In the sample taken at t = 0 h, peaks corresponding to multiply charged 
species of ClDEA-PEG-(RGD)2 224 are evident at m/z = 986.4 ([M+2H]2+), 658.8 
([M+3H]3+) and 494.4 ([M+4H]4+). LC-MS analysis at t = 4 h, indicated that none of the 
original peaks were evident, and new peaks at m/z = 979.3, 652.8 and 489.9 were 
observed instead. The new peaks correspond to multiply charged ions of  
FDEA-PEG-(RGD)2 248 ([M+2H]2+, [M+3H]3+, and [M+4H]4+ respectively), confirming 
FDEA-PEG-(RGD)2 248 as the product of the enzyme reaction. 
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Figure 16. Summed mass spectrum (m/z = 400–1000) of the LC-MS peak corresponding to the 
tetrameric species. A. Sample taken at t = 0 h, showing peaks corresponding to multiply 
charged species of ClDEA-PEG-(RGD)2 224. B. Sample taken at t = 4 h, showing peaks 
corresponding to multiply charged species of FDEA-PEG-(RGD)2 248. 
A series of control experiments, where the reaction was conducted in the absence of 
either enzyme or L-SeMet, did not result in any conversion to FDEA-PEG-(RGD)2 248, 
confirming that the reaction is enzyme catalysed. In the control reaction carried out in 
the absence of fluoride, consumption of ClDEA-PEG-(RGD)2 224 was observed, 
however, no FDEA-PEG-(RGD)2 248 was detected by HPLC. This result suggests the 
generation of a seleno-SAM intermediate, which cannot be converted to product 248 in 
the absence of fluoride. 
3.6.2. Evaluation of ClDEA-PEG-(RGD)4 225 as a substrate for the 
 fluorinase 
A similar HPLC-based experiment to that described in the previous section was 
conducted for ClDEA-PEG-(RGD)4 225 as a substrate for the enzyme, as shown in 
Scheme 16. ClDEA-PEG-(RGD)4 225 (20 µM) was added to a mixture of 
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L-SeMet (75 µM) and potassium fluoride (50 mM), in a total volume of 1 mL. The 
reaction was initiated by the addition of the fluorinase (1 mg.mL−1) and monitored every 
30 min over 4 h. 
 
Scheme 16. Fluorinase catalysed transhalogenation of ClDEA-PEG-(RGD)4 225 to  
FDEA-PEG-(RGD)4 249. 
The resultant HPLC profile (Figure 17), obtained using isocratic conditions 
(24 % MeCN + 0.05% TFA in water + 0.05% TFA), showed that the chlorinated 
substrate 225 was consumed, while a new peak, at tR = 9.2 min, steadily increased 
throughout the assay. The retention time of this new peak was identical to that of 
synthetic FDEA-PEG-(RGD)4 249, and its identity was confirmed by LC-MS. 
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Figure 17. HPLC time course (220 nm) of incubation of ClDEA-PEG-(RGD)4 225, green, (tR = 12.4 min) 
with the fluorinase, showing samples taken every 0.5 h over 4 h. A new peak was evident at 
tR = 9.2 min, yellow, identified as FDEA-PEG-(RGD)4 249. 
The summed mass spectrum of the peaks of the tetrameric species are shown below in 
Figure 18. In the sample taken at t = 0 h, peaks corresponding to multiply charged 
species of ClDEA-PEG-(RGD)4 225 are observed at m/z = 858.9 ([M+4H]4+) and 687.2 
([M+5H]5+). In the a sample analysed after an extended 16 h reaction time, peaks at 
m/z = 854.8 ([M+4H]4+) and 683.8 ([M+5H]5+) arising from FDEA-PEG-(RGD)4 249 
were observed. The presence of these ions confirmed FDEA-PEG-(RGD)4 249 as the 
product of the enzymatic transhalogenation. 
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Figure 18. Summed mass spectrum (m/z = 600–1000) of the LC-MS peak corresponding to the 
tetrameric species. A. Sample taken at t = 0 h, showing peaks corresponding to multiply 
charged species of ClDEA-PEG-(RGD)4 225. B. Sample taken at t = 4 h, showing peaks 
corresponding to multiply charged species of FDEA-PEG-(RGD)4 249. Identical 
fragmentation peaks (denoted with an asterisk (*)) appear in both spectra. 
Additional peaks were observed in spectra recorded at both t = 0 h and t = 16 h. These 
are denoted with an asterisk (*) in Figure 18. The peaks are identical in both spectra, 
suggesting the fragmentation of the parent species to produce ions which lack the 
halogen atom. Fragmentation of the (C-2)–C bond between the nucleoside and the 
acetylene to give 250, as illustrated in Scheme 17, would give ions calculated to have 
the masses of those observed; m/z = 792.2 is assigned to [M+3H+Na]4+, while the peak 
at m/z = 634.6 is assigned to [M+4H+Na]5+. 
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Scheme 17. Fragmentation of the halogenated tetrameric constructs 225 and 249 to ions corresponding 
to the observed mass (m/z). 
The results from these two assays illustrate the successful extension of the substrate 
scope of the fluorinase enzyme to larger multimeric peptides. Tolerance of these 
multimeric substrates suggests that the C-2 position of a chlorinated nucleoside 
represents an ideal site for the attachment of a diverse range of peptide cargos for use 
in enzymatic fluorination. These constructs were shown to be efficiently fluorinated 
under the action of the fluorinase enzyme, using fluoride ion under aqueous, pH neutral 
conditions. 
3.7. Binding assay of denrimeric RGDs to αVβ3 integrin 
With the knowledge that the multimeric constructs were suitable substrates for the 
fluorinase catalysed transhalogenation, the effect of multimerisation of the RGD motif 
using the linkers described above on their affinity for αVβ3 integrin was explored. 
The binding affinities of the FDEA-PEG-(RGD)2 248 and FDEA-PEG-(RGD)4 249 were 
determined by evaluating the binding of the peptide to immobilised αVβ3 integrin using 
the same ELISA assay described in Chapter 2.18 The experiments were conducted by 
Dr Ian Fleming at the University of Aberdeen. The IC50 values for the multimers 248 
and 249 are shown in Table 1 below. The IC50 values for two reference peptides and 
two monomeric RGD peptides described previously (201 and 207) are included for 
comparison. 
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Table 1. IC50 values of selected RGD-containing peptides measured as the ability to compete with 
c(RGDfK[PEG-PEG-biotin]) for binding to immobilised αVβ3 integrin. Results are the average 
± standard error (s.e.) from three independent experiments, each performed in triplicate. Q is 
the normalised affinity of the peptides, referenced to GRGDSPK. Measurements were 
performed by Dr Ian Fleming. aAffinities for these constructs were previously reported, and 
were measured using an identical assay. 
Compound IC50 ± s.e /µM  Q 
RGD 8.56 ± 2.24 4.019 
GRGDSPKa 2.13 ± 0.41 1.000 
c(RGDfK[N3]) 199a 0.09 ± 0.01 0.042 
FDEA-RGD 201a 0.33 ± 0.03 0.155 
FDEA-TEG-RGD 207a 0.074 ± 0.016 0.033 
FDEA-PEG-(RGD)2 248 0.060 ± 0.013 0.027 
FDEA-PEG-(RGD)4 249 0.024 ± 0.018 0.011 
 
The ELISA data show that the multimers have a lower IC50, 60 nM and 24 nM for the 
dimeric 248 and tetrameric 249 constructs respectively, than the two monomeric RGD 
peptides described previously (201 and 207). The IC50 values measured for the 
multimeric constructs are also lower than the parent azido-peptide 199. The multimeric 
compounds have much lower IC50 values compared to those of linear reference RGD-
containing peptides. 
The multimerisation of the RGD motif in 248 and 249 produced compounds which have 
better affinity to immobilised αVβ3 integrin than their monomeric analogues. The 
tetrameric analogue 249 has a lower IC50 compared to the dimeric analogue, and this 
difference found to be statistically significant (p < 0.05, Student’s t-test). The presence 
of two RGD motifs in the vicinity of the receptor leads to only a marginal increase in the 
affinity of the construct to αVβ3 integrin. The addition of a further two RGD units to the 
construct (to give a tetramer) gave a compound with much higher affinity, the highest 
affinity observed for any fluorinase RGD-based substrate to date.  
The linker between the two or four RGD units is not long, and the increased affinity is 
most likely due to an increased effective molarity at the binding site. Steric constraints 
will likely prevent multivalent binding of two RGD ligands to two individual αVβ3 integrin 
receptors. 
Many multimeric constructs reported in the literature have IC50 values in the 1–100 nM 
range,9 and the IC50 values obtained for the multimeric compounds described in this 
investigation are within this range. Direct comparison of the observed IC50 values to 
those in the literature is difficult, as most reports use alternate assays and different 
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competing peptides. The reports also do not generally report the normalisation the 
observed IC50 values to that of a reference peptide such as GRGDSPK. 
3.8. Radiosynthetic evaluation of multimeric RGDs 
The demonstration that large peptide assemblies of 10 or 20 amino acids are tolerated 
as fluorinase substrates offers an approach for mild and chemoselective fluorination of 
peptides for PET. As a consequence, we were interested in exploring the behaviour of 
the multimeric constructs upon translation to the PET environment, where the 
[18F]fluoride ion concentration is much lower (pM to nM) than the fluoride concentration 
employed in the enzyme assays described above (50 mM). The fluorinase-catalysed 
radiolabelling of ClDEA-PEG-(RGD)2 224 and ClDEA-PEG-(RGD)4 225 was therefore 
explored at the University of Glasgow’s radiochemistry laboratory, in collaboration with 
Dr Sally Pimlott and Dr Sue Champion. 
3.8.1. Initial radiolabelling experiments with ClDEA-PEG-(RGD)2 224 
Radiolabelling of ClDEA-PEG-(RGD)2 224 was investigated under similar conditions to 
the assays reported in Section 3.6.1, but using [18F]fluoride solution rather than high 
concentrations of [19F]fluoride. In addition, the enzyme concentration was increased 
from 1 mg.mL−1 (29 µM) to 10 mg.mL−1 (290 µM), as it had previously been shown that 
high enzyme concentrations resulted in increased incorporations of [18F]fluoride.49 
Lower concentrations of the multimeric substrate were initially employed as the 
conditions proved successful for [19F]fluoride, and the dimeric RGD substrate was not 
sufficiently soluble at higher concentrations used in previous fluorinase radiolabelling 
experiments. 
To this end a solution of [18F]fluoride ion (30.4 MBq) was added to a mixture of 
ClDEA-PEG-(RGD)2 224 (0.04 mM), L-SeMet (0.15 mM), and the fluorinase 
(10 mg.mL−1) in a total volume of 500 µL, as shown below in Scheme 18. The mixture 
was incubated at 37 °C for 30 min, before the enzyme was precipitated by heat 
denaturation at 95 °C and centrifugation at 3000-4000 rpm.  
158 
 
 
Scheme 18. Fluorinase catalysed transhalogenation reaction with ClDEA-PEG-(RGD)2 224 with 
[18F]fluoride to produce [18F]FDEA-PEG-(RGD)2 [18F]-248. 
A sample of the supernatant was analysed by HPLC coupled in series to a diode array 
UV detector and a radioactivity detector. The resultant radio-HPLC trace is illustrated 
below in Figure 19. Unlike previous successful radiolabelling experiments with the 
fluorinase enzyme,49–53 only a trace of the anticipated product [18F]-248 was observed. 
 
Figure 19. HPLC radioactivity trace of the reaction where ClDEA-PEG-(RGD)2 224 was incubated with 
the fluorinase and [18F]fluoride for 30 min. [18F]Fluoride is evident at the broad peak at 
tR = 2.2 min, while only traces of the expected product, [18F]FDEA-PEG-(RGD)2 [18F]-248, are 
observed at tR = 9.8 min. Run with under gradient conditions. 
[18F]Fluoride ion appears as a broad, tailing peak at tR = 2.2 min. This broad peak is 
due to the acidity of the mobile phase,54 in this case 0.05% TFA in a water/MeCN 
mixture at pH ~2.2.55 HF is a weak acid (pKa = 3.17), and [18F]fluoride therefore exists 
in an equilibrium between its protonated and deprotonated state.54 These states 
interact differently with the stationary phase of the C18 reverse phase column resulting 
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in the observed broad peak. The tailing of the peak and its overlap with the peaks of 
the product reduced the accuracy in determining incorporation. Reported 
incorporations were calculated by defining the baseline at the lowest point in the valley 
between the two overlapping peaks. 
As the incorporation of [18F]fluoride was low, the activity of the enzyme was 
investigated. To this end, a control experiment with ClDA 23 under identical labelling 
conditions was performed, as shown in Scheme 19. The concentration of each of the 
components of the reaction mixture was kept constant. The supernatant of a heat-
treated sample of the reaction mixture was analysed using the same HPLC conditions 
described above.  
 
Scheme 19. Fluorinase catalysed transhalogenation reaction with ClDA 23 with [18F]fluoride to produce 
[18F]FDA [18F]-22, used as a control experiment. 
The resultant radio-chromatogram is shown below in Figure 20. The chromatogram 
reveals that under the same conditions, the reaction of ClDA 23 is also poor, and only 
~10% of the [18F]fluoride was converted to [18F]FDA [18F]-22, suggesting that the 
conditions for labelling were not optimal. 
 
Figure 20. HPLC radioactivity trace of the reaction where ClDA 23 was incubated with the fluorinase 
and [18F]fluoride for 30 min. [18F]Fluoride is again observed as a broad peak at tR = 2.4 min. 
A new peak was observed at tR = 4.9, and identified as [18F]FDA [18F]-22.  
160 
 
3.8.2. Optimisation of radiolabelling conditions with ClDA 23 as a
 substrate 
The reaction conditions employed for radiolabelling in Chapter 2 or Section 3.1.2 both 
afforded the anticipated radiolabelled products in good yield, without the need for 
optimisation. However, the low radiochemical incorporations observed for the 
multimeric substrate necessitated investigation to identify more optimal reaction 
conditions. 
To this end, the transhalogenation reaction between ClDA 23 and [18F]fluoride ion was 
investigated under a variety of conditions, as summarised below in Table 2.  
Table 2. Conditions investigated for the fluorinase catalysed radiolabelling of ClDA 23 to 
[18F]FDA [18F]-22. Conditions changed for each experiment are highlighted in bold. 
Component concentration radiochemical 
incorporation ClDA 23/mM fluorinase/mg.mL−1 L-SeMet/mM 
0.04 10 0.125 10% 
0.04 10 (alt. batch) 0.125 10% 
0.04 2.8 (stoichiometric) 0.125 13% 
0.04 0.7 (catalytic) 0.125 5% 
0.04 10 0.020 9% 
0.3 0.7 0.125 9% 
0.3 10 0.125 60% 
0.3 20 0.125 65% 
0.6 20 0.125 90% 
 
Firstly, an alternative preparation of the fluorinase enzyme was investigated, but this 
resulted in similar radiochemical incorporations (~10%) as the original batch used. The 
effect of lowering the enzyme concentration to stoichiometric and catalytic levels was 
investigated. Surprisingly, use of stoichiometric amounts of enzyme did not significantly 
alter incorporation, suggesting that the ratio of enzyme to substrate may be an 
important factor affecting incorporation. Employing a catalytic amount of the enzyme 
led to a reduction in incorporation to 5%, whilst decreasing the L-SeMet concentration 
had no effect. 
When substrate concentration was increased from 0.04 mM to 0.3 mM in the presence 
of catalytic enzyme (0.7 mg.mL−1, 0.02 mM), the incorporation was found to recover to 
~9%. The result suggested that a combination of high substrate concentration and high 
enzyme concentration may be necessary for high radiochemical incorporation. 
Repetition of the reaction at much higher enzyme concentrations (10 mg.mL−1, 0.3 mM) 
in combination with a high substrate concentration (0.3 mM) resulted in significantly 
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higher radiochemical incorporations, approaching 60%. These incorporations were 
similar to that observed in previous, successful radiolabelling experiments. Further 
increasing the enzyme concentration to 20 mg.mL−1 only afforded a marginal increase 
in incorporation. However, increasing the substrate concentration to 0.6 mM, combined 
with 20 mg.mL−1 of fluorinase resulted in incorporations of approximately 90% within 
30 minutes. The HPLC radio-chromatogram of this experiment is shown below in 
Figure 21, with the peak for [18F]FDA [18F]-22 appearing at tR = 5.2 min.  
 
Figure 21. HPLC radioactivity trace of the reaction where ClDA 22 (0.6 mM) was incubated with the 
fluorinase (20 mg.mL−1) and [18F]fluoride for 30 min. [18F]FDA [18F]-22 was observed at 
tR = 5.2, with ~90% radiochemical incorporation. 
These experiments suggested that a combination of high fluorinase concentration 
coupled to high substrate concentration is required to achieve the highest possible 
radiochemical incorporations. When either of these concentrations is low, a reduction in 
incorporation is observed. These results led us to explore the radiolabelling of the 
multimeric substrates under these optimised conditions. 
3.8.3. Radiolabelling of ClDEA-PEG-(RGD)2 224 under optimised 
 conditions 
The optimised conditions require a substrate concentration of 0.6 mM for high 
radiochemical incorporations, however, the multimeric substrates  
ClDEA-PEG-(RGD)2 224 and ClDEA-PEG-(RGD)4 225 were found to be poorly soluble 
in water at this concentration. Reactions were therefore performed with a sufficient 
mass of substrate to give a final concentration of 0.3 mM (assuming that the compound 
was completely dissolved).  
The radiolabelling of ClDEA-PEG-(RGD)2 224 was explored as shown in Scheme 20, 
using the conditions described above. A sample of a solution of  
ClDEA-PEG-(RGD)2 224 (corresponding to 0.1 mg of 224) from a 1:1 mixture of 
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MeCN:water was added to a vial, and the solution concentrated to dryness under a 
stream of nitrogen, while heating to 95 °C. After cooling, L-SeMet (0.08 mM), and 
fluorinase (20 mg.mL−1) were added, followed by a solution of [18F]fluoride in water 
(380 µL) to give a final concentration of ClDEA-PEG-(RGD)2 224 of 0.3 mM. Some 
precipitation of the substrate was observed upon addition of aqueous [18F]fluoride, 
suggesting that the final concentration of substrate in solution was likely lower than the 
desired 0.3 mM. 
 
Scheme 20. Fluorinase catalysed transhalogenation reaction with ClDEA-PEG-(RGD)2 224 with 
[18F]fluoride to produce [18F]FDEA-PEG-(RGD)2 [18F]-248. 
The reaction was incubated at 37 °C for 30 minutes, before the enzyme was heat 
denatured and the mixture centrifuged. A sample of the supernatant was analysed by 
HPLC, and the resultant HPLC radio-chromatogram is shown in Figure 22, revealed a 
new peak at tR = 13.7 min, which was identified as [18F]FDEA-PEG-(RGD)2 [18F]-224 by 
spiking with a sample of [19F]FDEA-PEG-(RGD)2 248. 
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Figure 22. HPLC radioactivity trace of the reaction where ClDEA-PEG-(RGD)2 224 (0.3 mM) was 
incubated with the fluorinase (20 mg.mL−1) and [18F]fluoride for 30 min.  
[18F]FDEA-PEG-(RGD)2 [18F]-228 was observed at tR = 13.7 min, showing 10% 
radiochemical incorporation. Run under isocratic HPLC conditions. 
The radiochemical incorporation of [18F]fluoride into [18F]FDEA-PEG-(RGD)2 [18F]-248 
was much higher than observed in the initial experiment (shown in Figure 19 in 
Section 3.8.1), where only traces of the desired product were observed. 
Radiochemical incorporations were, however, lower than those observed for the 
unmodified substrate ClDA 23 (60%) under similar conditions. The lower radiochemical 
incorporation is most likely due to the substrate ClDEA-PEG-(RGD)2 224 being poorly 
soluble in water and limiting substrate concentration. 
A range of conditions were explored in an attempt to increase the final substrate 
concentration in solution. These experiments were conducted in a similar manner to 
those described above, but with a different preparation of ClDEA-PEG-(RGD)2 224 and 
fluorinase. 
Three different preparations of ClDEA-PEG-(RGD)2 224 were investigated. For the first 
preparation, the substrate 224 was freeze-dried directly in the reaction vessel in an 
attempt to increase the surface area of the compound and consequently its rate of 
dissolution. The second attempt involved the preparation of a low concentration 
enzyme:224 complex. After freeze-drying and resuspension in a smaller volume, it was 
hoped that 224 may be more soluble as a complex. The freeze dried compound was 
therefore added to a solution of the fluorinase in a large volume (1 mL, 224 
concentration 0.04 mM) before the enzyme-substrate solution was freeze dried. In a 
third preparation, 224 was pre-dissolved in DMSO (2 µL) before the radiolabelling 
experiment. 
In a typical experiment, the compound preparation was added to a solution of 
[18F]fluoride (138 µL, 15.2–29.7 MBq) in water, along with the enzyme (if required) and 
164 
 
L-SeMet. Reactions were incubated at 37 °C for 30 min or 120 min before the enzyme 
was removed by heating and centrifugation. The radiochemical incorporation for each 
of these experiments, determined by HPLC, is summarised below in Table 3. 
Table 3. Conditions investigated for increasing substrate concentration for the fluorinase catalysed 
radiolabelling of ClDEA-PEG-(RGD)2 224 to [18F]FDEA-PEG-(RGD)2 [18F]-248. Conditions 
changed for each experiment are highlighted in bold. 
Condition changed radiochemical 
incorporation ClDEA-PEG-(RGD)2 224 preparation reaction time/min 
freeze dried powder 30 10% 
freeze dried with enzyme 30 10% 
freeze dried with enzyme 120 10% 
pre-dissolved in DMSO (2 µL) 30 7% 
 
The radiochemical incorporation remained ~10% in all of the experiments, suggesting 
that the efforts described did not significantly increase the concentration of 
ClDEA-PEG-(RGD)2 224 in solution. Allowing the reaction to proceed for 2 h, rather 
than 30 minutes did not result in any significant increased radiochemical incorporation. 
These radiolabelling results indicated that ClDEA-PEG-(RGD)2 224 was a poor 
substrate under PET conditions, despite the good conversions observed in the “cold” 
experiments at high fluoride ion concentrations. This effect is most likely a combination 
of an inherently slower transhalogenation reaction, coupled to poor solubility of the 
substrate under the investigated conditions.  
3.8.4. Radiolabelling of ClDEA-PEG-(RGD)4 225 under optimised 
 conditions 
The transhalogenation reaction between the tetrameric construct  
ClDEA-PEG-(RGD)4 225 and [18F]fluoride, catalysed by the fluorinase, shown in 
Scheme 21, was also investigated under the optimised radiolabelling conditions. 
ClDEA-PEG-(RGD)4 225 showed very poor solubility and achieving solutions of 0.3 mM 
also proved difficult.  
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Scheme 21. Fluorinase catalysed transhalogenation reaction with ClDEA-PEG-(RGD)4 225 with 
[18F]fluoride to produce [18F]FDEA-PEG-(RGD)4 [18F]-249. 
A similar investigation into increasing the concentration of the tetrameric species in 
solution was undertaken. Freeze-dried ClDEA-PEG-(RGD)4 225 (0.2 mg), or  
225 (0.2 mg) in DMSO (2 µL) were added to L-SeMet (0.08 mM or 0.3 mM), and 
fluorinase (20 mg.mL−1), followed addition of a solution of [18F]fluoride in water (160 µL, 
25.0–35.4 MBq). Alternatively, L-SeMet (0.08 mM) and [18F]fluoride solution (25.1 MBq) 
were added to a freeze dried enzyme:225 complex. The reactions were allowed to 
proceed for 30 min or 120 min at 37 °C, before the enzyme was heat denatured and 
the mixture centrifuged. A sample of the supernatant was analysed by HPLC in order to 
assess incorporation. The conditions explored are summarised in Table 4. 
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Table 4. Conditions investigated for increasing substrate concentration for the fluorinase catalysed 
radiolabelling of ClDEA-PEG-(RGD)4 225 to [18F]FDEA-PEG-(RGD)4 [18F]-249. Conditions 
changed for each experiment are highlighted in bold. 
Condition changed radiochemical 
incorporation ClDEA-PEG-(RGD)4 225 preparation reaction time/min 
freeze dried powder 30 5% 
freeze dried with enzyme 30 5% 
pre-dissolved in DMSO (2 µL) 30 5% 
freeze dried powder 120 5% 
L-SeMet concentration to 0.3 mM 30 7% 
 
For all of the explored conditions, radiochemical incorporations of [18F]fluoride to 
generate [18F]FDEA-PEG-(RGD)4 [18F]-249 were found to be 5–7%, with the product 
observed at tR = 10.1 min. A representative HPLC radio-chromatogram is shown in 
Figure 23, for the reaction where the enzyme and substrate were co-mixed prior to the 
labelling reaction. Extending the reaction time and increasing the concentration of 
L-SeMet had a negligible effect on the observed radiochemical incorporation. 
 
Figure 23. HPLC radioactivity trace of experiment where ClDEA-PEG-(RGD)4 225 (0.3 mM) freeze dried 
with the fluorinase (20 mg.mL−1) prior to reaction. [18F]Fluoride and L-SeMet were added and 
the mixture incubated for 30 min. [18F]FDEA-PEG-(RGD)4 [18F]-249 was observed at 
tR = 10.1 min, showing 5% radiochemical incorporation. An additional peak was also 
observed at tR = 5.2 min. Run under gradient conditions. 
These results suggest that ClDEA-PEG-(RGD)4 225 was also a poor substrate for the 
fluorinase catalysed transhalogenation reaction with [18F]fluoride ion. Although “cold” 
reactions at high fluoride ion concentration were successful, again, poor solubility of the 
substrate, ClDEA-PEG-(RGD)4 225, in the aqueous reaction medium resulted in low 
incorporation of [18F]fluoride ion. 
The fluorinase is known to be a slow enzyme, even with its natural substrate 
S-adenosylmethioinine (kcat = 0.06 min−1).56 It was found in Chapter 2 that the 
transhalogenation rate observed with ClDEA 174, the acetylene-modified substrate for 
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the enzyme, operated at approximately 60% of the rate of the unmodified substrate. 
Extending the logic that modification of the substrate to these more complex multimeric 
derivatives would suggest that the transhalogenation reaction of these multimers with 
fluoride would be significantly slower. The inherently slower reaction, coupled to the 
low solubility of ClDEA-PEG-(RGD)2 224 and ClDEA-PEG-(RGD)4 225 appears to be 
responsible for the low radiochemical incorporations observed during reaction with 
[18F]fluoride. 
Unlike the experiments described in the previous section for ClDEA-PEG-(RGD)2 224, 
the isocratic conditions did not translate well for HPLC analysis of experiments using 
ClDEA-PEG-(RGD)4 225. Consequently HPLC was conducted using a simple 
5% MeCN to 95 % MeCN in water (with 0.05% TFA modifier) over a 20 minute 
gradient. Use of this gradient for 225 revealed the presence of an unidentified peak at 
tR = 5.2 min, shown in the trace above in Figure 23. 
The unidentified peak had the same retention time as [18F]FDA [18F]-22, the product of 
the optimisation reactions discussed in Section 3.8.2. In a control experiment, a 
solution of [18F]fluoride ion was added to the fluorinase enzyme and L-SeMet, without 
the addition of any nucleoside substrate. After 30 min incubation at 37 °C and 
subsequent heat precipitation of the enzyme, the supernatant was analysed by HPLC 
using the same gradient conditions. The resultant radio-chromatogram (Figure 24) 
revealed the presence of a radiolabelled compound, eluting at tR = 5.2 min. Spiking of 
this sample with a solution of [19F]FDA 22 revealed that the peaks co-elute, suggesting 
that the radioactive compound was indeed [18F]FDA [18F]-22.  
 
Figure 24. HPLC radioactivity trace of the control reaction where the fluorinase (20 mg.mL−1) was 
incubated with only [18F]fluoride for 30 min. [18F]FDA [18F]-22 was observed at tR = 5.2 min. 
Run with under gradient conditions. 
The conversion of approx. 20% of [18F]fluoride to [18F]FDA [18F]-22 under these 
conditions suggested that traces of S-adenosylmethioinine 20 (SAM) were present in 
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the reaction mixture. The native fluorinase enzyme from S. cattleya was known to co-
purify with the substrate, SAM 20, bound to the active site.57  
Upon incubation with [18F]fluoride, the low levels of residual SAM 20 would be 
converted, under the action of the enzyme, to [18F]FDA [18F]-22. During previous 
radiolabelling experiments involving the fluorinase, with either ClDEA 174 or 
ClDEA-TEG-RGD 204, the use of high substrate concentrations (0.3 mM) meant that 
these substrates effectively out-competed any residual SAM 20. This may be why 
significant conversion to [18F]FDA [18F]-22 was not observed in these experiments. 
An analysis of samples from radiolabelling of both ClDEA-PEG-(RGD)2 224 and 
ClDEA-PEG-(RGD)4 225 under gradient conditions revealed the presence of 
[18F]FDA [18F]-22 in both cases. This observation provided further evidence that both 
ClDEA-PEG-(RGD)2 224 and ClDEA-PEG-(RGD)4 225 were poorly soluble and were 
not present at sufficient concentration to reduce the background reaction with the 
residual SAM 20 in the fluorinase active site. 
The study showed that ClDEA-PEG-(RGD)2 224 and ClDEA-PEG-(RGD)4 225 do 
undergo a fluorinase catalysed transhalogenation reaction to their corresponding 
[18F]-fluorinated analogues, although radiochemical incorporations are low. Efforts to 
improve the incorporations for both substrates were unsuccessful, likely due to poor 
solubility of the multimeric substrates, rather than poor affinity for the fluorinase. 
3.9. Conclusions 
“Last step” radiolabelling using the fluorinase was extended from simple RGD 
constructs, to more complex multimeric RGD substrates, based on the discovery of a 
tolerance at the C-2 position of the substrate.  
Fluorine-18 radiolabelling of such multimeric RGD peptides had been reported 
previously, but generally required either a prosthetic group strategy,27–29 or required 
strong heating to form an aluminium [18F]fluoride complex.31,33,34 The fluorinase could 
offer a methodology for a “last step” radiolabelling procedure at room temperature, and 
under neutral pH conditions, provided that these complex substrates are tolerated by 
the enzyme. 
Two substrates were designed, bearing two and four cyclic RGD motifs respectively. 
The design aimed to capitalise on the increased binding affinity that is often observed 
for such multimers. The chlorinated and fluorinated analogues of the dimeric and 
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tetrameric alkyne were synthesised using a Sonogashira coupling strategy as the key 
step. Using such a reaction, the nucleobase required for the fluorinase 
transhalogenation was coupled to the linker bearing multiple alkyne motifs, while 
preserving the alkyne at the C-2 position of the base. The alkyne was proposed to be 
critical in maintaining the correct geometry of the linker, preventing the peptide from 
interfering with the transhalogenation reaction.  
Following the synthesis of these multimeric alkynes, the constructs were coupled to 
c(RGDfK[N3]) 199 using a copper-catalysed CuAAC reaction. After purification, the 
reaction afforded access to dimeric and tetrameric chlorinated substrates for the 
fluorinase catalysed transhalogenation. The fluorinated analogues were also 
successfully synthesised. The new multimeric assemblies, ClDEA-PEG-(RGD)2 224 
and ClDEA-PEG-(RGD)4 225, were assessed as substrates for the fluorinase and 
found to undergo enzyme-catalysed transhalogenation. 
The dimeric and tetrameric fluorinated products 248 and 249 were assessed for their 
affinity to immobilised αVβ3 integrin. The multimers showed lower IC50 values compared 
to their monomeric analogues, due to an increased effective molarity, rather than true 
multivalent binding. 
Transfer of the transhalogenation reactions to the PET environment proved 
challenging. Initial radiolabelling experiments with [18F]fluoride showed little conversion 
to radiolabelled products. The poor incorporations result led us to optimise the 
radiolabelling conditions with ClDA 23. Optimisation revealed that both high substrate 
and high enzyme concentration were required for efficient reaction. 
ClDEA-PEG-(RGD)2 224 and ClDEA-PEG-(RGD)4 225 were not sufficiently soluble 
under the aqueous reaction conditions, resulting in radiochemical incorporations of 
between 5–10%. Attempts to improve the solubility of the constructs were investigated, 
but found to have a negligible effect on the observed incorporations. 
Extension of this system to larger peptides or proteins will depend on the extent to 
which such substrates dissolve in aqueous solvent while maintaining stability. Evolved 
proteins, such as antibodies and enzymes, should have higher water solubility. If highly 
soluble substrates can be developed, this methodology presents a potentially attractive 
approach for “last step” radiolabelling of peptides and proteins for PET. 
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4. A difluoromethyl-bearing nucleoside substrate for 
the fluorinase 
4.1. The difluoromethyl group 
4.1.1. Applications of the difluoromethyl group 
Compared to the trifluoromethyl (R–CF3) group, the difluoromethyl group (R–CF2H) and 
fluoromethyl group (R–CH2F) remain comparatively unexplored in terms of their 
application to bioactive molecules.1 The unique physical properties of the 
difluoromethyl group have led to renewed interest in the development of synthetic 
methods for the introduction of this motif into organic molecules. Fluorinase enzymatic 
synthesis results in monofluorinated natural products,2 but no such products containing 
a CF2 group have been described to date. The enzymatic synthesis of such groups 
remains unexplored. It became of interest to explore the fluorinase for capacity to 
prepare a difluoromethyl group. 
The difluoromethyl group is found in a range of commercially important bioactive 
molecules. Such molecules include the anaesthetic isoflurane 251,3 anti-trypanosomal 
agent eflornithine 252,4 and penoxsulam 253,5 a broad leaf herbicide, illustrated below 
in Figure 1. 
 
Figure 1. Structures of some commercially important molecules containing the difluoromethyl group. 
The difluoromethyl group is anisotropic and possesses a hydrogen atom bonded to 
carbon bearing two strongly electron withdrawing fluorine substituents. As a 
consequence, the hydrogen atom is available as a hydrogen bond donor, although as a 
more lipophilic hydrogen bond donor than the more common hydrophilic O–H and N–H 
groups.6  
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For difluoromethyl ethers in particular, the anisotropy and inherent dipole of the 
difluoromethyl group allows such ethers to adopt two conformers with differing 
lipophilicity.7 This property makes them attractive for use in drug discovery as 
molecules bearing such groups can adjust their conformation to enhance electronic 
interactions with a biological target. 
These unique properties of the difluoromethyl group have led to its development as a 
bio-isostere8 of alcohols,9 thiols10 and hydroxamic acids.11 HCV NS3 protease, a drug 
target in the hepatitis C virus, cleaves its target at the C-terminus of a cysteine residue. 
While investigating product analogues to identify potential protease inhibitors, 
replacement of the cysteine thiol of a model peptide product 254, with a difluoromethyl 
group gave inhibitor 255, as shown in Figure 2 A. The difluoromethyl analogue 255 
showed a Ki 20 times lower than its more simple methyl analogue.  
 
Figure 2. The difluoromethyl group acts as an effective bio-isostere of A. thiols and B. alcohols. 
Similarly, replacement of the hydroxyl group in lyophosphatidic acid 256 analogues, a 
nuclear hormone receptor agonist, with a difluoromethyl group afforded analogue 257, 
as shown in Figure 2 B. The novel analogue showed improved selectivity for its 
nuclear receptor, while also avoiding acyl migration, a problem with more conventional 
analogues which conserve the hydroxyl group.10 
In both cases, the fluorine atoms were found to effectively mimic the two lone pairs 
present on the oxygen or sulfur atom. In addition, the difluoromethyl group proved a 
close match for the volume and electrostatic potential of the thiol in the hepatitis C 
protease inhibitor. The electropositive hydrogen atom was found to be able to mimic 
the proton of the thiol, and form a hydrogen bond-type interaction with the carbonyl of a 
lysine residue in the active site of its target. 
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4.1.2. Synthesis of the difluoromethyl group 
The role played by the difluoromethyl group in bioactive molecules has led to renewed 
interest in synthetic methods for its introduction into organic molecules.1 Traditional 
routes to access such motifs involve reaction of an aldehyde with sulfur 
tetrafluoride 258, as shown in Scheme 1.12 Sulfur tetrafluoride 258 is, however, a gas 
at room temperature (b.p. –38 °C), and safe handling concerns makes conducting such 
reactions a challenge. 
 
Scheme 1. A. Conversion of aldehydes to difluoromethyl groups using sulfur tetrafluoride 158 or 
reagents derived from sulfur tetrafluoride. B. Fluorination of 1-naphthaldehyde 261 with 
DAST 259 to give difluoromethylated product 262. 
In order to overcome the challenge of the reactive gas, a range of amino-sulfur 
trifluoride derivatives that are liquid at room temperature were developed. Such 
reagents include (diethylamino)sulfur trifluoride 259 (DAST)13,14 and 
bis(2-methoxyethyl)aminosulfur trifluoride 260 (Deoxofluor®),15 a more thermally stable 
derivative thereof. These reagents show similar reactivity to sulfur tetrafluoride, and are 
also capable of transforming aldehydes (such as 1-naphthaldehyde 261) to 
difluoromethyl products, as shown in Scheme 1. α,α-Difluoroamines have also been 
reported to be capable of converting aldehydes to difluoromethyl groups via a similar 
transformation.16 
In addition to the direct difluorination of carbonyl compounds, a number of methods 
have been developed for direct transfer of a difluoromethyl group to an appropriate 
substrate.1,17 Early versions of such transformations employed nucleophilic “RCF2-” 
species, such as difluoromethyl sulfones (265),18,19 sulfoxides20 or phosphonates as a 
source of the nucleophilic synthon upon treatment with a base.21 The resultant anion is 
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stabilised by the presence of the neighbouring electron withdrawing group. The 
stabilised anion reacts with a variety of electrophiles, including carbonyls, alkyl halides 
and cyclic sulfates to generate R-CF2-S or R-CF2-P species. Reductive cleavage of the 
CF2-S or CF2-P then gives a difluoromethyl group, as illustrated in Scheme 2 A.22 
 
Scheme 2. A. Difluoromethylation using a deprotonated sulfone to generate a difluoromethyl 
nucleophile.18 B. Difluoromethylation using a copper-mediated transfer of a CF2H group.23 
C. Difluoromethylation of a thiol by difluorocarbene.24 D. Difluoromethylation at unactivated 
C–H bonds.25 
Trimethyltrifluoromethylsilane (TMSCF3 or the Ruppert-Prakash reagent) can also be 
used to transfer a difluoromethyl group to acyl silanes and aldimines.26,27 Copper-
mediated nucleophilic transfer of the difluoromethyl group to an aryl iodide has also 
been reported, using either TMSCF2H23 (Scheme 2 B) or cadmium 
difluoromethylphosphonate28 as the difluoromethyl source. 
A more common approach for the introduction of the difluoromethyl group involves the 
reaction of a nucleophilic C, S, N, or O species with difluorocarbene 80.29 A number of 
reagents can be used to generate difluorocarbene 80 in situ, most commonly 
halodifluoromethanes,1,30–33 however, these are known ozone depleting agents and 
more environmentally benign sources are highly desired. Such sources include sodium 
chlorodifluoroacetate 270 (Scheme 2 C),24 diethyl bromodifluoromethyl phosphonate,34 
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and a number of metal trifluoromethide salts.29 Difluoromethyl triflate has also been 
utilised as an electrophile for reaction with phenols, giving aryl difluoromethyl ethers.35 
A radical-based approach has also been used to introduce the difluoromethyl group to 
alkenes and alkynes. Difluorodibromomethane or difluorobromochloromethane have 
been employed as sources of difluoromethyl radicals with a radical initiator such as 
CuCl36 or UV light.37 A milder radical C–H activation approach to difluorination has 
recently been reported by Baran et al.,25 where a combination of zinc 
bis(difluoromethylsulfinate) and tBuOOH allows difluoromethylation at electron poor 
sites of N-heterocycles (273), S-heterocycles and enones, as shown in Scheme 2 D. 
4.2. Aims 
The recent resurgence in interest in the synthesis and application of difluoromethyl 
groups led us to explore a possible synthesis of the motif with the fluorinase enzyme. 
The fluorinase has been well characterised2 in its ability to activate fluoride ion as a 
nucleophile and catalyse the formation of a C–F bond, as shown in Scheme 3 A. The 
synthesis of a difluoromethyl group by the enzyme would require the fluorinase to 
catalyse the reaction of fluoride with a pre-fluorinated SAM analogue 275 (FSAM), as 
shown in Scheme 3 B. Such a reaction could offer a route for the enzymatic synthesis 
of difluoromethylated product 276 (F2DA).  
 
Scheme 3.  A. Synthesis of a C–F bond by the fluorinase enzyme. B. Proposed enzymatic synthesis of a 
difluoromethyl group. C. α-Fluorosulfonium species reacting with iodide to generate methyl 
iodide. 
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There are no reports of any FSAM analogues, such as 275 above, bearing substituents 
at the 5'-position. The simplest α-fluorosulfonium species, 
(fluoromethyl)dimethylsulfonium (277) tetrafluoroborate, has been reported,38 where its 
reaction at a methyl group with iodide as a nucleophile was explored, as shown in 
Scheme 3 C. In addition, the use of diaryl fluoromethylsulfonium salts as 
fluoroalkylating agents has also been explored. The triflate and tetrafluoroborate salts 
of the motif were found to be air and moisture stable, and capable of transferring a 
fluoromethyl group to N, O and S nucleophiles.39 The literature reports of the 
α-fluorosulfonium motif suggested that FSAM 275 may be stable, however it would still 
be difficult to prepare this highly functionalised substrate synthetically. Without access 
to FSAM 275, assessment of the proposed α-fluorosulfonium species as fluorinase 
substrate would be difficult. 
The native reaction catalysed by the fluorinase enzyme is reversible (Scheme 4 A).40 
With this in mind, and the anticipated difficulty in preparing FSAM 275 synthetically, we 
decided to explore the proposed transformation in the reverse direction. Such a 
reaction would involve enzyme catalysed nucleophilic attack of L-Met at C-5' of 
F2DA 276, to generate FSAM 275, with concomitant release of fluoride ion, as shown in 
Scheme 4 B. The reverse reaction would therefore provide a simple tool to assess the 
viability of the enzymatic synthesis of a difluoromethyl group. 
 
Scheme 4. A. Cleavage of the C–F bond of FDA 22 by the fluorinase enzyme. B. Proposed enzymatic 
transformation of F2DA 276 to its corresponding FSAM analogue 275. 
In anticipation of exploring the reverse reaction of F2DA 276 with the fluorinase, 
F2DA 276 became a synthetic target. Investigation of F2DA 276 as a substrate with the 
fluorinase would indicate whether the proposed synthesis of a difluoromethyl group by 
an enzymatic route was possible. 
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4.3. Synthesis of 5',5'-difluoro-5'-deoxyadensine 276 (F2DA) 
The synthesis of 5',5'-difluoro-5'-deoxyadensine 276 has been previously reported by 
Jarvi et al.41,42 Fluorination of N,N-dibenzoyl-2',3'-O-isopropylidneadenosine-5'-
aldehyde 283 with diethylaminosulfur trifluoride 259 (DAST) was the key fluorination 
step, as illustrated in Scheme 5. 
The synthesis reported by Jarvi et al.41,42 involved oxidation of protected adenosine 280 
to the corresponding aldehyde, and trapping the resultant aldehyde as aminal 281, 
using conditions described by Moffat et al. 43 The trapping of the aldehyde as an aminal 
allowed separation of the otherwise unstable aldehyde from the dicyclohexylurea 
oxidation by-product. Further protection, followed by hydrolysis of aminal 282 
generated the aldehyde 283, the substrate for the key difluorination step. 
Aldehyde 283 was subjected to difluorination with DAST and generated 284 in 
18% yield. Deprotection of the dibenzoylimide and acetonide protecting groups 
furnished F2DA 276. Despite the low yield for the fluorination reaction, the synthetic 
route to F2DA 276 described by Jarvi et al.41,42 was explored. 
 
Scheme 5. Reagents employed in the synthesis of F2DA 276 reported by Jarvi et al.41,42 with 
difluorination by DAST as they key step. 
4.3.1. Synthesis of an adenosine-5'-aldehyde 
Adenosine 188 was protected as its acetonide with 2,2-dimethoxypropane in acetone, 
catalysed by perchloric acid, as shown in Scheme 6. Using a modified procedure 
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described by Jawalekar et al.,44 the free hydroxyl group of 285 was in situ protected as 
a TMS ether, before monobenzoylation of N-6 with benzoyl chloride gave 280.  
Moffatt oxidation43 of alcohol 280, using dicyclohexylcarbodiimide (DCC) and 
dichloroacetic acid in DMSO, followed by precipitation of the N,N'-dicyclohexylurea 
by-product by addition of oxalic acid, produced a solution of aldehyde hydrate 286 in 
methanol. N,N'-Diphenylethylenediamine was added to this solution, upon which, crude 
aminal 282 precipitated. Recovery of the precipitate and further purification by 
chromatography afforded aminal 282 in 27% yield.  
 
Scheme 6. Synthesis of aminal 282, as a source of aldehyde hydrate 286. 
Unlike the procedure employed by Jarvi et al.,41,42 where aminal 282 was further 
protected before its hydrolysis to the free aldehyde, Moffatt et al.43 described the direct 
use of aminal 282 as a source of aldehyde hydrate 286 (and its aldehyde). In an effort 
to avoid an additional synthetic step, aminal 282 was subjected to acid hydrolysis using 
Dowex WX4-400 (an acidic resin) in aqueous THF. Trials of the reaction resulted in an 
inseparable mixture of products. Aldehyde hydrate 286 was identified as a component 
of this mixture, however, could not be separated from the other by-products. 
As the yield of aminal 282 was low, and aldehyde hydrate 286 could not be isolated 
from the reaction mixture as a single species, alternative oxidations to give 
adenosine-5'-aldehyde were explored. Oxidation of both acetonide 285 and its 
N-benzoylated analogue 280 were trialled under Swern conditions, using 
2-iodoxybenzoic acid (IBX) in DMSO, or employing a combination of catalytic TEMPO 
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with one equivalent of bis(acetoxy)iodobenzene. None of these conditions, however, 
afforded the corresponding aldehyde in any appreciable conversion. 
As the Moffatt oxidation had been successful in generating a species at the aldehydic 
oxidation level, optimisation of this oxidation reaction was further explored. Inspired by 
the development of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) as a water 
soluble replacement for DCC in peptide couplings,45 the use of EDCI rather than DCC 
may improve purification of the aldehyde product. In addition, a dibenzoylated 
substrate was explored as a substrate for the oxidation, anticipating that the more 
lipophilic substrate may facilitate product separation from the water soluble urea 
oxidation by-products.  
To this end, acetonide 285 was dibenzoylated in excellent yield with TMSCl, and an 
excess of benzoyl chloride, as shown in Scheme 7. Oxidation of 287 under Moffatt 
conditions, but substituting DCC for EDCI.HCl, resulted in complete conversion of 287 
to a new product. Partitioning the reaction mixture between water and ethyl acetate, 
followed by concentration of the organic extracts in vacuo, gave a mixture of 
aldehyde 283 and its hydrate. Azeotropic removal of water by repeated co-evaporation 
with toluene furnished aldehyde 283 in quantitative yield, without further purification. 
 
Scheme 7. Protection of acetonide 285 as imide 287, followed by Moffatt oxidation with EDCI.HCl rather 
than DCC, gave aldehyde 283 in near quantitative yield over two steps. 
This modified synthetic procedure gave access to protected aldehyde 283, the required 
substrate for the fluorination reaction, in three steps rather than five, from adenosine. 
With aldehyde 283 in hand, the fluorination reaction was now explored. 
4.3.2. Difluorination of adenosine-5'-aldehyde 283 
The fluorination reaction was explored under the reported conditions,41,42 by addition of 
DAST 259 to a solution of aldehyde 283 in DCM in room temperature in a Teflon 
reaction flask, as shown in Scheme 8. After six hours, the reaction was quenched by 
the addition of saturated sodium bicarbonate solution, and the crude reaction mixture 
analysed by 19F{1H}NMR spectroscopy, as shown below in Figure 3. 
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Scheme 8. Fluorination of aldehyde 283 using DAST in DCM as reported by Jarvi et al.41,42 
 
Figure 3. A. 19F{1H} NMR spectrum (470 MHz, CDCl3) of the crude reaction mixture obtained after 
fluorination of aldehyde 283 with DAST, at room temperature in DCM. B. Expanded view of 
the region between −125 ppm and −131 ppm, revealing an AB system with a 2JFF coupling 
constant of 299.1 Hz. 
The 19F{1H}NMR spectrum of the product mixture, shown above in Figure 3 A, and 
revealed the presence of a number of fluorinated products. The chemical shifts 
reported for the two fluorine atoms of 284 are −65.8 ppm and −50.7 ppm,42 or −54.8 
ppm and −50.2 ppm,41 with a 2JFF coupling of 299.1 Hz. Examination of this region of 
this spectrum did not reveal any such peaks in this region, suggesting that 284 was not 
present in the product mixture. However, all other difluoromethyl containing compounds 
reported by Jarvi et al.42 have reported 19F chemical shifts of between −125 ppm and 
−131 ppm, suggesting an error in their reporting of the 19F chemical shifts for 284. 
Fluorine chemical shifts for difluoromethyl groups usually appear in the −110 ppm to 
−145 ppm range.46 Examination of the −110 ppm to −145 ppm region revealed an 
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AB spin system, as expected for 284, with a coupling constant of 299.1 Hz, shown 
above in Figure 3 B. 
The 19F{1H}NMR spectrum (Figure 3 A) suggested the presence of 284 in the product 
mixture, but many other fluorinated products were also evident. Purification of the 
product proved challenging, requiring multiple rounds of chromatography, and 
ultimately affording only traces of 284. As a consequence, optimisation of the 
fluorination of aldehyde 283 was further explored. Fluorination of 283 was carried out 
using a range of solvents, temperatures, and fluorination reagents, as summarised 
below in Table 1. 
Table 1. Summary of fluorination conditions trialled to optimise production of 284. 
reagent temperature/°C solvent 
DAST 259 20 DCM 
DAST 259 −78 DCM 
DAST 259 −78 THF 
DAST 259 −78 neat 
Deoxofluor® 260 −78 THF 
 
Product mixtures were analysed directly for the presence of 284 using 19F{1H}NMR 
spectroscopy, after a sodium bicarbonate quench and extraction into ethyl acetate. The 
19F{1H}NMR spectra are shown below in Figure 4. 
When the fluorination reaction was conducted using DAST 259 in DCM, reduction of 
the temperature from 20 °C to −78 °C led to a reduction in the number of fluorinated 
products observed in the mixture, as shown in Figure 4 A and B below. The peaks 
related to difluorinated product 284 (highlighted with an asterisk) were still present, 
though the appearance of multiple new peaks in this region suggested that a number of 
similar products were also being produced under these conditions. Changing the 
reaction solvent to THF had a significant effect on the product distribution. None of the 
desired product was formed, as shown in Figure 4 C. Conducting the reaction in neat 
DAST at −78 °C restored the production of 284 and reduced the formation of similar 
compounds (Figure 4 D), however, by-products were still observed, but 284 was not 
the major product. 
Changing the fluorination reagent from DAST to Deoxofluor® (which is only available 
commercially as a 50% solution in THF), resulted in the formation of 284 as the major 
fluorinated product, as evident in the 19F{1H}NMR spectrum of the product mixture 
shown in Figure 4 E. 
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Figure 4. Partial 19F{1H} NMR spectra (470 MHz, CDCl3) of the crude fluorination mixtures under a 
range of conditions. Peaks associated with the desired product, 284, are highlighted with an 
asterisk. 
The promising reaction using Deoxofluor® 260 in THF was repeated on larger scale, as 
illustrated in Scheme 9, and gave 284 in 10% yield after purification. The yield for the 
reaction is poor, however the simplicity with which aldehyde 283 is prepared meant that 
access to sufficient quantities (50 mg to 100 mg) of difluorinated product 284 was 
practical.  
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Scheme 9. Synthesis of 284 from aldehyde 283 using Deoxofluor® 260. 
As the original literature report42 of 284 appeared to have incorrectly quoted the 
19F NMR chemical shifts, the data obtained from characterisation of 284 was closely 
examined. The coupling constants observed in the 19F NMR spectrum illustrated below 
in Figure 5, 2JFF = 299.1 Hz, 2JFH = 55.1 Hz and 3JFH = 12.4 Hz and 10.1 Hz, match well 
with the reported values,42 as do all the resonances in the 1H NMR spectrum. The 
proton and fluorine spectroscopic data, combined with additional information obtained 
from HRMS and the 13C NMR spectrum, suggested that the component isolated from 
the reaction was indeed 284, and that the original reported 19F chemical shifts for 284 
were erroneously reported, or reported relative to a different standard. 
 
Figure 5. A. 19F{1H} NMR spectrum (282 MHz, CDCl3) of 284 after purification. B. Partial 19F NMR 
spectrum (282 MHz, CDCl3) of the region between −125 ppm and −132 ppm, revealing two 
doublet of doublet of doublets (ddd), with coupling constants of 2JFF = 299.1 Hz, 2JFH = 
55.1 Hz and 3JFH = 12.4 Hz and 10.1 Hz. 
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With protected F2DA 284 in hand, attention turned to the two deprotection steps, as 
shown in Scheme 10. The benzoyl groups were cleaved by reaction of 284 with a 
freshly saturated solution of ammonia in methanol, in a sealed tube at 60 °C for 16 h. 
After isolation of 288, the acetonide was cleaved using a mixture of TFA and water, to 
provide a sample of F2DA 276 as a colourless powder, in good yield. All spectroscopic 
data for 288 and 276 agreed well with those reported in the literature.41,42 
 
Scheme 10. Deprotection of the benzoyl groups and acetonide to give F2DA 276. 
4.4. Investigation of F2DA 276 binding to the fluorinase 
Prior to exploring F2DA 276 as a substrate for the fluorinase, the binding affinity of 276 
to the enzyme was investigated. Using a similar approach to that described in 
Chapter 2, the binding of F2DA 276 to the enzyme was investigated using isothermal 
titration calorimetry (ITC). Accordingly, a solution of F2DA 276 in a phosphate buffer 
was titrated into a solution of the fluorinase in the same buffer. The binding curve 
obtained is illustrated below in Figure 6 A, and the data was fitted assuming a single 
binding site. The binding curve for FDA 22, the natural substrate, with the fluorinase, 
described in Chapter 2, is shown in Figure 6 B for comparison. 
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Figure 6. Isothermal titration calorimetric determination of the binding affinity of A. F2DA 276 (0.72 mM) 
into the fluorinase (60.3 µM) and B. FDA 22 (1.03 mM) into the fluorinase (53.6 µM), as 
shown in Chapter 2. 
The titration curve revealed that F2DA 276 exhibited strong binding to the fluorinase. 
Fitting a one-site binding isotherm to the data allowed determination of the association 
constant (Ka) for this interaction, which was calculated as 27.1 ± 2.01 × 105 M−1. 
Comparison with FDA 22 revealed that F2DA 276 has a higher affinity for the fluorinase 
by a factor of nearly two. The presence of the second fluorine substituent at C-5' 
appears to increase the affinity of the nucleoside for the enzyme.  
The binding of F2DA 276 and FDA 22 to the fluorinase show similar trends in 
contribution to the total free energy change for the binding event, as illustrated in 
Figure 7. Both compounds show favourable enthalpic contributions, but F2DA 276 
shows a greater exotherm upon binding. The greater enthapic contribution for 
F2DA 276 is compensated for by a larger entropic penalty, which results in the similar 
nett free energy change to that observed for FDA 22.  
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Figure 7. Comparison of the thermodynamic parameters of binding for F2DA 276 and FDA 22. ΔH was 
measured directly, while the –TΔS term was calculated using T = 298.15 K. ΔG was 
calculated as the sum of these two terms. 
Fluorine is a poor hydrogen bond acceptor,47 however it is possible that the introduction 
of the difluoromethyl group, which has known hydrogen bond donor capacity, leads to 
additional favourable interactions within the active site. If an additional residue in the 
active site were to engage in a non-classical hydrogen bond to the difluoromethyl group 
of F2DA 276, the interaction would result in increased enthalpic gain and reduce the 
entropy. 
Further enthalpic gain likely arises from more lipophilic F2DA 276 moving from the 
aqueous environment into the hydrophobic active site of the fluorinase.48 Based on the 
retention time on a C18 reverse phase HPLC column run under identical conditions,49 
F2DA 276 (tR = 5.1 min) appears more lipophilic than FDA 22 (tR = 3.8 min). The 
difluoromethyl group locating in the well described hydrophobic fluorine pocket may 
result in enthalpic gain when compared to the less lipophilic fluoromethyl group. 
4.5. Evaluation of F2DA 276 as a substrate 
4.5.1. Evaluation of F2DA 276 with L-Met 21 as a co-substrate 
Confident that the candidate substrate, F2DA 276, binds to the enzyme, attention 
turned to investigating whether the fluorinase was able to catalyse substitution of one 
of the fluorine atoms of with L-methionine 21 (L-Met), as illustrated in Scheme 11. 
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Scheme 11. Proposed substitution of F2DA 276 with L-Met 21 to generate FSAM 275, catalysed by the 
fluorinase. 
To this end, F2DA 276 (0.3 mM) and L-Met 21 (0.5 mM) were incubated with the 
fluorinase enzyme (2 mg.mL−1) in phosphate buffer (20 mM) in a total volume of 
500 µL. Reaction progress was monitored by removal of samples (100 µL) at t = 0, 1, 
2, and 24 h, heat-treating the sample at 95 °C to denature the enzyme and stop any 
reaction. In each case, the mixture was centrifuged and precipitating the denatured 
fluorinase as a pellet and the cleared samples were analysed by HPLC. The results are 
illustrated below in Figure 8. 
 
Figure 8. HPLC time course (260 nm) of incubation of F2DA 276, blue, (tR = 5.3 min) with the fluorinase 
and L-Met 21, showing samples taken at t = 0, 1, 2 and 24 h.  
The HPLC trace did not reveal any change in the concentration of F2DA 276 over 24 h, 
and there were no significant new peaks were evident in the chromatogram. This data 
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suggested that the fluorinase is not capable of catalysing the proposed substitution, or 
that the equilibrium position of the reaction heavily favours the formation of F2DA 276. 
4.5.2. Evaluation of F2DA 276 with L-SeMet 161 as a co-substrate 
The reaction was further explored, using L-selenomethionine 161 (L-SeMet). 
L-SeMet 161 is a better nucleophile than L-methionine due to the presence of a higher 
energy HOMO on the selenium atom, and the increased polarizability of Se over S. The 
anticipated transformation of F2DA 276 to FSeSAM 289 is shown below in Scheme 12. 
 
Scheme 12. Proposed substitution of F2DA 276 with L-SeMet 161 to generate FSeAM 289, catalysed by 
the fluorinase. 
F2DA 276 was incubated with L-SeMet 161 (0.1 or 0.6 mM) and fluorinase enzyme in 
phosphate buffer in similar experiments to those described above. Reaction progress 
was again monitored by HPLC at t = 0, 1, 2, and 19 h, shown below in in Figure 9. 
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Figure 9. A. HPLC time course (260 nm) of incubation of F2DA 276, blue, with L-SeMet 161 (0.1 mM) 
and the fluorinase, showing samples taken at t = 0, 0.5, 1, 2 and 19 h. B. HPLC time course 
of incubation of F2DA 276 with L-SeMet 161 (0.6 mM) and the fluorinase, showing samples 
taken at t = 0, 1, 2 and 19 h. 
Again, there was no apparent reaction or conversion of F2DA 276 over the duration of 
the experiment. This suggests an inherently inert substrate, or that the reaction 
equilibrium lies heavily in favour of F2DA 276. 
The lack of any obvious reaction with either L-Met 21 or L-SeMet 161 suggested that 
the inherent properties of F2DA 276, possibly steric, electronic or a combination 
thereof, prevents substitution of one of the fluorine atoms at C-5'. As the fluorinase 
reaction is known to be reversible, the possibility that the equilibrium for this specific 
transformation lies far in favour of the difluorinated product also exists. Without access 
to a synthetic sample of FSAM 275 or its selenium analogue, distinguishing between 
equilibrium effects or inherent lack of reactivity is not straightforward. 
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4.6. Crystallography of F2DA 276 bound to the fluorinase 
To further probe the binding of F2DA 276 to the enzyme and to try to understand the 
lack of reactivity, conditions were explored for the preparation of a fluorinase-F2DA 276 
co-crystal. 
The fluorinase (6 mg.mL–1) was incubated with F2DA 276 at 2 mM (from 0.5 M DMSO 
stock solution), at 4 °C for 18 h, before a series of in house and commercial stochastic 
crystallisation screens were set up in collaboration with Dr Stephen McMahon and 
Prof. Jim Naismith. 
Crystals were obtained under a range of conditions, however, the best diffracting 
crystals grew from 40% PEG-monomethyl ether 2K, 0.1 M sodium citrate pH 4.5, and 
0.12 M ammonium tartrate. Cryoprotection of a crystal was achieved by doping the 
mother liquor with 20% glycerol and flash freezing in liquid nitrogen. The resultant 
diffraction data were collected at the European Synchrotron Radiation Facility beam 
ID23-1 at 100 K. The data were solved by molecular replacement from previous 
fluorinase crystal structures by Dr Stephen Mc Mahon, to generate a crystal structure 
of F2DA 276 bound into the active site of the fluorinase. The structure was solved to a 
resolution of 1.8 Å, and detail of the refined structure is shown in Figure 10. 
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Figure 10. A. F2DA 276 in the active site of the fluorinase. The two monomers of the fluorinase shown in 
blue and red. The structure was obtained with a molecule of tartrate bound in the active site. 
B. F2DA 276 in the fluorinase showing interactions with surrounding residues. C. Close up of 
the difluoromethyl group, showing distances to the key residues Ser-158 (NH and OH) and 
Thr-80 (OH). 
F2DA 276 was located in the active site, along with a molecule of tartrate (from the 
crystallisation buffer), as shown in Figure 10 A. Examination of the structure revealed 
that F2DA 276 made numerous contacts to active site residues (Figure 10 B), as had 
been observed with other nucleosides co-crystallised with the enzyme. The adenine 
base was found to engage in π-π stacking interactions with Phe-254 and Trp-50, while 
the endo- and exo-cyclic nitrogen atoms formed hydrogen bonding interactions to 
Ala-279 and Asn-215. The 2',3'-diol system of the ribose ring was found to participate 
in a hydrogen bonding interaction with Asp-16. 
Examination of the difluoromethyl group (Figure 10 C) revealed that the fluorine atoms 
were located in the hydrophobic fluoride binding pocket. The interactions previously 
identified as important for reaction appeared conserved. One of the fluorine atoms lies 
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3.0 Å from the OH group of Thr-80, while the second fluorine makes contacts with the 
amide NH and side chain OH of Ser-158 (3.2 Å and 2.9 Å respectively). The two 
fluorine atoms appear to “share” the contacts usually observed with FDA 22 in the 
active site. The hydrogen atom of the difluoromethyl group appears to engage in a 
hydrogen bond with one of the hydroxyl oxygen atoms of the co-bound tartrate, but 
does not appear to form close contacts to any amino acid residues in the active site. 
For direct comparison, the co-crystal structure of F2DA 276 was overlaid with that of 
FDA 22 and L-Met 21 bound in the active site of the fluorinase (PDB code: 1RQR),48 
solved previously at St Andrews. The overlays are shown below in Figure 11, with the 
pastel coloured structure and ligands with yellow C-atoms belonging to the FDA-L-Met 
structure. 
 
Figure 11. A. Overlay of the structure of fluorinase bound to FDA 22 (pastel colours) and F2DA 276 
(bright colours) showing no gross conformational change when bound to F2DA 276.  
B. Close up of the active site of the fluorinase showing an overlay of the two ligands, FDA 22 
(yellow carbons) and F2DA 276 (grey carbons). C. Close up of the active site showing 
orientation of the fluorine atoms of F2DA 276 compared to the orientation of the C–F bond of 
FDA 22. Distances (Å) from the fluorine atoms to key residues are shown for FDA 22 (yellow 
dashes) and F2DA 276 (grey dashes). 
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Binding of F2DA 276 does not result in any gross conformational change of the 
structure of the fluorinase, as shown in Figure 11 A. Upon closer examination, tartrate 
occupies the L-Met 21 binding site (Figure 11 B), adopting a similar conformation 
where one of the carboxylates engages in similar polar interactions to those observed 
for carboxylate group of L-Met 21. The adenine bases overlay very well, as does the 
ribose ring. It is clear in Figure 11 C that the fluorine atom of FDA 22, the natural 
product, lies between the two fluorine atoms of the difluoromethyl group of F2DA 276. 
The location of the two fluorine atoms and their suggested interactions with Thr-80 and 
Ser-158, as shown above, support the suggestion that the fluoromethyl group bridges 
the interactions usually engaged by the single fluorine atom of FDA 22.  
These observations suggest a possible reason why F2DA 276 is not a substrate for the 
fluorinase. The C–F bond is the strongest single bond observed in organic molecules, 
having a bond dissociation energy, on average, of 105.4 kJ.mol−1.50 The fluorinase 
enzyme has uniquely evolved the ability to catalyse the formation, and importantly for 
this case, the cleavage of this bond with L-Met 21 as an incoming nucleophile. The 
“sharing” of key interactions between the two fluorine atoms may no longer sufficiently 
activate one of the fluorines for substitution by L-Met 21 or L-SeMet 161. A second 
consequence of this “sharing” may be that neither of the fluorine atoms are aligned in 
the optimal conformation for an SN2-type substitution with an incoming nucleophile, 
increasing the kinetic barrier to reaction. The addition of a second electronegative 
fluorine atom at C-5' is expected to increase the strength of each of the C–F bonds, 
due to increased positive character at carbon.51,52 A combination of these three factors: 
“shared” interactions with activating residues, misaligned geometry of the C–F bond, 
and increased C–F bond strength, may all contribute to a lack of reactivity.  
4.7. Conclusions 
The difluoromethyl group was found to play an important role in a range of 
pharmaceuticals and agrochemicals in light of its unique physicochemical properties. In 
this context, we were interested in applying the fluorinase enzyme to the synthesis of 
difluoromethyl groups. It was proposed that the enzyme and the associated mild 
reaction conditions would complement existing methodology for synthesis of the –CF2H 
motif. 
To this end, 5',5'-difluoro-5'-deoxyadenosine 276 (F2DA) was synthesised and explored 
as a potential substrate for a reverse reaction with L-Met 21. Isothermal titration 
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calorimetry revealed that F2DA 276 bound to the fluorinase with a marginally larger Ka 
compared to that of the natural substrate, FDA 22. Assays were conducted where 
F2DA 276 was incubated with both L-Met 21, and the more potent nucleophile, 
L-SeMet 161. No reaction was observed in HPLC assays for either set of conditions, 
and increasing the concentration of the nucleophile also resulted in no reaction. 
A co-crystal structure of the fluorinase bound to F2DA 276 was obtained and revealed 
that F2DA 276 was oriented in the active site in a nearly identical manner to FDA 22, 
apart from the location of the two fluorine atoms. The two fluorine atoms were “sharing” 
interactions with Ser-158 and Thr-80, the two residues in the active site responsible for 
activating the fluorine atom for substitution. As a result, the conformation of neither of 
the C–F bonds matched that observed for the C–F bond in FDA 22, suggesting that the 
geometry of the bond was no longer optimal for SN2 attack by sulfur or selenium. These 
observations, coupled to the inherently stronger C–F bond observed in –CF2H 
compared to –CFH2 motifs may be responsible for preventing the substitution reaction 
catalysed by the fluorinase. 
Despite the fact that no reaction was observed with the native fluorinase, 
understanding the interaction of F2DA 276 in the active site of the enzyme may, in 
future, allow design of active enzyme mutants. Such mutants may be able to overcome 
the poor substrate alignment and loss of interactions of the fluorine atom with the 
enzyme surface, to evolve the desired reactivity for enzymatic synthesis of a 
difluoromethyl group. Evolution of this defluorination activity into the enzyme, however, 
remains to be further investigated. 
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5. Synthesis of [18F]fluoroacetate for assessment of 
acetyl CoA synthetase 2 activity in vivo 
Based on emerging evidence of the importance of acetyl CoA synthetase 2 (ACSS2) 
for growth and viability of a wide range of cancers, understanding and investigating 
ACSS2 expression and activity patterns within different cancers is an emerging area of 
research. We were approached by Prof. Eyal Gottlieb and Dr Zachary Schug at the 
Beatson Cancer Research Institute in Glasgow to collaborate in a study to investigate 
ACSS2 activity in colorectal cancers using PET.  
They required the development of a site-specific synthesis protocol for the production 
of [18F]fluoroacetate [18F]-1, for use in PET imaging experiments to assess ACSS2 
activity in vivo. Prior to discussing the optimisation of a synthetic method for production 
of [18F]fluoroacetate for their PET imaging study, the central metabolic role played by 
acetyl CoA, the metabolic intermediate produced by ACSS2, and its emerging role in 
the growth of cancers will be discussed.  
5.1. Acetyl coenzyme A  
Acetyl coenzyme A 290 (acetyl CoA, Figure 1) is a key intermediate in general 
metabolism, linking a number of anabolic and catabolic biosynthetic pathways. 
Acetyl CoA acts as shuttle of a 2-carbon acetate unit within the cell in the form of a high 
energy thioester of coenzyme A 291 (CoASH, Figure 1). Acetyl CoA 290 is sourced 
from the glycolysis or β-oxidation and is used for energy production, biosynthesis of 
cholesterol, fatty acids and other isoprenoids, and as a source of the acetyl group in 
numerous acetylations. 
 
Figure 1. Structures of acetyl coenzyme A 290 and coenzyme A 291, with the acetyl unit highlighted in 
bold. 
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5.1.1. Sources of acetyl CoA 
High energy molecules, such as glucose and fatty acids, pass through the glycolysis 
and β-oxidation pathways, providing a source of acetyl CoA 290 which can enter the 
citric acid cycle and generate ATP (Scheme 1). 
Glycolysis is the breakdown of glucose 292 into two molecules of pyruvate 293. 
Pyruvate 293, an important metabolic intermediate itself, is decarboxylated under the 
action of a large multi-enzyme complex (pyruvate dehydrogenase complex) to give 
acetyl CoA 290, and releasing an equivalent of NADH (reduced nicotinamide adenine 
dinucleotide, a cellular electron shuttle) in the process.1 The pyruvate dehydrogenase 
complex is localised within the mitochondrial matrix in eukaryotes and acetyl CoA 290 
produced from pyruvate is predominantly utilised in the citric acid cycle within the 
mitochondria.2 
 
Scheme 1. Metabolic production of acetyl CoA 290 within the mitochondrial matrix. Pyruvate 293, from 
glycolysis, or fatty acids from β-oxidation give acetyl CoA 290. The bold atoms highlight the 
2-C unit metabolised to acetyl CoA 290. 
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β-Oxidation takes place in the mitochondrial matrix, after shuttling long chain fatty acids 
through the mitochondrial as acyl CoAs 294.3 Long chain acyl CoAs 294 are broken 
down in a series of steps which approximate the reverse of fatty acid biosynthesis. 
Oxidation by acyl CoA dehydrogenase generates an α,β-unsaturated acyl CoA 295 and 
an equivalent of FADH2 (reduced flavin adenine dinucleotide) another cellular electron 
carrier.4 The trans-alkene produced undergoes hydration, catalysed by enoyl CoA 
hydratase to generate a β-L-hydroxy CoA moiety 296.5 Oxidation of the hydroxyl group 
by β-L-hydroxyacyl CoA dehydrogenase generates a β-keto acyl CoA 2976 which 
undergoes cleavage by β-ketothiolase and CoASH to generate acetyl CoA 290 and an 
acyl CoA 298 which is two carbons shorter than the original fatty acid.7 This cycle is 
repeated to accomplish a step-wise breakdown of the long chain fatty acid by a 
2-carbon unit each cycle, to generate acetyl CoA 290 which then enters the citric acid 
cycle within the mitochondrion. 
Both glycolysis and β-oxidation generate acetyl CoA 290 in the mitochondrial matrix, 
however, there is a requirement for acetyl CoA 290 in the cytosol for processes such 
as fatty acid biosynthesis and histone acetylation. Acetyl CoA 290 is not transported 
across the mitochondrial membranes directly, instead it is transported as an equivalent 
of citrate 300 (Scheme 2). When there is an abundance of citrate 300 within the 
mitochondrion (e.g. under conditions of excess dietary carbohydrates or fats), 
citrate 300 is transported out of the organelle by tricarboxylic acid translocase, part of 
the citrate shuttle system.8 In the cytosol, citrate 300 is cleaved to oxaloacetate 299 
and acetyl CoA 290 by ATP-citrate lyase, consuming an equivalent of ATP in the 
process.9 This process generates a pool of cytosolic acetyl CoA 290 for use in other 
metabolic processes. 
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Scheme 2. Biosynthesis of cytosolic acetyl CoA. Acetyl CoA 290 is transported out of the mitochondrial 
matrix after condensation with oxaloacetate 399 to give citrate 300. Citrate 300 is cleaved by 
ATP-citrate lyase to give cytosolic acetyl CoA 290. Dietary acetate is condensed with 
co-enzyme A 291 (CoASH) to give acetyl CoA 290. The bold atoms highlight the 2-C unit of 
acetyl CoA 290. 
A second source of acetyl CoA 290 within the cytosol is its direct synthesis from 
acetate 301 and CoASH 291 by acetyl CoA synthetase (ACSS) (Scheme 2).10 
Acetate 301 is primarily sourced from the gut microbiota, which ferment dietary fibre to 
acetate 301. This acetate 301 is absorbed into the bloodstream.11 Dietary ethanol is 
also a source of acetate 301, by successive oxidations to acetaldehyde and 
acetate 301 by alcohol and acetaldehyde dehydrogenases.12 Acetyl CoA synthetase 
and its role in lipid metabolism in cancer will be discussed in in Section 5.2. 
5.1.2. Acetyl CoA as a metabolic building block  
Fatty acid biosynthesis (Scheme 3) in the cytosol requires acetyl CoA 290 as a source 
of 2 carbon units. Acetyl CoA 290 is used in the initial step of fatty acid biosynthesis 
after condensation with an acyl carrier protein (ACP) to give acetyl ACP 303.13 
Acetyl ACP 303 is then condensed with malonyl ACP 304 (derived from 
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malonyl CoA 302 and ACP)13 to give a β-ketoacyl ACP 305. The malonyl CoA 302 
required for this elongation of the fatty acid chain is derived from carboxylation of 
acetyl CoA 290 with bicarbonate by acetyl CoA carboxylase.14,15 While 
malonyl CoA 302 is a 3 carbon unit, it donates a 2-carbon unit to the growing acyl 
chain, as the condensation incorporates a decarboxylation event. 
Malonyl CoA 302 is also utilised in the biosynthesis of a range secondary metabolites 
such as polyketides16 and flavonoids,17 providing 2 carbon units in a manner similar to 
fatty acid biosynthesis.  
 
Scheme 3. Fatty acid biosynthesis using acetyl CoA 290, and malonyl CoA 302 to give palmitic acid 309. 
Malonyl CoA 302 is synthesised from acetyl CoA 290 and is used as a C-2 surrogate. The 
bold atoms highlight the 2-C acetyl units present in the intermediates and products. 
Acetyl CoA 290 is also used for the biosynthesis of cholesterol18 and isoprenoids,19 via 
the mevalonate pathway (Scheme 4). This pathway begins with the condensation of 
two acetyl CoA 290 units by acetoacetyl CoA thiolase to give acetoacetyl CoA 310.20 A 
third unit of acetyl CoA is incorporated by 3-hydroxy-3-methylglutaryl CoA synthase 
(HMGCoA synthase) to give 3-hydroxy-3-methylglutaryl CoA 311 (HMGCoA).21 
HMGCoA is reduced by HMGCoA reductase to give mevalonate 312.22 Through a 
series of phosphorylations and a decarboxylation, mevalonate is converted to 
isopentenyl-5-pyrophosphate 313 (IPP), which is isomerised to dimethylallyl 
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pyrophosphate 314 (DMAPP). Condensation of IPP 313 and DMAPP 314 gives geranyl 
pyrophosphate 315 (GPP), which is condensed with another unit of IPP 313 to give 
farnesyl pyrophosphate 316 (FPP). FPP 316 occupies a branch point in the 
mevalonate pathway, from which prenylated compounds and sterols (such as 
cholesterol) are synthesised.19 
 
Scheme 4. The mevalonate pathway showing the utilisation of acetate units for the synthesis of 
HMGCoA 311. HMGCoA 311 used to synthesise farnesyl pyrophosphate 316, and then more 
complex molecules such as cholesterol. The bold atoms highlight the 2-C acetyl units present 
in the intermediates and products. 
5.1.3. Acetyl CoA as a source of acetyl units 
Acetyl CoA 290 is a source of acetate units for the post translational modification of 
proteins, including histones23 and other proteins such as tubulin24 and p53.25 
Modulation by N-acetylation and deacetylation of histone proteins by acetylases and 
deacetylases affects gene activity through conformational control of the local structure 
of DNA (Scheme 5).26 Within eukaryotic cells, 146 base pair sections of DNA are 
wrapped around an assembly of eight histone proteins.27 Acetylation of the lysine 
residues of these proteins, either at the N-terminus or within the polypeptide chain 
leads to a relaxation in the local structure of chromatin. This conformational change 
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allows access to enzymes responsible for transcription, thereby affecting gene 
expression.28 
Acetylation directly affects signalling within the body through neurotransmitters but also 
indirectly through histone-acetylation modulated transcription of regulatory kinases.29 
Choline 317 (Scheme 5) is acetylated by acetyl CoA 290 under the action of choline 
acetyltransferase to give acetylcholine 318,30,31 the primary neurotransmitter of the 
parasympathetic nervous system. 
N-Acetylated carbohydrates play an important role in cell surface stabilisation and 
reinforcement, as well as cell-cell recognition processes.32,33 N-Acetylated 
amino-sugars form part of the bacterial cell wall in both Gram positive and Gram 
negative bacteria.34 The peptidoglycan component of their call walls, comprised up of 
repeat units of N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM), linked by 
short peptides, provides structural rigidity and acts as a physical barrier to the 
environment.35 Acetylation of these carbohydrates, such as glucose derivative 319, 
proceeds under the action of N-acetyl transferase enzymes. In this case, 
glucosamine-6-phosphate N-acetyl transferase converts 319 to its corresponding 
N-acetyl analogue, such as N-acetyl-glucosamine-6-phosphate 320 (Scheme 5).36  
 
Scheme 5. Acetyl CoA 290 acts as a source of acetyl units, donating the acetyl subunit to a diverse 
array of biomolecules, including choline 317 for the synthesis of the neurotransmitter 
acetylcholine 318, to glucosamine-6-phosphate 319 to give N-acetylglucosamine-6-
phosphate 320, and to histones. Acetyl units are shown in bold. 
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5.1.4. Other functions of acetyl CoA 
Studies in Saccharomyces cerevisiae have shown that acetyl CoA 290 flux is intimately 
linked to cell growth and cell division through changes in the acetylation pattern of 
proteins in the cell. Specifically, acetyl CoA 290 flux is thought to be responsible for 
controlling the activity of acetyl transferases. A number of acetyl transferases have KM 
values of the same order of magnitude as the cellular acetyl CoA 290 concentration, 
and their activity is therefore sensitive to the acetyl CoA 290 concentration within the 
cell.37 The activity of these transferases, and therefore any downstream effects (such 
as gene regulation) are strongly associated with acetyl CoA 290 flux, making the 
understanding of mechanisms controlling the regulation of acetyl CoA 290 levels in the 
cell vital. 
Lin et al.38 showed that the acetylation of phosphoenolpyruvate carboxykinase (PCK), a 
key enzyme for gluconeogenesis, regulates of the activity of PCK. The authors 
proposed that the acetyl CoA level acts as an intracellular marker of the metabolic state 
of the cell, and changes in the levels of acetyl CoA 290 in the cell lead to a metabolic 
cascade which restores levels of glucose to those required for normal cellular function. 
In addition to this regulatory role, downstream changes in activity of 
phosphoenolpyruvate kinase led to changes in the chronological lifespan (CLS, a 
model system for understanding the aging process in eukaryotic cells) of the yeast 
cells.39 
In a study by Tu et al.,40 acetylation of components of a transcriptional coactivator 
complex, known as SAGA, was found to occur in response to the levels of acetyl 
CoA 290 within the cell. The SAGA complex itself is a histone acetyltransferase. The 
SAGA complex selectively acetylates histones which control the function of genes that 
are responsible for the growth phase induction in yeast cells, therefore acetyl CoA 290 
levels in the cell reflect their metabolic state and growth stage. 
5.2. Acetyl CoA Synthetase 
5.2.1. Acetyl CoA synthetase genes and proteins 
Acetyl CoA synthetase (ACSS) is an ATP-dependent enzyme that catalyses the 
ligation of acetate 301 and CoASH 291 to give acetyl CoA 290 (Scheme 6). Three 
ACSS genes (acss1, acss2 and acss3) have been identified, two of which (acss1 and 
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acss2) are known to code for acetyl CoA synthetases (ACSS1 and ACSS2) in 
humans.41 ACSS3 has yet to be isolated and characterised. 
 
Scheme 6. Synthesis of acetyl CoA 290 by acetyl CoA synthetase. 
ACSS1 is an isoform of the acetyl CoA synthetase found in the mitochondrial matrix in 
most tissues, but at elevated levels in the heart and skeletal muscle tissue.42 ACSS1 is 
upregulated under ketogenic (starvation) conditions as a means of using acetate for 
energy production throughout the rest of the body. Acetate 301 is derived from 
hydrolysis of acetyl CoA 290 (produced by hepatic β-oxidation) under the action of 
acetyl CoA hydrolase (which is also upregulated under ketogenic conditions in rat 
models).43 The activity of ACSS1 does not appear to vary in response to other 
metabolic processes.42 ACSS1 contributes to whole body utilisation of acetate as an 
energy source under conditions of starvation. 
The activity of the cytosolic 80 kDa human ACSS2 is intrinsically linked to the rate of 
lipid biosynthesis in the cells, and its activity is modulated through the action of sterol 
regulatory element-binding proteins (SREBPs). ACSS2 is responsible for the rate 
limiting step of the incorporation of acetate into fatty acids during de novo lipid 
biosynthesis.10 Unlike ACSS1, the activity ACSS2 increases under starvation 
conditions highlighting the anabolic role of ACSS2, compared to the catabolic role of 
ACSS1. The role of ACSS2 in the biosynthesis of lipids has led to an interest in this 
enzyme related to cancers, where increased metabolic rates are a defining 
characteristic. 
5.2.2. The role of ACSS2 in cancer 
Fatty acid synthase (FAS), a multifunctional enzyme complex responsible for de novo 
fatty acid biosynthesis, was identified as an oncogenic antigen present in some 
cancers which showed poor prognosis.44 The association of FAS with cancer has led to 
increased interest in lipid metabolism and its role in cancer. Radiolabelling experiments 
suggest that more than 90% of fatty acids in tumour cell triglycerides are derived from 
de novo fatty acid biosynthesis, under certain conditions. Understanding lipid 
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metabolism is thus fundamental to understanding disease origin and progression in 
cancer.45 
Recent work comparing the rate of uptake of [14C]acetate in four tumour cell lines 
relative to uptake in normal fibroblasts under normoxic conditions found that the tumour 
cells incorporated more of the [14C]-label into the lipid fraction. Fibroblasts excrete the 
label predominantly as [14C]CO2.46 Normal cells tend to utilise acetate as an energy 
source, channelling acetate through the citric acid cycle, while tumour cell lines appear 
to channel acetate towards de novo lipogenesis. Similarly, [14C]acetate uptake is 
increased in prostate cancer cells under hypoxic conditions.47 This uptake is associated 
with increased activity of ACSS2, whose activity has been found to be critical to the 
survival of these cancer cell lines.48 
Two further studies examining the role that ACSS2 plays in the metabolic activity of 
cancer cells and have argued that this enzyme could in future be a novel drug target in 
treatment of cancers. 
Tu et al.49 have used gene siRNA based silencing, knockout mouse models and small 
molecule inhibitor screens to show that uptake and incorporation of [14C]acetate is 
dependent on ACSS2 activity. In a large hepatic tumour model, ACSS2 knockdown 
resulted in a reduction in tumour burden in the liver, from 83% high tumour burden in 
wild type mice (ACSS2+/+), to 29% high tumour burden in double knockout mice 
(ACSS2−/−). Immunohistochemical analysis of human tumour sample microarrays 
showed high levels of ACSS2 expression in breast, lung and ovarian tumour sections, 
with little to no ACSS2 expression in normal tissues. The authors’ survey of samples 
from patients with triple negative breast cancer showed that shorter overall survival 
times were associated with high expression levels of ACSS2. PET imaging with 
[11C]acetate in the knockout models also showed increased uptake in tumours which 
expressed high levels of ACSS2. 
Gottlieb et al. have observed increased de novo lipid biosynthesis using [13C]glucose, 
[13C]acetate and [14C]acetate feeding experiments in cancer cells under metabolic 
stress (starvation and low oxygen perfusion). Increased de novo lipid biosynthesis 
resulted in an increased production of short chain fatty acids as detected by LC-MS/MS 
in lipid extracts of cell homogenates. Up to 50% labelling of the cellular acetyl-CoA pool 
(compared to 10% under normoxic and fed conditions) and increased sensitivity of the 
cells to inhibitors of fatty acid synthase was observed.50 In these cell lines, screening of 
over 60 lipid metabolism gene knockouts using siRNA-mediated gene silencing 
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revealed the largest effect on cell growth was observed in cell lines where the ACSS2 
gene was silenced. Further analysis of reported patterns of ACSS2 expression or 
ACSS2 copy number across a broad range cancer cell lines showed high expression of 
ACSS2 and large gene copy number gain of ACSS2 in multiple cancers, including 
breast cancers (invasive ducal carcinoma and invasive lobular carcinoma) and 
aggressive prostate cancer treatment. 
Gottlieb et al. further found that silencing of ACSS2 using doxycycline-induced siRNA 
in either in cell masses or xenograft tumour mouse models resulted in growth inhibition 
of the cancers.50 Interestingly, mice that had received the knockdown treatment were 
found to be more viable than those which did not receive treatment and were healthier 
overall after reduction of ACSS2 activity. These results again strongly implicate ACSS2 
as a potential drug target for cancers. 
As a consequence of these promising early results into the activity of ACSS2 and its 
role in cancers, Prof. Eyal Gottlieb and Dr Zachary Schug at the Beatson Cancer 
Research Institute in Glasgow wished to further investigate this association in 
colorectal cancers using PET. Colorectal cancers are of relevance as free acetate 301 
in the bloodstream is predominantly produced by fermentation of dietary fibre by gut 
bacteria. The close localisation of the tumours to the site of acetate 301 production is 
hypothesised to affect its metabolism in these types of tumours. Microarray data, 
similar to that used to identify links between ASCC2 expression in breast and prostate 
cancers has also revealed upregulation of ACSS2 in colorectal cancers. This 
upregulation was strongly associated with tumour stage, prompting further investigation 
into ACSS2 activity in colorectal cancers.51 
Ideally, [11C]acetate [11C]-301 would be used for this purpose, but [11C]-based PET 
tracers were not available for use in Glasgow at the Beatson Cancer Research Institute 
at present. A variety of [18F]-based tracers are already established at the facility, and 
we were approached to develop a synthesis of [18F]fluoroacetate [18F]-1 as a surrogate 
for [11C]acetate [11C]-301 for investigating ACSS2 activity in vivo. 
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5.3. Fluoroacetate  
5.3.1. Fluoroacetate as a metabolic toxin 
Fluoroacetate 1 is a potent toxin, found naturally in a number plant species, including 
Dichapetalum cymosum, from which fluoroacetate was initially isolated in 1943.52,53 
Fluoroacetate 1, known commercially as “1080”,54 has found application as a 
vertebrate pesticide due to its high toxicity and low cost, however, the non-specificity of 
fluoroacetate 1 has led to increasing control measures and restrictions in the use of 
fluoroacetate 1 as a pesticide.55 
The toxicity of fluoroacetate 1 arises from its incorporation into fluorocitrate 2 by the 
citric acid cycle enzymes (Scheme 7). It is firstly converted to 
fluoroacetyl coenzyme A 322 (fluoroacetyl CoA) by the action of acetyl CoA 
synthetase (ACSS). Citrate synthase then catalyses the condensation of 
fluoroacetyl CoA 322 and oxaloacetate 299 to produce (2R,3R)-fluorocitrate 2.56 
(2R,3R)-Fluorocitrate 2, the only toxic stereoisomer of fluorocitrate,57 is then converted 
by aconitase to 4-hydroxy-trans-aconitate 324, a product which is also a potent inhibitor 
of aconitase. The inhibition of aconitase shuts down the citric acid cycle, and 
downstream energy production ceases within cells. 58  
213 
 
 
Scheme 7. A. Normal progression of the citric acid cycle showing condensation of acetyl CoA 290 with 
oxaloacetate 299 to give citrate 300 which is then converted to isocitrate 321 by aconitase. 
B. When fluoroacetate 1 enters the citric acid cycle as fluoroacetyl CoA 322, 
(2R,3R)-fluorocitrate 2 is produced, which is converted to 4-hydroxy-trans-aconitate 324, a 
potent inhibitor of aconitase.  
5.3.2. Synthesis and applications of [18F]fluoroacetate [18F]-1 
Despite fluoroacetate 1 being highly toxic (LD50 0.1–5 mg.kg−1 in small mammals),54 
radiolabelled [18F]fluoroacetate [18F]-1 has found wide scope in the literature as a tracer 
with applications in studying cerebral metabolism,59,60 and imaging of prostate 
cancers.61,62 The use of [18F]fluoroacetate [18F]-1 arises as PET radiotracers are 
synthesised and administered in sub nano- and pico- molar quantities, levels well 
below the toxic threshold of fluoroacetate. 
[18F]Fluoroacetate [18F]-1 is most commonly synthesised by a SN2 substitution of a 
suitably activated substrate with pre-dried [18F]fluoride.62,63 We were approached by the 
Beatson Institute due to previous research published by the St Andrews group where 
the product of the fluorinase enzyme reaction, 5ʹ-fluoro-5ʹ-deoxyadenosine 22 (FDA), 
was converted to fluoroacetate 1 via chromium(VI)-mediated Kuhn-Roth oxidation.64 
This procedure was successfully repeated with fluorinase generated [18F]FDA [18F]-22, 
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which, after Kuhn-Roth oxidation and purification, gave [18F]fluoroacetate [18F]-1 in 
good yields, as shown in Scheme 8.  
 
Scheme 8. Chemoenzymatic synthesis of [18F]fluoroacetate [18F]-1 by an exhaustive oxidation of 
fluorinase-generated 5'-[18F]fluoro-5'-deoxyadenosine [18F]-22. 
5.4. Aims 
The reported chemoenzymatic synthesis of [18F]fluoroacetate [18F]-1 using the 
fluorinase reported a 36 ± 11% (n = 4) decay corrected radiochemical yield (RCY). The 
total synthesis time was not reported, although reaction times were reported to be 1 h 
and 20 min respectively for the two synthetic steps. The radiochemical purity of the 
isolated [18F]fluoroacetate [18F]-1 was found to be 96% by radio-HLPC. The 
[18F]fluoroacetate [18F]-1 synthesised in that report was not employed in any PET 
imaging studies. 
The aim of this project was to develop and optimise the [18F]fluoroacetate [18F]-1 
synthesis under site-specific conditions at the Beatson Institute in Glasgow. For this 
study, 50 MBq of [18F]fluoroacetate [18F]-1 was required upon completion of the 
synthesis, starting from a maximum of 500 MBq [18F]fluoride, a non-decay corrected 
RCY of 10%. The [18F]fluoroacetate [18F]-1 was also required to be >98% 
radiochemically pure and to be free of chromate for formulation in sterile PBS for 
injection into a mouse model. We were interested in trialling this method for the 
production of [18F]fluoroacetate [18F]-1 for imaging of breast and colorectal cancers in 
mice, as part of a larger study assessing metabolism of acetate 301 and ACSS2 
activity in these of tumours.  
In order for the synthesis to be viable, the scale and yield of the reactions needed to be 
addressed, along with an assessment of the purity of the final product and in a 
formulation suitable for injection.  
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5.5. Method development 
5.5.1. Kuhn-Roth oxidation investigation 
At the outset, the Kuhn-Roth oxidation was investigated under cold conditions, using a 
synthetic sample of the FDA 22, prepared in a three-step sequence from 
adenosine 188.  
Adenosine 188 was protected as its 2',3'-acetonide 285 in the presence of perchloric 
acid, 2,2-dimethoxypropane (DMP) and acetone, in good yield as shown in Scheme 9. 
Acetonide 285 was then heated in THF in the presence of tosyl fluoride (TsF) and 
tetrabutylammonium fluoride (TBAF) in a one-pot transformation of the 5'-alcohol to the 
corresponding 5-fluorinated acetonide 325 also in good yield. The acetonide 325 was 
then hydrolysed in a mixture of trifluoroacetic acid and water to yield the trifluoroacetate 
(TFA) salt of FDA 22 in moderate yield.  
 
Scheme 9. Synthesis of FDA 22 from adenosine 188. 
A sample of FDA 22 was subjected to the Kuhn-Roth oxidation conditions as described 
by Li et al.64 This chromium (VI)-mediated oxidation was expected to afford fluoroacetic 
acid 160, which could be extracted from the acidic reaction mixture before being 
liberated as aqueous fluoroacetate 1 following base extraction, as illustrated below in 
Scheme 10. 
 
Scheme 10. Oxidation of FDA 22 to fluoroacetic acid 160, followed by isolation as fluoroacetate 1. 
A freshly prepared solution of chromium (VI) oxide in sulfuric acid was added to a 
solution of FDA 22 in water and the mixture was heated to 140 °C for 10 minutes, 
before being cooled on ice. The mixture was carefully diluted with water, before the 
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aqueous phase was extracted with three portions of diethyl ether, in order to extract the 
newly formed fluoroacetic acid 160. The ether extracts were combined, and extracted 
with aqueous sodium bicarbonate solution (8 mg.ml−1) to liberate fluoroacetate 1 into 
the sodium bicarbonate solution, after separation of the two phases. 
Under cold conditions, the reaction progress was monitored by 19F NMR spectroscopy 
(Figure 2). In the 19F{1H} NMR spectrum, FDA 22 shows a resonance at −231.3 ppm 
(Figure 2 A), corresponding to the fluorine at C-5', while the peak for the 
trifluoroacetate counter ion appears at −75.7 ppm. After the oxidation and extraction 
process, the peak for FDA 22 is no longer present (Figure 2 B), but a new peak is 
present at −217.2 ppm in the 19F{1H} NMR spectrum. This peak appears as a triplet in 
the 19F NMR spectrum (Figure 2 C), with a coupling constant of 42.8 Hz, typical for a 
2JFH coupling. These data confirm that the Kuhn-Roth oxidation is efficient in converting 
all FDA 22 into fluoroacetate 1, and produces no other detectable fluorinated 
by-products.  
 
Figure 2. A. 19F{1H} NMR spectrum (470 MHz, D2O) of the trifluoroacetate salt of FDA 22.  
B. 19F{1H} NMR spectrum (470 MHz, D2O) of the oxidation mixture after extraction, showing 
a single peak at 271.2 ppm. C. Partial 19F NMR (470 MHz, D2O) spectrum showing the 
fluoroacetate 1 triplet inset. 
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5.5.2. Enzymatic synthesis of [18F]fluoroacetate [18F]-1 
The Kuhn-Roth oxidation was successful under “cold” conditions. The procedure was 
then transferred to “hot” conditions, where the fluorinase would be used to convert 
[18F]fluoride and S-adenosylmethionine 20 (SAM) into [18F]FDA [18F]-22, after which 
oxidation would be expected to give [18F]fluoroacetate [18F]-1 (Scheme 11). 
 
Scheme 11. [18F]Fluoroacetate [18F]-1 synthesis from S-adenosylmethionine 20 using the fluorinase. 
The fluorinase enzyme was over-expressed as described in Chapter 2 and freeze-
dried in 5 mg portions, each to be used for a single labelling experiment. Unlike 
conventional 18F-labelling reactions, fluorinase-catalysed reactions do not require any 
pre-drying of the [18F]fluoride ion prior to labelling. Accordingly, [18F]fluoride in aqueous 
solution (0.3 mL, 83–269 MBq), was added to a premixed solution of the fluorinase 
enzyme (5 mg), SAM 20 (0.13 mg), L-AAO (L-Amino acid oxidase, 1 mg) in a total 
volume of 315 µL in an Eppendorf tube. L-AAO was also added to the freeze dried 
enzyme to oxidise any L-methionine 21 in the reaction mixture (present in commercial 
SAM 20 samples and produced during the fluorination reaction) to the corresponding 
oxo-acid 25 to shut down the reverse defluorination reaction, as shown in Scheme 12.  
 
Scheme 12. L-AAO converts L-methionine 21 into the corresponding oxo-acid 25, reducing the rate of the 
reverse reaction. 
The reaction was allowed to proceed at 37 °C for 30 mins, before the enzyme was 
denatured (heating to 140 °C for 5 minutes) and centrifuged at 4500 rpm for 
10 minutes. Radioactivity recovery after the centrifugation step was good, with 
218 
 
84% ± 4% (n = 3) of the activity recovered in the supernatant, with the remainder of the 
activity remaining trapped in the pellet. 
An analytical sample of the supernatant was analysed by HPLC, using a hydrophilic 
interaction liquid chromatography (HILIC) column, with an ammonium 
bicarbonate/acetonitrile gradient, to assess [18F]fluoride incorporation into 
[18F]FDA [18F]-22. This type of HILIC column is suited for the separation of highly 
hydrophilic compounds, such as fluoroacetate 1. The incorporation of [18F]fluoride 
(retention time, tR = 19.0 min, into [18F]FDA [18F]-22 (tR = 5.6 min) was excellent (Figure 
3), with an average incorporation of 95% ± 6% (n = 3). The identity of the two peaks 
was confirmed by spiking with [18F]fluoride and [19F]FDA 22 respectively. This result 
highlights the efficiency of the fluorinase in catalysing C–18F bond formation, even at 
the low fluoride concentrations associated with PET labelling. 
 
Figure 3. HILIC radio-HPLC trace of the supernatant from the enzymatic labelling reaction, showing 
99% incorporation of [18F]fluoride (tR = 19.0 min) into [18F]FDA [18F]-22 (tR = 5.6 min). 
The remainder of the supernatant, containing the bulk of [18F]FDA [18F]-22 was added 
to 250 µL of a solution of chromium (VI) oxide in sulfuric acid in a sealed vial and this 
mixture heated to 140 °C for one hour, before being cooled on ice. The oxidation 
mixture was diluted with water (1 mL) and extracted into diethyl ether (5-6 × 1 mL), and 
the ether extracts were combined. In the strongly acidic oxidation mixture, 
[18F]fluoroacetate [18F]-1 exists predominantly as [18F]fluoroacetic acid [18F]-160, which 
was previously found to extract efficiently into diethyl ether. 
The extraction efficiency was investigated by measuring the activity extracted after 
each 1 ml ether extraction. In one experiment, the oxidation mixture was found to 
contain 115 MBq of activity prior to the extractions, and this extraction efficiency was 
determined by measuring the activity in the combined diethyl ether extracts after each 
extraction. The results are illustrated in Figure 4 below. After six extractions, it was 
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found that 68% of the total activity was extracted, but that the total percentage activity 
extracted was reaching a plateau. Further extraction would likely not recover much 
more radioactivity, therefore 5 × 1 mL extractions were deemed to offer a reasonable 
recovery. Over three runs, the average extraction efficiency was found to be 
74% ± 8% (n = 3). 
 
Figure 4. Extraction efficiency of diethyl ether extractions of acidic oxidation mixture, showing 
cumulative activity extracted after each 1 mL extraction of the acidic oxidation mixture with 
diethyl ether.  
The ether extracts were yellow in colour, likely due to extraction of traces of aqueous 
Cr(VI) into the diethyl ether. The original protocol developed by Li et al.64 suggested the 
passage of this ether extract through a Sep-Pak Si Light cartridge in order to remove 
adventitious chromate, sulfate or other ion contaminants. However, upon passage of 
the solution through a Sep-Pak Si Light cartridge, the diethyl ether eluent, which 
contained the bulk of the activity, remained pale yellow in colour.  
An aliquot of this diethyl ether solution was extracted with sodium bicarbonate solution 
(0.25 mL, 8 mg.mL−1). The basic sodium bicarbonate solution converts the 
[18F]fluoroacetic acid [18F]-160, which is soluble in diethyl ether, into 
[18F]fluoroacetate [18F]-1, which should be soluble in the aqueous sodium bicarbonate 
solution. The majority (61%) of the activity was isolated in the aqueous phase after the 
extraction with the sodium bicarbonate solution, while the remainder was found in the 
diethyl ether fraction. The non-decay corrected yield of isolated 
[18F]fluoroacetate [18F]-1 was found to be 23% ± 17% (n = 2).  
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The sodium bicarbonate extract was analysed by HPLC, using the HILIC Fast Acid 
system described above, in order to assess the radiochemical purity of the final 
[18F]fluoroacetate [18F]-1. As can be seen from Figure 5, there appears a single large 
peak in the chromatogram at tR = 8.4 minutes, which corresponds to 
[18F]fluoroacetate [18F]-1, showing a very high (>99%) radiochemical purity. A small 
trace of [18F]fluoride was detected (tR = 20.2 min), but accounted for less than 1% of 
the total activity in the final sample. Spiking the sample with 10 mM fluoroacetate 1 
confirmed that the radiolabelled product was indeed [18F]fluoroacetate [18F]-1.  
 
Figure 5. Radiochemical and UV chromatograms obtained after isolation of [18F]fluoroacetate [18F]-1, 
showing greater than 99% radiochemical purity of the final product.  
In effort to remove the coloured impurity, a second aliquot of the diethyl ether 
containing [18F]fluoroacetic acid [18F]-160 was passed through an alumina N Sep-Pak 
cartridge, which effectively retained the [18F]fluoroacetic acid [18F]-160. The product 
was eluted as [18F]fluoroacetate [18F]-1 by passing 0.5 mL phosphate buffered saline 
(PBS) solution through the cartridge. However, this alternative solid phase extraction 
procedure did not prevent leakage of the yellow contaminant into the final solution.  
While the radiochemical purity of the final product was high, leakage of chromate 
through the Sep-Pak Si Light and alumina N cartridges and the associated yellow 
colour of the final product was a concern. The final product was most likely 
contaminated with Cr(VI), and as a consequence was not ideal for in vivo injection into 
a mouse model. 
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In view of the fact that [18F]fluoroacetate [18F]-1 was still required for the imaging study, 
the chemical synthesis of [18F]fluoroacetate [18F]-1 by a method that does not utilise 
Cr(VI) was investigated. 
5.5.3. Chemical synthesis of [18F]fluoroacetate [18F]-1 
Literature syntheses of [18F]fluoroacetate [18F]-1 involve an SN2 reaction on an 
appropriately substituted acetate ester such as tosylate 327 or mesylate 49, followed 
by hydrolysis of the fluorinated ester 328. This is illustrated in Scheme 13.  
 
Scheme 13. [18F]Fluoroacetate [18F]-1 synthesis by SN2 substitution followed by hydrolysis, reported by 
Kang et al.63 and Welch et al.62 
Kang et al.63 reported the synthesis of [18F]fluoroacetate [18F]-1 from both O-mesyl 49 
and O-tosyl 327 derivatives of ethyl glycolate. Incorporation of [18F]fluoride was higher 
for ethyl O-mesylglycolate 49 as the substrate, in the presence of tetrabutylammonium 
bicarbonate in acetonitrile. Following hydrolysis of the ester with KOH, 
[18F]fluoroacetate [18F]-1 was purified by trapping on an ion exchange resin, and elution 
through an alumina N cartridge (to trap residual [18F]fluoride) with sodium bicarbonate 
solution and water to give [18F]fluoroacetate [18F]-1 in 24.5% radiochemical yield (RCY). 
Welch et al.62 reported a synthesis from ethyl O-mesylglycolate 49, using Kyrptofix 222 
and potassium carbonate combination in acetonitrile. In contrast to Kang et al.’s 
method, they chose to purify the ethyl [18F]fluoroacetate [18F]-328 by trapping on a 
Waters HLB cartridge (a reverse phase system with affinity for both lipophilic and polar 
molecules) and washing with water to remove unreacted [18F]fluoride. Ethyl 
[18F]fluoroacetate [18F]-328 was then eluted from the cartridge with ethanol before 
being hydrolysed by addition of NaOH, with concomitant ethanol removal under 
reduced pressure. Neutralisation and dilution into water gave a formulation of 
[18F]fluoroacetate [18F]-1, suitable for injection, in 55% decay corrected RCY. 
Other syntheses of [18F]fluoroacetate [18F]-1 have also been reported by 
Fujibayashi et al.,65 Yeung et al.,66 and Wuest et al.,67 however, these involve 
automated synthesis platforms, suitable for working with high amounts of activity, or 
employ equipment not available to us in the Beatson Laboratory. 
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The small animal imaging facility based at the Beatson Cancer Research Institute in 
Glasgow requires delivery of 50 MBq of [18F]fluoroacetate [18F]-1 in 0.5 mL of a sterile 
solution, suitable for injection. This activity and volume requirement restricts synthesis 
options, as the maximum activity that can be safely handled at the manual synthesis 
facility is 500 MBq. Both the Kang63 and Welch62 procedures involve delivery of high 
activities of [18F]fluoroacetate [18F]-1 into large volumes (e.g. 5 mL), and delivery of 
activity into this volume is not suitable for this study.  
This required modification of the literature methods, specifically to address the 
formulation into 0.5 mL. A potential solution involved combining a reported chemical 
synthesis with the work up and formulation procedure from the enzymatic synthesis, as 
this had the capability to deliver [18F]fluoroacetate [18F]-1 in a small volume.  
The precursor, ethyl O-mesylglycolate 49 was synthesised by reaction of ethyl 
glycolate 329 with mesyl chloride in the presence of triethylamine. The crude product 
was purified by distillation under reduced pressure to give ethyl O-mesylglycolate 49 as 
a colourless oil in 54% yield (Scheme 14). With the precursor in hand, attention turned 
to the synthesis of [18F]fluoroacetate [18F]-1 using the more common SN2 approach. 
 
Scheme 14. Synthesis of ethyl O-mesylglycolate 329 from ethyl glycolate 49. 
[18F]Fluoride is supplied as a dilute solution in water, therefore the synthesis began by 
azeotropic distillation and removal of the water by dilution into an acetonitrile solution of 
potassium carbonate and Kryptofix 222 and heating under a stream of argon. The 
[18F]fluoride was dried further by addition and subsequent distillation of three portions 
of anhydrous acetonitrile to give [18F]fluoride as the potassium-Kryptofix 222 salt 
[18F]-45. The salt was taken up into an anhydrous acetonitrile solution of 
ethyl O-mesylglycolate 49 and heated in a sealed vial at 100 °C for 5 minutes to furnish 
ethyl [18F]fluoroacetate [18F]-328, as summarised in Scheme 15.  
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Scheme 15. Azeotropic drying of [18F]fluoride, where n>m, and reaction with ethyl O-mesylglycolate 49 to 
give ethyl [18F]fluoroacetate [18F]-328. 
After transfer of the reaction solution to a new vial and rinsing of the reaction vial with 
water, a sample of the mixture was taken for HPLC analysis using the same HILIC 
conditions described above. The radio-HPLC trace of this sample (Figure 6) showed 
two products (tR = 3.46 min and tR = 8.18 min), along with residual [18F]fluoride 
(tR = 18.9 min). The incorporation of [18F]fluoride was generally very good (81% ± 20%, 
n = 8). The larger peak at tR = 3.46 min was identified as ethyl [18F]fluoroacetate 
[18F]-328, while the smaller peak with tR = 8.18 min was found to have a retention time 
identical to that of [18F]fluoroacetate [18F]-1. The presence of [18F]fluoroacetate [18F]-1 is 
most probably due to the addition of water to the reaction mixture, leading to basic 
hydrolysis of [18F]-328 to give [18F]fluoroacetate [18F]-1. 
 
Figure 6. Radio-HPLC trace of the reaction mixture after 5 min heating and dilution with water, showing 
the presence of ethyl [18F]fluoroacetate [18F]-328, [18F]fluoroacetate [18F]-1 produced by 
hydrolysis, and residual [18F]fluoride. 
Ester hydrolysis was completed by dilution with water and addition of 1 M NaOH 
solution, and the mixture warmed to 40 °C for 5 minutes. Radio-HPLC analysis (Figure 
7) showed that all of the ethyl [18F]fluoroacetate [18F]-328 had been hydrolysed to 
[18F]fluoroacetate [18F]-1. Residual [18F]fluoride was also observed in the mixture, along 
with a minor unknown fluorinated product (tR = 3.8 min).  
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Figure 7. Radio-HPLC of the reaction mixture post-hydrolysis showing [18F]fluoroacetate [18F]-1 as the 
predominant species, residual [18F]fluoride, and an additional unknown fluorinated compound 
with tR = 3.8 min. 
With a crude mixture of [18F]fluoroacetate [18F]-1 in hand, attention turned to its 
purification using the extraction protocol described in the enzymatic synthesis. The 
basic reaction mixture was acidified with 1 M H2SO4 generating [18F]fluoroacetic acid 
[18F]-160 which was extracted into diethyl ether. Extraction efficiencies were slightly 
lower than those observed in the fluorinase-based synthesis (67% vs 74% 
respectively). This decrease may be due to variation in the pH of the aqueous phase 
between the two methods.  
The ether extracts containing [18F]fluoroacetic acid [18F]-160 were passed through a Si 
Sep-Pak cartridge to remove any residual water and associated ions from the mixture. 
In order to formulate and deliver the product into phosphate buffered saline (PBS), 
[18F]fluoroacetic acid [18F]-160 was extracted directly into a small volume of PBS 
(pH 7.4). The PBS would convert the ether-soluble [18F]fluoroacetic acid [18F]-160 
(pKa 2.59) to water soluble [18F]fluoroacetate [18F]-1, which would be extracted into the 
PBS. 
Upon trialling this work up procedure, however, [18F]fluoroacetic acid [18F]-160 was 
adsorbed from the diethyl ether onto the Si Sep-Pak in some experiments, rather than 
eluting through the cartridge as expected. This behaviour was not predictable or 
reproducible. The combination of traces of water in the ether extracts and the acidic 
nature of silica-based solid phases may result in the radiolabelled product partitioning 
as either [18F]fluoroacetic acid [18F]-160 or [18F]fluoroacetate [18F]-1, and subsequently 
behaving differently on the stationary phase, depending on the exact conditions of each 
extraction. In cases when the [18F]fluoroacetate [18F]-1 was retained on the cartridge, it 
was eluted simply with 0.5 mL of PBS, as required for the study. In search of a 
repeatable procedure, an alternative to the Si Sep-Pak was investigated. 
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Changing from a silica based Sep-Pak cartridge to a neutral alumina (Alumina N) 
Sep-Pak led to reproducible behaviour of the [18F]fluoroacetate [18F]-1, which was now 
consistently trapped on this type of cartridge. The [18F]fluoroacetate [18F]-1 could be 
eluted from the Alumina N Sep-Pak with 0.5 mL PBS, through a sterile 0.22 µm filter, 
and into a vial for administration to the animals for the study.  
Radio-HPLC of the final solution for injection (Figure 8) showed that the primary 
product was [18F]fluoroacetate [18F]-1 (tR = 8.3 min) that had been isolated in 99% ± 1% 
(n = 9) radiochemical purity (RCP). There was evidence of trace amounts of the 
unknown by-product (tR = 4.1 min) in the final sample, however at low enough levels 
that the product still passed the minimum RCP requirements (>97%).  
 
Figure 8. Radio-HPLC of [18F]fluoroacetate [18F]-1, after elution from an alumina column, showing 
>98% radiochemical purity for this sample. Overlay is the UV trace at 210 nm, which also 
shows reveals no other detectable UV active impurities.  
The non-decay corrected radiochemical yield for the synthesis of [18F]fluoroacetate 
[18F]-1 was 18% ± 7% (n=8). Considering the limitations with the amount of activity 
available to work with, these yields provided access to sufficient activity (33 MBq in the 
lowest yielding preparative experiment to 111 MBq in the highest), of [18F]fluoroacetate 
[18F]-1, delivered in 0.5 mL PBS, and suitable for use in tumour models in mice. 
5.6. Imaging of ACSS mouse model 
[18F]Fluoroacetate [18F]-1 was synthesised for an imaging study aimed to investigate 
ACSS2 activity in tumours in knockout mouse models, and to establish if the tumours 
were responsive to ACSS2 gene-silencing. The imaging protocol was also intended for 
use as an in vivo pharmacodynamic biomarker for developing potential therapeutics. 
Towards these aims, two PET imaging investigations were undertaken.  
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Initially, the behaviour of [18F]fluoroacetate [18F]-1 in a healthy control mouse, was 
contrasted with the behaviour of [18F]fluoroacetate [18F]-1 in a diseased mouse (ApcMin/+ 
line, bearing 70+ small intestinal tumours and colorectal tumours).68 These experiments 
were designed to establish an imaging protocol in the mice and to determine optimal 
imaging parameters for [18F]fluoroacetate [18F]-1. These experiments were also 
expected to offer information about [18F]fluoroacetate [18F]-1 uptake in healthy vs 
disease models. 
Following these experiments, the study would move to a breast cancer xenograft, 
ACSS2 knockout model to evaluate whether RNAi (RNA interference) gene silencing of 
ACSS2 affects uptake of [18F]fluoroacetate [18F]-1 in the tumours. 
Dr Zachary Schug and Dr Eyal Gottlieb, of the Beatson Institute for Cancer Research, 
who were leading the ACSS2 investigation provided the mice for the study, while 
imaging acquisitions and data analysis were conducted at the institute by Dr Gaurav 
Malviya and Agata Mrowinska. 
5.6.1. Assessment of [18F]fluoroacetate [18F]-1 in healthy and ApcMin/+ 
 models 
[18F]Fluoroacetate[18F]-1 was administered to a healthy mouse, which was imaged 
under dynamic scanning conditions to investigate the kinetics of tracer uptake in vivo 
and to establish optimal time points for static imaging in the disease model. The mouse 
was injected intravenously with [18F]fluoroacetate [18F]-1 (5.41 MBq) and a 2 hour 
dynamic PET scan was acquired, along with a CT (computerised tomography) scan, for 
correcting for attenuation and providing anatomical detail. 
The CT scan and PET scan snapshot from the 2 hour dynamic scan for the healthy 
control are shown below in Figure 9. The PET images (Figure 9 A, B and C) show the 
tracer excretion via the urinary system, with activity accumulating in the kidneys and 
bladder (largest region of activity at this time point). This mode of excretion is well 
established for [18F]fluoroacetate [18F]-1.62,69 Also evident from the PET scan is activity 
uptake in the bone (seen as high density regions in the CT scan, Figure 9 D, E and F), 
resulting from metabolism of [18F]fluoroacetate [18F]-1 to [18F]fluoride, a degradation 
product which has high affinity for calcium present in the bone.62 
227 
 
 
Figure 9. PET scan of a healthy mouse through the A. transverse, B. sagittal and C. coronal planes, 
and the corresponding CT images (D., E. and F. respectively). The large hotspot in B and C 
corresponds to excretion through the bladder. The smaller hotspot (right of the bladder in B, 
lower right of the bladder in C) was unexpected. Bone uptake is also observed along the 
vertebrae, and in the fore- and hindquarters. Images acquired by Dr Gaurav Malviya and 
Agata Mrowinska. 
Unexpectedly, a second area in the abdomen (superior to the bladder) showed 
increased uptake of [18F]fluoroacetate [18F]-1, and this uptake was consistently higher 
than the surrounding tissues throughout the duration of the PET scan. It was initially 
thought that this might be a tumour. The corresponding region in the CT scan and post 
mortem dissection of the mouse revealed no abnormal structures, and suggested that 
activity appeared to be accumulating in the cecum, the proximal region of the large 
intestine. In herbivores, the cecum contains large numbers of bacteria which assist in 
the breakdown of plant material. The broader focus of this study on ACSS2 expression 
in colon and breast cancers, means that non-specific uptake in the intestinal area of a 
healthy control, was problematic if this is repeated in the disease models. 
The dynamic scan showed that optimal uptake in the caecum was 60 minutes post 
injection, and subsequent static imaging experiments in the disease model mice were 
acquired near this time point. 
Two diseased ApcMin/+ mice were administered with [18F]fluoroacetate [18F]-1 (4.49 MBq 
each, one intravenously, one intraperitoneally due to poor condition of the mouse). 
These mice were imaged after 45 min and 90 min respectively, under static scanning 
conditions with 10 min PET acquisitions, followed by a CT acquisition, with the images 
shown in Figure 10. The second mouse died during the scanning period, but due to the 
90 minute accumulation window, the PET data were still representative of uptake and 
distribution during the time the mouse was alive.  
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Figure 10. Overlaid PET-CT images of the two ApcMin/+ mice, acquired after 45 minutes uptake (left) and 
90 minutes uptake (right), through the transverse (A,D), sagittal (B,E) and coronal (C,F) 
planes. Evident in both scans is an area of high accumulation of tracer in the bowel region, 
corresponding to uptake in the caecum. Additional area of higher than background uptake 
(white arrows) are also observed. Images acquired by Dr Gaurav Malviya and Agata 
Mrowinska. 
[18F]Fluoroacetate [18F]-1 accumulated in the cecum of the ApcMin/+ in both the 45 min 
and 90 min uptake mice, and uptake of activity in bone and bladder was also evident. 
This distribution was similar to that observed in the wild type mouse. In both scans, 
there appeared to be slightly increased general uptake in the bowel area (white 
arrows). As this model lacked large, well-defined tumours, it was difficult to assign this 
increased uptake specifically to the multiple small tumours in the small intestine and 
colon. The presence of the tracer in the caecum of the ApcMin/+ was confirmed after the 
mice were culled by removing the small intestine and colon, and imaging these in the 
PET scanner (Figure 11).  
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Figure 11. Image and PET scan of the small intestine and colon of the ApcMin/+ mice after A. 45 min 
uptake and B. 90 min uptake. Both scans show high activity in the caecum, along with other 
areas throughout the intestine, possibly areas of tumour activity (red arrows). Activity is also 
observed associated with faecal pellets (black and white arrows). Images acquired by Dr 
Gaurav Malviya and Agata Mrowinska. 
In the intestines of both ApcMin/+ mice, high tracer accumulation was observed in the 
caecum. Biliary excretion of [18F]fluoroacetate [18F]-1 has been reported previously,69 
but interestingly, high activity concentrations are observed associated with faecal 
pellets in the colon in the mouse which received [18F]fluoroacetate [18F]-1 intravenously 
(black and white arrows, Figure 11). This region is distal from where bile enters the 
digestive tract and activity here is unlikely to be associated with biliary excretion. This 
suggests the presence of a mechanism whereby the tracer is absorbed from the blood 
across the lower intestinal wall and concentrated in the faecal pellets, possibly under 
the action of gut bacteria. Also evident from the images are other areas within the small 
intestine which also show high activity accumulation (red arrows, Figure 11). These 
areas do not appear to be associated with the caecum or faeces and are thought to be 
areas of tumour activity. 
Non-tumour associated [18F]fluoroacetate [18F]-1 uptake in the abdomen area is 
potentially problematic for investigating breast and colorectal cancers in mouse models 
as it would obscure the observation and quantification of uptake into areas of tumour 
activity. A xenograft model was therefore proposed for these investigations. 
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5.6.2. Xenograft breast cancer model 
Breast cancer BT474 ER+/HER+ xenografts were proposed to investigate the difference 
in uptake of [18F]fluoroacetate [18F]-1 in the tumours in control mice, and in mice where 
the ACCS2 gene was silenced in the xenograft by a doxycycline (DOX) induced siRNA 
system. The experiment was designed to assess the suitability of a [18F]fluoroacetate-
based imaging experiment for use as an in vivo biochemical marker for acetate 
consumption, reflective of ACSS2 activity, towards investigating ACSS2 as a possible 
therapeutic target. 
The imaging time point in the xenograft study was determined by performing a dynamic 
PET scan in a mouse bearing a xenograft breast cancer tumour on its right flank. After 
injection of a 5.43 MBq dose of [18F]fluoroacetate [18F]-1, tracer uptake was monitored 
in the tumour over 2 hours to determine the maximum uptake time point.  
 
Figure 12. PET images through A. transverse, B. sagittal and C. coronal sections of a mouse bearing a 
BT474 xenograft tumour on the right flank (white arrows), showing increase uptake in the 
tumour. D. Maximal uptake curve shows steady accumulation of the tracer in the tumour 
region, reaching a maximum after approximately 45 min. Images and data acquired by Dr 
Gaurav Malviya and Agata Mrowinska. 
The PET images shown in Figure 12 A–C, left, show increased uptake of 
[18F]fluoroacetate [18F]-1 in the tumour, located on the upper right flank (white arrow) 
relative to background. Maximum uptake was observed 45 minutes post-injection 
(Figure 12 D). Subsequent static scans were therefore acquired 45 minutes post 
injection. [18F]Fluoroacetate [18F]-1 accumulated in the caecum and bladder, as 
observed in the previous PET imaging experiments in the healthy and ApcMin/+ mice, 
while defluorination and accumulation of [18F]fluoride in the bone was also observed. 
[18F]Fluoroacetate [18F]-1 imaging was then used to determine whether doxycycline-
induced (DOX) gene silencing affected acetate uptake in two groups of nude Balb/c 
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mice bearing xenograft tumours (BT 474 ER+/HER+ type) (2 per group). One group was 
exposed to DOX (+DOX), and the second not (−DOX). The mice were each injected 
with a dose of [18F]fluoroacetate [18F]-1, and imaged in the PET scanner 45 minutes 
post injection. DOX exposure initiates gene silencing of ACSS2 via RNA interference 
(RNAi) in this model, reducing the expression of ACSS2 within the tumour cells. Mice 
not exposed to DOX will have basal levels of ACSS2 expression within the tumour 
cells.50 
 
Figure 13. PET-CT image of a −DOX mouse bearing a breast cancer xenograft tumour on the right flank 
(white arrow), through A. transverse, B. sagittal and C. coronal sections. D. Image of the 
nude Balb/c mouse showing a breast cancer xenograft tumour on the right flank (black 
arrow). PET-CT image of a +DOX mouse with the same tumour type xenograft (white arrow), 
through D. transverse, E. sagittal and F. coronal sections. Images acquired by Dr Gaurav 
Malviya and Agata Mrowinska. 
In both +DOX and –DOX mice, uptake of [18F]fluoroacetate [18F]-1 into the xenograft 
tumour is observed in the PET images, as shown in Figure 13 A–C and E–G. 
Accumulation of [18F]fluoroacetate [18F]-1 is also observed in the caecum, with 
excretion through the urinary system and accumulation in the bladder. Uptake is 
quantified by measuring the standardised uptake value (SUV, Equation 1), a measure 
of activity in a particular region (measured from the PET image) or organ of interest 
(from post mortem gamma counting) per unit weight of the organ at time t, as a function 
of total injected activity per unit body weight.  
𝑆𝑈𝑉 = 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛 𝑜𝑟𝑔𝑎𝑛 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡
(𝑡𝑜𝑡𝑎𝑙 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 )
                                      Eq.1 
Maximum standard uptake value (SUVmax) in the tumours and caeca were calculated 
from the uptake maxima in regions of interest in the PET images in the –DOX and 
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+DOX mice after 45 minutes (Figure 14). The data show that average SUVmax for 
[18F]fluoroacetate [18F]-1 in the caecum is higher than uptake into the tumours. The 
ratio of the SUV between the tumours and the heart or liver (as reference organs) 
shows that uptake into the tumours is marginally greater than the reference organs, by 
a factor of about 1.3. 
 
Figure 14. Maximum standard uptake values (SUVmax) in the tumours and caeca in the two groups of 
mice (–DOX and +DOX), along with ratio of SUVmax in the areas of interest compared to the 
liver and heart. Data compiled by Dr Gaurav Malviya and Agata Mrowinska. 
The difference in average SUVmax in the tumours between the –DOX and +DOX groups 
is within the standard deviation of the two groups. The +DOX group, which would be 
expected to have lower functional ACSS2 levels in the tumour as a result of 
doxycycline induced gene silencing, has similar uptake of [18F]fluoroacetate [18F]-1 
compared to tumours from the –DOX group. At this time point (45 minutes), 
[18F]fluoroacetate [18F]-1 uptake appears independent of ACSS2 levels within the 
tumour cells, suggesting that another mechanism may be operating which controls 
uptake and accumulation of [18F]fluoroacetate [18F]-1 in the cells. 
The average SUV for all organs for the –DOX and +DOX groups, assessed post 
mortem, is shown in Figure 15. SUV is highest in the faeces, trachea, large bowel and 
bone. No difference in SUV is discernible between the two groups. Faecal and large 
bowel uptake were observed in the PET images, however measurement of SUV shows 
that the activity uptake is largely associated with faecal matter, supporting the 
hypothesis that [18F]fluoroacetate [18F]-1 is being excreted through the small intestine 
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and being concentrated in faecal bacteria. High SUVs in areas other than tumour 
represents high background uptake of [18F]fluoroacetate [18F]-1, an undesirable quality 
for a tracer to be used in quantifying differences in uptake in xenograft tumours. 
 
Figure 15. Average SUV in the two groups of mice (–DOX and +DOX), showing standard deviation, 
across multiple organs after dissection post mortem. Highest SUV appears in the faeces, 
bone and trachea, large bowel, followed by the tumour. One of the animals in the –DOX 
group had a cyst on the bladder. Data compiled by Dr Gaurav Malviya and Agata Mrowinska. 
[18F]Fluoroacetate [18F]-1 uptake and metabolism has been reported to be a poor 
model of acetate metabolism in monkey and pig studies.69 [18F]Fluoroacetate [18F]-1 
showed different uptake kinetics, having a much longer residency time in the blood 
compared to [11C]acetate [11C]-301. This difference in behaviour may be due to 
differences in kinetics of transport into the cells via monocarboxyl transporters between 
[18F]fluoroacetate [18F]-1 and [11C]acetate [11C]-301. 
If acetate 301 and fluoroacetate 1 transport kinetics differ, rather than uptake and 
accumulation of the radiotracer being reflective of the rate of incorporation of 
[18F]fluoroacetate [18F]-1 by ACSS2, uptake may be reflective simply of transport 
kinetics. Differences in activity of ACSS2 in the two groups of mice may be masked by 
transport kinetics, as this step is independent of ACSS2 activity, and consequently also 
DOX-induced gene silencing. 
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5.7. Conclusions 
A chemoenzymatic method for the synthesis of [18F]fluoroacetate [18F]-1 was explored 
based on a fluorinase enzyme catalysed fluorination of S-adenosylmethionine 20 with 
[18F]fluoride. [18F]Fluorodeoxyadenosine [18F]-22 (FDA), the product of this reaction was 
subject to Kuhn-Roth oxidation to generate [18F]fluoroacetate [18F]-1. While the 
enzymatic incorporations of [18F]fluoride, and final radiochemical yields of 
[18F]fluoroacetate [18F]-1 were both good, contamination of the final product with Cr(VI) 
species led to the investigation of an alternate chemical synthesis of [18F]fluoroacetate 
[18F]-1. 
[18F]Fluoroacetate [18F]-1 was synthesised chemically by SN2 reaction of [18F]fluoride 
with ethyl O-mesylglycolate 49, followed by basic hydrolysis of the ester. Purification 
and formulation of [18F]fluoroacetate [18F]-1 was then optimised to give a synthetic 
route to generate high radiochemical purity [18F]fluoroacetate [18F]-1 (99% ± 1% 
(n = 9)), in good radiochemical yields (18% ± 7% (n = 8)) which was then used to 
investigate ACSS2 in xenograft mice models. 
[18F]Fluoroacetate [18F]-1 did not appear to be the optimal tracer for monitoring the 
physiological effect of gene silencing of ASCC2 in BT474 breast cancer xenograft 
models. The tracer shows low uptake in the tumour compared to reference areas such 
as the heart or liver. This low uptake was likely due to rate limiting transport of 
[18F]fluoroacetate [18F]-1 into the cells, rather than being reflective of low ACSS2 
activity. [18F]Fluoroacetate [18F]-1 also showed significant uptake in the faeces and 
caecum. Significant uptake of radioactivity in the bone is a result of adventitious 
defluorination and release of [18F]fluoride, further compromising [18F]fluoroacetate 
[18F]-1 as a candidate radiotracer for assessing lipid metabolism in vivo. 
Despite [18F]fluoroacetate [18F]-1 being a poor tracer for comparison of ASCC2 activity 
in mouse models, the synthesis of this radiotracer was successfully established at the 
Beatson Cancer Research Institute in Glasgow. The availability of a validated synthetic 
method for the routine production of [18F]fluoroacetate [18F]-1 means that PET tracer 
remains available for use in future by other research groups at the facility, should they 
require [18F]fluoroacetate [18F]-1 for a small animal PET imaging study. 
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6. Experimental 
6.1. General Experimental 
Air and moisture sensitive reactions were carried out under an atmosphere of argon in 
flame-dried glassware. Room temperature (rt) refers to 18-25 °C. All evaporations and 
concentrations were performed under reduced pressure (in vacuo). All reagents (from 
Sigma Aldrich UK, Fluka UK, Alfa Aesar UK, Acros UK or Fisher UK) were of synthetic 
grade and were used without further purification, unless stated otherwise. 
c(RGDfK[N3]) 199 was purchased from Peptides International, USA. When necessary, 
reagents were dried or purified prior to use according to standard methods.1 Anhydrous 
solvents (DCM, THF, Et2O) were obtained from MBraun MB SPS-800 solvent 
purification system by passage through two drying columns and dispensed under an 
argon atmosphere. Anhydrous MeOH and MeCN were distilled from calcium hydride in 
a recycling still.1  
The course of reactions was followed by thin-layer chromatography (TLC) using 
aluminium plates coated with silica gel (60F245 Merck). TLC plates were examined 
under UV light (254 nm and 266 nm) before being visualised with ammonium 
heptamolybdate, anisaldehyde-sulfuric acid, alkaline potassium permanganate or ceric 
sulfate-sulfuric acid and developed by heating. Column chromatography was 
performed on Merck Geduran silica gel 60 (250-400 mesh) under a positive pressure of 
compressed air eluting with solvents (reported as v/v) as supplied. Reverse phase 
column chromatography was performed using Extract Clean C18-HC prepacked 
cartridges. 
NMR spectra were recorded at 298 K on Bruker Avance 300, Avance II 400, or Avance 
500. Avance III 500, or Avance III HD 500 instruments. 1H and 13C NMR spectra were 
recorded using deuterated solvent as the lock and the residual solvent signal as the 
internal standard. 19F NMR spectra were referenced to CFCl3 as an external standard. 
Chemical shifts are reported in parts per million (ppm) and coupling constants (J) are 
given in Hertz (Hz). The abbreviations for the multiplicity of the proton, carbon and 
fluorine signals are as follows: s singlet, d doublet, dd doublet of doublets, ddd doublet 
of doublet of doublets, t triplet, dt doublet of triplets, q quartet, m multiplet, br s broad 
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singlet. Compounds are numbered according to customary purine numbering. When 
necessary, resonances were assigned using two-dimensional experiments (COSY, 
HSQC, HMBC, TOCSY).  
Optical rotations were measured with a Perkin Elmer 341 polarimeter in a 10.0 cm cell 
at the wavelength of the sodium D-line (λ = 589 nm). Specific rotations are given in 
implied units of 10−1deg cm2 g−1 and concentrations (c) are given in g/100 mL. High 
resolution electrospray ionisation mass spectra were obtained on a Micromass LCT or 
ThermoFisher Excalibur Orbitrap spectrometers operating in positive or negative mode, 
from solutions in MeOH, MeCN or water by the Mass Spectrometry Service at the 
University of St Andrews. MALDI MS was acquired using a 4800 MALDI TOF/TOF 
Analyser (ABSciex) equipped with a Nd:YAG 355 nm laser and calibrated using a 
mixture of peptides by Mass Spectrometry Service at the University of St Andrews. 
Infrared spectra were measured on a Perkin Elmer Spectrum GX FTIR apparatus 
spectrometer either as KBr pellets, or as a thin film between NaCl plates, or on a 
Shimadzu IRAffinity-1S spectrometer with a diamond ATR attachment. Absorption 
maxima are given in units of wavenumbers (cm–1). Melting points were recorded on an 
Electrothermal IA9100 melting point apparatus, or on a Griffin MPA 350.BM2.5 melting 
point apparatus and are uncorrected. 
X-ray diffraction data were collected on a Mercury 70 diffractometer using graphite 
monochromated Mo-Kα radiation at 100 K by means of phi and omega scans. 
Structures were solved by direct methods and refined by full-matrix least squares 
techniques. 
HPLC analyses/semi-preparations were performed using either a Shimadzu 
Prominence (SIL-20A HT autosampler, CL-20AT ternary pump, DGU-20A3R solvent 
degasser, SPD 20A UV detector and CBM-20A controller module) or a Varian Prostar 
(Varian 400 autosampler, Varian Prostar 230 solvent delivery system, Varian Prostar 
235 UV-Vis detector) or a Dionex UltiMate 3000 system (autosampler, pump, column 
oven, diode array detector, and Berthold Flowstar LB513 radioactivity detector) with 
reverse phase or HILIC column as indicated in individual experiment. 
LC-MS analysis was performed on a Waters 2795 HPLC coupled in parallel to a 
Waters 2996 photodiode array detector and Micromass LCT TOF mass spectrometer 
in ESI in positive mode using the column indicated in the individual experiment. 
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Activity of fluorine-18 containing samples was measured using a Capintech Amersham 
radioisotope calibrator ARC-120. 
Samples were freeze dried from frozen solutions in water or tBuOH in water (20% v/v) 
in a Christ Alpha 1-2 LO Plus freeze drier. 
Protein concentrations were measured on a NanoDrop 1000 spectrophotometer at 
280 nm using an extinction coefficient of 10.42 as calculated by ExPASy ProtParam 
tool.2 SDS-PAGE was run using NuPAGE 4–12% BisTris gels (Novex) in MOPS SDS 
running buffer. Proteins were visualised using Instant Blue Coomassie-based gel stain 
(Expedion). 
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6.2. Compound preparation for Chapter 2 
6.2.1.  2′,3′,5′-Tri-O-acetylguanosine 184 
Pyridine (4.70 mL, 58.3 mmol, 5.5 eq.) and acetic anhydride 
(7.01 mL, 74.1 mmol, 7.0 eq.) were slowly added to a cooled 
(0 °C) suspension of guanosine (3.00 g, 10.6 mmol, 1.0 eq.) in 
DMF (40 mL). The mixture was heated to 85 °C for 2.5 h, 
resulting in a clear yellow solution. After cooling to rt, the volatile components were 
removed under reduced pressure to give an off-white powder, which was suspended in 
iPrOH (70 mL) and heated under reflux for 1 h. After cooling, the white solid was 
isolated by filtration and the residue was washed with cold Et2O (20 mL) and dried 
under vacuum to afford the product 184 as a colourless amorphous powder (3.53 g, 
81%): Rf = 0.20 (90:10 DCM:MeOH);  [α]D20 −26.0 (c 0.96, DMSO); mp 228–229 °C 
(iPrOH); vmax 3437, 3130, 1749, 1374, 1235, 1052 cm−1; δH (400.1 MHz, d6-DMSO): 
10.74 (1 H, s, N-H), 7.94 (1 H, s, H-8), 6.54 (2 H, br s, NH2), 5.98 (1 H, d, J 6.0, H-1′), 
5.79 (1 H, dd, J 6.0, 6.0, H-2′), 5.49 (1 H, dd, J 6.0, 4.1, H-3′), 4.42-4.21 (3 H, m, H-4, 
H-5′a, H-5′b), 2.11 (3 H, s, OAc), 2.04 (3 H, s, OAc), 2.03 (3 H, s, OAc); 
δC (100.6 MHz, d6-DMSO): 170.1, 169.4, 169.2 (CH3C(O)), 156.6 (C-6), 153.9 (C-2), 
151.9 (C-4), 135.6 (C-8), 116.8 (C-5), 84.4 (C-1′), 79.5 (C-4′), 72.0 (C-2′), 70.3 (C-3′), 
63.1 (C-5′), 20.5, 20.4, 20.2 (CH3C(O)); m/z (ES+) 841 ([2M+Na]+, 100%), 432 
([M+Na]+, 89); HRMS (ES+) calc. for C16H19N5O8Na [M+Na]+ 432.1131, found 432.1122. 
Data are in agreement with the literature.3 
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6.2.2. 2-Amino-6-chloro-9β-(2′,3′,5′-tri-O-acetyl-D-ribofuranosyl)-purine 
 185 
N,N-dimethylaniline (0.16 mL, 1.22 mmol, 1.0 eq.) and POCl3 
(0.68 mL, 7.33 mmol, 6.0 eq.) were slowly added to a solution 
of 184 (500 mg, 1.22 mmol, 1.0 eq.) and tetraethylammonium 
chloride (405 mg, 2.44 mmol, 2.0 eq.) in MeCN (20 mL). The 
mixture was heated to 100 °C for 25 min, before the volatile components were removed 
to give a yellow syrup. The syrup was reconstituted with CHCl3 (20 mL) and ice water 
(20 mL) and stirred vigorously for 30 min. The phases were separated and the aqueous 
phase extracted with CHCl3 (3 × 30 mL). The combined organic phases were washed 
with aqueous NaHCO3 (5% w/v, 2 × 30 mL) before being dried over MgSO4, filtered 
and concentrated. The crude product was purified by column chromatography (DCM to 
95:5 DCM:MeOH) to afford the product 185 as a yellow foam (323 mg, 62%): Rf = 0.54 
(90:10 DCM:MeOH);  [α]D
20 −6.1 (c 1.04, CHCl3); mp 142–143 °C (DCM); 
 vmax 3373, 3212, 1747, 1618, 1376, 1233, 1051 cm−1; δH (400.1 MHz, CDCl3): 7.87 
(1 H, s, H-8), 6.00 (1 H, d, J 5.0, H-1′), 5.95 (1 H, dd, J 5.0, 5.0, H-2′), 5.74 (1 H, m, 
H-3′), 5.24 (2 H, br s, NH2), 4.51-4.31 (3 H, m, H-4, H-5′a, H-5′b), 2.14 (3 H, s, OAc), 
2.10 (3 H, s, OAc), 2.08 (3 H, s, OAc); δC (100.6 MHz, CDCl3): 170.6, 169.7, 169.5 
(CH3C(O)), 159.2 (C-2), 153.2 (C-6), 152.1 (C-4), 140.8 (C-8), 117.2 (C-5) 86.8 (C-1′), 
80.2 (C-4′), 72.9 (C-2′), 70.6 (C-3′), 63.1 (C-5′), 20.9, 20.7, 20.6 (CH3C(O));  
m/z (ES+) 450 ([M+Na]+, 100%); HRMS (ES+) calc. for C16H18ClN5O7Na [M+Na]+ 
450.0792, found 450.0796. Data are in agreement with the literature.4 
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6.2.3. 6-Chloro-2-iodo-9β-(2′,3′,5′-tri-O-acetyl-D-ribofuranosyl)-purine 186 
CH2I2 (1.57 mL, 19.5 mmol, 10 eq.) and isoamyl nitrite (0.76 mL, 
5.7 mmol, 3.0 eq.) were slowly added to a suspension of 185 
(811 mg, 1.90 mmol, 1.0 eq.), copper(I) iodide (379 mg, 
1.99 mmol, 2.0 eq.) and iodine (481 mg, 1.90 mmol, 1.0 eq.) in 
THF (20 mL). The mixture was heated under reflux for 3 h, cooled to rt and filtered 
through a pad of celite. The filtrate was concentrated and purified by column 
chromatography (CHCl3 to 99:1 CHCl3:EtOH to 98:2 CHCl3:EtOH) and the fractions 
containing product combined, concentrated and the resultant gum was recrystallised 
from EtOH (30 mL) to give the product 186 as a yellow powder (700 mg, 69%): 
 Rf = 0.15 (99:1 CHCl3:EtOH);  [α]D20 +9.0 (c 0.61, CHCl3); mp 179–181 °C (CHCl3); 
vmax 1748, 1585, 1551, 130, 1218, 1138 cm−1; δH (400.1 MHz, CDCl3): 8.20 (1 H, s, 
H-8), 6.18 (1 H, d, J 5.4, H-1′), 5.76 (1 H, dd, J  5.6, 5.4, H-2′), 5.56 (1 H, dd, J 5.6, 4.4, 
H-3′), 4.47-4.34 (3 H, m, H-4, H-5′a, H-5′b), 2.15 (3 H, s, OAc), 2.11 (3 H, s, OAc), 2.08 
(3 H, s, OAc); δC (125.77 MHz, CDCl3): 170.3, 169.7, 169.5 (CH3C(O)), 152.1 (C-6), 
151.2 (C-4), 143.2 (C-8), 132.4 (C-2), 117.2 (C-5), 86.8 (C-1′), 81.0 (C-4′), 73.5 (C-2′), 
70.7 (C-3′), 63.1 (C-5′), 21.0, 20.7, 20.6 (CH3C(O)); m/z (ES+) 561 ([M+Na]+ 100%); 
HRMS (ES+) calc. for C16H16ClIN4O7Na [M+Na]+ 560.9650, found 560.9655. Data are in 
agreement with the literature.5 
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6.2.4. 2-Iodoadenosine 179 
In a heavy walled tube, a suspension of 186 (1.08 g, 2.00 mmol, 
1.0 eq.) in MeOH (8 mL) was cooled to 0 °C. Ammonia gas was 
bubbled through the solution for 1 h, before the tube was sealed 
and heated to 60 °C for 19 h. The vessel was cooled to rt and 
carefully opened, before the solution was degassed by bubbling argon through the 
solution for 1 h. The clear yellow solution was concentrated, and the residue 
recrystallised from hot water (8 mL). A second batch of crystals was obtained after 
concentration of the mother liquor and a second recrystallisation from hot water (4 mL). 
After drying under vacuum, 2-iodoadenosine 179 was obtained as colourless crystals 
(536 mg, 68%): Rf = 0.02 (95:5 DCM:MeOH);  [α]D20 −34.7 (c 0.97, DMSO); mp 139–
140 °C (water); vmax 3321, 3191, 2924, 1652, 1592, 1339, 1306 cm−1; δH (400.1 MHz, 
d6-DMSO): 8.30 (1 H, s, H-8), 7.74 (2 H, br s, NH2), 5.80 (1 H, d, J 6.2, H-1′), 5.46 (1 H, 
d, J 6.2, C-2′ OH), 5.21 (1 H, d, J 4.9, C-3′ OH), 5.04 (1 H, dd, J 6.4, 5.1, C-5′ OH), 
4.54-4.50 (1 H, m, H-2′), 4.13-4.09 (1 H, m, H-3′), 3.95-3.92 (1 H, m, H-4′), 3.64 (1 H, 
ddd, J 12.0, 5.1, 4.1, H-5′a), 3.54 (1 H, ddd, J 12.0, 6.4, 4.0, H-5′b); δC (100.6 MHz, 
d6-DMSO): 155.9 (C-6), 149.8 (C-2), 139.4 (C-8), 120.9 (C-4), 119.0 (C-5), 87.2 (C-1′), 
85.8 (C-4′), 73.6 (C-2′), 70.5 (C-3′), 61.4 (C-5′); m/z (ES+) 416 ([M+Na]+ 100%); HRMS 
(ES+) calc. for C10H13IN5O4 [M+H]+ 394.0012, found 394.0016. Data are in agreement 
with the literature.5 
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6.2.5. 2-(Trimethylsilylethynyl)adenosine 187 
Triethylamine (0.28 mL, 2.04 mmol, 1.5 eq.) and 
ethynyltrimethylsilane (0.39 mL, 2.73 mmol, 2.0 eq.) were 
added to a suspension of Pd(PPh3)2Cl2 (95.6 mg, 
0.136 mmol, 0.1 eq.), copper(I) iodide (25.9 mg, 
0.136 mmol, 0.1 eq.) and 2-iodoadenosine 179 (536 mg, 1.36 mmol, 1.0 eq.) in 
DMF (8 mL). The mixture was heated to 85 °C for 90 min, after which time the volatile 
components were removed. The residue was diluted with EtOAc (15 mL) and washed 
with aqueous disodium EDTA solution (10% w/v, 30 mL) before being dried over 
Na2SO4 and concentrated. The crude product was purified by column chromatography 
(CHCl3 to 98:2 CHCl3:MeOH to 95:5 CHCl3:MeOH) to afford the product 187 as an 
amorphous light brown powder (296 mg, 60%): Rf = 0.13 (95:5 DCM:MeOH);  [α]D20 
−40.0 (c 0.25, DMSO); mp 156–157 °C (DCM); vmax 3332, 3260, 2958, 2920, 2169, 
1653, 1590, 1335, 851 cm−1; δH (500.0 MHz, d6-DMSO): 8.46 (1 H, s, H-8), 7.52 (2 H, 
br s, NH2), 5.88 (1 H, d, J 5.9, H-1′), 5.48 (1 H, d, J 6.2, C-2′ OH), 5.20 (1 H, d, J 4.9, 
C-3′ OH), 5.14 (1 H, dd, J 5.7, 5.7, C-5′ OH), 4.50-4.47 (1 H, m, H-2′), 4.13-4.11 (1 H, 
m, H-3′), 3.96-3.94 (1 H, m, H-4′), 3.66-3.64 (1 H, m, H-5′a), 3.58-3.54 (1 H, m, H-5′b), 
0.24 (9 H, s, Si(CH3)3); δC (125.8 MHz, d6-DMSO): 155.9 (C-6), 149.3 (C-4), 144.8 
(C-2), 140.4 (C-8), 118.8 (C-5), 104.5 (C≡CSi), 88.7 (C≡CSi), 87.1 (C-1′), 85.7 (C-4′), 
73.9 (C-2′), 70.3 (C-3′), 61.4 (C-5′), 0.36 (Si(CH3)3); m/z (ES+) 386 ([M+Na]+, 33%), 
364 ([M+H]+, 100); HRMS (ES+) calc. for C15H21N5O4Si [M+H]+ 364.1436, found 
364.1432. Data are in agreement with the literature.6 
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6.2.6. 2-Ethynyladenosine 180 
In a heavy walled tube, ammonia gas was bubbled through a 
solution of methanol (5 mL) for 1 h., before 187 (269 mg, 
0.739 mmol, 1 eq.) was carefully added. The tube was sealed 
and stirred at rt for 4 h. The vessel was carefully opened, 
before the solution was degassed by bubbling argon through the solution for 1 h. The 
solution was concentrated, and the residue recrystallised from hot water (5 mL). A 
second batch of crystals was obtained after concentration of the mother liquor and a 
second recrystallisation from hot water (2 mL) to give 180 as a pale brown amorphous 
powder (166 mg, 77%): Rf = 0.16 (90:10, DCM:MeOH);  [α]D20 -56 (c 0.28, DMSO); 
mp 200–201 °C (dec.) (H2O); vmax 3255, 2928, 2116, 1654, 1336, 1023 cm-1; 
δH (400.1 MHz, d6-DMSO): 8.43 (1 H, s, H-8), 7.53 (2 H, br s, NH2), 5.86 (1 H, d, J 6.1, 
H-1′), 5.47 (1 H, d, J 6.2, C-2′ OH), 5.20-5.17 (2 H, m, C-3′ OH, C-5′ OH), 4.57-4.53 
(1 H, m, H-2′), 4.13-4.11 (1 H, m, H-3′), 4.02 (1H, s, C≡CH), 3.96-3.93 (1 H, m, H-4′), 
3.66 (1 H, ddd, 11.9, 4.2, 4.2, H-5′a), 3.55 (1 H, ddd, 11.9, 6.7, 3.9, H-5′b); 
δC (75.5 MHz, d6-DMSO): 155.9 (C-6), 149.1 (C-4),144.7 (C-2), 140.7 (C-8), 119.1 
(C-5), 87.5 (C-1′), 85.8 (C-4′), 83.2 (C≡CH), 75.1 (C≡CH), 73.6 (C-2′), 70.5 (C-3′), 61.5 
(C-5′); m/z (ES+) 314 ([M+Na]+, 100%); HRMS (ES+) calc. for C12H13N5O4Na [M+Na]+ 
314.0865, found 314.0868. Data are in agreement with the literature.6 
  
248 
 
6.2.7. 5′-Chloro-5′-deoxy-2-ethynyladenosine (ClDEA) 174 
Pyridine (45 μL, 1.38 mmol, 2.0 eq.) followed by thionyl chloride 
(100 μL, 0.550 mmol, 5.0 eq.) were added to a solution of 187 
(100 mg, 0.275 mmol, 1.0 eq.) in MeCN (6 mL) at 0 °C. The 
mixture was stirred for 18 h and allowed to warm to rt. The 
volatile components were removed, and the residue was diluted with MeOH (1.5 mL), 
water (0.3 mL) and aqueous ammonia solution (35% v/v, 0.3 mL), and the solution 
stirred for 3 h. After concentration, the residue was purified by column chromatography 
(95:5 CHCl3:MeOH) to give the product 174 as a pale yellow powder (40.0 mg, 47%): 
Rf = 0.21 (90:10 DCM:MeOH);  [α]D20 −32.9 (c 0.30, DMSO); mp >285 °C (dec.) (CHCl3); 
vmax 3375, 2106, 1668, 1324, 741 cm−1; δH (500.1 MHz, d6-DMSO): 8.42 (1 H, s, H-8), 
7.53 (2 H, br s, NH2), 5.91 (1 H, d, J 5.7, H-1′), 5.62 (1 H, d, J 6.0, C-2′ OH), 5.48 (1 H, 
d, J 5.2, C-3′ OH), 4.72-4.68 (1 H, m, H-2′), 4.28-4.14 (1 H, m, H-3′), 4.15-4.05 (1 H, m, 
H-4′), 4.02 (1 H, s, C≡CH), 3.95 (1 H, dd, 11.6, 5.1, H-5′a), 3.86 (1 H, dd, 11.6, 
6.4, H-5′b); δC (125.8 MHz, d6-DMSO): 155.9 (C-6), 149.3 (C-2), 144.6 (C-4), 140.6 
(C-8), 118.9 (C-5), 87.2 (C-1′), 83.8 (C-4′), 83.4 (C≡CH), 74.9 (C≡CH), 72.8 (C-2′), 71.3 
(C-3′), 44.7 (C-5′); m/z (ES+) 332 ([M+Na]+, 100%); HRMS (ES+) calc. for 
C12H1235ClN5O3Na [M+Na]+ 332.0526, found 332.0522. 
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6.2.8. 2ʹ,3ʹ-O-Isopropylidene-2-(trimethylsilylethynyl)adenosine 191 
Amberlyst-15 H+ resin (100 mg) and 
2,2-dimethoxypropane (340 µL, 2.75 mmol, 10 eq.) were 
added to a solution of 2-(trimethylsilylethynyl)adenosine 
187 (100 mg, 0.275 mmol, 1.0 eq.) in DMF (5 mL), and the 
mixture heated to 60 °C for 18 h. The reaction mixture was 
cooled to rt and filtered through a pad of celite, before being concentrated. The yellow 
oil was purified by column chromatography (95:5 DCM:MeOH) to give the product 191 
as a pale yellow foamy solid (79 mg, 71%): Rf = 0.27 (95:5 DCM:MeOH); 
  [α]D
20 −132.5 (c 0.08, CHCl3); mp 177–179 °C (DCM); vmax 3469, 3369, 3252, 2927, 
2857, 1658, 1095, 864 cm–1; δH (400.1 MHz, CDCl3): 7.85 (1 H, s, H-8), 5.91 (2 H, br s, 
NH2), 5.83 (1 H, d, J 4.8, H-1ʹ), 5.75 (1 H, dd, J 11.5, 2.4, OH-5ʹ), 5.19-5.11 (2 H, m, 
H-2ʹ, H-3ʹ), 4.51 (1 H, br s, H-4ʹ), 4.01-3.96 (1 H, m, H-5ʹa), 3.83-3.74 (1 H, m, H-5ʹb), 
1.62 (3 H, s, C(CH3)2), 1.35 (3 H, s, C(CH3)2), 0.28 (9 H, s, Si(CH3)3); δC (75.5 MHz, 
CDCl3): 155.7 (C-6), 148.7 (C-4), 145.8 (C-2), 141.1 (C-8), 120.6 (C-5), 114.1 
(C(CH3)2), 102.4 (C≡C-Si), 94.1 (C-1ʹ), 92.7 (C≡C-Si), 86.2 (C-4ʹ), 83.1 (C-2ʹ), 81.8 
(C-3ʹ), 63.4 (C-5ʹ), 27.8 (C(CH3)2), 25.4 (C(CH3)2), -0.28 (Si(CH3)3)); m/z (ES+) 426 
([M+Na]+, 100%), 404 ([M+H]+, 28); HRMS (ES+) calc. for C18H25N5O4SiNa [M+Na]+ 
426.1574, found 426.1569. 
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6.2.9. 5′-Deoxy-5ʹ-fluoro-2ʹ,3ʹ-O-isopropylidene-2-ethynyladenosine 192 
TsF (92.0 mg, 0.528 mmol, 3.0 eq.) and TBAF (1 M in THF, 
1.10 mL, 1.06 mmol, 6.0 eq.) were added to a solution of 191 
(71.0 mg, 0.176 mmol, 1.0 eq.) in THF (5 mL). The mixture was 
heated to 60 °C for 18 h, and cooled to rt. The volatile 
components were removed and the orange residue was purified 
by column chromatography (DCM to 95:5 DCM:MeOH) to give the product 192 as a 
yellow powder (42.0 mg, 71%): Rf = 0.37 (95:5 DCM:MeOH); [α]D20 –22.0 (c 0.10, 
CHCl3); mp 242–245 °C (DCM); vmax 3319, 3244, 3165, 1161, 1593, 1360, 1213, 1082. 
729, 640 cm−1; δH (300.1 MHz, d6-DMSO): 8.35 (1 H, s, H-8), 7.57 (2 H, br s, NH2), 
6.20 (1 H, d, J 2.2, H-1ʹ), 5.39 (1 H, dd, J 6.2, 2.2, H-2ʹ), 5.07-5.03 (1 H, m, H-3ʹ),  
4.77–4.48 (2 H, m, H-5ʹ), 4.49-4.33 (1 H, m, H-4), 4.04 (1 H, s, C≡CH), 1.55 (3 H, s, 
C(CH3)2), 1.34 (3 H, s, C(CH3)2); δC (75.5 MHz, d6-DMSO): 155.9 (C-6), 148.8 (C-4), 
144.9 (C-2), 140.4 (C-8), 118.9 (C-5), 113.6 (C(CH3)2), 89.1 (C-1ʹ), 84.5 (d, J 18.2, 
C-4ʹ), 83.4 (C-2ʹ), 83.3 (C≡CH), 82.8 (d, J 168.7, C-5ʹ), 80.2 (d, J 6.7, C-3ʹ), 75.1 
(C≡CH), 27.0 (C(CH3)2), 25.2 (C(CH3)2); δF (282.3 MHz, d6-DMSO): −227.13 (ddd, 
J 46.9, 46.7, 22.1, CH2F); m/z (ES+) 356 ([M+Na]+, 100%), 334 ([M+H]+, 52); HRMS 
(ES+) calc. for C15H16N5O3FNa [M+Na]+ 356.1135, found 356.1143. 
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6.2.10. 5′-Deoxy-5ʹ-fluoro-2-ethynyladenosine (FDEA) 176 
A solution of 192 (40.0 mg, 0.120 mmol) in a mixture of 
TFA:water (9:1 v/v, 5.0 mL) at 0 °C was stirred for 3 h whilst 
warming to rt. The volatile components were removed, and the 
residue co-evaporated with EtOH (3 × 10 mL) and Et2O (10 mL) 
to give a brown solid. The residue was purified by column chromatography  
(90:10 CHCl3:MeOH) to give the product 176 as a white powder (18.5 mg, 53%):  
Rf = 0.21 (90:10 CHCl3:MeOH); [α]D20 -46.0 (c 0.20, DMSO); mp 218 °C (dec.) (CHCl3); 
vmax 3179, 3210, 1660, 1592, 1332, 1125, 725 cm−1; δH (499.9 MHz, d6-DMSO): 8.34 
(1 H, s, H-8), 7.54 (2 H, br s, NH2), 5.92 (1 H, d, J 5.0, H-1ʹ), 5.66 (1 H, d, J 5.7, OH-2'), 
5.45 (1 H, d, J 5.4, OH-3'), 4.73-4.59 (2 H, m, H-5ʹ), 4.57-4.54 (1 H, m, H-2ʹ), 4.24-4.21 
(1 H, m, H-3ʹ), 4.16-4.09 (1 H, m, H-4), 4.02 (1 H, s, C≡CH); δC (125.7 MHz, d6-DMSO): 
155.9 (C-6), 149.3 (C-4), 144.9 (C-2), 140.2 (C-8), 118.9 (C-5), 87.5 (C-1ʹ), 83.4 
(C≡CH), 82.9 (d, J 168.3, C-5ʹ), 82.5 (d, J 18.3, C-4ʹ), 75.0 (C≡CH), 73.2 (C-2ʹ), 69.4 (d, 
J 6.1, C-3ʹ); δF (470.3 MHz, d6-DMSO): −227.55 (1F, ddd, J 47.6, 47.6, 23.9, CH2F); 
m/z (ES+) 316 ([M+Na]+, 100%), 294 ([M+H]+, 7); HRMS (ES+) calc. for C12H12FN5O3Na 
[M+Na]+ 316.0822, found 316.0816. 
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6.2.11. 5′-Chloro-5′-deoxyadenosine 23 
Pyridine (0.61 mL, 7.48 mmol, 2.0 eq.) and thionyl chloride 
(1.36 mL, 18.7 mmol, 5.0 eq.) were slowly added to a suspension 
of adenosine 188 (1.00 g, 3.74 mmol, 1.0 eq.) in MeCN (40 mL) at 
0 °C. The mixture was stirred for 18 h, while warming to room 
temperature. The volatile components were removed, and the yellow residue 
reconstituted with MeOH (15 mL), water (5 mL) and aqueous ammonia solution  
(35% v/v, 15 mL), and the solution stirred for 3 h. After concentration, the residue was 
purified by recrystallisation from water to give 5′-chloro-5′-deoxyadenosine 23 as an off-
white amorphous powder (1.00 g, 94%): Rf = 0.12 (90:10, DCM:MeOH); 
 [α]D
20 -27.4 (c 1.1, 1 M HCl); mp 175-179 °C (water); vmax 3210, 1649, 1482, 1424, 1336, 
1302, 645 cm−1; δH (300.1 MHz, d6-DMSO): 8.35 (1H, s, H-8), 8.16 (1H, s, H-2), 7.32 
(2H, br s, NH2), 5.93 (1H, d, J 5.7, H-1ʹ), 5.60 (1H, d, J 5.9, OH-2ʹ), 5.47 (1H, d, J 5.2, 
OH-3ʹ), 4.76 (1H, ddd, J 5.9, 5.7, 5.4, H-2ʹ), 4.22 (1H, ddd, J 5.4, 5.2, 5.1, H-3ʹ), 
4.11-4.06 (1H, m, H-4ʹ), 3.95 (1H, dd, J 11.6, 5.1, H-5ʹa), 3.84 (1H, dd, J 11.6, 6.4, 
H-5ʹb); δC (75.5 MHz, d6-DMSO): 156.1 (C-6), 152.7 (C-2), 149.4 (C-4), 139.7 (C-8), 
119.1 (C-5), 87.4 (C-1ʹ), 83.7 (C-4ʹ), 72.6 (C-2ʹ), 71.3 (C-3ʹ), 44.8 (C-5ʹ); m/z (ES+) 286 
([M+H]+ 100%), Data are in agreement with literature values.7 
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6.2.12. ClDEA-RGD 200 
Fresh aqueous sodium ascorbate solution 
(20 mM, 798 µL, 10 eq.) and 
CuSO4.TBTA solution (10 mM stock in 
55% DMSO, 319 µL, 2 eq.) were added to 
a solution of ClDEA 174 (0.49 mg, 
0.0016 mmol, 1 eq.) and 
c(RGDfK[N3]) 199 (1.3 mg, 0.0020 mmol, 
1.25 eq.) in water (9.5 mL), and the 
mixture left to react for 30 min, at which point HPLC sampling showed all the alkyne to 
be consumed. The reaction mixture was passed through an ExtractClean C18-HC 
(1000 mg) cartridge (preconditioned with water), and the product eluted with 1:1 
water:MeCN (2 × 10 mL). The water:MeCN fractions were combined and concentrated 
to dryness under a stream of air, and the crude product purified by preparative HPLC 
(Shimadzu Prominence, using Phenomenex Kingsorb C18 (250 × 10.00 mm, 5µ) 
column); mobile Phase: A (H2O + 0.05% TFA), B (MeCN + 0.05% TFA); linear gradient: 
20% B to 42%B in 18 min, 42% B to 95% B in 1 min; hold at 95% B for 5 min, 95% B to 
20% B in 1 min, and re-equilibration at 20%B for 10 min; flow rate: 2.5 mL.min–1; 
detection 220 nm). Fractions containing product (tR = 10.9 min) were collected, 
concentrated under a stream of air, and lyophilised from a tBuOH in water (20% v/v) 
solution affording 200 (0.72 mg, 48%): δH (500.0 MHz, d6-DMSO + 15% D2O): 8.48 
(1 H, s, H-8), 8.32 (1 H, s, triazole-H), 7.19–7.09 (5 H, m, D-Phe ArH), 5.97 (1 H, d, 
J 5.6, H-1ʹ), 4.80 (1 H, dd, J 5.4, 5.6, H-2'), 4.59 (1 H, dd, J 9.6, 5.5, Asp α-H), 4.49 
(1 H, dd, J 7.5, 5.4, Arg α-H), 4.37 (2 H, t, J 6.8, Lys ε), 4.34–4.28 (2 H, m, Lys α-H, 
H-3'), 4.16–4.10 (3 H, m, H-4', D-Phe α-H, Gly α-Ha), 3.99 (1 H, dd, J 11.7, 4.8, H-5'a), 
3.92 (1 H, dd, J 11.7, 6.4, H-5'b), 3.38–3.32 (2 H, m, Gly α-Hb, Asp β-Ha), 3.06 (2 H, t, 
J 7.1, Arg δ-CH2), 2.77–2.68 (1 H, m, D-Phe β-Ha), 2.58 (1 H, dd, J 14.4, 9.6, Asp 
β-Hb), 2.08–1.97 (1 H, m, D-Phe β-Hb), 1.89–1.79 (2 H, m, Lys β-CH2), 1.73–1.52 (4 H, 
m, Lys δ-CH2, Arg β-CH2), 1.50–1.33 (2 H, m, Arg δ-CH2), 1.28–1.12 (2 H, m, Lys 
γ-CH2); m/z (MALDI-TOF) calc. for C39H5235ClN16O10 [M+H]+: 939.37, found 939.37. 
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6.2.13. FDEA-RGD 201 
Fresh aqueous sodium ascorbate solution 
(20 mM, 813 µL, 10 eq.) and CuSO4.TBTA 
solution (10 mM stock in 55% DMSO, 
325 µL, 2 eq.) were added to a solution of 
FDEA 176 (0.48 mg, 0.0016 mmol, 1 eq.) 
and c(RGDfK[N3]) 199 (1.3 mg, 0.0020 
mmol, 1.25 eq.) in a mixture of DMSO 
(3 mL) and water (6.7 mL). The mixture 
was left to react at rt for 70 min, at which point HPLC sampling showed all the alkyne to 
be consumed. The reaction mixture diluted with water (2 mL) and was passed through 
an ExtractClean C18-HC (1000 mg) cartridge (preconditioned with water), washed with 
water (10 mL), and the product eluted with 1:1 water:MeCN (2 × 10 mL). The 
water:MeCN fractions were combined and concentrated to dryness under a stream of 
air, and the crude product purified by preparative HPLC (Shimadzu Prominence, using 
Phenomenex Kingsorb C18 (250 × 10.00 mm, 5µ) column); mobile phase:  
A (H2O + 0.05% TFA), B (MeCN + 0.05% TFA); linear gradient: 20% B to 42% B in 18 
min, 42% B to 95% B in 1 min; hold at 95% B for 5 min, 95% B to 20% B in 1 min, and 
re-equilibration at 20%B for 10 min; flow rate: 2.5 mL.min–1; detection 220 nm). 
Fractions containing product (tR = 10.2 min) were collected, concentrated under a 
stream of air, and lyophilised from a tBuOH in water (20% v/v) solution affording 201 
(0.74 mg, 49%): δH (500.0 MHz, d6-DMSO + 15% D2O): 8.48 (1 H, s, H-8), 8.26 (1 H, s, 
triazole-H), 7.21–7.04 (5 H, D-Phe ArH), 5.99 (1 H, d, J 5.7, H-1ʹ), 4.75–4.70 (1 H, m,  
½ H-5a', ½ H-5b'), 4.67–4.61 (2 H, m, H-2' ½ H-5a', ½ H-5b'), 4.59 (1 H, dd, J 9.6, 5.5, 
Asp α-H), 4.49 (1 H, dd, J 7.4, 5.5, Arg α-H), 4.37 (2 H, t, J 6.9, Lys ε), 4.34–4.29 (2 H, 
m, Lys α-H, H-3'), 4.19–4.09 (3 H, m, H-4', D-Phe α-H, Gly α-Ha), 3.35–3.23 (2 H, m, 
Gly α-Hb, Asp β-Ha), 3.06 (2 H, t, J 7.1, Arg δ-CH2), 2.76–2.69 (1 H, m, D-Phe β-Ha), 
2.58 (1 H, dd, J 14.2, 9.6, Asp β-Hb), 2.08–1.99 (1 H, m, D-Phe β-Hb), 1.90–1.80 (2 H, 
m, Lys β-CH2), 1.74–1.51 (4 H, m, Lys δ-CH2, Arg β-CH2), 1.49–1.32 (2 H, m,  
Arg δ-CH2), 1.30–1.10 (2 H, m, Lys γ-CH2); δF (470.5 MHz, d6-DMSO + 15% D2O): 
227.01 (1 F, dt, J 47.4, 24.2, CH2F); m/z (MALDI-TOF) calc. for C39H52FN16O10 [M+H]+: 
923.40, found 923.41. 
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6.3. Compound preparation for Chapter 3 
6.3.1. Methyl 3,5-bis(prop-2-yn-1-yloxy)benzoate 227 
Propargyl bromide (80% w/w in toluene, 9.9 mL, 89.2 mmol, 3 eq.) 
was added to a suspension of methyl 3,5-dihydroxybenzoate 
(5.00 g, 29.7 mmol, 1 eq.) and K2CO3 (12.3 g, 89.2 mmol, 3 eq.) in 
acetone (50 mL), and the mixture heated under reflux for 48 h. 
The mixture was cooled before being filtered in vacuo, and the residue washed with 
acetone (3 × 20 mL). The combined filtrates were concentrated, and the resultant solid 
was dissolved in DCM and passed through a short plug of silica, eluting with DCM, and 
the fractions containing product concentrated in vacuo. The crude product was 
recrystallised from of MeOH to give 227 as pale yellow crystals (6.32 g, 87%): Rf = 0.61 
(DCM); vmax 3267, 1713, 1597, 1352, 1039, 632 cm−1; mp 104–107 °C (MeOH); 
δH (500.1 MHz, CDCl3): 7.29 (2 H, d, J 2.4, H-2, H-6), 6.81 (1 H, t, J 2.4, H-4), 4.72 
(4 H, d, J 2.4, CH2), 3.91 (3 H, s, OCH3), 2.54 (2 H, t, J 2.4, C≡C-H); δC (125.8 MHz, 
CDCl3): 166.6 (C=O), 158.6 (C-3, C-5), 132.3 (C-1), 109.0 (C-2, C-6), 107.5 (C-4), 78.1 
(C≡C-H), 76.1 (C≡C-H), 56.3 (CH2), 52.5 (OCH3); m/z (ES+) 267 ([M+Na]+, 100%), 245 
([M+H]+, 10); HRMS (ES+) calc. for C14H12O4Na [M+Na]+ 267.0628, found 267.0623. 
Data are in agreement with the literature.8 
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6.3.2. Methyl 3,5-bis((3-(trimethylsilyl)prop-2-yn-1-yl)oxy)benzoate 228 
n-BuLi (2.5 M in hexanes, 21.7 mL, 54.3 mmol, 2.1 eq.) was 
added dropwise to a solution of diisopropylamine (8.41 mL, 
59.6 mmol, 2.3 eq.) in THF (20 mL) at −78 °C. This solution 
was stirred for 20 min before dialkyne 227 in THF (40 mL) was added dropwise and 
this mixture stirred for 30 min before TMSCl (7.56 mL, 59.6 mmol, 2.3 eq.) was added 
slowly. This mixture was stirred for 10 min, before being allowed to warm to rt and stir 
for 16 h. The reaction was quenched by addition of sat. aqueous NH4Cl (50 mL) before 
volatile components were removed under reduced pressure. The mixture was diluted 
with DCM (100 mL) and the phases separated and the aqueous phase extracted with 
DCM (3 × 50 mL). The combined organic phases were washed with sat. aqueous 
NaHCO3 (50 mL) and brine (50 mL) and dried over Na2SO4 before being filtered and 
concentrated in vacuo. The crude product was purified by column chromatography 
(petroleum ether to 90:10 petroleum ether: Et2O to 80:20 petroleum ether: Et2O) to give 
228 as a colourless oil (8.41 g, 84%): Rf = 0.49 (80:20 petroleum ether: Et2O); 
 vmax 3147, 1720, 1651, 1595, 1045, 841, 760 cm−1; δH (499.9 MHz, CDCl3): 7.30 (2 H, 
d, J 2.4, H-2, H-6), 6.79 (1 H, t, J 2.4, H-4), 4.69 (4 H, s, CH2), 3.90 (3 H, s, OCH3), 
0.17 (18 H, s, Si(CH3)3); δC (125.7 MHz, CDCl3): 166.7 (C=O), 158.8 (C-3, C-5), 132.1 
(C-1), 109.1 (C-2, C-6), 107.9 (C-4), 99.6 (C≡CTMS), 93.5 (C≡CTMS), 57.2 (CH2), 52.4 
(OCH3), −0.18 (Si(CH3)3); m/z (ES+) 799 ([2M+Na+, 15%), 411 ([M+Na]+, 100), 389 
([M+H]+, 7); HRMS (ES+) calc. for C20H28O4Si2Na [M+Na]+ 411.1418, found 411.1409. 
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6.3.3. 3,5-Bis((3-(trimethylsilyl)prop-2-yn-1-yl)oxy)benzyl alcohol 229 
Lithium aluminium hydride (3.70 g, 97.4 mmol, 4.5 eq.) was 
added portion-wise to a solution of ester 228 (8.41 g, 
21.6 mmol, 1 eq.) in Et2O (100 mL) at 0 °C, and the 
suspension allowed to warm to rt and stirred for 3 h. The reaction was quenched after 
cooling the mixture to 0 °C, by the slow addition of water (3.7 mL), NaOH (2 M, 
3.7 mL), and additional water (11.1 mL). The mixture stirred for 15 min before addition 
of MgSO4, and further stirring for 15 min before the solids were removed by filtration, 
and the solvents removed in vacuo. The crude product was purified by column 
chromatography (67:33 petroleum ether: Et2O) to give 229 as a colourless oil (5.06 g, 
65%): Rf = 0.32 (50:50 petroleum ether: Et2O); vmax 3410, 1651, 1595, 1364, 1043, 842 
cm−1; δH (500.1 MHz, CDCl3): 6.59 (2 H, d, J 2.3, H-2, H-6), 6.51 (1 H, t, J 2.3, H-4), 
4.63 (4 H, s, ArOCH2), 4.60 (2 H, s, HOCH2Ar), 1.95 (1 H, br s, OH), 0.17 (18 H, s, 
Si(CH3)3); δC (125.8 MHz, CDCl3): 159.1 (C-3, C-5), 143.5 (C-1), 106.3 (C-2, C-6), 
101.6 (C-4), 100.0 (C≡CTMS), 93.0 (C≡CTMS), 65.2 (HOCH2Ar), 57.0 (ArOCH2),  
−0.2 (Si(CH3)3); m/z (ES+) 383 ([M+Na]+, 100%), 367 ([M+H]+, 31); HRMS (ES+) calc. 
for C19H28O3Si2Na [M+Na]+ 383.1469, found 383.1458. Data are in agreement with the 
literature.9 
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6.3.4. 3,5-Bis((3-(trimethylsilyl)prop-2-yn-1-yl)oxy)benzaldehyde 223 
Dess-Martin periodinane (5.50 g, 13.0 mmol, 1.1 eq.) was 
added to a solution of alcohol 229 (4.25 g, 11.8 mmol, 1 eq.) in 
DCM (100 mL), and the solution stirred at rt for 1 h. The reaction 
was quenched by the addition of sat. aqueous NaHCO3 (100 mL), followed by Et2O 
(200 mL) and Na2S2O3 (11.0 g) and the biphasic mixture stirred vigorously for 1 h. The 
phases were separated and the aqueous phase extracted with Et2O (3 × 100 mL). The 
combined organic phases were dried over Na2SO4 before being filtered and 
concentrated in vacuo to give to give aldehyde 223 as a colourless oil without further 
purification (4.30 g, quant.): Rf = 0.86 (50:50 petroleum ether: Et2O); vmax 2959, 1703, 
1595, 1292, 1252, 1157, 1059, 851 cm−1; δH (500.1 MHz, CDCl3): 9.91 (1 H, s, 
ArCHO), 7.12 (2 H, d, J 2.4, H-2), 6.86 (1 H, t, J 2.4, H-4), 4.71 (4 H, s, CH2),  
0.17 (18 H, s, Si(CH3)3); δC (125.8 MHz, CDCl3): 191.7 (ArCHO), 159.4 (C-3, C-5), 
138.4 (C-1), 109.2 (C-4), 108.9 (C-2, C-6), 99.3 (C≡CTMS), 93.8 (C≡CTMS), 57.2 
(CH2), −0.2 (Si(CH3)3); m/z (ES+) 413 ([M+MeOH+Na]+, 100%), 381 ([M+Na]+, 30), 359 
([M+H]+, 5); HRMS (ES+) calc. for C19H27O3Si2 [M+H]+ 359.1493, found 359.1452. 
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6.3.5. 3,6,9,12-Tetraoxapentadec-14-yn-1-ol 231 
NaH (60% dispersion in mineral oil, 0.61 g, 15.3 mmol, 1.1 eq.) 
was added to a solution of tetraethyleneglycol (5.00 g, 
25.7 mmol, 1.9 eq.) in THF (50 mL) at 0 °C. The suspension was allowed to warm to rt 
and stirred for 60 min, before being re-cooled to 0 °C. Propargyl chloride (0.98 mL, 
14 mmol, 1.0 eq.) was added dropwise over 20 min, before the mixture was warmed to 
rt and stirred for 2 h. The reaction was quenched by addition of sat. aqueous NH4Cl 
(10 mL), and volatile components removed in vacuo. The residue was diluted with 
DCM (100 mL) and water (30 mL) and the phases separated. The aqueous phase was 
extracted with DCM (3 × 50 mL). The combined organic phases were dried over 
Na2SO4 before being filtered and concentrated in vacuo. The crude product was 
purified by column chromatography (50:50 petroleum ether: acetone) to give 231 as a 
colourless oil (1.49 g, 47%): Rf = 0.26 (50:50 petroleum ether: acetone); vmax 3394, 
2875, 1716, 1250, 1105 cm−1; δH (500.1 MHz, CDCl3): 4.20 (2 H, d, J 2.4, CH2C≡CH), 
3.73–3.60 (16 H, m, PEG CH2), 2.43 (1 H, t, J 2.4, CH2C≡CH), 2.23 (1 H, br s, 
CH2OH); δC (125.8 MHz, CDCl3): 79.7 (CH2C≡CH), 74.7 (CH2C≡CH), 72.7 (CH2OH), 
70.8, 70.7, 70.7, 70.5, 70.5, 69.2, 61.9 (PEG CH2), 58.5 (CH2C≡CH); m/z (ES+) 255 
([M+Na]+, 65); HRMS (ES+) calc. for C11H20O5Na [M+Na]+ 255.1203, found 255.1195. 
Data are in agreement with the literature.10 
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6.3.6. 3,6,9,12-Tetraoxapentadec-14-yn-1-yl tosylate 232 
Tosyl chloride (1.46 g, 7.65 mmol, 1.2 eq.) was added to 
a solution of alcohol 231 (1.48 g, 6.41 mmol, 1 eq.) and 
Et3N (2.66 mL, 19.1 mmol, 3 eq.) in DCM (20 mL) at 
0 °C, and the solution stirred at rt for 18 h. The reaction was quenched by addition of 
sat. aqueous NH4Cl (50 mL) and DCM (50 mL), the phases separated and the aqueous 
phase extracted with DCM (4 × 50 mL). The combined organic phases were washed 
with aqueous HCl solution (1 M, 50 mL), followed by brine (50mL), and dried over 
Na2SO4 before being filtered and concentrated in vacuo. The crude product was 
purified by column chromatography (DCM to 98:2 DCM: MeOH to 95:5 DCM: MeOH) to 
give 232 as a pale yellow oil (2.22 g, 90%): Rf = 0.71 (95:5 DCM: MeOH);  
vmax 2870, 1456, 1352, 1175, 1096, 920, 664, 556 cm−1; δH (500.1 MHz, CDCl3): 
 7.81–7.78 (2 H, m, H-2ʹ, H-6ʹ), 7.35–7.26 (2 H, m, H-3ʹ, H-5ʹ), 4.19 (2 H, d, J 2.4, 
CH2C≡CH), 4.17–4.14 (2 H, m, PEG CH2), 3.70–3.61 (10 H, m, PEG CH2), 3.59–3.57 
(4 H, m, PEG CH2), 2.45 (3 H, s, C4ʹ-CH3), 2.42 (1 H, t, J 2.4, CH2C≡CH); δC (125.8 
MHz, CDCl3): 144.9 (C-1ʹ), 133.1 (C-4ʹ), 130.0 (C-3ʹ, C-5ʹ), 128.1 (C-2ʹ, C-6ʹ), 79.8 
(CH2C≡CH), 74.7 (CH2C≡CH), 70.9, 70.7, 70.7, 70.7, 70.5, 70.5, 69.4, 69.3, 68.1 (PEG 
CH2), 58.4 (CH2C≡CH), 21.8 (C4ʹ-CH3); m/z (ES+) 409 ([M+Na]+, 83%), 425 ([M+Na]+, 
100). Data are in agreement with the literature.10 
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6.3.7. 1-Azido-3,6,9,12-tetraoxapentadec-14-yne 233 
NaN3 (0.441 g, 7.87 mmol, 2.5 eq.) was added to a solution of 
tosylate 232 (1.00 g, 2.71 mmol, 1 eq.) in DMF (5 mL), and the 
solution stirred at 50 °C for 18 h. DMF was removed in vacuo, and the residue was 
purified by column chromatography (50:50 petroleum ether: Et2O) to give the azide 233 
as a colourless oil (552 mg, 79%): Rf = 0.13 (50:50 petroleum ether: Et2O); 
 vmax 2866, 1456, 1350, 1096, 839, 775 cm−1; δH (500.1 MHz, CDCl3): 4.20 (2 H, d,  
J 2.4, CH2C≡CH), 3.73–3.60 (14 H, m, PEG CH2), 3.41–3.36 (2 H, m, CH2N3), 2.42  
(1 H, t, J 2.4, CH2C≡CH); δC (125.8 MHz, CDCl3): 79.8 (CH2C≡CH), 74.6 (CH2C≡CH), 
70.8, 70.8, 70.8, 70.8, 70.6, 70.2, 69.3 (PEG CH2), 58.6 (CH2C≡CH), 50.8 (CH2N3); 
m/z (ES+) 537 ([2M+Na]+, 52%), 280 ([M+Na]+, 27), 258 ([M+H]+, 100); HRMS (ES+) 
calc. for C11H20N3O4 [M+H]+ 258.1448, found 258.1452. Data are in agreement with the 
literature.11 
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6.3.8. 1-Amino-3,6,9,12-tetraoxapentadec-14-yne 222 
PPh3 (2.13 g, 8.12 mmol, 1.2 eq.) and water (0.12 mL, 
6.76 mmol, 1 eq.) were added to a solution of azide 233 (1.74 g, 
6.76 mmol, 1 eq.) in THF (15 mL), and the solution stirred at rt for 72 h. All volatiles 
were removed in vacuo, and the residue was purified by column chromatography (DCM 
to 95:5 DCM: MeOH to 90:10 DCM: MeOH to 89:10:1 DCM: MeOH: Et3N) to give the 
amine 222 as a colourless oil (1.36 g, 87%): Rf = 0.13 (89:10:1 DCM: MeOH: Et3N); 
vmax 2872, 1668, 1350, 1109, 947 cm−1; δH (500.1 MHz, CDCl3): 4.19 (2 H, d, J 2.4, 
CH2C≡CH), 3.71–3.61 (12 H, m, PEG CH2), 3.51 (2 H, t, J 5.3, CH2CH2NH2), 2.86 (2 H, 
t, J 5.3, CH2CH2NH2), 2.42 (1 H, t, J 2.4, CH2C≡CH), 1.78 (2 H, br s, NH2);  
δC (125.8 MHz, CDCl3): 79.7 (CH2C≡CH), 74.7 (CH2C≡CH), 73.4, 70.7, 70.7, 70.7, 
70.5, 70.4, 69.2 (PEG CH2), 58.5 (CH2C≡CH), 41.9 (CH2NH2); m/z (ES+) 254 ([M+Na]+, 
62%), 232 ([M+H]+, 100). Data are in agreement with the literature.11 
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6.3.9. N-(3',5'-bis((3-(trimethylsilyl)prop-2-yn-1-yl)oxy)benzyl)-3,6,9,12-
 tetraoxapentadec-14-yn-1-amine 234 
Acetic acid (0.60 mL, 10.6 mmol, 2 eq.) and 
NaB(OAc)3H (4.50 g, 21.22 mmol, 4 eq.) were 
slowly added to a solution of aldehyde 223 (1.90 g, 
5.31 mmol, 1 eq.) and amine 222 (1.35 g, 
5.84 mmol, 1.1 eq.) in THF (10 mL), and the mixture stirred at rt for 18 h. The mixture 
was diluted with Et2O (50 mL) and quenched by careful addition of sat. aqueous 
NaHCO3 (50 mL), before the phases were separated and the aqueous phase extracted 
with Et2O (3 × 50 mL). The combined organic phases were dried over Na2SO4 before 
being filtered and concentrated in vacuo The crude product was purified by column 
chromatography (DCM to 97:3 DCM: MeOH to 95:5 DCM: MeOH) to give 234 as a 
colourless oil (1.09 g, 35%): Rf = 0.44 (90:10 DCM: MeOH); vmax 2870, 1597, 1456, 
1252, 1152, 1105, 1061, 854 cm−1; δH (499.9 MHz, CDCl3): 6.57 (2 H, d, J 2.2, H-2ʹ, 
H-6ʹ), 6.47 (1 H, t, J 2.2, H-4ʹ), 4.62 (4 H, s, CH2C≡CSi), 4.17 (2 H, d, J 2.4 CH2C≡CH), 
3.73 (2 H, bs, NHCH2Ar), 3.68–3.57 (14 H, m, PEG CH2), 2.77 (2 H, t, J 5.1, 
CH2NHCH2Ar), 2.41 (1 H, t, J 2.4, CH2C≡CH), 2.23 (1 H, br s, NH), 0.16 (18 H, s, 
Si(CH3)3); δC (125.7 MHz, CDCl3): 159.0 (C-3ʹ, C-5ʹ), 142.7 (C-1ʹ), 107.7 (C-2ʹ, C-6ʹ), 
101.0 (C-4ʹ), 100.1 (2 × CH2C≡CSi), 92.7 (2 × CH2C≡CSi), 79.7 (CH2C≡CH), 74.7 
(CH2C≡CH), 70.7, 70.7, 70.6, 70.6, 70.5, 70.4, 69.2 (PEG CH2), 58.5 (CH2C≡CH), 56.9 
(2 × CH2C≡CSi), 58.8 (NHCH2Ar), 48.6 (CH2NHCH2Ar), −0.17 (Si(CH3)3); m/z (ESI+) 
574 ([M+H]+, 100%); HRMS (ESI+) calc. for C30H48NO6Si2 [M+H]+ 574.3015, found 
574.3003. 
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6.3.10. N,N-bis(3',5'-bis((3-(trimethylsilyl)prop-2-yn-1-yl)oxy)benzyl)-
 3,6,9,12-tetraoxapentadec-14-yn-1-amine 235 
Acetic acid (0.60 mL, 10.6 mmol, 2 eq.) and 
NaB(OAc)3H (4.50 g, 21.22 mmol, 4 eq.) were slowly 
added to a solution of aldehyde 233 (1.90 g, 5.31 mmol, 
1 eq.) and amine 222 (1.35 g, 5.84 mmol, 1.1 eq.) in 
THF (10 mL), and the mixture was stirred at rt for 18 h. 
The mixture was diluted with Et2O (50 mL) and 
quenched by careful addition of sat. aqueous NaHCO3 
(50 mL), before the phases were separated and the aqueous phase extracted with 
Et2O (3 × 50 mL). The combined organic phases were dried over Na2SO4 before being 
filtered and concentrated in vacuo. The crude product was purified by column 
chromatography (DCM to 97:3 DCM: MeOH to 95:5 DCM: MeOH) to give 235 as a 
colourless oil (500 mg, 21%): Rf = 0.85 (90:10 DCM: MeOH); vmax 2959, 1597, 1456, 
1361, 1252, 1153, 1061, 856, 762 cm−1; δH (300.1 MHz, CDCl3): 6.62 (4 H, d, J 2.3, 
H-2ʹ, H-6ʹ), 6.47 (2 H, t, J 2.4, H-4ʹ), 4.63 (8 H, s, CH2C≡CSi), 4.18 (2 H, d, J 2.4 
CH2C≡CH), 3.69–3.52 (18 H, m, PEG CH2, CH2N(CH2Ar)2), 2.67 (2 H, t, J 6.1, 
CH2N(CH2Ar)2), 2.41 (1 H, t, J 2.4, CH2C≡CH), 0.17 (36 H, s, Si(CH3)3);  
δC (75.5 MHz, CDCl3): 158.9 (C-3ʹ, C-5ʹ), 142.4 (C-1ʹ), 108.3 (C-2ʹ, C-6ʹ), 100.8 (C-4ʹ), 
100.2 (4 × CH2C≡CSi), 92.7 (4 × CH2C≡CSi), 79.8 (CH2C≡CH), 74.7 (CH2C≡CH), 70.7, 
70.7, 70.7, 70.5, 70.5, 70.1, 69.2 (PEG CH2), 59.1 (CH2N(CH2Ar)2), 58.2 (CH2C≡CH), 
57.0 (4 × CH2C≡CSi), 52.9 (CH2N(CH2Ar)2), −0.11 (Si(CH3)3); m/z (ES+) calc. isotope 
pattern for C49H74NO8Si4 [M+H]+ 916.4 (100%), 917.4 (53), 918.4 (13), 919.4 (10), 
found 916.5 (100%), 917.5 (53), 918.5 (14), 919.5 (8). 
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6.3.11. 5ʹ-Chloro-5ʹ-deoxy-2-iodoadenosine 238 
Pyridine (103 μL, 1.27 mmol, 2.0 eq.) and thionyl chloride 
(103 μL, 1.91 mmol, 3.0 eq.) were slowly added to a suspension 
of 179 (250 mg, 0.363 mmol, 1.0 eq.) in MeCN (12 mL) at 0 °C. 
The mixture was stirred at 0 °C for 4 h, warmed to rt and stirred 
for a further 18 h. The volatile components were removed, and the residue was diluted 
with MeOH:water:aqueous ammonia solution (35% v/v) (10:2:1, 10 mL) and the 
solution stirred for 2 h. After concentration, the residue was purified by column 
chromatography (95:5 DCM:MeOH to 90:10 DCM:MeOH) to afford the product 238 as 
a white foam (167 mg, 64%): Rf = 0.47 (20:80 petroleum ether:acetone); 
  [α]D
20 -6.3 (c 0.51, MeOH); mp 127–130 °C (DCM); vmax 3155, 1637, 1589, 1650, 1288, 
1049, 656 cm−1; δH (500.1 MHz, d4-MeOD): 8.15 (1 H, s, H-8), 5.95 (1 H, d, J 5.1, H-1′), 
4.77 (1 H, dd, J 5.2, 5.1, H-2′), 4.39 (1 H, dd, J 5.2, 4.2, H-3′), 4.27-4.24 (1 H, m, H-4′), 
3.95 (1 H, dd, 11.8, 5.3, H-5′a), 3.85 (1 H, dd, 11.8, 5.2, H-5′b); δC (125.8 MHz,  
d4-MeOD): 155.7 (C-6), 149.6 (C-4), 139.7 (C-8), 119.3 (C-5), 119.1 (C-2), 89.1 (C-1′), 
84.1 (C-4′), 73.4 (C-2′), 71.4 (C-3′), 43.6 (C-5′); m/z (ES+) 434 ([M+Na]+ 60%), 412 
([M+H]+, 24); HRMS (ES+) calc. for C10H1135ClN5O3INa [M+Na]+ 433.9487, found 
433.9477. 
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6.3.12. 2ʹ,3ʹ-O-Isopropylidene-2-iodoadenosine 239 
2,2-Dimethoxypropane (1.55 mL, 12.7 mmol, 10 eq.) and 
perchloric acid (70% v/v in water, 75 μL, 0.839 mmol, 0.67 eq.) 
were slowly added to a suspension of 179 (500 mg, 1.27 mmol, 
1.0 eq.) in acetone (15 mL) at 0 °C. The mixture was allowed to 
slowly warm to rt, and stirred for a further 18 h. The reaction was 
quenched by addition of sat. aqueous NaHCO3 solution (1 mL) and concentrated in 
vacuo. The residue was adsorbed onto silica and purified by column chromatography 
(20:80 petroleum ether:acetone) to give the product 239 as a white foam (550 mg, 
quant.): Rf = 0.56 (20:80 petroleum ether:acetone);  [α]D20 −19.2 (c 1.26, MeOH); 
mp 131–135 °C (petroleum ether:acetone); vmax 3192, 1638, 1589, 1570, 1209, 1070, 
849, 823 cm−1; δH (500.1 MHz, CDCl3): 7.73 (1 H, s, H-8), 6.08 (2 H, br s, NH2), 5.79 
(1 H, d, J 5.3, H-1ʹ), 5.36 (1 H, dd, J 11.8, 1.9, C-5ʹ OH), 5.18 (1 H, dd, J 5.7, 5.3, H-2ʹ), 
5.11 (1 H, dd, J 5.7, 1.4, H-2ʹ), 4.52 (1 H, ddd, J 1.8, 1.7, 1.4, H-4ʹ), 3.99 (1 H, m, 
H-5ʹa), 3.82 (1 H, m, H-5ʹb), 1.63 (3 H, s, C(CH3)2), 1.38 (3 H, s, C(CH3)2); 
δC (125.8 MHz, CDCl3): 155.5 (C-6), 149.2 (C-4), 140.3 (C-8), 121.0 (C-5), 119.4 (C-2), 
114.3 (C(CH3)2), 94.2 (C-1ʹ), 86.1 (C-4ʹ), 82.8 (C-2ʹ), 81.7 (C-3ʹ), 63.5 (C-5ʹ), 27.8 
(C(CH3)2), 25.4 (C(CH3)2); m/z (ES+) 456 ([M+Na]+ 100%), 434 ([M+H]+, 23); 
HRMS (ES+) calc. for C13H16N5O4INa [M+Na]+ 456.1039, found 456.1031. 
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6.3.13. 5ʹ-Fluoro-5ʹ-deoxy-2ʹ,3ʹ-O-isopropylidene-2-iodoadenosine 240 
TsF (442 mg, 2.54 mmol, 2.0 eq.) and TBAF (1 M in THF, 
5.08 mL, 5.08 mmol, 4.0 eq.) were added to a solution of 239 
(550 mg, 1.27 mmol, 1.0 eq.) in THF (16 mL). The mixture was 
heated to 60 °C for 18 h, and cooled to rt. The volatile components 
were removed and the orange residue was purified by column 
chromatography (80:20 petroleum ether:acetone to 70:30 petroleum ether:acetone to 
60:40 petroleum ether:acetone) to give the product 240 as a white foam (270 mg, 
49%): Rf = 0.79 (50:50 petroleum ether:acetone);  [α]D20 −7.2 (c 1.06, MeOH); mp 88–90 
°C (petroleum ether:acetone); vmax 3169, 1636, 1587, 1568, 1204, 1072, 1009, 870, 
754, 656 cm−1; δH (500.1 MHz, CDCl3): 7.81 (1 H, s, H-8), 6.14 (1 H, d, J 2.1, H-1ʹ), 
6.05 (2 H, br s, NH2), 5.25-5.23 (1 H, m, H-2ʹ), 5.07 (1 H, dd, J 6.2, 3.5, H-3ʹ), 4.68 
(1 H, ddd, J 46.9, 10.3, 3.6, H-5ʹa), 4.63 (1 H, ddd, J 47.0, 10.3, 5.2, H-5ʹb), 4.53-4.46 
(1 H, m, H-4'), 1.63 (3 H, s, C(CH3)2), 1.40 (3 H, s, C(CH3)2); δC (125.8 MHz, CDCl3): 
155.2 (C-6), 149.6 (C-4), 139.2 (C-8, d, J 3.5), 119.8 (C-5, C-2), 114.8 (C(CH3)2), 90.5 
(C-1ʹ), 85.9 (C-4ʹ, d, J 19.3), 84.6 (C-2ʹ), 82.9 (C-5ʹ, d, J 171.6), 80.7 (C-3ʹ, d, J 7.0), 
27.2 (C(CH3)2), 25.4 (C(CH3)2); δF (470.3 MHz, CDCl3): −227.93 (ddd, J 47.0, 46.9, 
22.7, CH2F); m/z (ES+) 458 ([M+Na]+ 100%), 436 ([M+H]+ 37); HRMS (ES+) calc. for 
C13H15N5O3FINa [M+Na]+ 458.0096, found 458.0086. 
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6.3.14. 5ʹ-Fluoro-5ʹ-deoxy-2-iodoadenosine 241 
Anhydrous TsOH (16.0 mg, 0.0930 mmol, 0.15 eq.) was added to 
a solution of 240 (270 mg, 0.620 mmol) in MeOH (10 mL), and the 
mixture was heated to reflux for 48 h, before being concentrated 
The residue was adsorbed onto silica and purified by column 
chromatography (50:50 petroleum ether:acetone) to give the product 241 as a white 
powder (245 mg, 71%): Rf = 0.0.23 (50:50 petroleum ether:acetone); [α]D20 −23.8 (c 0.32, 
DMSO); vmax 3144, 2181, 1639, 1298, 1074, 912, 752, 656 cm−1; mp 210 °C (decomp.) 
(petroleum ether:acetone);. δH (500.1 MHz, d4-MeOD): 8.09 (1 H, s, H-8), 8.00 (2 H, br 
s, NH2), 5.99 (1 H, d, J 4.2, H-1ʹ), 4.74 (1 H, ddd, J 48.0, 10.6, 2.8, H-5ʹa), 4.68 (1 H, 
ddd, J 47.4, 10.6, 3.8, H-5ʹb), 4.57-4.55 (1 H, m, H-2ʹ), 4.39 (1 H, dd, J 5.2, 5.2, H-3ʹ), 
4.27-4.17 (1 H, m, H-4'); δC (125.8 MHz, d4-MeOD): 155.7 (C-6), 149.5 (C-2), 138.9 
(C-8, d, J 4.5), 119.4 (C-5), 119.2 (C-2), 89.0 (C-1ʹ), 83.1 (C-4ʹ, d, J 18.7), 82.1 (C-5ʹ, d, 
J, 170.5), 74.2 (C-2ʹ), 69.6 (C-3ʹ, d, J 5.3); δF (470.3 MHz, d4-MeOD): −232.1 (ddd, 
J 48.0, 47.4, 26.8, CH2F); m/z (ES+) 418 ([M+Na]+ 100%), 396 ([M+H]+ 12); HRMS 
(ES+) calc. for C10H11FIN5O3Na [M+Na]+ 417.9784, found 417.9774.  
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6.3.15. ClDEA-PEG-(C≡CH)2 219 
Pd(PPh3)2Cl2 (6.8 mg, 0.0097 mmol, 
0.1 eq.), copper(I) iodide (1.9 mg, 
0.0097 mmol, 0.1 eq.) and 
triethylamine (68 µL, 0.49 mmol, 
5 eq.) were added to a solution of iodo compound 238 (40 mg, 0.097 mmol, 1.0 eq.) 
and alkyne 234 (112 mg, 0.194 mmol, 2.0 eq.) in degassed DMF (5 mL). The mixture 
was heated to 80 °C for 48 h, after which time the volatile components were removed 
in vacuo. The residue was partly purified by column chromatography (50:50 petroleum 
ether:acetone to 40:60 petroleum ether:acetone to 80:20 petroleum ether:acetone to 
80:20 EtOAc:acetone to 10:90 MeOH:acetone to 10:89:1 MeOH:acetone:1% aqueous 
ammonia (30%)) to afford fractions containing the coupled product (identified by 
ESMS). After concentration, the fractions were further purified by column 
chromatography (acetone to 5:95 MeOH:acetone to 10:90 MeOH:acetone) to afford the 
crude coupled product (20 mg) which was used directly, without further purification. 
The crude product (20 mg) was dissolved in MeOH (10 mL) and 3HF.Et3N (200 µL) 
was added and the mixture stirred for 18 h. The reaction was quenched by addition of 
sat. aqueous NaHCO3 (2 mL) and the mixture concentrated under reduced pressure. 
The mixture was partly purified by column chromatography (99:1 acetone:aqueous 
ammonia (30%) to 5:94:1 MeOH:acetone:aqueous ammonia (30%) to 10:89:1 
MeOH:acetone: aqueous ammonia (30%)). Fractions containing product were 
combined and concentrated. The residue was dissolved in MeCN: water (20:80) and 
purified by semi-preparative HPLC on the Shimadzu system (Phenomenex Kingsorb 
C18 (250 × 10.00 mm, 5µ); mobile Phase: A (H2O + 0.05% TFA), B (MeCN +  
0.05% TFA); linear gradient: 20% B at 0 min to 70% B at 18 min, to 95% B at 19 min, 
to 20% B at 24 min, to 20% B at 30 min; flow rate: 2.5 mL.min–1; detection 220 nm. 
Fractions containing product (tR = 16.7 min) were concentrated under a stream of 
compressed air, and lyophilised from a solution of tBuOH in water (20% v/v) affording 
219 as a white solid (3.4 mg, 4.2% over two steps): δH (500.1 MHz, 1:1 D2O:d3-MeCN): 
8.78 (1 H, s, H-8), 7.15 (2 H, d, J 2.2, H-2’’), 7.08 (1 H, t, J 2.2, H-4''), 6.43 (1 H, d, 
J 4.9, H-1ʹ), 5.20 (4 H, d, J 2.3, OCH2C≡CH), 5.11 (1 H, dd, J 5.0, 4.9, H-2'), 4.87 (2 H, 
s, ArC≡CCH2PEG), 5.84 (1 H, dd, J 5.0, 5.0, H-3'), 4.77 (1 H, H-4', under HDO peak, 
observed in 2D), 4.61 (2 H, s, PEGCH2NHCH2Ar), 4.40 (1 H, dd, J 12.2, 3.9, H-5'a), 
4.34 (1 H, dd, J 12.2, 5.0, H-5'b), 4.22–4.08 (14 H, m, PEG-CH2), 3.63 (2 H, t, J 5.0, 
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PEGCH2NHCH2Ar), 3.44 (2 H, t, J 2.3 CH2C≡CH); δC (125.8 MHz, 1:1 D2O:d3-MeCN): 
158.4 (C-3'', C-5''), 154.4 (C-6), 148.7 (C-4), 143.8 (C-2), 140.5 (C-8), 132.8 (C-1''), 
118.3 (C-5, observed in 2D), 109.1 (C-2'', C-6''), 102.1 (C-4''), 87.6 (C-1ʹ), 83.4 
(ArC≡CCH2PEG), 83.0 (C-4ʹ), 82.9 (2 × C≡CH), 78.0 (2 × C≡CH), 76.5 (C-2ʹ), 73.4 
(C-3ʹ), 70.5, 69.5, 69.4, 69.3, 69.2, 69.2, 68.9, 64.8 (PEG-CH2), 68.7 (ArC≡CCH2PEG), 
57.8 (ArC≡CCH2PEG), 55.6 (2 × OCH2C≡CH), 50.0 (PEGCH2NHCH2Ar), 46.0 
(PEGCH2NHCH2Ar), 44.7 (C-5ʹ); m/z (ES+) calc. isotope pattern for C34H43ClN6O9 
[M+H]+ 713.3 (100), 714.3 (36), 715.3 (32), 716.3 (12), found 713.3 (40), 714.3 (100), 
715.3 (87), 716.3 (28); HRMS (ES+) calc. for C34H4335ClN6O9 [M+H]+ 714.2755, found 
714.2749. 
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6.3.16. ClDEA-PEG-(C≡CH)4 220 
Pd(PPh3)2Cl2 (13 mg, 0.018 mmol, 
0.1 eq.), copper(I) iodide (3.5 mg, 
0.018 mmol, 0.1 eq.) and triethylamine 
(129 µL, 0.923 mmol, 5 eq.) were 
added to a solution of iodo compound 
238 (76 mg, 0.185 mmol, 1.0 eq.), 
alkyne 235 (338 mg, 0.369 mmol, 
2.0 eq.) and PPh3 (24 mg, 0.092 mmol, 0.5 eq.) in degassed DMF (5 mL). The mixture 
was heated to 57 °C for 48 h, after which time the volatile components were removed 
in vacuo. The residue was partly purified by column chromatography (Et2O to 70:30 
Et2O:acetone) to afford fractions containing the coupled product (identified by ESMS). 
The compound was taken up into toluene (50 mL) and NaS2O7 solution (20% w/v, 
50 mL) and the mixture heated to 60 °C for 1 h. After cooling, the phases were 
separated and the aqueous phase extracted with toluene (3 × 20 mL), and the organic 
phases combined, dried over Na2SO4 and concentrated. The product was further 
purified by column chromatography (90:10 petroleum ether:acetone to 70:30 petroleum 
ether:acetone to 60:40 petroleum ether:acetone) to afford the crude coupled product 
(40 mg), which was used directly in the next step, without further purification. 
The crude product (40 mg) was dissolved in MeOH (15 mL) and 3HF.Et3N (250 µL) 
was added and the mixture stirred for 20 h. The reaction was quenched by addition of 
sat. aqueous NaHCO3 (4 mL) and the mixture concentrated under reduced pressure. 
The mixture was partly purified by column chromatography (DCM to 92.5:7.5 
DCM:MeOH). Fractions containing product were combined and concentrated. The 
residue was dissolved in MeCN: water (20:80) and purified by semi-preparative HPLC 
on the Shimadzu system (Phenomenex Kingsorb C18 (250 × 10.00 mm, 5µ); mobile 
Phase: A (H2O + 0.05% TFA), B (MeCN + 0.05% TFA); linear gradient: 20% B at 0 min 
to 70% B at 20 min, to 95% B at 21 min; to 95% B at 25 min, B to 5% B at 26 min, to 
5% B at 35 min; flow rate: 2.5 mL.min–1; detection 220 nm. Fractions containing 
product (tR = 18.7 min) were concentrated under a stream of compressed air, and 
lyophilised from a solution of tBuOH in water (20% v/v) affording 220 as a white solid 
(5.3 mg, 2.8% over two steps): δH (499.9 MHz, d4-MeOD): 8.31 (1 H, s, H-8), 6.69 (4 H, 
d, J 2.3, H-2’’, H-6’’), 6.47 (2 H, t, J 2.3, H-4''), 6.00 (1 H, d, J 4.9, H-1ʹ), 4.74 (1 H, dd, 
J 5.0, 4.9, H-2'), 4.70 (8 H, d, J 2.4, OCH2C≡CH), 4.42 (2 H, s, ArC≡CCH2PEG),  
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4.39 (1 H, dd, J 5.0, 4.9, H-3'), 4.27 (1 H, m, H-4'), 3.97 (1 H, dd, J 11.9, 4.9, H-5'a), 
3.86 (1 H, dd, J 11.9, 4.9, H-5'b), 3.75-3.55 (18 H, m, PEG-CH2, PEGCH2N(CH2Ar)2), 
2.95 (4 H, t, J 2.4, CH2C≡CH), 2.66 (2 H, t, J 5.8, PEGCH2N(CH2Ar)2); δC (125.7 MHz, 
MeOD): 158.7 (2 × C-3'', 2 × C-5''), 152.0 (C-6), 150.1 (C-4, observed in 2D), 146.2 
(C-2), 142.2 (2 × C-1''), 140.5 (C-8), 119.8 (C-5, observed in 2D), 107.9 (2 × C-2'',  
2 × C-6''), 100.6 (2 × C-4''), 86.0 (ArC≡CCH2PEG, observed in 2D), 82.3 
(ArC≡CCH2PEG, observed in 2D), 88.9 (C-1ʹ), 83.8 (C-4ʹ), 79.3 (4 × C≡CH, observed 
in 2D), 78.5 (C-2ʹ), 75.5 (4 × C≡CH), 73.6 (C-3ʹ), 71.2, 70.3, 70.2, 70.2, 70.0, 70.0, 
69.5, 69.1 (PEG-CH2), 58.6 (2 × PEGCH2N(CH2Ar)2), 58.0 (ArC≡CCH2PEG), 55.6  
(4 × OCH2C≡CH), 52.6 (PEGCH2N(CH2Ar)2), 43.8 (C-5ʹ); m/z (ES+) calc. isotope 
pattern for C47H52ClN6O11 [M+H]+ 911.3 (100), 912.3 (51), 913.3 (32), 914.3 (16), 915.3 
(4); found 911.3 (100), 912.3 (56), 913.3 (38), 914.3 (17), 915.3 (5). HRMS (ES+) calc. 
for C47H5235ClN6O11 [M+H]+ 911.3377, found 911.3358.  
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6.3.17. FDEA-PEG-(C≡CH)2 245 
Pd(PPh3)2Cl2 (15.4 mg, 0.022 mmol, 
0.1 eq.), copper(I) iodide (4.2 mg, 
0.022 mmol, 0.1 eq.) and triethylamine 
(150 µL, 1.10 mmol, 5 eq.) were added 
to a solution of iodo compound 241 (87 mg, 0.22 mmol, 1.0 eq.) and alkyne 234 
(101 mg, 0.176 mmol, 0.8 eq.) in degassed DMF (4 mL). The mixture was heated to 
60 °C for 48 h, after which time the volatile components were removed in vacuo. The 
resulting residue was partly purified by column chromatography (50:49:1 
Et2O:acetone:Et3N to 20:79:1 Et2O:acetone:Et3N to 99:1 acetone:Et3N to 70:20:10 
EtOAc:isopropanol:water) to afford fractions containing the coupled product (identified 
by MS), which were combined and concentrated. 
The crude product was dissolved in MeOH (20 mL) and 3HF.Et3N (800 µL) was added 
and the mixture stirred overnight. The reaction was quenched by addition of sat. 
aqueous NaHCO3 (20 mL) and the mixture concentrated under reduced pressure. The 
aqueous mixture was loaded onto a reverse phase cartridge (1000 mg Extract Clean 
C18-HC, preconditioned with water), washed with water (10 mL), and the product eluted 
with water: MeCN (50:50) (2 × 10 mL). The eluted fractions were combined and 
concentrated. The residue was dissolved in MeCN: water (20:80) and purified by semi-
preparitive HPLC on the Shimadzu system (Phenomenex Luna C18 (250 × 10.00 mm, 
5µ); mobile Phase: A (H2O + 0.05% TFA), B (MeCN + 0.05% TFA); linear gradient: 
20% B at 0 min to 56% B at 13 min, to 95% B at 14 min; to 95% B at 19 min, B to 20% 
B at 20 min, to 20% B at 30 min; flow rate: 2.5 mL.min–1; detection 220 nm. Fractions 
containing product (tR = 13.8 min) were concentrated under a stream of compressed 
air, and lyophilised from a solution of tBuOH in water (20% v/v) affording 245 as a white 
solid (5.3 mg, 2.5% over two steps): δH (500.0 MHz, d4-MeOD): 8.26 (1 H, s, H-8), 6.73 
(2 H, d, J 2.3, H-2’’, H-6’’), 6.69 (1 H, t, J 2.3, H-4''), 6.04 (1 H, d, J 4.4, H-1ʹ), 4.82-4.61 
(6 H, m, OCH2C≡CH, H-5'), 4.54 (1 H, m, H-2'), 4.43 (2 H, s, ArC≡CCH2PEG), 4.39 
(1 H, dd, J 5.2, 5.2, H-3'), 4.29-4.17 (3 H, m, PEGCH2NHCH2Ar, H-4'), 3.83-3,57 (14 H, 
m, PEG-CH2), 3.28 (2 H, t, J 5.1, PEGCH2NHCH2Ar), 3.00 (2 H, t, J 2.4 CH2C≡CH); 
 δC (125.8 MHz, d4-MeOD): 160.7 (C-3'', C-5''), 156.9 (C-6), 150.6 (C-4), 146.6 (C-2), 
141.3 (d, J 4.9, C-8), 134.5 (C-1''), 120.0 (C-5), 110.6 (C-2''), 103.8 (C-4''), 90.0 (C-1ʹ), 
85.9 (ArC≡CCH2PEG), 84.6 (d, J 18.2, C-4ʹ), 83.6 (d, J 163.8, C-5ʹ), 82.9 
(ArC≡CCH2PEG), 79.4 (C≡CH), 77.4 (C≡CH), 75.9 (C-2ʹ), 71.6, 71.5, 71.4, 71.3, 71.1 
274 
 
(PEG-CH2), 73.4 (d, J 4.9, C-3ʹ), 70.6, 66.6 (PEG-CH2), 59.4 (ArC≡CCH2PEG), 56.9 
(OCH2C≡CH), 51.9 (PEGCH2NHCH2Ar), 47.9 (PEGCH2NHCH2Ar); δF (470.5 MHz,  
d4-MeOD): −232.48 (1F, ddd, J 47.8, 47.8, 28.4, CH2F); m/z (ES+) 697 ([M+H]+ 100%); 
HRMS (ES+) calc. for C34H42FN6O9 [M+H]+ 697.2992, found 697.2984.  
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6.3.18. FDEA-PEG-(C≡CH)4 247 
Pd(PPh3)2Cl2 (15.4 mg, 0.022 mmol, 
0.1 eq.), copper(I) iodide (4.2 mg, 
0.022 mmol, 0.1 eq.) and triethylamine 
(150 µL, 1.10 mmol, 5 eq.) were added 
to a solution of iodo compound 241 
(87 mg, 0.22 mmol, 1.0 eq.) and alkyne 
235 (403 mg, 0.440 mmol, 2 eq.) in 
degassed DMF (4 mL). The mixture 
was heated to 60 °C for 48 h, after which time the volatile components were removed 
in vacuo. The residue was partly purified by column chromatography (50:49:1 
Et2O:acetone:Et3N to 99:1 acetone:Et3N) to afford fractions containing the coupled 
product (identified by ESMS), which were combined and concentrated. 
The crude product was dissolved in MeOH (20 mL) and 3HF.Et3N (800 µL) was added 
and the mixture stirred for 18 h. The reaction was quenched by addition of sat. 
aqueous NaHCO3 (20 mL) and the mixture concentrated under reduced pressure. The 
aqueous mixture was loaded onto a reverse phase cartridge (1000 mg Extract Clean 
C18-HC, preconditioned with water), washed with water (10 mL), and the product eluted 
with water: MeCN (50:50) (2 × 10 mL) and MeCN (2 × 10 mL). The water:MeCN and 
MeCN fractions were combined and concentrated. The residue was dissolved in 
MeCN: water (33:66) and purified by semi-preparative HPLC on the Shimadzu system 
(Phenomenex Luna C18 (250 × 10.00 mm, 5µ); mobile Phase: A (H2O + 0.05% TFA), B 
(MeCN + 0.05% TFA); linear gradient: 33% B at 0 min to 70% B at 13 min, to 95% B at 
14 min; to 95% B at 95 min, B to 33% B at 20 min, to 33% B at 30 min; flow rate: 2.5 
mL.min–1; detection 220 nm. Fractions containing product (tR = 13.3 min) were 
concentrated under a stream of compressed air, and lyophilised from a solution of 
tBuOH in water (20% v/v) affording 247 as a white solid (5.4 mg, 2.3% over two steps): 
δH (500.1 MHz, d4-MeOD): 8.23 (1 H, s, H-8), 6.95–6.57 (6 H, m, H-2’’, H-4''), 6.02 
(1 H, d, J 4.2, H-1ʹ), 4.80-4.62 (14 H, m, OCH2C≡CH, PEGCH2N(CH2Ar)2, H-5'), 4.53 
(1 H, dd, J 4.6, 4.6 H-2'), 4.39-4.37 (3 H, m, ArC≡CCH2PEG, H-3'), 4.26-4.11 (1 H, m, 
H-4'), 3.76-3.62 (14 H, m, PEG-CH2), 3.31 (2 H, under solvent peak, 
PEGCH2N(CH2Ar)2), 2.99 (4 H, t, J 2.3 CH2C≡CH); δF (470.3 MHz, d4-MeOD): −232.61 
(1 F, ddd, J 47.6, 47.6, 27.9 Hz), CH2F); m/z (ES+) calc. isotope pattern for 
C47H52FN6O11 [M+H]+ 895.4 (100), 896.4 (53), 897.4 (16), 898.4 (2); found 895.4 (100), 
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896.4 (52), 897.4 (13), 898.4 (2); HRMS (ES+) calc. for C47H52FN6O11 [M+H]+ 895.3673, 
found 895.3660.  
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6.3.19. ClDEA-PEG-(RGD)2 224 
 
A suspension of ClDEA-PEG-(C≡CH)2 219 (0.72 mg, 1.0 µmol, 1 eq.) and 
c(RGDfK[N3]) 199 (1.60 mg, 2.53 µmol, 2.5 eq.) in water (6.05 mL) was sonicated until 
homogenous. To this solution, aqueous sodium ascorbate (507 µL, 20 mM, 10 eq.), 
followed by CuSO4-TBTA complex (203 µL, 10 mM in 55:45 DMSO: water) were 
added, and the reaction allowed to proceed for 75 min at rt, when HPLC analysis 
showed reaction to be complete. The reaction mixture was loaded onto a reverse 
phase cartridge (1000 mg Extract Clean C18-HC, preconditioned with water), washed 
with water (5 mL), and the product eluted with water: MeCN (50:50) (2 × 5 mL). The 
eluted fractions were combined and solvents removed under reduced pressure. The 
residue was dissolved in MeCN: water (20:80) and purified by semi-preparative HPLC 
on the Shimadzu system (Phenomenex Kingsorb C18 (250 × 10.00 mm, 5µ); mobile 
Phase: A (H2O + 0.05% TFA), B (MeCN + 0.05% TFA); linear gradient: 20% B at 0 min 
to 70% B at 20 min, to 95% B at 21 min; to 95% B at 25 min, B to 5% B at 26 min, to 
5% B at 35 min; flow rate: 2.5 mL.min–1; detection 220 nm, Fractions containing 
product (tR = 10.4 min) were concentrated under a stream of compressed air, and 
lyophilised from a solution of tBuOH in water (20% v/v) affording 224 as a white solid 
(1.8 mg, 78%): δH (500.1 MHz, D2O): 8.23 (1 H, s, H-8), 7.88 (2 H, s, triazole-H),  
7.02–6.92 (10 H, m, D-Phe ArH), 6.63 (2 H, br s, H-2ʹ', H-6ʹ'), 6.57 (1 H, br s, H-4ʹ'), 
5.93 (1 H, d, J 4.7, H-1ʹ), 5.15 (4 H, br s, ArO-CH2-triazole), 4.68–4.65 (3 H, m, Asp α-
H, H-2'), 4.47–4.40 (3 H, m, D-Phe α-H, H-3'), 4.35–4.31 (5 H, m, H-4', Arg α-H, 
AdoC≡CCH2O), 4.28–4.20 (4 H, m, Lys ε-CH2), 4.18–4.13 (4 H, m, CH2NHCH2Ar, Gly 
α-Ha), 3.72–3.43 (16 H, m, Lys α-H, PEG CH2), 3.44 (2 H, d, J 14.7, Gly α-Hb),  
3.18–3.09 (6 H, m, CH2NHCH2Ar, Arg δ-CH2), 2.96 (2 H, dd, J 13.0, 5.8, D-Phe β-Ha), 
2.78 (2 H, dd, J 13.0, 11.0, D-Phe β-Hb), 2.69–2.61 (2 H, m, Asp β-Ha), 2.56–2.47 (2 
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H, m, Asp β-Hb), 1.84–1.77 (2 H, m, Arg β-Ha), 1.67–1.57 (6 H, m, Lys δ-CH2,  
Arg β-Hb), 1.50–1.37 (8 H, m, Lys β-CH2, Arg δ-Hb), 0.69–0.57 (4 H, m, Lys γ-CH2); 
m/z (MALDI) calc. for C88H12035ClN28O23 [M+H]+: 1971.9, found 1971.9.  
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6.3.20. ClDEA-PEG-(RGD)4 225 
 
Fresh aqueous sodium ascorbate (291 µL, 20 mM, 10 eq.), followed by CuSO4-TBTA 
complex (117 µL, 10 mM in 55:45 DMSO: water) were added to a solution of 
ClDEA-PEG-(C≡CH)4 220 (0.67 mg, 0.58 µmol, 1 eq.) in DMSO: water (75:25, 1.5 mL) 
and a solution of c(RGDfK[N3]) 119 (1.83 mg, 2.91 µmol, 5 eq.) in DMSO: water (75:25, 
1.5 mL). The reaction was allowed to proceed for 70 min at rt, when HPLC analysis 
showed reaction to be complete. The reaction mixture was diluted with water (4 mL) 
and loaded onto a reverse phase cartridge (1000 mg Extract Clean C18-HC, 
preconditioned with water), washed with water (10 mL), and the product eluted with 
water: MeCN (50:50) (2 × 5 mL) and water: MeCN (25:75) (1 × 5 mL). The eluted 
fractions were combined and excess MeCN removed under a stream of compressed 
air to give a cloudy, aqueous solution. MeCN (200 µL) was added until the solution 
became clear and this mixture purified by semi-preparative HPLC on the Shimadzu 
system (Phenomenex Kingsorb C18 (250 × 10.00 mm, 5µ); mobile Phase: A (H2O + 
0.05% TFA), B (MeCN + 0.05% TFA); linear gradient: 5% B to 50% B at 10 min, to 
95% B at 11 min; to 95% B at 14 min, to 5% B at 15 min, to 5% B at 25 min; flow rate: 
2.5 mL.min–1; detection 220 nm, tR = 12.1–12.6 min). Fractions containing product  
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(tR = 10.2 min) were concentrated under a stream of compressed air, and lyophilised 
from a solution of tBuOH in water (20% v/v) affording 225 as a white solid (1.4 mg, 
70%): δH (500.1 MHz, 10% d3-MeCN in D2O): 8.44 (1 H, s, H-8), 8.13 (4 H, s, 
triazole-H), 7.26–7.15 (20 H, m, D-Phe ArH), 6.82 (6 H, br s, H-2ʹ', H-4ʹ', H-6ʹ'), 6.06 
(1 H, d, J 4.6, H-1ʹ), 5.31 (8 H, br s, ArO-CH2-triazole), 4.85 (4 H, t, J 7.4, Asp α-H), 
4.79 (1 H, H-2', overlapped by HOD, observed in 2D), 4.77 (4 H, dd, J 10.0, 6.1, D-Phe 
α-H), 4.53 (1 H, t, J 5.1, H-3'), 4.47–4.38 (19 H, m, H-4', Lys ε-CH2, Arg α-H, 
CH2N(CH2Ar)2, AdoC≡CCH2O), 4.32 (4 H, d, J 15.0, Gly α-Ha), 4.02 (1 H, dd, J 12.2, 
3.6, H-5'a), 3.98 (1 H, dd, J 12.2, 4.9, H-5'b), 3.94 (4 H, dd, J 11.0, 4.0 Lys α-H),  
3.82–3.66 (14 H, m, PEG CH2), 3.60 (4 H, d, J 15.0, Gly α-Hb), 3.33–3.25 (10 H, m, 
CH2N(CH2Ar)2, Arg δ-CH2), 3.09 (4 H, dd, J 13.2, 6.1, D-Phe β-Ha), 2.98 (4 H, dd, 
J 13.2, 10.0, D-Phe β-Hb), 2.93 (4 H, dd, J 16.6, 7.4, Asp β-Ha), 2.77 (4 H, dd, J 16.6, 
7.4, Asp β-Hb), 2.01–1.94 (4 H, m, Arg β-Ha), 1.85–1.72 (16 H, m, Lys β-CH2,  
Arg β-Hb, Arg γ-Ha), 1.66–1.56 (12 H, m, Lys δ-CH2, Arg γ-Hb), 0.97–0.92 (8 H, m, Lys 
γ-CH2); m/z (MALDI) calc. for C155H20835ClN50O39 [M+H]+: 3428.6, found 3428.5.  
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6.3.21. FDEA-PEG-(RGD)2 248 
 
Fresh aqueous sodium ascorbate (541 µL, 20mM, 10 eq.), followed by CuSO4-TBTA 
complex (216 µL, 10 mM in 55:45 DMSO: water) were added to a solution of 
FDEA-PEG-(C≡CH)2 245 (1.0 mg, 1.08 µmol, 1 eq.) and c(RGDfK[N3]) 199 (1.7 mg, 
7.70 µmol, 2.5 eq.) in DMSO: water (50:50, 6.5 mL). The reaction was allowed to 
proceed for 70 min at rt, when HPLC analysis showed reaction to be complete. The 
reaction mixture was loaded onto a reverse phase cartridge (1000 mg Extract Clean 
C18-HC, preconditioned with water), washed with water (10 mL), and the product eluted 
with water: MeCN (50:50) (2 × 10 mL) and MeCN (1 × 10 mL). The water: MeCN 
fractions were dried under a stream of compressed air. The residue was suspended in 
MeCN:H2O (20:80) and this mixture purified by semi-preparative HPLC on the 
Shimadzu system (Phenomenex Kingsorb C18 (250 × 10.00 mm, 5µ); mobile Phase: A 
(H2O + 0.05% TFA), B (MeCN + 0.05% TFA); linear gradient: 20% B to 42% B at 8 min, 
42% B to 95% B at 9 min; 95% B at 14 min, 95% B to 20% B at 15 min, 20% B at 25 
min; flow rate: 2.5 mL.min–1; detection 220 nm. Fractions containing product (tR = 10.0 
min) were concentrated under a stream of compressed air, and lyophilised from a 
solution of tBuOH in water (20% v/v) affording 248 as a white solid (0.67 mg, 27%): m/z 
(MALDI) calc. for C88H120FN23O23 [M+H]+: 1955.9, found 1955.9.  
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6.3.22. FDEA-PEG-(RGD)4 249 
 
Fresh aqueous sodium ascorbate (262 µL, 20mM, 10 eq.), followed by CuSO4-TBTA 
complex (145 µL, 10 mM in 55:45 DMSO:water) were added to a solution of 
FDEA-PEG-(C≡CH)4 247 (0.75 mg, 0.72 µmol, 1 eq.) and c(RGDfK[N3]) 199 (2.28 mg, 
3.62 µmol, 5 eq.) in DMSO: water (50:50, 4.3 mL). The reaction was allowed to 
proceed for 90 min at rt, when HPLC analysis showed reaction to be complete. The 
reaction mixture was loaded onto a reverse phase cartridge (1000 mg Extract Clean 
C18-HC, preconditioned with water), washed with water (10 mL), and the product eluted 
with water: MeCN (50:50) (2 × 10 mL) and MeCN (1 × 10 mL). The water: MeCN and 
MeCN fractions were dried a stream of compressed air. The residue was suspended in 
MeCN:H2O (20:80) and this mixture purified by semi-preparative HPLC on the 
Shimadzu system (Phenomenex Kingsorb C18 (250 × 10.00 mm, 5µ); mobile Phase: A 
(H2O + 0.05% TFA), B (MeCN + 0.05% TFA); linear gradient: 20% B to 42% B at 18 
min, 42% B to 95% B at 19 min; 95% B at 24 min, 95% B to 20% B at 25 min, 20% B at 
35 min; flow rate: 2.5 mL.min–1; detection 220 nm. Fractions containing product  
(tR = 13.3 min) were concentrated under a stream of compressed air, and lyophilised 
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from a solution of tBuOH in water (20% v/v) affording 249 as a white solid (0.66 mg, 
27%): C155H208FN50O39 [M+H]+: 3412.6, found 3412.6.  
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6.4. Compound preparation for Chapter 4 
6.4.1. 2ʹ,3ʹ-O-Isopropylideneadenosine 285 
2,2-Dimethoxypropane (45.8 mL, 374 mmol, 10 eq.) and perchloric 
acid (70% in water, 3.54 mL, 24.7 mmol, 0.67 eq.) were slowly 
added to a suspension of adenosine 188 (10.0 g, 37.4 mmol, 
1.0 eq.) in acetone (200 mL) at 0 °C. The mixture was allowed to 
slowly warm to rt, and stirred for a further 18 h. The reaction was 
quenched by addition of aqueous ammonia (30%, 20 mL) and concentrated. The 
residue was taken up into DCM (150 mL) and water water (100 mL) was added. The 
phases were separated and the aqueous phase washed with EtOAc (3 × 100 mL) 
before the organic phases were combined, dried over Na2SO4, and concentrated to a 
white powder. The powder was suspended in Et2O (200 mL), and filtered before being 
washed with further Et2O (3 × 100 mL) to give 285 as a white powder (9.16 g, 80%.). 
Rf = 0.21 (95:5 DCM:MeOH);  [α]D20 -65.3 (c 0.42, DMSO); mp 218-220 °C (DCM); 
vmax 3721, 3110, 1687, 1605, 1208, 1085, 715 cm−1; δH (300.0 MHz, d6-DMSO): 8.34 
(1 H, s, H-8), 8.15 (1 H, s, H-2), 7.36 (2 H, br s, NH2), 6.12 (1 H, d, J 3.1, H-1ʹ), 5.34 
(1 H, dd, J 6.2, 3.1, H-2ʹ), 5.25 (1 H, dd, J 6.0, 5.1, C-5ʹ OH), 4.69 (1 H, dd, J 6.2, 2.5, 
H-3ʹ), 4.23-4.19 (1 H, m, H-4ʹ), 3.60-3.47 (1 H, m, H-5ʹa, H-5ʹb), 1.54 (3 H, s, C(CH3)2), 
1.32 (3 H, s, C(CH3)2); δC (125.8 MHz, CDCl3): 156.2 (C-6), 152.7 (C-2), 148.8 (C-4), 
139.7 (C-8), 119.1 (C-5), 113.1 (C(CH3)2), 89.6 (C-1ʹ), 86.4 (C-4ʹ), 83.2 (C-2ʹ), 81.4 
(C-3ʹ), 61.6 (C-5ʹ), 27.1 (C(CH3)2), 25.2 (C(CH3)2); m/z (ES+) 308 ([M+H]+,100%), 330 
([M+Na]+, 29). 
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6.4.2. N-Benzoyl-2ʹ,3ʹ-O-isopropylideneadenosine 280 
A suspension of 2ʹ,3ʹ-O-isopropylideneadenosine 285 
(1.53 g, 4.98 mmol, 1.0 eq.) in dry pyridine (5 mL) was 
concentrated to dryness in vacuo, before being 
re-suspended in dry pyridine (20 mL). To this suspension, 
TMSCl (3.20 mL, 15.2 mmol, 3.0 eq.) was slowly added and 
the mixture stirred for 30 min and BzCl (0.75 mL, 6.4 mmol, 
1.3 eq.) was added and the mixture stirred for a further 3 h. The reaction was cooled to 
0 °C and quenched by the careful addition of water (5 mL). Aqueous ammonia (35%, 
10 mL) was added, and the mixture stirred for 30 min before being concentrated under 
reduced pressure. The residue was purified by column chromatography (DCM to 95:5 
DCM:MeOH), and fractions containing product were combined and concentrated to 
dryness, before the residue was recrystallised from MeOH to give the product 280 as a 
white foamy solid (1.48 g, 72%): Rf = 0.17 (95:5 DCM:MeOH);  [α]D20 -93.5 (c 1.09, 
CHCl3); mp 135–138 °C (MeOH); vmax 3348, 1708, 1605, 1591, 1462, 1327, 1256, 
1211, 1056, 702 cm−1; δH (500.1 MHz, CDCl3): 9.08 (1 H, br s, NH), 8.79 (1 H, s, H-2), 
8.07 (1 H, s, H-8), 8.03–8.01 (2 H, m, H-2''), 7.64-7.60 (1 H, m, H-4''), 7.55-7.52 (2 H, 
m, H-3''), 5.94 (1 H, d, J 5.1, H-1′), 5.79-5.76 (1 H, m, 5'-OH), 5.23 (1 H, dd, J 5.7, 5.1, 
H-2′), 5.12 (1 H, dd, J 5.7, 1.4, H-3′), 4.56-4.55 (1 H, m, H-4'), 4.01-3.98 (1 H, m, H-5'a), 
3.84-3.79 (1 H, m, H-5'b), 1.66 (3 H, s, C(CH3)2), 1.39 (3 H, s, C(CH3)2);  
δC (125.8 MHz, CDCl3): 164.9 (C=O), 152.7 (C-4), 150.5 (C-2), 149.8 (C-6), 142.6 
(C-8), 133.3 (C-4''), 133.1 (C-1''), 129.1 (C-2''), 128.2 (C-3''), 122.4 (C-5'), 114.4 
(C(CH3)2), 94.6 (C-1′), 87.1 (C-4′), 83.8 (C-2′), 81.9 (C-3′), 63.2 (C-5′), 27.6, 25.3 
(C(CH3)2); m/z (ES+) 845 ([2M+Na]+, 100%), 434 ([M+Na]+, 64), 412 ([M+H]+, 64). Data 
are in agreement with the literature.12 
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6.4.1. N-Benzoyl-5'-deoxy-2',3'-O-isopropylidene-5',5'-(N',N''-
 diphenylethylenediamino)adenosine 282 
N,N'-dicyclohexylcarbodiimide (150 mg, 0.729 mmol, 3 eq.) 
and dichloroacetic acid (10 µL, 0.122, 0.5 eq.) were added 
to a solution of alcohol 280 (100 mg, 0.243 mmol, 1.0 eq.) 
in dry DMSO (1 mL). The mixture was stirred at rt for 
90 min, before oxalic acid solution (62 mg in 0.2 mL 
MeOH) was added, the mixture stirred for a further 30 min 
before being filtered and the solids washed with cold MeOH. To the filtrate, 
N,N’-diphenylethylenediamine (59 mg, 0.280 mmol, 1.15 eq.) was added, and the 
mixture stirred for 30 min, before being cooled to 4 °C, upon which a white solid 
precipitated from the solution. The solids were collected by filtration, further purified by 
column chromatography (DCM to 95:5 DCM:MeOH), followed by a second round of 
column chromatography (DCM to 90:0 DCM:MeOH), to give the product 282 as a white 
solid (40 mg, 27%): Rf = 0.19 (95:5 DCM:MeOH);  [α]D20 +23.0 (c 1.13, CHCl3); 
vmax 3335, 1709, 1599, 1501, 1076, 749, 512 cm−1; mp 132–135 °C (decomp.); 
δH (500.1 MHz, d6-acetone): 8.60 (1 H, s, H-8), 8.19 (1 H, s, H-2), 8.15-8.13 (2 H, m, 
H-2''), 7.67-7.64 (1 H, m, H-4''), 7.59-7.55 (2 H, m, H-3''), 7.16-7.09 (4 H, m, H-3'''), 
6.88-6.87 (2 H, m, H-2a'''), 6.73-6.67 (4 H, m, H-2b''', H-4'''), 6.29 (1 H, d, J 2.2, H-1′), 
5.87 (1 H, d, J 3.5, H-5′), 5.45 (1 H, dd, J 6.4, 2.2, H-2′), 5.36 (1 H, dd, J 6.4, 4.6, H-3′), 
4.63 (1 H, dd, J 4.6, 3.5, H-4'), 3.76-3.72 (1 H, m, CH2a), 3.67-3.63 (1 H, m, CH2b), 
3.60-3.57 (2 H, m, CH2c,d) 1.43 (3 H, s, C(CH3)2), 1.31 (3 H, s, 
C(CH3)2); δC (125.8 MHz, d6-acetone): 165.7 (C=O), 152.7 (C-4), 152.6 (C-2), 151.1 
(C-6), 147.9, 147.8 (C-1''’), 143.6 (C-8), 135.0 (C-1''), 133.2 (C-4''), 129.8, 129.7 
(C-3'’'), 129.4 (C-3''), 129.2 (C-2''), 122.6 (C-5’), 118.1, 118.5 (C-4’''), 114.6, 114.2 
(C-2’''), 113.2 (C(CH3)2), 89.2 (C-1′), 80.1 (C-4′), 84.5 (C-2′), 81.4 (C-3′), 74.3 (C-5′), 
48.2, 47.3 (CH2), 27.6, 25.8 (C(CH3)2); m/z (ES+) 626 ([M+Na]+, 100%), 604 ([M+H]+, 
41); Data in agreement with literature values.12 
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6.4.2. N,N-Dibenzoyl-2ʹ,3ʹ-O-isopropylideneadenosine 287 
TMSCl (2.50 mL, 19.7 mmol, 3.0 eq.) was slowly added to a 
suspension of 2ʹ,3ʹ-O-isopropylideneadenosine 285 (2.00 g, 
6.50 mmol, 1.0 eq.) in dry pyridine (20 mL) at 0 °C, and the 
mixture allowed to warm to rt while stirring for 1.5 h. The 
mixture was again cooled to 0 °C and BzCl (1.66 mL, 
14.3 mmol, 2.2 eq.) added and the mixture allowed to warm 
to rt while stirring for 2.5 h. The reaction was cooled to 0 °C 
and quenched by the careful addition of water (5 mL). The reaction mixture was diluted 
with CHCl3 (50 mL) and water (50 mL) and the phases separated. The organic phase 
was washed with H2SO4 (1 M, 50 mL), sat. aqueous NaHCO3 (50 mL), sat. aqueous 
CuSO4 (50 mL), H2SO4 (1 M, 50 mL) and water (50 mL). The organic phase was dried 
over Na2SO4 and concentrated to a white powder. The residue was purified by column 
chromatography (DCM to 99:1 DCM:MeOH) to give the product 287 as a white foamy 
solid (3.32 g, 99%): Rf = 0.07 (99:1 DCM:MeOH);  [α]D20 -70.9 (c 0.60, CHCl3); 
 vmax 2988, 1699, 1599, 1578, 1236, 1074, 829, 694, 640 cm−1; mp 129-133 °C; 
δH (500.1 MHz, CDCl3): 8.63 (1 H, s, H-2), 8.24 (1 H, s, H-8), 7.86-7.83 (4 H, m, H-2''), 
7.51-7.48 (2 H, m, H-4''), 7.38-7.34 (4 H, m, H-3''), 5.94 (1 H, d, J 4.5, H-1′), 5.21 (1 H, 
dd, J 6.0, 4.5, H-2′), 5.09 (1 H, dd, J 6.0, 1.4, H-3′), 4.57-4.53 (1 H, m, H-4'), 3.97 (1 H, 
dd, J 12.7, 1.7, H-5'a), 3.79 (1 H, dd, J 12.7, 2.1, H-5'b), 1.65 (3 H, s, C(CH3)2), 1.38 
(3 H, s, C(CH3)2); δC (125.8 MHz, CDCl3): 172.2 (C=O), 152.6 (C-4), 152.0 (C-2), 151.7 
(C-6), 144.5 (C-8), 133.9 (C-1''), 133.3 (C-4''), 129.6 (C-2''), 129.0 (C-3'', C-5), 114.4 
(C(CH3)2), 94.3 (C-1′), 86.6 (C-4′), 83.4 (C-2′), 81.7 (C-3′), 63.3 (C-5′), 27.7, 25.3 
(C(CH3)2); m/z (ES+) 554 ([M+K]+, 100%), 538 ([M+Na]+, 59). Data are in agreement 
with the literature.13 
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6.4.3. N,N-Dibenzoyl-2ʹ,3ʹ-O-isopropylideneadenosine-5ʹ-aldehyde 283 
Dichloroacetic acid (120 µL, 1.45 mmol, 0.5 eq.) was added 
dropwise to a cooled solution of 287 (1.50 g, 2.91 mmol, 
1.0 eq.) and EDCI.HCl (1.34 g, 6.98 mmol, 3.4 eq.) in DMSO 
(8 mL). The reaction mixture was stirred at room temperature 
for 3 h, before being quenched by addition of water (15 mL) 
and EtOAc (15 mL) and the mixture stirred vigorously for 15 
min. The resultant phases were separated and the aqueous 
phase extracted with EtOAc (2 × 15 mL) and the combined organic phases washed 
with brine (20 mL). The organic phase was dried over Na2SO4 and concentrated to a 
colourless oil. The residue was co-evaporated with toluene (5 × 25 mL) to give the 
product 283 as a white foam (1.49 g, quant), which was used directly without further 
purification. Rf = 0.65 (95:5 DCM:MeOH);  [α]D20 -11.5 (c 1.11, CHCl3); mp 110–113 °C 
(DCM); vmax 2358, 1697, 1599, 1578, 1449, 1236, 1072, 694, 640 cm−1; δH (500.1 MHz, 
CDCl3): 9.35 (1 H, s, H-5'), 8.53 (1 H, s, H-2), 8.17 (1 H, s, H-8), 7.87-7.83 (4 H, m, 
H-2''), 7.51-7.48 (2 H, m, H-4''), 7.38-7.34 (4 H, m, H-3''), 6.27 (1 H, br s, H-1′), 5.52 
(1 H, dd, J 6.2, 1.9, H-3′), 5.34 (1 H, d, J 6.2, H-2′), 4.71 (1 H, d, J 1.9, H-4'), 1.61 (3 H, 
s, C(CH3)2), 1.41 (3 H, s, C(CH3)2); δC (125.8 MHz, CDCl3): 199.4 (C-5′), 172.3 (C=O), 
152.5 (C-4), 152.3 (C-2), 151.6 (C-6), 144.3 (C-8), 134.0 (C-1''), 133.3 (C-4''), 129.6 
(C-2''), 128.9 (C-3''), 125.4 (C-5), 114.4 (C(CH3)2), 93.2 (C-4′), 92.5 (C-1′), 84.7 (C-2′), 
83.4 (C-3′), 26.7, 25.1 (C(CH3)2); m/z (ES+) 536 ([M+Na]+, 42%) ; HRMS (ES+) calc. for 
C27H23N5O6Na [M+Na]+ 536.1541, found 536.1534. Data are in agreement with the 
literature.14 
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6.4.4. N,N-Dibenzoyl-5ʹ,5ʹ-difluoro-5ʹ-deoxy-2ʹ,3ʹ-O-
 isopropylideneadenosine 284 
Deoxofluor® (50% in THF, 4.5 mL, 10.6 mmol, 4.0 eq.) was 
slowly added to a solution of aldehyde 283 (1.36 g, 2.64 
mmol, 1.0 eq.) at −78 °C in a Teflon flask, and the mixture 
stirred while warming to rt for 16 h. The reaction was 
quenched by careful dropwise addition of sat. aqueous 
NaHCO3 (50 mL) and the mixture diluted with EtOAc (80 mL). 
The phases were separated and the aqueous phase 
extracted with EtOAc (3 × 30 mL) before the combined organic phases were washed 
with brine (50 mL). The organic phase was dried over MgSO4 and concentrated. The 
residue was purified by column chromatography (50:50 cyclohexane:EtOAc) to give the 
crude product 284, which was further purified by column chromatography (80:20 
cyclohexane:EtOAc to 70:30 cyclohexane:EtOAc) to give the product as a yellow foam 
(138 mg, 10%): Rf = 0.16 (70:30 cyclohexane:EtOAc);  [α]D20 -20.0 (c 0.21, CHCl3); mp 
101–105 °C (DCM); vmax 2988, 1699, 1599, 1559, 1236, 1211, 694 cm−1; δH (300.6 
MHz, CDCl3): 8.67 (1 H, s, H-2), 8.16 (1 H, s, H-8), 7.87-7.83 (4 H, m, H-2''), 7.52-7.45 
(2 H, m, H-4''), 7.39-7.32 (4 H, m, H-3''), 6.28 (1 H, br s, H-1′), 5.97 (1 H, td, J 55.1, 4.5, 
H-5′), 5.39 (1 H, dd, J 6.1, 2.0, H-2′), 5.27 (1 H, dd, J 6.1, 2.9 H-3'), 4.47 (1 H, dddd. J 
12.6, 10.1, 4.5, 2.9, H-4′), 1.64 (3 H, s, C(CH3)2), 1.41 (3 H, s, C(CH3)2); δC (125.8 MHz, 
CDCl3): 172.3 (C=O), 152.5 (C-2), 152.4 (C-6), 152.3 (C-4), 143.6 (C-8), 134.1 (C-1''), 
133.2 (C-4''), 129.6 (C-2''), 128.9 (C-3''), 127.9 (C-5), 115.3 (C(CH3)2), 113.7 (t, J 244.3, 
C-5'), 91.6 (C-1′), 85.9 (t, J 26.2, C-4′), 84.3 (C-2′), 80.0 (t, J 3.7, C-3'), 27.1, 25.3 
(C(CH3)2); δF (282.3 MHz, CDCl3): –130.60 (1 F, ddd, J 299.1, 55.1, 12.6, CHF2), –
126.44 (1 F, ddd, J 299.1, 55.1, 10.1, CHF2); m/z (ES+) 1093 ([2M+Na]+, 52%), 558 
([M+Na]+, 100), 536 ([M+H]+, 15); HRMS (ES+) calc. for C27H23N5O5F2Na [M+Na]+ 
558.1565, found 558.1549. All data are in agreement with the literature,14 except for the 
19F NMR chemical shifts. The discrepancy is discussed in Section 4.3.2. 
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6.4.5. 5ʹ,5ʹ-Difluoro-5ʹ-deoxy-2ʹ,3ʹ-O-isopropylideneadenosine 288 
In a heavy walled tube, a solution of 284 (57 mg, 0.11 mmol, 
1.0 eq.) in MeOH (5 mL) was cooled to 0 °C. Ammonia gas was 
bubbled through the solution for 1 h, before the tube was sealed 
and heated to 60 °C for 19 h. The vessel was cooled to rt and 
carefully opened, before the solution was degassed by bubbling 
argon through the solution for 2 h before being concentrated. The residue was purified 
by column chromatography (DCM to 99:2 DCM:MeOH to 97:3 DCM:MeOH) to give the 
product 288 as a white foam (35 mg, 45%): Rf = 0.56 (90:10 DCM:MeOH); 
mp 160-161 °C (DCM); δH (500.1 MHz, CDCl3): 8.34 (1 H, s, H-2), 7.87 (1 H, s, H-8), 
6.19 (1 H, br s, H-1′), 6.01 (2 H, br s, NH2), 6.00 (1 H, td, J 55.5, 6.0, H-5′), 5.43-5.41 
(1 H, m, H-2′), 5.36-5.24 (1 H, m, H-3'), 4.44-4.39 (1 H, m, H-4′), 1.63 (3 H, s, C(CH3)2), 
1.41 (3 H, s, C(CH3)2); δC (125.8 MHz, CDCl3): 155.9 (C-6), 155.3 (C-2), 149.2 (C-4), 
139.8 (C-8), 120.4 (C-5), 114.4 (t, J 124.5, C-5'), 112.0 (C(CH3)2), 91.6 (C-1′), 86.6 (dd, 
J 28.8, 24.4, C-4′), 84.5 (C-2′), 80.7 (t, J 5.7, C-3'), 27.1, 25.3 (C(CH3)2); 
δF (470.4 MHz, CDCl3): –129.62 (1 F, ddd, J 299.5, 55.5, 9.7, CHF2), –125.32 (1 F, 
ddd, J 299.5, 55.5, 10.8, CHF2); m/z (ES+) 350 ([M+Na]+, 35%), 328 ([M+H]+, 100); 
HRMS (ES+) calc. for C13H16N5O3F2 [M+H]+ 328.1216, found 328.1214. Data are in 
agreement with the literature.14 
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6.4.6. 5ʹ,5ʹ-Difluoro-5'-deoxyadenosine (F2DA) 276 
A solution of 288 (16 mg, 0.048 mmol) in a mixture of TFA:water 
(9:1 v/v, 1.0 mL) at 0 °C was stirred for 3 h whilst warming to rt. The 
volatile components were removed, and the residue co-evaporated 
with toluene (3 × 10 mL). The mixture was taken up into MeOH 
(1 mL) and neutralised by addition of NaOH (2 M, 2 drops) before being concentrated 
in vacuo. The residue was purified by column chromatography (90:10 CHCl3:MeOH) to 
give the product 276 as a white powder (14 mg, 86%): Rf = 0.18 (90:10 DCM:MeOH); 
mp 189–190 °C (CHCl3); δH (500.1 MHz, d6-DMSO): 8.32 (1 H, s, H-8), 8.16 (1 H, s, 
H-2), 7.35 (2 H, br s, NH2), 6.31 (1 H, td, J 55.0, 4.8, H-5′), 5.98 (1 H, d, J 6.2, H-1′), 
5.71 (1 H, d, J 6.3, 2'-OH), 5.67 (1 H, d, J 5.1, 3'-OH), 4.77 (1 H, ddd, J 6.3, 6.2, 5.9, 
H-2′), 4.38-4.36 (1 H, m, H-3'), 4.10-4.04 (1 H, m, H-4′); δC (125.8 MHz, d6-DMSO): 
156.1 (C-6), 152.8 (C-2), 149.6 (C-4), 139.5 (C-8), 119.1 (C-5), 113.8 (C-5', observed 
in 2D), 87.6 (C-1′), 82.2 (C-4′, observed in 2D), 72.5 (C-2′), 69.3 (C-3'); δF (470.5 MHz, 
d6-DMSO): –127.98 (1 F, ddd, J 291.1, 55.0, 9.9, CHF2), –126.97 (1 F, ddd, J 299.5, 
55.0, 12.8, CHF2); m/z (ES+) 310 ([M+Na]+ 5%), 288 ([M+H]+ 100); HRMS (ES+) calc. 
for C10H12N5O3F2 [M+H]+ 288.0903, found 288.0896. Data are in agreement with the 
literature.14 
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6.5. Compound preparation for Chapter 5 
6.5.1. 5ʹ-Fluoro-5ʹ-deoxy-2ʹ,3ʹ-O-isopropylideneadenosine 325 
TsF (0.851 g, 4.88 mmol, 1.5 eq.) and TBAF (1 M in THF, 9.77 mL, 
9.77 mmol, 3.0 eq.) were added to a solution of acetonide 285 
(1.00 g, 3.26 mmol, 1.0 eq.) in THF (100 mL). The mixture was 
heated to 60 °C for 18 h, and cooled to rt. The volatile components 
were removed and the orange residue was purified by column 
chromatography (50:50 petroleum ether:acetone) to give the product 325 as a white 
powder (790 mg, 78%): Rf = 0.21 (50:50 petroleum ether:acetone);  [α]D20 -60.7 (c 0.42, 
DMSO); mp 144-146 °C (petroleum ether:acetone); vmax 3301, 3149, 1681, 1604, 1076, 
850, 721 cm−1; δH (500.1 MHz, CDCl3): 8.36 (1 H, s, H-2), 7.94 (1 H, s, H-8), 6.20 (1 H, 
d, J 2.2, H-1ʹ), 5.72 (2 H, br s, NH2), 5.38-5.36 (1 H, m, H-2ʹ), 5.10 (1 H, dd, J 6.3, 3.1, 
H-3ʹ), 4.73-4.48 (3 H, m, H-5ʹa, H-5ʹb, H-4'), 1.64 (3 H, s, C(CH3)2), 1.40 (3 H, s, 
C(CH3)2); δC (125.8 MHz, CDCl3): 155.6 (C-6), 153.4 (C-2), 149.6 (C-4), 139.4 (C-8), 
120.3 (C-5), 114.8 (C(CH3)2), 90.1 (C-1ʹ), 85.7 (C-4ʹ, d, J 19.3), 84.7 (C-2ʹ), 83.0 (C-5ʹ, 
d, J, 171.9), 80.9 (C-3ʹ, d, J, 6.7), 27.3 (C(CH3)2), 25.5 (C(CH3)2); δF (376.4 MHz, 
CDCl3): −230.13 (ddd, J 46.9, 46.9, 27.9, CH2F); m/z (ES+) 332 ([M+Na]+, 27%),310 
([M+H]+, 37); HRMS (ES+) calc. for C13H17N5O3F [M+H]+ 310.10, found 310.1303. 
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6.5.2. 5ʹ-Fluoro-5ʹ-deoxyadenosine 22 
 A solution of 325 (710 mg, 0.120 mmol) in a mixture of TFA:water 
(9:1 v/v, 5.0 mL) at 0 °C was stirred for 18 h whilst warming to rt. 
The volatile components were removed, and the residue 
co-evaporated with EtOH (3 × 10 mL) and Et2O (10 mL) to give a 
syrup. The residue was neutralised with NaOH (2 M) and concentrated before being 
purified by column chromatography (90:10 DCM:MeOH) to give the crude product. The 
crude product was recrystallised from water, before being freeze dried to yield 22 a 
white powder (230 mg, 37%): Rf = 0.27 (90:10 DCM:MeOH); [α]D20 -61.1 (c 0.80, 
DMSO); mp 164-168 °C (water); vmax 3310, 3158, 1679, 1652, 1209, 723 cm−1;.  
δH (500.1 MHz, D2O): 8.27 (1 H, s, H-2), 8.19 (1 H, s, H-8), 6.09 (1 H, d, J 5.0, H-1ʹ), 
4.81-4.68 (1 H, m, H-5ʹa, under D2O peak), 4.71-4.68 (2 H, m, H-5ʹb, H-3ʹ), 4.50 (1 H, 
dd, J 5.0, 5.0, H-2ʹ), 4.36 (1 H, ddt, J 30.3, 5.1, 2.8, H-4'); δC (125.8 MHz, D2O): 155.4 
(C-6), 152.7 (C-2), 148.8 (C-4), 139.5 (C-8, d, J 4.2), 118.6 (C-5), 87.4 (C-1ʹ), 83.1 
(C-4ʹ), 82.4 (C-5ʹ, d, J 148.8), 73.8 (C-2ʹ), 69.4 (C-3ʹ, d, J 5.0); δF (282.3 MHz, D2O): 
−231.9 (ddd, J 47.2, 47.2, 30.3, CH2F); m/z (ES+) 270 ([M+H]+, 100%), 292 ([M+Na]+, 
31); HRMS (ES+) calc. for C10H13FN5O3 [M+H]+ 270.0997, found 270.0989.  
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6.5.3. Ethyl O-mesylglycolate 49 
Triethylamine (3.4 mL, 53 mmol, 2.2 eq.) was slowly added to a 
solution of ethyl glycolate (2.3 mL, 24 mmol, 1.0 eq.) and mesyl 
chloride (1.6 mL, 21 mmol, 0.88 eq.) in DCM (20 mL) at 0 °C. The 
mixture was allowed to warm to room temperature and stirred for 1 h, before being 
quenched by addition of aqueous hydrochloric acid (1 M, 50 mL). The phases were 
separated and the organic phase washed with water (3 × 50 mL) before being dried 
over anhydrous Na2SO4 and concentrated. The resultant oil was purified by distillation 
under reduced pressure and ethyl O-mesylglycolate 49 was collected at 105 °C (1.8 
torr) as a colourless oil (2.05 g, 54%): vmax 1755, 1352, 1170, 1047, 804, 524 cm−1; δH 
(500.1 MHz, CDCl3): 4.76 (2 H, s, CH2OSO2CH3), 4.27 (2 H, q, J 7.1, CH2CH3), 3.21 (3 
H, s, SO2CH3), 1.31 (3 H, t, J 7.1, CH2CH3); δC (125.8 MHz, CDCl3): 166.9 (CO), 64.9 
(CH2OSO2CH3), 62.1 (CH2CH3), 39.1 (SO2CH3), 14.1 (CH2CH3); m/z (ES+) 205 
([M+Na]+ 100%); HRMS (ES+) calc. for C5H10O5SNa [M+Na]+ 205.0141, found 
205.0136. Data are in agreement with the literature.15 
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6.6. Fluorinase overexpression and purification 
E. coli BL21 (DE3) Gold cells bearing the pET-28a(+)-flA16 vector were grown while 
shaking (180 rpm) in autoinduction medium (4 × 400 mL in 2 L flasks) or in Luria Broth 
(4 × 1000 mL in 2 L flasks) containing kanamycin (100 µg.mL–1) at 37 °C overnight. In 
protocols where Luria Broth was used, optical density (OD600) was measured 
periodically and expression was induced when OD600 reached 0.6 by addition of IPTG 
to a final concentration of 0.5 mM. 
After 48 h (autoinduction) or 18 h (Luria Broth + IPTG), cells were harvested by 
centrifugation (4500 rpm, 20 min), and the cell pellet resuspended in lysis buffer  
(100–300 mL, 150 mM NaCl, 20 mM TRIS pH8, 20 mM imidazole), before protease 
inhibitor cocktail (1 × Complete Mini, EDTA-free, Roche), and bovine pancreatic 
DNAse (Sigma, 5 mg) were added. The cells were lysed using a cell disruptor 
(Constant Systems) at 30 kPSI. The lysate was centrifuged (20 000 rpm, 20 min) and 
the resulting pellet discarded before the supernatant was filtered (0.45 µm). The 
recombinant protein was purified from the lysate by passing the supernatant though a 
Ni2+ affinity column (Ni-NTA Agarose, Qiagen or Ni Sepharose 6 Fast Flow, GE, 5-7 mL 
bed volume) which was pre-equilibrated with the lysis buffer. The bound protein was 
washed (3 × 15 mL, 20 mM TRIS pH 8, 20 mM imidazole, 500 mM NaCl) before being 
eluted (3 × 15 mL, 20 mM TRIS pH 8, 400 mM imidazole, 500 mM NaCl). Fractions 
containing the desired fluorinase were pooled. 
Adenosine deaminase (ADA) suspension (50 µL calf spleen ADA type XI, Sigma 
Aldrich) was added to the fractions containing fluorinase, and the mixture dialysed 
against buffer (20 mM TRIS pH 8 and 150 mM NaCl, or 20 mM phosphate buffer 
pH 7.8 and 150 mM NaCl, 7 L) overnight. The non-His-tagged ADA enzyme was 
separated from the fluorinase by passing the supernatant though a Ni2+ affinity column 
(Ni-NTA Agarose, Qiagen or Ni Sepharose 6 Fast Flow, GE, 5-7 mL bed volume) which 
was pre-equilibrated with the dialysis buffer. The bound protein was washed 
(2 × 15 mL, 20 mM TRIS pH 8, 20 mM imidazole, 500 mM NaCl) before being eluted 
(2 × 15 mL, 20 mM TRIS pH 8, 500 mM imidazole, 500 mM NaCl).and the resultant 
eluate dialysed against buffer (50 mM phosphate buffer pH 7.8, 7 L) overnight. The 
solution was concentrated by centrifugation (Amicon Ultra-15, 10 000 kDa cutoff) to 
give recombinant fluorinase (5-20 mg.mL−1). 
Adenosine 188 removal was monitored by HPLC of samples of fluorinase which had 
been adjusted to the same protein concentration, denatured by heating at 95°C for 
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5 min, before being clarified by centrifugation (13 000 rpm, 10 min). Samples of the 
supernatant (60 µL) were removed for analysis by HPLC. 
HPLC analysis was performed on a Varian Prostar system using a Kingsorb 3µm C18 
(150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% TFA in water 
(solvent A) and 0.05% TFA in MeCN (solvent B); Linear gradient: 0% solvent B for to 
30% of solvent B in 15 min, from 30% to 95% of solvent B in 2 min and finally 95% 
solvent B to flush the column; Flow rate: 1 mL.min−1; Detection: 260 nm; Injection 
volume: 20 µL. 
Where freeze dried fluorinase was used, the enzyme solution was aliquotted into 
portions (5 mg or 10 mg, based on fluorinase), before being lyophilised, and stored at 
−78 °C until needed. 
For X-ray crystallography, the deaminated fluorinase was subject to His-Tag removal 
by dialysis in the presence thrombin (10 units, from human plasma, Roche) against 
buffer (20 mM TRIS pH 8, 150 mM NaCl, 5 L). Gel filtration (10mM Tris-HCl pH 7 and 
30mM NaCl) through a Superdex S-200 (HR16/60) column (Pharmacia Biotech) 
afforded fluorinase free of thrombin and the His-Tag. The solution was concentrated by 
centrifugation (Amicon Ultra-15, 10 000 kDa cutoff) to give His-Tag free recombinant 
fluorinase (6.5 mg.mL−1) 
6.7. Enzymatic Assays for Chapter 2 
6.7.1. ClDEA 174 to FDEA 176 
In a total reaction volume of 800 µL, recombinant fluorinase (5 mg.mL−1) was incubated 
with phosphate buffer pH 7.8 (20 mM), ClDEA 174 (0.2 mM), L-SeMet (0.1 mM) and KF 
(75 mM) at 37 °C. Samples (100 µL) were periodically removed, denatured by heating 
at 95°C for 3 min, before being clarified by centrifugation (13 000 rpm, 10 min). 
Samples of the supernatant (60 µL) were removed for analysis by HPLC. Control 
experiments without enzyme, L-SeMet and fluoride were also performed and showed 
no formation of FDEA 176. In the control without fluoride, conversion of ClDEA 174 to 
methyl selenoether 194 was observed. 
HPLC analysis was performed on a Varian Prostar system using a Kinetix 5µm XB-C18 
100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% TFA in 
water (solvent A) and 0.05% TFA in MeCN (solvent B); Linear gradient: 5% solvent B 
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for 2 min, then from 5% to 25% of solvent B in 10 min, from 25% to 50% of solvent B in 
3 min and finally 95% solvent B to flush the column; Flow rate: 1 mL.min−1; Detection: 
260 nm; Injection volume: 20 µL. For LC-MS analysis, the same column and the linear 
gradient, where TFA was replaced with formic acid, were employed with a flow rate of 
0.5 mL.min−1. 
6.7.2. ClDEA 174 and ClDA 23 rate comparison experiments 
For kinetic comparison of ClDA 23 and CLDEA 174, separate reactions with the two 
substrates were performed in duplicate. 
In a total reaction volume of 1000 µL, recombinant fluorinase (2.5 mg.mL−1, in 
phosphate buffer) was incubated with ClDA 23 (0.25 mM) or ClDEA 174 (0.25 mM), 
L-SeMet (0.075 mM) and KF (50 mM) at 37 °C. Samples (100 µL) were removed every 
15 min for 2 h, denatured by heating at 95°C for 3 min, before being clarified by 
centrifugation (13 000 rpm, 10 min). Samples of the supernatant (60 µL) were removed 
for analysis by HPLC. 
Concentration of the products, FDA 20 and FDEA 176 were determined by comparison 
of HPLC peak area to those of standard curves. 
HPLC analysis for both sets of experiments was performed on a Varian Prostar system 
using a Kinetix 5µm XB-C18 100A (150 mm × 4.6 mm) column and a guard cartridge. 
Mobile phase: 0.05% TFA in water (solvent A) and 0.05% TFA in MeCN (solvent B); 
Linear gradient: 5% solvent B for 2 min, then from 5% to 25% of solvent B in 10 min, 
from 25% to 50% of solvent B in 3 min and finally 95% solvent B to flush the column; 
Flow rate: 1 mL.min−1; Detection: 260 nm; Injection volume: 20 µL. 
6.7.3. Michaelis-Menten investigation of ClDEA 174 
For Michaelis Menten kinetics, ClDEA 174 was incubated with the fluorinase at 10 µM, 
25 µM, 50 µM, 100 µM, 250 µM and 500 µM, in duplicate. 
In a total reaction volume of 600 µL, recombinant fluorinase (0.15 mg.mL−1) and 
phosphate buffer (pH 7.8, 20 mM) was incubated with ClDEA 174 (at the appropriate 
concentration) and L-Met (10 mM) at 37 °C. Samples (100 µL) were removed every 
15 min for 1.5 h, denatured by heating at 95°C for 5 min, before being clarified by 
centrifugation (13 000 rpm, 10 min). Samples of the supernatant (60 µL) were removed 
for analysis by HPLC. 
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HPLC analysis for both sets of experiments was performed on a Varian Prostar system 
a Kinetix 5µm XB-C18 100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile 
phase: 0.05% TFA in water (solvent A) and 0.05% TFA in MeCN (solvent B); Linear 
gradient: 5% solvent B for 2 min, then from 5% to 25% of solvent B in 10 min, from 
25% to 50% of solvent B in 3 min and finally 95% solvent B to flush the column; Flow 
rate: 1 mL.min−1; Detection: 260 nm; Injection volume: 20 µL. 
Concentration of the methyl thioether product 197 in each sample was determined by 
comparison of HPLC peak area to those of a standard curve of ClDEA 174. Kinetic 
data were analysed using GraphPad Prism software, and kinetic constants fitted both 
with and without the effect of substrate inhibition. 
6.7.4. ClDEA 174 and ClDA 23 competition experiments 
For the competition experiment, both substrates were added to the same final 
concentration (0.2 mM). 
In a total reaction volume of 1000 µL, recombinant fluorinase (6 mg.mL−1, in phosphate 
buffer) was incubated with ClDA 23 (0.2 mM) and ClDEA 074 (0.2 mM), L-SeMet 
(0.08 mM) and KF (75 mM) at 37 °C. Samples (100 µL) were removed, denatured by 
heating at 95°C for 3 min, before being clarified by centrifugation (13 000 rpm, 10 min). 
Samples of the supernatant (60 µL) were removed for analysis by HPLC. 
HPLC analysis for both sets of experiments was performed on a Varian Prostar system 
a Kinetix 5µm XB-C18 100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile 
phase: 0.05% TFA in water (solvent A) and 0.05% TFA in MeCN (solvent B); Linear 
gradient: 5% solvent B for 2 min, then from 5% to 25% of solvent B in 10 min, from 
25% to 50% of solvent B in 3 min and finally 95% solvent B to flush the column; Flow 
rate: 1 mL.min−1; Detection: 260 nm; Injection volume: 20 µL. 
6.7.5. Enzymatic production and click reaction of FDEA 174 with 
 c(RGDfK[N3]) 199 
In a total volume of 300 µL in water, ClDEA 174 (0.2 mM), L-SeMet (0.1 mM), 
potassium fluoride (75 mM), phosphate buffer (20 mM) and fluorinase (5 mg.mL−1) 
were combined left to react at 37°C for 2 h. The mixture was heated to 95°C for 5 min, 
and centrifuged at 13 000 rpm for 10 min. Supernatant was used for the subsequent 
click reaction. 
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Enzymatically produced FDEA 176 (0.1 mM) and c(RGDfK[N3]) 199 (0.2 mM) and fresh 
sodium ascorbate solution (0.5 mM) was added to water (23 µL) (“t = 0 min” sample 
removed (50 µL) and analysed by HPLC) before CuSO4.TBTA solution (1.0 mM) and 
the mixture left to react for 70 min. A “t = 70 min” sample removed (50 µL) and 
analysed by HPLC. 
HPLC analysis was performed on a using the Varian instrument, Varian Prostar system 
a Kinetix 5µm XB-C18 100A (150 mm × 4.6 mm) column and a guard cartridge; mobile 
phase: A (H2O + 0.05% TFA), B (MeCN + 0.05% TFA); linear gradient: 5% B for 2 min, 
5% to 25% B in 10 min, 25% to 50% B in 6 min, 50% B to 95% B in 2 min; hold at 95% 
B for 3 min, 95% B to 5% B in 2 min, and re-equilibration at 95% B for 10 min; flow 
rate: 1 mL.min–1; detection 220 and 254 nm); injection volume: 20 µL.  
6.7.6. LC-MS of Click Reaction with 0.5 eq. of c(RGDfK[N3]) 199 
An enzymatic mixture of FDEA 176 (with residual ClDEA 174) (0.2 mM) and 
c(RGDfK[N3]) 199 (0.1 mM) and fresh sodium ascorbate solution (0.075 mM) was 
added to water (158 µL) before CuSO4.TBTA solution (0.075 mM) was added and the 
mixture left to react for 15 h to go to completion. A sample (50 µL + 100 µL water) was 
analysed by LC-MS. 
LC-MS analysis was performed on a using the Waters/Micromass instrument, using 
Phenomenex Kinetix 5µm XB-C18 100A (150 mm × 4.6 mm) column and a guard 
cartridge; mobile phase: A (H2O + 0.05% TFA), B (MeCN + 0.05% TFA); linear 
gradient: 5% B for 2 min, 5% to 25% B in 10 min, 25% to 50% B in 6 min, 50% B to 
95% B in 2 min; hold at 95% B for 3 min, 95% B to 5% B in 2 min, and re-equilibration 
at 95% B for 10 min; flow rate: 1 mL.min–1; detection 220 and 254 nm); injection 
volume: 20 µL.; mobile phase: A (H2O + 0.1% formic acid), B (MeCN + 0.1% formic 
acid); linear gradient: 5% B for 2 min, 5% to 25% B in 10 min, 25% to 50% B in 6 min, 
50% B to 95% B in 2 min; hold at 95% B for 3 min, 95% B to 5% B in 2 min, and 
re-equilibration at 95% B for 10 min; flow rate: 0.5 mL.min–1; injection volume: 50 µL. 
6.7.7. Synthesis of [18F]FDEA [18F]-176 and [18F]FDEA-RGD [18F]-201 
Synthesis of [18F]FDEA [18F]-176 and [18F]FDEA-RGD [18F]-201 were performed by Dr. 
Mayca Onega at Imanova Ltd at Hammersmith Hospital, London. 
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6.7.8. In vivo evaluation of [18F]FDEA-RGD [18F]-201 
The experiments conducted for this section were performed in accordance with the 
U.K. Animals (Scientific Procedures) Act 1986. The procedures used in the present 
study are approved by the Animal Ethical Review Committee of Imperial College. 
Dosing of the rats, metabolite analysis and post mortem gamma counting were 
conducted by Dr Sharon Ashworth, while imaging acquisitions and data analysis 
conducted by both Dr. Mayca Onega and Dr Sharon Ashworth at Imanova Ltd at 
Hammersmith Hospital, London. 
6.8. Enzymatic experiments for Chapter 3 
6.8.1. ClDEA-PEG-(C≡CH)2 219 to FDEA-PEG-(C≡CH)2 245 
In a total reaction volume of 1000 µL, recombinant fluorinase (10 mg.mL−1) was 
incubated with ClDEA-PEG-(C≡CH)2 219 (0.3 mM), L-SeMet (0.5 mM) and KF (75 mM) 
at 37 °C. Samples (100 µL) were periodically removed, denatured by heating at 95°C 
for 3 min, before being clarified by centrifugation (13 000 rpm, 10 min). Samples of the 
supernatant (100 µL) were removed for analysis by HPLC. Control experiments without 
enzyme, L-SeMet and fluoride were also performed and showed no formation of 
FDEA-PEG-(C≡CH)2 245. In the control without fluoride, conversion of ClDEA-PEG-
(C≡CH)2 245 to SeEAM-PEG-(C≡CH)2 was observed. 
HPLC analysis was performed on a Varian Prostar system using a Kinetix 5µm XB-C18 
100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% TFA in 
water (solvent A) and 0.05% TFA in MeCN (solvent B); Linear gradient: 5% solvent B 
to 95% solvent B over 20 min, 95% solvent B for 4 min then to 5% solvent B in 1 min 
and hold for 10 min to re-equilibrate the column; Flow rate: 1 mL.min−1; Detection: 
260 nm; Injection volume: 20 µL. 
6.8.2. ClDEA-PEG-(RGD)2 224 to FDEA-PEG-(RGD)2 248 
In a total reaction volume of 1000 µL, recombinant fluorinase (1 mg.mL−1) was 
incubated with ClDEA-PEG-(RGD)2 224 (0.04 mM), L-SeMet (0.075 mM) and KF 
(50 mM) at 37 °C. Samples (100 µL) were periodically removed, denatured by heating 
at 95°C for 3 min, before being clarified by centrifugation (13 000 rpm, 10 min). 
Samples of the supernatant (100 µL) were removed for analysis by HPLC. Control 
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experiments without enzyme, L-SeMet and fluoride were also performed and showed 
no formation of FDEA-PEG-(RGD)2 248. In the control without fluoride, conversion of 
ClDEA-PEG-(RGD)2 224 to SeEAM-PEG-(RGD)2 was observed. 
HPLC analysis was performed on a Shimadzu Prominence system using a Kinetix 5µm 
XB-C18 100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% 
TFA in water (solvent A) and 0.05% TFA in MeCN (solvent B); Isocratic: 22% solvent B 
for 20 min, then from 22% to 95% of solvent B in 1 min, hold at 95% B for 2 min, and 
back to 22% B for 7 min to re-equilibrate the column. Flow rate: 1 mL.min−1; Detection: 
220 nm; Injection volume: 20 µL. 
6.8.3. ClDEA-PEG-(RGD)4 225 to FDEA-PEG-(RGD)4 249 
In a total reaction volume of 1000 µL, recombinant fluorinase (1 mg.mL−1) was 
incubated with ClDEA-PEG-(RGD)4 225 (0.02 mM), L-SeMet (0.075 mM) and KF 
(50 mM) at 37 °C. Samples (100 µL) were periodically removed, denatured by heating 
at 95°C for 3 min, before being clarified by centrifugation (13 000 rpm, 10 min). 
Samples of the supernatant (100 µL) were removed for analysis by HPLC. Control 
experiments without enzyme, L-SeMet and fluoride were also performed and showed 
no formation of FDEA-PEG-(RGD)4 249. In the control without fluoride, conversion of 
ClDEA-PEG-(RGD)4 225 to SeEAM-PEG-(RGD)4 was observed. 
HPLC analysis was performed on a Shimadzu Prominence system using a Kinetix 5µm 
XB-C18 100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% 
TFA in water (solvent A) and 0.05% TFA in MeCN (solvent B); Isocratic: 24% solvent B 
for 20 min, then from 22% to 95% of solvent B in 1 min, hold at 95% B for 2 min, and 
back to 24% B for 7 min to re-equilibrate the column. Flow rate: 1 mL.min−1; Detection: 
220 nm; Injection volume: 20 µL. 
6.8.4. ClDA 23 to [18F]FDA [18F]-22 
A standard experiment for the synthesis of [18F]FDA [18F]-22 is described below. In 
experiments to determine optimal incorporation conditions, each factor was changed as 
described in Table 1. Concentrations shown are final concentrations. 
To a solution of ClDA 23 (0.04 mM, 20 µL), L-SeMet (0.075 mM, 38 µL) and fluorinase 
(5 mg, freeze dried), a solution of [18F]fluoride in water (200 µL, 56.1 MBq) was added 
and the final volume made up to 500 µL with water. The mixture was incubated at 
37 °C for 30 min before the enzyme was denatured by heating the sample to 100 °C for 
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5 min. The sample was centrifuged (3000-4000 rpm) for 5 min before a sample of the 
supernatant was analysed using the Dionex HPLC system. 
Table 1. Conditions investigated for optimization of incorporation of [18F]fluoride to [18F]FDA [18F]-22. 
Conditions changed are shown in bold. All reactions performed in a total volume of 500 µL. 
Component final concentration 
ClDA 23/mM fluorinase/mg.mL−1 L-SeMet/mM 
0.04 10 0.125 
0.04 10 (alt. batch) 0.125 
0.04 2.8 (stoichiometric) 0.125 
0.04 0.7 (catalytic) 0.125 
0.04 10 0.020 
0.3 0.7 0.125 
0.3 10 0.125 
0.3 20 0.125 
0.6 20 0.125 
 
6.8.5. ClDEA-PEG-(RGD)2 224 to [18F]FDEA-PEG-(RGD)2 [18F]-248 
A standard experiment for the synthesis of [18F]-248 is described below. In experiments 
to determine optimal incorporation conditions, each factor was changed as described in 
Table 2. Final concentrations of each component were used according to the optimised 
conditions described above, were the substrate was used at 0.3 mM, L-SeMet at 
0.08 mM and fluorinase at 20 mg.mL−1.  
To ClDEA-PEG-(RGD)2 224 (0.1 mg) and fluorinase (2.88 mg), L-SeMet (6 µL, 2 mM) 
was added, followed by a solution of [18F]fluoride in water (138 µL, 42.4 MBq). The 
mixture was incubated at 37 °C for 30 min before the enzyme was denatured by 
heating the sample to 100 °C for 5 min. The sample was centrifuged (3000-4000 rpm) 
for 5 min before a sample of the supernatant was analysed by HPLC. 
Analysis was performed on a Dionex system using a Kinetix 5µm XB-C18 100A 
(150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% TFA in water 
(solvent A) and 0.05% TFA in MeCN (solvent B); Isocratic: 22% solvent B for 20 min, 
then from 22% to 95% of solvent B in 1 min, hold at 95% B for 2 min, and back to 22% 
B for 7 min to re-equilibrate the column. An alternate gradient was also used in some 
experiments: Linear gradient: 5% solvent B to 95% solvent B over 20 min, 95% solvent 
B for 4 min then to 5% solvent B in 1 min and hold for 10 min to re-equilibrate the 
column; Flow rate: 1 mL.min−1; Detection: 220 nm; Injection volume: 10-50 µL. 
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Table 2. Conditions investigated for optimization of incorporation of [18F]fluoride to [18F]-248. 
Conditions changed are shown in bold. 
Condition changed 
224 preparation reaction time (min) 
freeze dried powder 30 
freeze dried with enzyme 30 
pre-dissolved in DMSO (2µL) 30 
freeze dried with enzyme 120 
 
6.8.6. ClDEA-PEG-(RGD)4 225 to [18F]FDEA-PEG-(RGD)4 [18F]-249 
A standard experiment for the synthesis of [18F]-249 is described below. In experiments 
to determine optimal incorporation conditions, each factor was changed as described in 
Table 3. Final concentrations of each component were used according to the optimised 
conditions described above, were the substrate was used at 0.3 mM, L-SeMet at 
0.08 mM and fluorinase at 20 mg.mL−1. 
To ClDEA-PEG-(RGD)4 225 (0.2 mg) and fluorinase (3.34 mg), L-SeMet (7 µL, 2 mM) 
was added, followed by a solution of [18F]fluoride in water (160 µL, 34.4 MBq). The 
mixture was incubated at 37 °C for 30 min before the enzyme was denatured by 
heating the sample to 100 °C for 5 min. The sample was centrifuged (3000-4000 rpm) 
for 5 min before a sample of the supernatant was analysed by HPLC. 
Analysis was performed on a Dionex system using a Kinetix 5µm XB-C18 100A 
(150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% TFA in water 
(solvent A) and 0.05% TFA in MeCN (solvent B); Linear gradient: 5% solvent B to 95% 
solvent B over 20 min, 95% solvent B for 4 min then to 5% solvent B in 1 min and hold 
for 10 min to re-equilibrate the column; Flow rate: 1 mL.min−1; Detection: 220 nm; 
Injection volume: 10-50 µL. 
Table 3. Conditions investigated for optimization of incorporation of [18F]fluoride to [18F]-249. 
Conditions changed are shown in bold. 
Condition changed 
225 preparation reaction time (min) 
freeze dried powder 30 
freeze dried with enzyme 30 
pre-dissolved in DMSO (2µL) 30 
freeze dried powder 120 
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6.9. Enzymatic Experiments for Chapter 4 
6.9.1. F2DA 276 with L-Met 21 
In a total volume of 500 µL in water, F2DA 276 (0.3 mM), L-Met (0.5 mM), phosphate 
buffer (20 mM) and fluorinase (2 mg.mL−1) were combined left to react at 37°C for 24 h. 
Samples were removed at t = 0 h, t = 1 h, t = 2 h, and t = 24 h. The samples were 
heated to 95°C for 5 min, and centrifuged at 13 000 rpm for 10 min. Supernatant was 
then analysed by HPLC. 
HPLC analysis was performed on a Varian Prostar system using a Kinetix 5µm XB-C18 
100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile phase: 0.05% TFA in 
water (solvent A) and 0.05% TFA in MeCN (solvent B); Linear gradient: 5% solvent B 
for 2 min, then from 5% to 25% of solvent B in 10 min, from 25% to 50% of solvent B in 
3 min and finally 95% solvent B to flush the column; Flow rate: 1 mL.min−1; Detection: 
260 nm; Injection volume: 20 µL. 
6.9.2. F2DA 276 with L-SeMet 161 
In a total volume of 500 µL in water, F2DA 276 (0.3 mM), L-SeMet (0.1 or 0.6 mM), 
phosphate buffer (20 mM) and fluorinase (1, 2 or 5 mg.mL−1) were combined left to 
react at 37°C for 19 h. Samples were removed at t = 0 h, t = 1 h, t = 2 h, and t = 24 h. 
The samples were heated to 95°C for 5 min, and centrifuged at 13 000 rpm for 10 min. 
Supernatant was then analysed by HPLC. 
HPLC analysis was performed on a Varian Prostar system using a Kinetix 5µm XB-C18 
100A (150 mm × 4.6 mm) column and a guard cartridge. Mobile phase:  0.05% TFA in 
water (solvent A) and 0.05% TFA in MeCN (solvent B); Linear gradient: 5% solvent B 
for 2 min, then from 5% to 25% of solvent B in 10 min, from 25% to 50% of solvent B in 
3 min and finally 95% solvent B to flush the column; Flow rate: 1 mL.min−1; Detection: 
260 nm; Injection volume: 20 µL. 
6.10. Synthesis of [18F]FAc [18F]-1 for Chapter 5 
6.10.1. Enzymatic synthesis of [18F]FAc [18F]-1 
To a solution of SAM 20 (20 mM, 20 µL), L-amino acid oxidase (1 mg) and fluorinase 
(5 mg, freeze dried), a solution of [18F]fluoride in water (300 µL, 83-269 MBq) was 
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added and the mixture vortexed before being incubated at 37 °C for 30 min. The 
enzyme was denatured by heating the sample to 140 °C for 5 min, before the sample 
was centrifuged (3000-4000 rpm) for 5 min. The supernatant was transferred to a new 
vial containing CrO3/H2SO4 (prepared by adding 1 g CrO3 to 3 mL 33% H2SO4, 250 µL) 
and the mixture heated to 140 °C for 20 min. The mixture was cooled on ice, and water 
added (1 mL) before the aqueous phase was extracted with Et2O (5 × 1 mL). The ether 
extracts were combined and passed through a Si Sep-Pak Light, and the cartridge 
washed with further Et2O (1 mL). The ether was extracted with sodium carbonate 
solution (8 mg.mL−1, 500 µL) to give a solution of [18F]fluoroacetate [18F]-1 (23% non-
decay corrected radiochemical yield, n=2). 
HPLC analysis was performed on the Dionex system using a ZIC-pHILIC, 5 µm PEEK 
(150 mm × 2.1 mm) column and a guard cartridge. Mobile phase: 50 mM ammonium 
bicarbonate (solvent A) and MeCN (solvent B); Linear gradient: 90% solvent B for 
3 min, then from 90% to 20% of solvent B in 0.5 min, 20% solvent B for 4.5 min, then to 
90% solvent B in 0.5 min, and hold for 26.5 min to re-equilibrate the column; Flow rate: 
0.2 mL.min−1; Injection volume: 10-50 µL. 
6.10.2. Chemical synthesis of [18F]FAc [18F]-1 
A solution of Kryptofix 222/K2CO3 (250 µL, prepared by adding K2CO3 (12 mg) in water 
(0.5 mL) to Kryptofix 222 (100 mg) in MeCN (2 mL)) was added to a solution of 
[18F]fluoride (49-553 MBq) in [18O]H2O in a Wheaton v-vial. The vial was sealed, and 
the fluoride ion dried at 100 °C under a stream of argon by azeotropic distillation by 
addition of MeCN (3 × 500 µL). The argon stream was removed and ethyl 
O-mesylglycolate 49 (1.3-1.5 mg) in MeCN (300 µL) was added to the dried 18F-fluoride 
ion, and the mixture gently shaken before being heated to 100 °C for 5 min. The vial 
was cooled in water (20 °C) for 5 min. The solution was transferred to a new vial and 
the original v-vial rinsed with water (300 µL) and this too added to the new vial. 
Additional water (700 µL), and NaOH solution (1.0 M, 200 µL) was added to the new 
vial and the mixture incubated at 40 °C for 5 min. Et2O (1 mL) was added, and the 
mixture shaken, the phases allowed to separate, and the aqueous phase transferred to 
a new vial and H2SO4 (1 M, 1 mL) was added. The acidified mixture was extracted with 
Et2O (5 × 1 mL) and the ether extracts combined before being loaded onto an Alumina-
N Sep-Pak. The Sep-Pak was washed with Et2O (0.5 mL), followed by air (2 mL). The 
Sep-Pak was attached to a PBS-treated sterile 0.22 µm filter, and [18F]fluoroacetate 
[18F]-1 was eluted into a sealed Wheaton v-vial from the Sep-Pak with phosphate 
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buffered saline (0.5 mL, pH 7.5), and the Sep-Pak and filter blown dry with air (1 mL). 
Argon was bubbled through the [18F]fluoroacetate-saline solution which was heated to 
100 °C for 5 min. This gave [18F]fluoroacetate [18F]-1 (10-103 MBq, 6-26% RCY) in 
phosphate buffered saline, shown to be >99% radiochemically pure by HPLC (retention 
time 8.10 min). 
HPLC analysis was performed on the Dionex system using a ZIC-pHILIC, 5 µm PEEK 
(150 mm × 2.1 mm) column and a guard cartridge. Mobile phase: 50 mM ammonium 
bicarbonate (solvent A) and MeCN (solvent B); Linear gradient: 90% solvent B for 
3 min, then from 90% to 20% of solvent B in 0.5 min, 20% solvent B for 4.5 min, then to 
90% solvent B in 0.5 min, and hold for 26.5 min to re-equilibrate the column; Flow rate: 
0.2 mL.min−1; Injection volume: 10-50 µL. 
6.10.3. In vivo evaluation of [18F]FAc [18F]-1 
Dr Zachary Schug and Dr Eyal Gottlieb, of the Beatson Institute for Cancer Research, 
who were leading the ACSS2 investigation, provided the mice for the study, while 
imaging acquisitions and data analysis were conducted at the institute by Dr Gaurav 
Malviya and Agata Mrowinska. 
6.11. Miscellaneous 
6.11.1. Preparation of 10 mM CuSO4.TBTA (55% DMSO solution) 
Copper (II) sulfate pentahydrate (50 mg) was dissolved in water (10 mL), and to this, a 
solution of TBTA 202 (tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine,17 Sigma 
Aldrich) (116 mg) in DMSO (11 mL) was added. The solution was well mixed to 
generate the complex, which was stored at room temperature until use. 
6.11.2. Isothermal titration calorimetry 
Isothermal titration calorimetry experiments were performed using a VP-ITC (microCal). 
The fluorinase was dialysed into phosphate buffer (20 mM, pH 7.8, 5 L) twice prior to 
titration. The final dialysis buffer also used for instrument equilibration. Pre-weighed, 
freeze-dried compounds for titration were dissolved in dialysis buffer to make solutions 
of ~1 mM. Solutions were degassed at 25 °C prior to titration of into a solution of 
fluorinase (~ 60 µM in 1.4 mL) at 25 °C. The first injection was 2 µL, followed by 
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multiple 10 µL injections. Data were analysed by MicroCal Origin software using a 
single binding site model. 
6.11.3. X-Ray crystallography of the fluorinase and FDEA 176 and 
 F2DA 276 
Purified fluorinase was concentrated to 6.5 mg ml−1 and incubated with 1 mM 
FDEA 176 (from 0.5 M stock in DMSO) at room temperature overnight prior to the 
setting of crystallization trials. Crystal trials were set with an Art Robbins Gryphon at 
protein/ligand to precipitant ratios of 1:1, 2:1 and 1:2 using in-house stochastic screens 
alongside commercially available crystallization screens. Crystals were obtained in 
several conditions but those diffracting the best grew from 20% PEG 3350, 0.2 M 
ammonium formate. 
Purified fluorinase was concentrated to 6.5 mg ml−1 and incubated with 2 mM F2DA 276 
(from 0.5 M stock in DMSO) at room temperature overnight prior to the setting of 
crystallization trials. Crystal trials were set with an Art Robbins Gryphon at 
protein/ligand to precipitant ratios of 1:1, 2:1 and 1:2 using in-house stochastic screens 
alongside commercially available crystallization screens. Crystals were obtained in 
several conditions but those diffracting the best grew from 40% PEG-MME (2K), 0.1 M 
sodium citrate pH 4.5 and 0.12 M ammonium tartrate. 
X-ray data was collected at the DIAMOND light source (for the FDEA-fluorinase 
structure) or at the European Synchrotron Radiation Facility (for the F2DA-fluorinase 
structure). Analysis and refinement were performed by Dr Stephen McMahon and Prof. 
Jim Naismith at the University of St Andrews. 
6.11.4. Evaluation of RGD compound affinity to αVβ3 
Binding affinity of cold bioconjugates was determined by Dr. Ian Fleming at the 
University of Aberdeen. Binding affinity of compounds to purified αVβ3 integrin was 
determined by ELISA as described in Zanda et al.18 
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